melphalan profile

Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	460612
CHEMBL ID	852
CHEBI ID	28876
SCHEMBL ID	5872
MeSH ID	M0013330

Synonym
phenylalanine mustard
alanine nitrogen mustard
sk 15673
nsc-8806
BIDD:GT0044
smr000058720
MLS002153368
AB00053282-07
AB00053282-08
BRD-K87827419-001-02-8
DIVK1C_000653
KBIO1_000653
4-[bis(2-chloroethyl)amino]-l-phenylalanine
melphalan, powder
SPECTRUM_000397
PRESTWICK_1006
BSPBIO_002407
alkeran
levofalan
melfalan
nci-c04853
l-sarcolysin
cb 3025
(2s)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
l-pam
sk-15673
alanine, 3-[p-[bis(2-chloroethyl)amino]phenyl]-, l-
l-sarcolysine
l-sarkolysin
nsc8806
l-phenylalanine mustard
IDI1_000653
SPECTRUM5_001601
SMP2_000174
NCGC00090757-01
melphalanum [inn-latin]
l-3-(para-(bis(2-chloroethyl)amino)phenyl)alanine
hsdb 3234
nsc 241286
levofolan
ccris 374
rcra waste no. u150
l-phenylalanine, 4-(bis(2-chloroethyl)amino)-
brn 2816456
alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl)-, l-
melfalano [inn-spanish]
levopholan
p-l-sarcolysine
rcra waste number u150
einecs 205-726-3
C07122
148-82-3
melphalan
p-n,n-bis(2-chloroethyl)amino-l-phenylalanine
p-bis(beta-chloroethyl)aminophenylalanine
3-(p-(bis(2-chloroethyl)amino)phenyl)-l-alanine
4-(bis(2-chloroethyl)amino)-l-phenylalanine
DB01042
l-3-(p-(bis(2-chloroethyl)amino)phenyl)alanine
3-p-(di(2-chloroethyl)amino)-phenyl-l-alanine
p-l-sarcolysin
p-n-bis(2-chloroethyl)amino-l-phenylalanine
l-phenylalanine, 4-[bis(2-chloroethyl)amino]-
phenylalanine nitrogen mustard
p-di-(2-chloroethyl)amino-l-phenylalanine
nsc-241286
D00369
melphalan (jp17/usp/inn)
alkeran (tn)
NCGC00090757-02
KBIO3_001627
KBIOGR_001284
KBIO2_000877
KBIO2_003445
KBIO2_006013
KBIOSS_000877
SPECTRUM3_000684
SPECTRUM4_000882
SPBIO_000287
SPECTRUM2_000074
NINDS_000653
SPECTRUM1500382
NCGC00090757-03
mustard, phenylalanine
HMS2090B09
HMS2091B16
cb-3025 ,
chebi:28876 ,
CHEMBL852 ,
sarcolycin, l-
HMS502A15
MLS001333666
melphalanum
melfalano
8057-25-8
1217854-43-7
(s)-2-amino-3-(4-(bis(2-chloroethyl)amino)phenyl)propanoic acid
2-amino-3-{4-[bis-(2-chloro-ethyl)-amino]-phenyl}-propionic acid(melphalan)
2-amino-3-{4-[bis-(2-chloro-ethyl)-amino]-phenyl}-propionic acid(l-pam)
2-amino-3-{4-[bis-(2-chloro-ethyl)-amino]-phenyl}-propionic acid (melphalan)
(s)-2-amino-3-{4-[bis-(2-chloro-ethyl)-amino]-phenyl}-propionic acid
bdbm50025837
2-amino-3-[4-bis(2-chloroethyl)amino]phenylpropanoic acid
2-amino-3-{4-[bis-(2-chloro-ethyl)-amino]-phenyl}-propionic acid
(2s)-2-azanyl-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
A808810
NCGC00090757-04
(2s)-2-azaniumyl-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoate
3-(p-(bis(2-chloroethyl)amino)phenyl)alanine
AY33600000 ,
niosh/ay3360000
alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl)-
NCGC00260071-01
tox21_202522
4-[bis(2-chloroethyl)-amino]-l-phenylalanine
4-[bis(2-chloroethyl)amino]-(l)-phenylalanine
nsc757098
pharmakon1600-01500382
nsc-757098
dtxsid6020804 ,
dtxcid00804
cas-148-82-3
tox21_111010
4-[bis-(2-chloroethyl)amino]-l-phenylalanine
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
HMS2235D21
CCG-39704
3025 c.b.
4-14-00-01689 (beilstein handbook reference)
melphalan [usan:usp:inn:ban:jan]
q41or9510p ,
unii-q41or9510p
NCGC00090757-05
melphalan [iarc]
melphalan [jan]
melphalan [orange book]
melphalan [ep monograph]
melphalan [inn]
melphalan [mart.]
melphalan [mi]
melphalan [vandf]
melphalan [usp monograph]
melphalan [hsdb]
melphalan [usan]
melphalan [who-dd]
EPITOPE ID:141802
AKOS015895374
S8266
DL-442
HY-17575
CS-3120
l-phenylalanine mustard (l-pam)
gtpl7620
phelinun
SCHEMBL5872
tox21_111010_1
NCGC00090757-06
4-[bis(2-chloroethyl)-amino]-l-phenyl-alanine
W-108096
AB00053282_09
mfcd00057717
(2s)-2-amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanoic acid
SR-05000001667-1
sr-05000001667
SBI-0052787.P003
Q2298283
AS-13314
EN300-7479343
l01aa03
para-di(2-chloroethyl)amino-l-phenylalanine
3(p-(bis(2-chloroethyl)amino)phenyl)-l-alanine
melphalan (usp monograph)
melphalan (mart.)
melphalan (usan:usp:inn:ban:jan)
l-sarcolysin phenylalanine mustard
p-di(chloroethyl)amino-l-phenylalanine
melphalan (iarc)
melphalanum (inn-latin)
melphalan (ep monograph)
wr-19813
l-phenylalanine,4-(bis(2-chloroethyl)amino)-
para-di(2-chloroethyl)aminophenylalanine
melphalan usp, 2 mg
p-di-(2-chloroethyl)amino-l-phenylalnine
p-n-bis(2-chloroethyl)amino)phenyl)-l-alanine
melfalano (inn-spanish)
4-bis(2-chloroethyl)amino-l-phenylalanine

Excerpt	Reference	Relevance
"Melphalan is an alkylating agent used as part of conditioning prior to pediatric hematopoietic cell transplantation (HCT). "	( Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation. Apsel Winger, B; Chan, D; Dvorak, CC; Gobburu, JVS; Li, S; Long-Boyle, J; Lu, Y, 2022)	2.45
"Melphalan is a bifunctional alkylating agent that covalently binds to nucleophilic sites in the DNA and effective in the treatment, but unfortunately has limited therapeutic benefit."	( Newly Synthesized Melphalan Analogs Induce DNA Damage and Mitotic Catastrophe in Hematological Malignant Cancer Cells. Gaipl, US; Ionov, M; Krzeczyński, P; Lubgan, D; Marczak, A; Poczta, A; Rogalska, A, 2022)	1.78
"Melphalan (Mel) is an antineoplastic widely used in cancer and other diseases. "	( Solid-State Formation of a Potential Melphalan Delivery Nanosystem Based on β-Cyclodextrin and Silver Nanoparticles. Donoso-González, O; Kogan, MJ; Lang, E; Noyong, M; Sierpe, R; Simon, U; Yutronic, N, 2023)	2.63
"Melphalan (L-PAM) is an ageless drug."	( Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma. Al-Janazreh, H; Canale, FA; Cutrona, G; D'Arrigo, G; Gentile, M; Martino, EA; Martino, M; Mendicino, F; Morabito, F; Morabito, L; Neri, A; Todoerti, K; Tripepi, G; Vigna, E, 2021)	1.71
"Melphalan is a bifunctional alkylating agent that elicits its cytotoxic activity by rapidly forming an initial DNA monoadduct, which then produces an inter-strand crosslink. "	( A systematic review of inter-individual differences in the DNA repair processes involved in melphalan monoadduct repair in relation to treatment outcomes. Burns, KE; Helsby, NA; van Kan, M, 2021)	2.28
"Melphalan is an efficient chemotherapeutic agent that is currently used to treat retinoblastoma (Rb); however, the inherent risk of immunogenicity and the hazardous integration of this drug in healthy cells is inevitable. "	( Co-delivery of miR-181a and melphalan by lipid nanoparticles for treatment of seeded retinoblastoma. Chain, JL; Derbali, RM; Hamel, P; Hardy, P; Superstein, R; Tabatabaei, SN; Yang, C, 2019)	2.25
"Melphalan is a widely used cytotoxic agent in cancer treatments. "	( Analysis of novel melphalan hydrolysis products formed under isolated lung perfusion conditions using liquid chromatography/tandem mass spectrometry. Boschmans, J; de Bruijn, E; Lemière, F; Van Schil, P, 2013)	2.17
"Melphalan is an efficacious alternative agent in patients undergoing CRS/HIPEC for aggressive and recurrent peritoneal surface malignancies. "	( Melphalan: a promising agent in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Gushchin, V; Jimenez, W; Nieroda, C; Sardi, A; Shankar, S; Sittig, M, 2014)	3.29
"Melphalan is a highly effective alkylating agent which causes many types of DNA lesions, including DNA base alkylation damage that is repaired by base excision repair (BER)."	( Functional analysis of the involvement of apurinic/apyrimidinic endonuclease 1 in the resistance to melphalan in multiple myeloma. Du, J; Li, M; Li, Z; Wang, D; Wang, G; Xie, J; Yang, S; Zeng, L; Zhang, L; Zhou, L, 2014)	1.34
"Melphalan is an effective chemotherapeutic agent. "	( Alternative treatment for retinoblastoma: Intra-arterial chemotherapy with melphalan. Aviño, J; Barranco, H; De Freytas, A; Harto-Castaño, M; Martinez-Costa, R, 2015)	2.09
"Melphalan is an alkylating agent frequently used in an intravenous formulation to treat hematologic malignancies and solid tumors in both adults and children. "	( Stability of Melphalan in 0.9% Sodium Chloride Solutions Prepared in Polyvinyl Chloride Bags for Intravenous Injection. Desmaris, RP; Mercier, L; Paci, A, 2015)	2.23
"Melphalan is a frequently used chemotherapeutical agent for the treatment of myeloma, breast cancer, ovarian cancer and sarcoma of soft tissue. "	( Covalent adducts of melphalan with free amino acids and a model peptide studied by liquid chromatography/tandem mass spectrometry. Dewaele, D; Lemière, F; Sobott, F, 2016)	2.2
"Melphalan is a bifunctional alkylating agent that covalently binds to the nucleophilic sites present in DNA. "	( Separation and identification of trinucleotide-melphalan adducts from enzymatically digested DNA using HPLC-ESI-MS. Linscheid, M; Mohamed, D, 2008)	2.05
"Melphalan is a chemically unstable antineoplastic drug which in the current commercial formulation (Alkeran(®) for Injection) has some limitations with regard to solubility, stability and biocompatibility."	( Preclinical comparison of intravenous melphalan pharmacokinetics administered in formulations containing either (SBE)7 m-β-cyclodextrin or a co-solvent system. Charman, SA; Katneni, K; Koltun, M; McIntosh, MP; Morizzi, J; Shackleford, DM, 2010)	1.35
"Melphalan is an important cytotoxic drug. "	( [The variance of melphalan doses related to kilogram of body weight and the consequences]. Vokurka, S, 2010)	2.14
"Melphalan is a bifunctional alkylator that creates inter- and intra-strand DNA cross-links."	( Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks? Arseneau, J; Foulkes, WD; Kushner, YB; Osher, DJ, 2011)	2.53
"Melphalan (MEL) is a chemotherapeutic agent used in breast cancer therapy; however, MEL's side effects limit its clinical applications. "	( Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest. Casanova, F; da Costa, DC; da Silva, JL; Fialho, E; Quarti, J; Ramos, CA, 2012)	2.07
"Melphalan is a chemotherapeutic agent that shows increased pharmacological activity with heat."	( Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model. Glehen, O; Mohamed, F; Stuart, OA; Sugarbaker, PH, 2004)	1.27
"Melphalan is a chemotherapeutic drug that exerts its cytotoxic effect mainly through the formation of DNA adducts. "	( Immunohistochemical detection of melphalan-DNA adducts in colon cancer cells in vitro and human colorectal liver tumours in vivo. Koevoets, C; Kuppen, PJ; Mulder, GJ; Rothbarth, J; Tilby, MJ; Tollenaar, RA; van de Velde, CJ, 2004)	2.05
"Melphalan is an alkylating substance used as a therapeutic agent; its mutagenicity is related to its ability to produce monoadducts and to form DNA cross-links. "	( Melphalan-induced DNA damage in p53(+/-) and wild type mice analysed by the comet assay. Cinelli, S; Cordelli, E; Lascialfari, A; Pacchierotti, F; Ranaldi, R, 2004)	3.21
"Melphalan is an alkylating agent, which is commonly used as an antineoplastic drug. "	( Melphalan reduces the severity of experimental colitis in mice by blocking tumor necrosis factor-alpha signaling pathway. Alioshkin, V; Pukhalsky, A; Sabelnikov, A; Shmarina, G, 2007)	3.23
"As melphalan is a phenylalanine derivative, the pharmacokinetic variability may be determined by genetic polymorphisms in the L-type amino acid transporters LAT1 (SLC7A5) and LAT2 (SLC7A8)."	( Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan. Brockmöller, J; Heider, U; Hohloch, K; Kaiser, R; Kühne, A; Muhlke, S; Niere, W; Overbeck, T; Schirmer, M; Sezer, O; Trümper, L, 2007)	1.06
"Melphalan is an alkylating agent approved for the treatment of multiple myeloma and ovarian cancer. "	( Melphalan and its role in the management of patients with multiple myeloma. Avonto, I; Boccadoro, M; Bringhen, S; Falco, P; Gay, F; Morabito, F; Palumbo, A, 2007)	3.23
"Melphalan is a particularly well suited agent for use with autologous bone marrow rescue and produces response in chemo-resistant tumours."	( High dose melphalan with autologous marrow rescue in cancer treatment. Dady, PJ; Dewar, JM; Forgeson, GV, 1984)	1.39
"Melphalan (Alkeran) is an alkylating agent commonly used in the treatment of multiple myeloma and other neoplasia. "	( Selection and characterization of Chinese hamster ovary cell mutants resistant to melphalan (L-phenylalanine mustard). Elliott, EM; Ling, V, 1981)	1.93
"Melphalan is an anti-neoplastic agent formulated for parenteral use as a sterile, non-pyrogenic, freeze-dried powder."	( New injectable melphalan formulations utilizing (SBE)(7m)-beta-CD or HP-beta-CD. Ma, DQ; Rajewski, RA; Stella, VJ, 1999)	1.38
"Melphalan is a bifunctional alkylating agent that covalently binds with intracellular nucleophilic sites. "	( Analysis of melphalan adducts of 2'-deoxynucleotides in calf thymus DNA hydrolysates by capillary high-performance liquid chromatography-electrospray tandem mass spectrometry. Berneman, Z; Deforce, D; Esmans, EL; Hoes, I; Lemière, F; Van Bockstaele, D; Van den Eeckhout, EG; Van Dongen, W; Vanhoutte, K, 1999)	2.13
"Melphalan is an effective drug in the treatment of myeloma, but is potentially toxic to progenitor cells."	( The effects of prior induction therapy with melphalan on subsequent peripheral blood progenitor cell transplantation for myeloma. Ahsan, G; Kazmi, MA; Schey, SA, 2001)	1.29
"Melphalan is a more potent leukemogen than cyclophosphamide or radiotherapy."	( Risk of leukemia after chemotherapy and radiation treatment for breast cancer. Bernstein, L; Boice, JD; Curtis, RE; Flannery, JT; Greenberg, RS; Hoover, RN; Moloney, WC; Schwartz, AG; Stovall, M; Weyer, P, 1992)	1
"Melphalan (MEL) is an aromatic alkylating agent which is useful for the treatment of a number of human cancers, including myeloma and ovarian cancer. "	( Selective enhancement of antitumor activity of N-acetyl melphalan upon conjugation to monoclonal antibodies. McKenzie, IF; Pietersz, GA; Smyth, MJ, 1987)	1.96

Excerpt	Reference	Relevance
"Melphalan has a steep dose-response curve, but the use of high doses results in unacceptable myelosuppression. "	( A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Adamson, PC; Balis, FM; Belasco, JE; Berg, SL; Blaney, SM; Craig, C; Lange, B; Poplack, DG, 1995)	2
"CE-melphalan at 2 mg/mL has 24-hour stability at RT and can be used for extended infusion times or may be compounded ahead of time."	( Stability of Captisol-enabled versus propylene glycol-based melphalan at room temperature and after refrigeration. Bashir, Q; Champlin, RE; Ciurea, SO; Gulbis, AM; Kawedia, JD; Liu, X; Qazilbash, MH; Ramchandran, S; Titus, M, 2022)	1.48
"Melphalan has been widely used for the treatment of several types of cancers despite its gonadotoxic effects."	( Melphalan induced germ cell toxicity and dose-dependent effects of β-aminoisobutyric acid in experimental rat model: Role of oxidative stress, inflammation and apoptosis. Jena, G; Kumar, V; Panghal, A, 2023)	3.07
"Melphalan resistance has been considered one of the major obstacles to improve outcomes in multiple myeloma (MM) therapy; unfortunately, the mechanistic details of this resistance remain unclear. "	( Functional analysis of the involvement of apurinic/apyrimidinic endonuclease 1 in the resistance to melphalan in multiple myeloma. Du, J; Li, M; Li, Z; Wang, D; Wang, G; Xie, J; Yang, S; Zeng, L; Zhang, L; Zhou, L, 2014)	2.06
"Melphalan has the strongest, and carboplatin the weakest association with reduction in ERG response amplitudes; but for the most part, these changes are minimal and likely clinically insignificant. "	( Electroretinogram monitoring of dose-dependent toxicity after ophthalmic artery chemosurgery in retinoblastoma eyes: six year review. Abramson, DH; Brodie, SE; Dunkel, IJ; Francis, JH; Gobin, YP; Marr, BP; Riedel, ER, 2014)	1.85
"Melphalan (L-PAM) has been an integral part of multiple myeloma (MM) treatment as a conditioning regimen before stem cell transplant (SCT). "	( The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma. Kang, MH; Reynolds, CP; Singh, H; Tagde, A, 2014)	2.07
"Melphalan has been used in the treatment of various hematologic malignancies for almost 60 years. "	( In vitro and in vivo activity of melflufen (J1)in lymphoma. Delforoush, M; Enblad, G; Gullbo, J; Larsson, R; Strese, S; Wickström, M, 2016)	1.88
"Melphalan has been a mainstay of multiple myeloma (MM) therapy for many years. "	( Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Ciavarella, S; Cives, M; Dammacco, F; De Matteo, M; Rizzo, FM; Silvestris, F, 2013)	2.11
"Melphalan has a steep dose-response curve, but the use of high doses results in unacceptable myelosuppression. "	( A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Adamson, PC; Balis, FM; Belasco, JE; Berg, SL; Blaney, SM; Craig, C; Lange, B; Poplack, DG, 1995)	2
"Melphalan has brought the first improvement in the therapy of multiple myeloma at the beginning of the sixties. "	( [Treatment of multiple myeloma--melphalan monotherapy after bone marrow transplantation]. Adam, Z; Hájek, R; Král, Z; Krejcí, M; Vásová, I; Vorlícek, J, 1996)	2.02
"Melphalan has brought the first improvement in the therapy of multiple myeloma at the beginning of the sixties. "	( Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation. Adam, Z; Hájek, R; Král, Z; Vásová, I, 1996)	2
"Melphalan has rarely been used as a single agent for conditioning prior to allogeneic marrow transplantation. "	( Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women. Horton, C; Mehta, J; Powles, R; Singhal, S; Swansbury, GJ; Treleaven, J, 1996)	3.18
"Melphalan at 30 mg/m2 has little activity among patients with metastatic colorectal carcinoma."	( Phase II trial of intravenous melphalan for metastatic colorectal carcinoma. A Southwest Oncology Group study. Baker, LH; Coltman, CA; Constanzi, JJ; Goodman, P; Knight, WA; Macdonald, JS; Taylor, SA, 1990)	1.29
"Melphalan has been reported to be actively transported into tumor cells by two amino acid carrier systems. "	( Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. Greig, NH; Momma, S; Rapoport, SI; Smith, QR; Sweeney, DJ, 1987)	2.02
"Melphalan has been evaluated against a series of seven childhood rhabdomyosarcomas, each derived from a different patient and maintained in vivo as xenografts in immune-deprived mice. "	( Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma. Cook, RL; Houghton, JA; Houghton, PJ; Lutz, PJ, 1985)	3.15

Excerpt	Reference	Relevance
"Melphalan did not increase the doubling of turbidity that idarubicin hydrochloride shows upon simple dilution."	( Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Martinez, JF; Trissel, LA, 1993)	1.31
"Melphalan can rarely cause interstitial pneumonitis and fibrosis. "	( Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation. Akasheh, MS; Freytes, CO; Vesole, DH, 2000)	3.19
"Melphalan showed lower cytotoxicity at short exposure times and high drug concentrations, while chlorambucil exhibited higher cytotoxicity at longer exposure times."	( Concentration and time-dependent inter-relationships for cytotoxicities of nitrogen mustard drugs against lymphoblasts in-vitro. Ehrsson, H; Ringborg, U; Wallin, I, 1988)	1

Excerpt	Reference	Relevance
"Melphalan treatment significantly altered all the above-mentioned parameters and the high dose (100 mg/kg) of BAIBA restored melphalan-induced toxicity in a significant manner by exerting antioxidant, anti-inflammatory and antiapoptotic effects."	( Melphalan induced germ cell toxicity and dose-dependent effects of β-aminoisobutyric acid in experimental rat model: Role of oxidative stress, inflammation and apoptosis. Jena, G; Kumar, V; Panghal, A, 2023)	3.07
"Melphalan treatment of hiPSC-CMs induced oxidative stress, caused Ca"	( Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cells. Castellino, SM; Du, Y; Fischbach, P; Fu, H; Li, D; Liu, R; Mandawat, A; Maxwell, JT; Rampoldi, A; Sun, F; Wu, R; Xu, C, 2020)	3.44
"Melphalan, as a treatment for retinoblastoma, has been applied intra-arterially by catheterisation of the ophthalmic artery or intravitreally, aiming to reduce systemic side effects of intravenous drug therapy. "	( Investigating short-term toxicity of melphalan in a model of an isolated and superfused bovine retina. Aisenbrey, S; Bartz-Schmidt, KU; Hagemann, U; Hofmann, K; Januschowski, K; Krupp, C; Mueller, S; Schnichels, S; Spitzer, MS, 2016)	2.15
"Melphalan pretreatment or cotreatment with dl1520 enhanced inhibition of proliferation by dl1520 by up to 60% and increased apoptosis by up to 25%."	( Synergistic cytotoxicity against human tumor cell lines by oncolytic adenovirus dl1520 (ONYX-015) and melphalan. Ferguson, PJ; Figueredo, R; Koropatnick, J; Sykelyk, A, )	1.07
"Melphalan-treated CCRF-CEM leukaemia cells were analysed by the trapped-in-agarose DNA immunostaining (TARDIS) method using fluorescein immunofluorescence and Hoechst dye-DNA fluorescence."	( Quantification of DNA adducts in individual cells by immunofluorescence: effects of variation in DNA conformation. Frank, AJ; Tilby, MJ, 2003)	1.04
"In melphalan-treated cells one can detect both 10 kb and 20 kb DNA intermediates, indicating that in such cells the gaps present in a replicon are not filled at the same time which allows the detection of a molecule which is formed by the joining of two 10 kb DNA intermediates."	( Two discrete DNA replication intermediates are formed in melphalan-treated cells. Lönn, S; Lönn, U, 1983)	1.03
"For melphalan, neither pretreatment agent produced any change in tumor response."	( Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU. Twentyman, P; Workman, P, 1982)	0.96
"The melphalan treated patients showed a significantly higher overall objective response frequency (59%), according to Myeloma Task Force criteria, when compared to those treated with BCNU (40%) or CCNU (42%)."	( Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982)	1.07
"Melphalan treatment alone improved the median survival to 31 days for animals with localized myeloma and 34 days in animals with disseminated disease."	( Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation. Berger, JD; Claringbold, PG; Glancy, RJ; Manning, LS; O'Donoghue, HL; Turner, JH, 1993)	1.21
"Melphalan treatment should be avoided in patients who are candidates for high-dose chemotherapy."	( Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone. Gutensohn, K; Hassan, HT; Hummel, K; Kröger, N; Krüger, W; Lölliger, C; Renges, H; Zander, AR; Zeller, W, 1998)	1.02
"When melphalan treatment was used to produce tumor-bearing mice with an intact delayed hypersensitivity response but devoid of a significant antibody response, the drug-treated animals were found to have high levels of ADCC effector cells in situ."	( Immunologic factors influencing the intra-tumor localization of ADCC effector cells. Haskill, S; Parthenais, E, 1978)	0.71
"Melphalan treatment resulted in arrest of cells in late S- and G2-phases in a population of unsynchronized cells."	( Interphase cell death as related to the cell cycle of melphalan-treated human myeloma cells. Fernberg, JO; Lewensohn, R; Skog, S, 1991)	1.25
"In melphalan-treated patients where LCLs were established serially, the melphalan Do increased after further melphalan treatment in vivo and decreased when no further treatment was given."	( Melphalan-resistant lymphoblastoid cell lines established from patients with ovarian cancer treated with cross-linking agents. Daunter, B; Khoo, SK; Maynard, K; Musk, P; Parsons, PG, 1985)	2.23
"Melphalan treatment of the cells produced an increased secretion of IgG and IgM, whereas adriamycin did not."	( Melphalan treatment of human peripheral T cells promotes Ig production by B cells in vitro. Baral, E; Blomgren, H; Rotstein, S; Virving, L; von Stedingk, LV; Wasserman, J, 1985)	2.43
"Treatment with melphalan-based therapy significantly induced the expression of PD-1 on CD8"	( Anti-PD-1 checkpoint blockade improves the efficacy of a melphalan-based therapy in experimental melanoma. Johansson, J; Kiffin, R; Martner, A; Olofsson Bagge, R, 2021)	1.22
"Treatment with melphalan is currently standard of care for younger and fit patients when followed by hematopoietic stem cell transplantation (HSCT), and in transplant ineligible patients when used in combination regimens."	( Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. Cho, YK; Hofmeister, CC; Lamprecht, M; Li, J; Phelps, MA; Pichiorri, F; Poi, MJ; Sborov, DW; VanGundy, Z, 2017)	0.79
"Treatment with melphalan plus the proteasome inhibitor MG132 reduced global protein degradation for MM cells to roughly 60% of that seen without drugs, but the reduction was approximately three times greater for CCL-156 cells."	( Evidence that aberrant protein metabolism contributes to chemoresistance in multiple myeloma cells. Burgis, NE; Lewis, BS; Sipes, RK; Xia, X, 2012)	0.72
"Treatment with melphalan resulted in 2 (20%) complete responses and 1 (10%) partial response (response rate, 30%; 95% CI 8%, 65%)."	( Melphalan for the treatment of patients with recurrent epithelial ovarian cancer. Davis-Perry, S; Hernandez, E; Houck, KL; Shank, R, 2003)	2.1
"Treatment with melphalan (6 mg) and prednisolone (35 mg) for 4 days every 6 weeks decreased the fever and alleviated his symptoms."	( Primary amyloidosis with pulmonary involvement which presented exudative pleural effusion and high fever. Fujimoto, N; Ito, M; Kosaka, H; Masuoka, H; Nakano, T; Ota, S, 2003)	0.66
"Treatment with melphalan and prednisolone was initiated without beneficial response."	( [Granulocyte-colony stimulating factor-producing myeloma with clinical manifestations mimicking chronic neutrophilic leukemia]. Kusaba, N; Mishima, K; Ohkubo, F; Okamura, T; Sata, M; Shimamastu, K; Yoshida, H, 2004)	0.66
"Treatment with melphalan, a classic DNA-damaging agent, led to the induction of the DNA damage checkpoint and growth arrest in the G2 phase of the cell cycle."	( Cross-talk between DNA damage and cell survival checkpoints during G2 and mitosis: pharmacologic implications. Bozko, P; Larsen, AK; Sabisz, M; Skladanowski, A, 2005)	0.67
"Treatment with melphalan and dexamethasone allowed stabilization during more than six months."	( [Original case report of amyloidosis with pleural involvement: the role of echocardiography in the diagnosis]. Billotet, C; Roubille, C; Roubille, F, 2006)	0.67
"Treatment with melphalan was as effective as ovariectomy, but the combination of melphalan with ovariectomy was no more effective than either treatment alone."	( Enhanced cytostatic effectiveness of aniline mustard against 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors during regression in response to ovariectomy. Benckhuysen, C; Ter Hart, HG; Van Dijk, PJ, )	0.47
"Treatment with melphalan or cyclophosphamide resulted in a decrease in the serum IgE level and in the level of Bence Jones protein in the urine."	( Immunoglobulin E (IgE) multiple myeloma: a case report and review of the literature. Asakawa, H; Endo, T; Kikuchi, K; Munakata, J; Nomura, T; Okumura, H; Otake, M, 1981)	0.6
"Treatment with melphalan, paclitaxel, perfosfamide or tamoxifen failed to enrich for mismatch repair-deficient cells, and no change in sensitivity to these agents was detected in the clonogenic assays."	( The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Aebi, S; Fink, D; Haas, M; Howell, SB; Kim, HK; Nebel, S; Norris, PS, 1998)	0.64
"Treatment with melphalan and prednisolone was effective against the myeloma as well as the scleredema and acanthosis nigricans."	( [Scleredema, acanthosis nigricans and IgA/Kappa multiple myeloma]. Bernardo, A; Farinha, F; Massa, A; Ribeiro, P; Valente, L; Velho, GC, 1997)	0.64
"Treatment with melphalan and prednisone results in an objective response in 50%-60% of patients."	( Management of patients with multiple myeloma: emphasizing the role of high-dose therapy. Kyle, RA, 2001)	0.65
"Treatment with melphalan and prednisone resulted in great improvement of cutaneous lesions and paraproteinemia remission."	( Necrobiotic xanthogranuloma with lambda paraproteinemia: case report of successful treatment with melphalan and prednisone. Criado, PR; Lopes, LF; Pegas, JR; Ramos, CF; Tebcherani, AJ; Valente, NY; Vasconcellos, C, 2002)	0.88
"The treatment with melphalan was discontinued and the spread of the KS was arrested by irradiation and bleomycin."	( Multiple myeloma associated with Kaposi sarcoma. Djaldetti, M; Gafter, U; Kende, L; Lask, D; Mandel, EM; Weiss, S, 1977)	0.58
"Treatment with melphalan and steroids resulted in a three year remission."	( [Alpha-chain disease presenting as malabsorption syndrome with exudative enteropathy (author's transl)]. Havemann, K; Kalbfleisch, H; Martini, GA; Menge, H; Riecken, EO; Roth, S; Sodomann, CP, 1976)	0.6
"Treatment with melphalan was associated with histologic evidence of reversible gastrointestinal toxicity, reversible myelosuppression, and histologic evidence of acute renal tubular necrosis, with no differences being observed between mice that had been pretreated with BSO and those that had been pretreated with vehicle."	( Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine. Bigner, DD; Friedman, HS; Griffith, OW; McMahon, DP; Postels, DG; Skapek, SX; VanDellen, AF, 1991)	2.06
"Treatment with melphalan had no effect on already induced suppressor T cells as shown by incubation of spleen cells with melphalan (0.15-5 micrograms/1 X 10(7) cells) after incubation with ConA."	( Effect of melphalan in vitro on induction of murine suppressor T cells by ConA. Ben-Efraim, S; Ophir, R, 1985)	1.01
"Treatment with melphalan and prednisolone resulted in remission of both myeloma and myopathy."	( Amyloid myopathy and myeloma: response to treatment. Sheehan-Dare, RA; Simmons, AV, 1987)	0.61
"Treatment with melphalan, cyclophosphamide, and prednisone was associated with long-term survival (median, 540 days)."	( Prognostic factors for multiple myeloma in the dog. Hurvitz, AI; Leifer, CE; MacEwen, EG; Matus, RE, 1986)	0.61

Excerpt	Reference	Relevance
" Mild or moderate limb toxicity is usual, but severe toxic reactions in the limb sometimes occur."	( Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. Gianoutsos, MP; Thompson, JF, )	0.35
" One of the peptides, L-propyl-m-sarcolysyl-L-p-fluorophenylalanine (PSF), is highly toxic to melanoma cells."	( Cytotoxicity and DNA cross-linking induced by peptide conjugated m-L-sarcolysin in human melanoma cells. Hansson, J; Lewensohn, R; Ringborg, U, )	0.13
" In a previous investigation we found that Peptichemio was less toxic to human lymphoblasts than m-L-sarcolysin."	( Increased toxicity and DNA cross-linking by peptide bound m-L-sarcolysin (Peptichemio) as compared to melphalan and m-L-sarcolysin in human melanoma cell lines. Ehrsson, H; Hansson, J; Lewensohn, R; Ringborg, U, )	0.35
"4-fold more toxic toward bright cells."	( Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. al-Achi, A; Herman, TS; Holden, SA; Teicher, BA, 1990)	0.28
" Our studies with one such agent, the vasodilator hydralazine, have clearly demonstrated that it can increase the tumor cytotoxicity of drugs which are known to be more toxic under hypoxic conditions."	( Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Acker, B; Chaplin, DJ; Olive, PL, 1989)	0.54
" When the dose of methyl-CCNU was further increased to 40 mg kg-1 toxic death occurred, which was, however, significantly reduced by 'priming' with the low dose given."	( Priming with low doses of methyl-CCNU reduce the toxicity of high doses of methyl-CCNU and melphalan, and increase the lifespan of mice implanted with Lewis lung carcinoma. Livnat, I; Perk, K; Zimber, A, 1988)	0.5
"05) more toxic than melphalan."	( In vitro comparative studies of the myelotoxicity and antitumor activity of 6-[bis-(2-chloroethyl)-amino]-6-deoxy-D-glucose versus melphalan utilizing the CFU-C and HTSCA assays. Dufour, M; Isabel, G; Lazarus, P; Panasci, LC, 1986)	0.8
" While almost all patients experienced toxic reactions during the therapy, only 3%--4% of recipients of melphalan (L-PAM; P) and 4%--5% of recipients of L-PAM + 5-FU(F)(PF) failed to complete 2 years of therapy because of toxicity."	( Acute toxicity during adjuvant chemotherapy for breast cancer: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents. Fisher, B; Foster, R; Glass, A; Lerner, H; Margolese, R; Plotkin, D; Redmond, C; Shibata, H; Wieand, HS; Wolmark, N; Wolter, J, )	0.35
" These results suggest the existence of a novel zinc-inducible mechanism which protects cells against the toxic effects of alkylating agents."	( Zinc-induced resistance to alkylating agent toxicity. Enger, MD; Griffith, JK; Hildebrand, CE; Tobey, RA, 1982)	0.26
"To determine if a lower perfusion flow rate would reduce leakage and consequently toxic effects."	( Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment. Abu-Abid, S; Aderka, D; Bar-On, J; Gutman, M; Halpern, P; Kudlik, N; Lev, D; Rudich, V; Setton, A; Sorkin, P, 1995)	0.29
" Consequently, the systemic hemodynamic, metabolic, and hematologic toxic effects are virtually abolished."	( Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment. Abu-Abid, S; Aderka, D; Bar-On, J; Gutman, M; Halpern, P; Kudlik, N; Lev, D; Rudich, V; Setton, A; Sorkin, P, 1995)	0.29
" Interestingly, these 2 conjugates, differing only in melphalan position, showed completely different cytotoxicity in terms of IC50 values, Pep 1 being 24 times more toxic to all cells; but the 2 were equally specific to melanoma cells."	( Receptor-mediated cytotoxicity of alpha-MSH fragments containing melphalan in a human melanoma cell line. Botyánszki, J; Ghanem, G; Libert, A; Loir, B; Medzihradszky, K; Morandini, R; Süli-Vargha, H, 1994)	0.77
" Age over 60 years, female sex and more severe acute regional toxic reactions were correlated with an increased incidence of systemic side-effects."	( Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eggermont, AM; Klaase, JM; Kroon, BB; Nieweg, OE; Sonneveld, EJ; van Dongen, JA; van Geel, BN; Vrouenraets, BC, 1996)	0.54
" In summary, the DexaBEAM/G-CSF/CBV strategy appears to be safe and effective for salvage treatment in patients with poor risk malignant lymphomas."	( Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas. Berdel, WE; Hoppe, B; Knauf, WU; Koenigsmann, MP; Notter, M; Oberberg, D; Reufi, B; Thiel, E, 1996)	0.29
" Within the NHL group, 21 patients were in 2nd or subsequent complete remission (CR) at transplant, 34 had sensitive disease and 11 resistant disease; 46 patients were transplanted in 1st CR due to the presence of > or = 2 adverse prognostic features at diagnosis or to a slow CR."	( BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Caballero, MD; Corral, M; del Cañizo, MC; García-Sanz, R; Gonzalez, M; Heras, I; Jean-Paul, E; León, A; Moraleda, JM; Rifon, J; Rocha, E; Rubio, V; San Miguel, JF; Vázquez, L; Vidriales, B, 1997)	0.3
" Toxicity information for IFN had been collected using patient-completed diaries so the actual duration of each adverse event could be determined."	( Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. Browman, G; Cole, B; James, K; Johnston, D; Li, T; Pater, J; Sugano, D; Zee, B, 1998)	0.3
"The optimal toxic reaction of the normal tissues in perfused limbs after isolated limb perfusion (ILP) is unknown."	( Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. Eggermont, AM; Hart, GA; Klaase, JM; Kroon, BB; Nieweg, OE; van Geel, BN; Vrouenraets, BC, 1999)	0.3
"These data suggest that, in our cohort of patients, the combination of total-body irradiation and melphalan is safe and associated with good antileukemia activity, making ABMT an appealing alternative for postremission therapy in children with acute myeloid leukemia in first CR."	( Total-body irradiation and melphalan is a safe and effective conditioning regimen for autologous bone marrow transplantation in children with acute myeloid leukemia in first remission. The Italian Association for Pediatric Hematology and Oncology-Bone Mar Bonetti, F; Cesaro, S; De Stefano, P; Fagioli, F; Giorgiani, G; Lanino, E; Locatelli, F; Messina, C; Montagna, D; Pession, A; Prete, A; Rondelli, R; Santoro, N; Zecca, M, 1999)	0.82
" Toxic mortality prior to day + 100 was 29% in the L-PAM group and 9% in the non-L-PAM group of patients."	( Allograft with unrelated donor accentuates the gastrointestinal toxicity associated with high-dose melphalan and total body irradiation preparative for bone marrow transplantation in children. Hovi, L; Saarinen-Pihkala, U; Taskinen, M; Vettenranta, K, 2000)	0.52
" The results of this study demonstrate that the use of CD34(+) cells is safe and has no adverse effects either with respect to haematological, immune reconstitution or to infections after HDT."	( High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells. Blystad, AK; Delabie, J; Holte, H; Kvalheim, G; Kvaløy, S; Smeland, E, 2001)	0.31
"O6-Benzylguanine (BG) inactivates O6-alkylguanine-DNA alkyltransferase (AGT), resulting in an increase in the sensitivity of cells to the toxic effects of O6-alkylating agents."	( Effect of O6-benzylguanine on nitrogen mustard-induced toxicity, apoptosis, and mutagenicity in Chinese hamster ovary cells. Cai, Y; Chung, AB; Dolan, ME; Ludeman, SM; Wilson, LR, 2001)	0.31
" BEAM allogeneic transplantation with early reduction in immunosuppression is safe (no treatment-related deaths) and effective in advanced Hodgkin's disease where autografts have failed."	( BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective. Cooney, JP; Parthasarathy, M; Stiff, PJ; Toor, AA, 2003)	0.32
" While BEAC and BEAM appears to have equal antitumour efficacy in patients with NHL, BEAM seems to be more toxic to the gastrointestinal tract."	( BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Jantunen, E; Kuittinen, T; Nousiainen, T, 2003)	0.32
" To determine a safe and tolerable dose for efficacy studies the acute toxicity following intravenous injection in the tail vein was monitored using a 14-day schedule with up to four doses."	( Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo. Bashir-Hassan, S; De La Torre, M; Ehrsson, H; Gullbo, J; Larsson, R; Lewensohn, R; Lindhagen, E; Luthman, K; Nygren, P; Tullberg, M, 2004)	0.56
" These results suggest that CD34 selection of reduced-intensity PBSC allografts may cause adverse effects upon specific antimicrobial immunity which can lead to fatal infections, particularly in high-risk patients."	( Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality. Hartwig, UF; Herr, W; Huber, C; Kolbe, K; Kreiter, S; Meyer, RG; Schneider, PM; Ullmann, AJ; Wehler, T; Winkelmann, N, 2005)	0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" We conclude that MEL200 is a safe and efficacious treatment in selected elderly myeloma patients."	( High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol. Jantunen, E; Kuittinen, T; Lehtonen, P; Mahlamäki, E; Nousiainen, T; Penttilä, K, 2006)	0.74
" When irradiated cells residing in G2 phase are exposed to very low doses of cisplatin at a toxic dose of 5%."	( Inhibition of homologous recombination repair with Pentoxifylline targets G2 cells generated by radiotherapy and induces major enhancements of the toxicity of cisplatin and melphalan given after irradiation. Bohm, L, 2006)	0.53
" Specific grade 3/4 haematological (3%) or cardiac adverse events occurred infrequently."	( Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Berenson, JR; Bessudo, A; Boccia, R; Bozdech, M; Ferretti, D; Flam, M; Jilani, S; Louie, R; Lutzky, J; Moss, R; Patel, R; Russell, K; Siegel, D; Stadtmauer, E; Steis, R; Swift, RA; Talisman Pomeroy, J; Volk, J; Wong, SF; Yeh, HS, 2006)	0.64
" These cases demonstrate that it is feasible and safe to perform HSCT in pediatric patients with low nGFR using melphalan- and thiotepa-based preparative therapy."	( Autologous hematopoietic stem cell transplant with melphalan and thiotepa is safe and feasible in pediatric patients with low normalized glomerular filtration rate. Gross, TG; Grovas, A; Klopfenstein, K; Rosselet, R; Termuhlen, AM, 2006)	0.8
" HDT and autologous transplant is safe and feasible in elderly myeloma patients."	( Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Alousi, AM; Champlin, RE; Couriel, DR; De Lima, M; Flosser, T; Giralt, SA; Hosing, C; Kebriaei, P; Mendoza, F; Popat, U; Qazilbash, MH; Qureshi, SR; Saliba, RM; Wang, M; Weber, DM, 2007)	0.34
" Genetic variation in 4F2hc, LAT1, and LAT2 does not appear to be a major cause of inter-individual variability in pharmacokinetics and of adverse reactions to melphalan."	( Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan. Brockmöller, J; Heider, U; Hohloch, K; Kaiser, R; Kühne, A; Muhlke, S; Niere, W; Overbeck, T; Schirmer, M; Sezer, O; Trümper, L, 2007)	0.74
" In addition, we studied glutathione S-transferase GSTM1, GSTT1, and GSTP1 polymorphisms in relation to adverse events."	( Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. Brockmöller, J; Heider, U; Hohloch, K; Kaiser, R; Kühne, A; Meineke, I; Muhlke, S; Niere, W; Overbeck, T; Sezer, O; Trümper, L, 2008)	0.63
" The most common grade 3/4 hematologic adverse events (AEs) were neutropenia (31%/0%), thrombocytopenia (25%/2%), and anemia (13%/0%)."	( Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Berenson, JR; Hilger, J; Lee, SP; Mapes, R; Morrison, B; Nassir, Y; Swift, R; Vescio, RA; Wilson, J; Yang, HH; Yellin, O, 2008)	0.62
"ILI is a safe alternative to the more invasive and laborious ILP technique to treat melanoma confined to a limb."	( Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Kam, PC; Kroon, HM; Moncrieff, M; Thompson, JF, 2009)	0.58
" In conclusion, bortezomib-based regimens are safe and effective and should be considered as appropriate treatment options for MM patients with any degree of RI."	( Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P, 2010)	0.36
" On the other hand, most of the compounds afforded clear evidence of being far less toxic towards human HGF gingival fibroblasts, HPC pulp cells and HPLF periodontal ligament fibroblasts which are non-malignant cells."	( Cytotoxic 2-benzylidene-6-(nitrobenzylidene)cyclohexanones which display substantially greater toxicity for neoplasms than non-malignant cells. Chu, Q; Das, U; Dimmock, JR; Doroudi, A; Inci Gul, H; Kawase, M; Pati, HN; Sakagami, H; Stables, JP, 2010)	0.36
" Thalidomide, in combination with MP, is associated with adverse events (AEs) including peripheral neuropathy and venous thromboembolism."	( Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Bladé, J; Davies, F; Delforge, M; Facon, T; Garcia Sanz, R; Kropff, M; Leal da Costa, F; Moreau, P; Morgan, G; Palumbo, A; Schey, S, 2010)	0.57
" The pharmacokinetics of melphalan and the clinical efficacy and adverse effects of ILI from various centres are summarised."	( Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity. Kam, PC; Thompson, JF, 2010)	0.96
" Nonhematologic grade 3/4 adverse events were reported in 35% of once-weekly patients and 51% of twice-weekly patients (P = ."	( Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D, 2010)	0.36
" However, numerous adverse effects limited their use."	( Optimization of the N-lost drugs melphalan and bendamustine: synthesis and cytotoxicity of a new set of dendrimer-drug conjugates as tumor therapeutic agents. Gust, R; Scheffler, H; Scutaru, AM; Wenzel, M; Wolber, G, 2010)	0.64
"Dose reduction and shortening of duration of perfusion in isolated limb perfusion with TNF-α and Melphalan (TM-ILP) are associated with less systemic toxicity and seem to be safe and effective on short-term."	( TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome. Bastiaannet, E; Hoekstra, HJ; Hoven-Gondrie, ML; Suurmeijer, AJ; van Ginkel, RJ, 2011)	0.59
"Dose reduction and shorter duration of TM-ILP seem to be safe and effective regarding long-term patient outcome, as 5-year local control rates and (limb)-survival are not compromised."	( TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome. Bastiaannet, E; Hoekstra, HJ; Hoven-Gondrie, ML; Suurmeijer, AJ; van Ginkel, RJ, 2011)	0.37
" In conclusion, the new BeEAM regimen is safe and effective for heavily pretreated lymphoma patients."	( BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Caballero, MD; Capria, S; Cuberli, F; Falcioni, S; Ferrara, F; Galieni, P; Gaudio, F; Gherlinzoni, F; Giardini, C; Gobbi, M; Isidori, A; Malerba, L; Meloni, G; Ocio, EM; Rocchi, M; Santoro, A; Sarina, B; Specchia, G; Stefani, PM; Visani, G, 2011)	0.63
" In both arms, greater rates of severe hematologic adverse events were associated with RI (eGFR < 50 mL/min), however, therapy discontinuation rates were unaffected."	( Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I, 2011)	0.65
"This technique is potentially safe and effective at a low cost and may play a promising role, especially in the treatment of recurrent and/or resistant vitreous disease in retinoblastoma, as an alternative to enucleation and/or external beam radiotherapy."	( Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track. Balmer, A; Beck-Popovic, M; Gaillard, MC; Moulin, AP; Munier, FL; Soliman, S, 2012)	0.38
" Unfortunately, recent clinical reports associate adverse vascular toxicities with SSIOAC using melphalan, the most commonly used chemotherapeutic."	( Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis. Haik, BG; Jackson, JS; Johnson, D; Mandrell, TD; Soderland, C; Steinle, JJ; Stewart, CF; Thompson, KE; Toutounchian, J; Wang, F; Williams, JS; Wilson, MW; Yates, CR; Zhang, Q, 2012)	0.6
" Palifermin has permitted safe dose escalation of melphalan up to 180 mg/m(2) in patients with RI."	( Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: resul Abidi, MH; Abrams, J; Agarwal, R; Al-Kadhimi, Z; Ayash, L; Cronin, S; Deol, A; Lum, L; Ratanatharathorn, V; Uberti, J; Ventimiglia, M; Zonder, J, 2012)	2.07
" In an attempt to design an efficacious and safe prehematopoietic stem cell transplantation conditioning regimen, we investigated the cytotoxicity of the combination of busulfan (B), melphalan (M), and gemcitabine (G) in lymphoma cell lines in the absence or presence of drugs that induce epigenetic changes."	( Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Andersson, BS; Champlin, RE; Li, Y; Murray, D; Nieto, Y; Valdez, BC; Wang, G, 2012)	0.57
" (4) No fever, septicemia and other systemic toxic effects occurred."	( [Analysis on the safety of ophthalmic artery cannulation for intra-arterial chemotherapy in 42 patients with intraocular stage retinoblastoma]. Li, YS; Liu, HY; Liu, QL; Mao, GS; Miao, LX; Sun, YF; Wang, J; Wang, XL; Wang, YF; Yang, XJ; Yuan, HL; Zhao, F, 2012)	0.38
"Ophthalmic artery cannulation for IAC is a safe and effective method in treating intraocular stage retinoblastoma."	( [Analysis on the safety of ophthalmic artery cannulation for intra-arterial chemotherapy in 42 patients with intraocular stage retinoblastoma]. Li, YS; Liu, HY; Liu, QL; Mao, GS; Miao, LX; Sun, YF; Wang, J; Wang, XL; Wang, YF; Yang, XJ; Yuan, HL; Zhao, F, 2012)	0.38
" We conclude that FBM-A is an effective and safe conditioning regimen for adults up to age 69 with hematologic malignancies who have low-, intermediate-, or high-risk scores according to the DRI."	( Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte ant Adams, RH; Betcher, JA; Dueck, AC; Fauble, VD; Khera, N; Klein, JL; Leis, JF; Noel, P; Reeder, CB; Slack, JL; Sproat, LO, 2013)	0.6
"Ten studies with original IViT ocular side effect data were included in this systematic review."	( Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review. Mohney, BG; Smith, BD; Smith, SJ, 2014)	0.4
" We conclude that with appropriate patient selection and a risk-adapted treatment approach, HDM/SCT is safe and effective in patients with AL amyloidosis and cardiac involvement."	( Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement. Berk, JL; Doros, G; Girnius, S; Meier-Ewert, HK; Quillen, K; Ruberg, FL; Sanchorawala, V; Seldin, DC; Sloan, JM, 2014)	0.68
" In an effort to minimize these adverse effects, we conducted bone marrow transplantation (BMT) from unrelated volunteer donors using a conditioning regimen without BU or TBI."	( Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N, 2014)	0.64
"This conditioning regimen of FLAG combined with L-PAM (which did not contain BU and TBI) was associated with good outcomes and minimal late adverse effects in children with acute leukemia who have undergone allogeneic BMT from unrelated volunteer donors."	( Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N, 2014)	0.64
"In this retrospective study, a chemotherapy protocol using dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) was evaluated for efficacy and adverse event profile as a first line rescue protocol in 86 client-owned dogs previously treated with a CHOP-based protocol."	( The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma. Monteith, G; Parsons-Doherty, M; Poirier, VJ, 2014)	0.88
"0-graded systemic adverse events."	( Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma. Abramson, DH; Brodie, SE; Dunkel, IJ; Francis, JH; Gobin, YP; Marr, BP; Tendler, I, 2015)	0.42
" The incidence of grade 3 mucositis and stomatitis was low (10% and 5%, respectively) with no grade 4 mucositis or stomatitis reported (graded according to National Cancer Institute Common Terminology Criteria for Adverse Events)."	( A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. Aljitawi, OS; Allen, LF; Arce-Lara, C; Bhat, G; Callander, N; Hari, P; Nath, R; Stockerl-Goldstein, K, 2015)	0.63
"While no toxic effects for a concentration of 80 μg/ml were observed, both b- and a-waves were significantly reduced after application of 160 (b-wave 43."	( Investigating short-term toxicity of melphalan in a model of an isolated and superfused bovine retina. Aisenbrey, S; Bartz-Schmidt, KU; Hagemann, U; Hofmann, K; Januschowski, K; Krupp, C; Mueller, S; Schnichels, S; Spitzer, MS, 2016)	0.71
"Epiretinal or intraretinal concentrations of 80-μg/ml melphalan do not cause toxic effects in this in vitro model."	( Investigating short-term toxicity of melphalan in a model of an isolated and superfused bovine retina. Aisenbrey, S; Bartz-Schmidt, KU; Hagemann, U; Hofmann, K; Januschowski, K; Krupp, C; Mueller, S; Schnichels, S; Spitzer, MS, 2016)	0.96
" Although this technique can save eyes otherwise destined for enucleation, ocular salvage may be accompanied by local toxic effects."	( Anterior Ocular Toxicity of Intravitreous Melphalan for Retinoblastoma. Abramson, DH; Brodie, SE; Francis, JH; Marr, BP, 2015)	0.68
" We report a series of 5 patients from this cohort who developed anterior segment toxic effects."	( Anterior Ocular Toxicity of Intravitreous Melphalan for Retinoblastoma. Abramson, DH; Brodie, SE; Francis, JH; Marr, BP, 2015)	0.68
"Intravitreous injection of melphalan may result in toxic effects on the anterior segment of the eye, in addition to retinal abnormalities, and appears to be more common in the meridian of the injection where the drug concentration is highest."	( Anterior Ocular Toxicity of Intravitreous Melphalan for Retinoblastoma. Abramson, DH; Brodie, SE; Francis, JH; Marr, BP, 2015)	0.98
"The purpose of this study is to evaluate the fluctuations of coagulation parameters during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) and confirm beyond doubt that epidural anaesthesia is safe with this type of operations."	( Lack of significant intraoperative coagulopathy in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) indicates that epidural anaesthesia is a safe option. Alevizos, L; Daskalou, T; Eleftheriadis, S; Iatrou, C; Korakianitis, O; Mavroudis, C; Stamou, K; Tentes, AA; Vogiatzaki, T, 2015)	0.42
"Our results support the belief that epidural analgesia is a safe option in cytoreductive surgery and HIPEC despite certain intraoperative fluctuations in coagulation parameters."	( Lack of significant intraoperative coagulopathy in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) indicates that epidural anaesthesia is a safe option. Alevizos, L; Daskalou, T; Eleftheriadis, S; Iatrou, C; Korakianitis, O; Mavroudis, C; Stamou, K; Tentes, AA; Vogiatzaki, T, 2015)	0.42
" We, therefore, investigated the cellular toxic effects of melphalan, topotecan and carboplatin on the RPE in a cell culture model."	( Toxic effects of melphalan, topotecan and carboplatin on retinal pigment epithelial cells. Aisenbrey, S; Hagemann, U; Januschowski, K; Schnichels, S; Schrader, M; Süsskind, D, 2016)	1.02
"Morphological monitoring and toxicity assays indicate a direct toxic effect of melphalan and the other two cytostatic drugs on ARPE19 cells."	( Toxic effects of melphalan, topotecan and carboplatin on retinal pigment epithelial cells. Aisenbrey, S; Hagemann, U; Januschowski, K; Schnichels, S; Schrader, M; Süsskind, D, 2016)	1
" We conclude that OP administration of BEAM conditioning is safe and may offer significant advantages, including decreased length of hospitalization, reduced costs, decreased risks for severe toxicities and infectious complications, and likely improvement in patient satisfaction and quality of life."	( Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective. Baran, A; Barr, PM; Becker, MW; Friedberg, JW; Liesveld, JL; Milner, LA; Phillips, GL; Reid, RM; Wedow, L, 2016)	0.43
" The adverse events during TAS were generally tolerable, but 39 (10."	( Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. Choi, YS; Eom, HS; Han, JJ; Kang, HJ; Kim, HJ; Kim, K; Kim, MK; Kim, SH; Kwon, J; Lee, JH; Lee, JJ; Lee, JO; Lee, WS; Min, CK; Moon, JH; Yoon, DH; Yoon, SS, 2017)	0.46
" Peri- and post-procedural adverse events (AE) were registered."	( Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study. Brüning, R; Engelke, C; Gebauer, B; Koch, SA; Lotz, G; Radeleff, B; Scholtz, JE; Vogel, A; Vogl, TJ; Wacker, F; Willinek, W; Zeile, M, 2017)	0.46
" The common adverse events (AEs) were in line with the well-known toxicity profiles associated with VMP."	( A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. Bae, SB; Bae, SH; Cho, DY; Choi, CW; Do, YR; Hyun, MS; Jeong, SH; Jo, DY; Joo, YD; Kim, BS; Kim, H; Kim, HG; Kim, HJ; Kim, JA; Kim, JS; Kim, K; Kim, KH; Kim, MK; Kim, SH; Kim, SJ; Kim, SY; Kim, YS; Kwak, JY; Lee, HS; Lee, JH; Lee, JJ; Lee, JO; Lee, MH; Lee, SM; Lee, WS; Lim, SN; Min, CK; Moon, JH; Mun, YC; Nam, SH; Park, JS; Park, KW; Park, MR; Park, SK; Shin, HJ; Song, MK; Yi, HG; Yoon, SS, 2017)	0.67
"HAIC offers a safe and effective salvage treatment strategy in heavily pretreated patients with LMBC and no further treatment options."	( Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer: efficacy, safety and prognostic parameters. Bogner, S; Peis, MW; Reinboldt, MP; Schuler, M; Tewes, M; Theysohn, JM; Welt, A, 2017)	0.46
"The ILI technique proved safe and effective in elderly patients."	( Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study. Barbour, A; Coventry, BJ; Giles, MH; Henderson, MA; Kroon, HM; Paddle, P; Serpell, J; Smithers, BM; Speakman, D; Thompson, JF; Wall, M, 2017)	0.46
"1 and Common Terminology Criteria for Adverse Events (CTCAE) v4."	( Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. Choi, J; Gangi, A; Gupta, S; Hardman, D; Karydis, I; Ottensmeier, C; Pearce, N; Sileno, S; Stedman, B; Takhar, A; Thomas, K; Wheater, MJ; Wilson, I; Zager, JS, 2018)	0.76
" A less toxic regimen might improve the outcome of patients with lymphoma after transplantation."	( High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity. Boehm, A; Keil, F; Koller, E; Menschel, E; Moestl, M; Noesslinger, T; Panny, M; Simanek, R, 2018)	0.48
" Adverse events (AEs) and toxicity were evaluated."	( Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Brüning, R; Ferrucci, PF; Kirstein, MM; Manns, MP; Marquardt, S; Prevoo, W; Radeleff, B; Trillaud, H; Tselikas, L; Vicente, E; Vogel, A; Wacker, FK; Wiggermann, P; Zeile, M, 2019)	0.76
"PHP is a standardised and safe procedure that provides promising response rates and survival data in patients with iCCA, especially in non-metastatic disease."	( Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Brüning, R; Ferrucci, PF; Kirstein, MM; Manns, MP; Marquardt, S; Prevoo, W; Radeleff, B; Trillaud, H; Tselikas, L; Vicente, E; Vogel, A; Wacker, FK; Wiggermann, P; Zeile, M, 2019)	0.76
" • PHP is a standardised and safe procedure that provides promising response rates and survival data in patients with intrahepatic cholangiocarcinoma (iCCA), especially in non-metastatic disease."	( Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Brüning, R; Ferrucci, PF; Kirstein, MM; Manns, MP; Marquardt, S; Prevoo, W; Radeleff, B; Trillaud, H; Tselikas, L; Vicente, E; Vogel, A; Wacker, FK; Wiggermann, P; Zeile, M, 2019)	0.76
" Although considered bioequivalent, there remains limited literature directly evaluating the adverse events between the two agents."	( Evaluating the adverse effects of melphalan formulations. Glotzbecker, B; Laubach, J; McDonnell, AM; Ni, J; Soiffer, R; Xiang, E, 2019)	0.79
" These data may assist in better understanding the anticipated adverse effects of a high-dose melphalan conditioning therapy."	( Evaluating the adverse effects of melphalan formulations. Glotzbecker, B; Laubach, J; McDonnell, AM; Ni, J; Soiffer, R; Xiang, E, 2019)	1.01
"Isolated limb perfusion (ILP) is a safe and well-established treatment for in-transit metastases of melanoma."	( Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma. Belgrano, V; Katsarelias, D; Mattsson, J; Nilsson, JA; Olofsson Bagge, R; Pettersson, J, 2019)	0.51
"UL-ILI is safe to perform and effective, resulting in low limb toxicity."	( Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study. Barbour, A; Coventry, BJ; Henderson, MA; Kroon, HM; Serpell, J; Smithers, BM; Thompson, JF, 2019)	0.51
" Current treatments have many adverse effects."	( Low retinal toxicity of intravitreal carboplatin associated with good retinal tumour control in transgenic murine retinoblastoma. Cassoux, N; Doz, F; Fréneaux, P; Leboucher, S; Lemaître, S; Poyer, F; Thomas, CD, 2020)	0.56
"Patients with primary HLH transplanted 2009-2016 after treosulfan- or melphalan-based conditioning regimens were analyzed in a retrospective multicenter study for survival, engraftment, chimerism, and adverse events."	( Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning. Albert, MH; Bader, P; Beier, R; Burkhardt, B; Chada, M; Ehl, S; Greil, J; Gruhn, B; Janka, G; Kühl, JS; Lang, P; Lehmberg, K; Meisel, R; Müller, I; Ozga, AK; Schlegel, PG; Schulz, A; Seidel, M; Speckmann, C; Sykora, KW; Wawer, A; Wössmann, W; Wustrau, K, 2020)	0.79
"ILI is safe and effective to treat melanoma in-transit metastases."	( Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. Barbour, A; Beasley, GM; Coventry, BJ; Daou, H; Delman, KA; Farley, CR; Farma, JM; Farrow, NE; Henderson, MA; Kenyon-Smith, TJ; Kroon, HM; Lowe, MC; Miura, JT; Mosca, PJ; Mullen, D; Potdar, A; Serpell, J; Smithers, BM; Speakman, D; Sun, J; Teras, J; Thompson, JF; Tyler, DS; Zager, JS, 2020)	0.56
" The experimental programme was safe and active in a multicentre setting, with only two episodes of grade 4 non-haematological toxicity (hepatotoxicity and mucositis), and no cases of systemic fungal infections; two patients died of toxicity (bacterial infections)."	( A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial. Allione, B; Calimeri, T; Cattaneo, C; Donadoni, G; Facchetti, F; Ferrari, D; Ferreri, AJM; Foppoli, M; Fumagalli, L; Lleshi, A; Pecciarini, L; Ponzoni, M; Re, A; Rigacci, L; Rossi, G; Sassone, M; Spina, M; Verga, L, 2021)	0.62
"Current melphalan-based regimens for intravitreal chemotherapy for retinoblastoma vitreous seeds are effective but toxic to the retina."	( Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model. Bogan, CM; Boyd, KL; Bridges, TM; Calcutt, MW; Chen, SC; Daniels, AB; Friedman, DL; Kaczmarek, JV; Lindsley, CW; Liu, Q; Liu, X; Pierce, JM; Richmond, A; Tao, YK, 2021)	1.06
"To define a safe treatment dose of ipilimumab (IPI) and nivolumab (NIVO) when applied in combination with percutaneous hepatic perfusion with melphalan (M-PHP) in metastatic uveal melanoma (mUM) patients (NCT04283890), primary objective was defining a safe treatment dose of IPI/NIVO plus M-PHP."	( Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial. Blank, CU; Burgmans, MC; Jonker-Bos, MA; Kapiteijn, E; Lutjeboer, J; Martini, CH; Roozen, CFM; Speetjens, FM; Sporrel-Blokland, M; Tijl, FGJ; Tong, TML; van der Meer, RW; van Erkel, AR; van Persijn van Meerten, EL; van Rijswijk, CSP; Zoethout, RWM, 2023)	1.51
" Grade III/IV adverse events (AE) were observed in 2/3 patients in cohort 1 and in 3/4 patients in cohort 2, including Systemic Inflammatory Response Syndrome (SIRS), febrile neutropenia and cholecystitis."	( Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial. Blank, CU; Burgmans, MC; Jonker-Bos, MA; Kapiteijn, E; Lutjeboer, J; Martini, CH; Roozen, CFM; Speetjens, FM; Sporrel-Blokland, M; Tijl, FGJ; Tong, TML; van der Meer, RW; van Erkel, AR; van Persijn van Meerten, EL; van Rijswijk, CSP; Zoethout, RWM, 2023)	1.31
"Combining M-PHP with IPI/NIVO was safe in this small cohort of patients with mUM at a dose of IPI 1 mg/kg and NIVO 3 mg/kg."	( Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial. Blank, CU; Burgmans, MC; Jonker-Bos, MA; Kapiteijn, E; Lutjeboer, J; Martini, CH; Roozen, CFM; Speetjens, FM; Sporrel-Blokland, M; Tijl, FGJ; Tong, TML; van der Meer, RW; van Erkel, AR; van Persijn van Meerten, EL; van Rijswijk, CSP; Zoethout, RWM, 2023)	1.31
" The most common adverse effects were febrile neutropenia (98%), mucositis (72%) and colitis (60%)."	( Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation. Boudreault, JS; Feng, X; Plante, MÉ, )	0.34
"For adult patients with MM undergoing aHCT, the outpatient setting is safe and reduces the total length of hospital stay and thus overall transplant costs."	( Effectiveness, Safety, and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma. Edwards, K; Hashmi, H; Maldonado, A; Marini, J; Neppalli, A; Weeda, E, 2023)	0.91

Excerpt	Reference	Relevance
"9 mg) followed by a second dose on day 2, calculated on the basis of pharmacokinetic data to achieve a target area under the concentration-time curve (AUC)."	( Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma. Ardiet, C; Chauvin, F; Clavel, M; Guastalla, JP; Ploin, DY; Rebattu, P; Tranchand, B, 1992)	0.54
" The pharmacokinetic advantages of ILP can be quantified by the ratio of AUCa/AUCs, median value 37."	( The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. Blackie, R; Burnside, G; Byrne, DS; Hughes, J; Kerr, DJ; MacKie, RM; McKay, AJ; Scott, RN, 1992)	0.52
" bolus pharmacokinetic data."	( Pharmacokinetics of very high-dose oral melphalan in cancer patients. Alberts, DS; Asbury, RF; Boros, L; Goodman, TL; Hickox, DE; Peng, YM; Penn, TE, 1990)	0.55
" In this patient, melphalan pharmacokinetics was different from that of patients without important renal dysfunction for the area under the concentration curve (1,324 mg."	( [Pharmacokinetics of high-dose melphalan (200 mg/m2) in a case of total renal insufficiency]. Ardiet, C; Biron, P; Mercatello, A; Philip, T; Tranchand, B, 1988)	0.89
" administration were determined in 17 patients with various malignancies for the purpose of assessing interpatient and intrapatient pharmacokinetic variability."	( Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. Beschorner, JC; Bitran, JD; Choi, KE; Fullem, LJ; Golick, JA; Ratain, MJ; Williams, SF, 1989)	0.54
" No correlation was found between GFR and the terminal plasma half-life time."	( Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients. Ehrsson, H; Eksborg, S; Mellstedt, H; Osterborg, A; Wallin, I, 1989)	0.58
" When L-PAM was given 24 h before DDP, the elimination half-life (t 1/2 beta), plasma clearance (Clp), and volume of distribution (Vd beta) of L-PAM were, respectively: 46."	( Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients. Cavalli, F; D'Incalci, M; Sessa, C; Willems, Y; Zucchetti, M, 1988)	0.27
"The pharmacokinetic parameters of the alkylating agent melphalan were determined in 15 children and 11 adults with advanced malignant solid tumors."	( Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases. Ardiet, C; Biron, P; Philip, T; Rebattu, P; Tranchand, B, 1986)	0.78
" The elimination half-life (t1/2 less than 80 min) allows autologous bone marrow transplantation 24 h after the drug administration."	( Pharmacokinetics of high-dose melphalan in children and adults. Gouyette, A; Hartmann, O; Pico, JL, 1986)	0.56
" The apparent plasma elimination half-life (t1/2) was 17."	( The effect of systemic hyperthermia on melphalan pharmacokinetics in mice. Bleehen, NM; Donaldson, J; Honess, DJ; Workman, P, 1985)	0.54
" The initial loss with a half-life (t1/2) of approximately 5 to 10 min is interpreted as rapid uptake of melphalan by the tissue of the perfused extremity."	( Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Briele, HA; Das Gupta, TK; Djuric, M; Jung, DT; Mortell, T; Patel, MK, 1985)	0.81
" No significant difference was seen in pharmacokinetic parameters between patients undergoing and not undergoing forced diuresis."	( High dose melphalan in children with advanced malignant disease. A pharmacokinetic study. Baurain, R; Cornu, G; de Selys, A; Ninane, J; Trouet, A, 1985)	0.67
" Such a pharmacokinetic effect could account for part of the potentiation of MEL and CY action observed in tumours with large single doses of MISO."	( The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse. Hinchliffe, M; McNally, NJ; Stratford, MR, 1983)	0.51
"A pharmacokinetic study of high dose intravenous melphalan, 180 mg/m2, was performed in eight patients."	( Pharmacokinetics of high dose melphalan. Hersh, MR; Knight, WA; Kuhn, JG; Ludden, TM, 1983)	0.81
"0166 min-1, Tmax = 59."	( The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. Hamilton, P; Lennard, A; Rawlins, MD; Woodhouse, KW, 1983)	0.57
" Mass spectrometry confirmation of each drug from patient sample separations is presented to provide unambiguous identification for valid pharmacokinetic parameter determination."	( HPLC, MS, and pharmacokinetics of melphalan, bisantrene and 13-cis retinoic acid. Alberts, DS; Davis, TP; Goodman, GE; Peng, YM, 1982)	0.54
" The results are discussed in relation to the pharmacokinetic availability of drugs in the plasma compartment of patients treated by different therapuetic regimens."	( Pharmacokinetic approach to in vitro testing of ovarian cancer cell sensitivity. Balconi, G; D'Incalci, M; Erba, E; Garattini, S; Morasca, L; Ottolenghi, L; Salmona, A, 1980)	0.26
" On a pharmacokinetic basis, chlorambucil's greater in vitro stability, its more rapid and predictable systemic availability after oral dosing, and its extremely low urinary excretion make it a more predictable alkylating agent for clinical use than melphalan, especially for patients with reduced renal function."	( Comparative pharmacokinetics of chlorambucil and melphalan in man. Alberts, DS; Chang, SY; Chen, HS; Evans, TL; Larcom, BJ, 1980)	0.7
"The development of time-dependent pharmacodynamic models in cancer chemotherapy has been extremely limited."	( Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. Brennan, J; Gallo, JM; Halbherr, T; Hamilton, TC; Laub, PB; O'Dwyer, PJ; Ozols, RF, 1995)	0.48
" Pharmacokinetic sampling was performed so as to describe the clearance of melphalan in this population and in an attempt to carry out pharmacodynamic modeling for toxicity and response."	( Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer. Ambinder, RM; Egorin, MJ; Ellis, PG; Jodrell, DI; Kreis, W; Smith, DC; Trump, DL; Zuhowski, EG, 1993)	0.76
" For all patients, AUC, CIT, Vdss, t1/2 beta and MRT were significantly correlated with creatinine clearance; the different pharmacokinetic parameters calculated showed great interindividual variations."	( Pharmacokinetics of high-dose melphalan in adults: influence of renal function. Harousseau, JL; Kergueris, MF; Larousse, C; Milpied, N; Moreau, P, )	0.42
" The present study showed that previous carboplatin administrations induced wide variations of melphalan pharmacokinetic parameters between the two administrations."	( [Effect of carboplatin on the pharmacokinetics of melphalan administered intravenously]. Ardiet, C; Biron, P; Bouffet, E; Brunat-Mentigny, M; Nasri, F; Philip, I; Tranchand, B, 1994)	0.76
" Pharmacokinetic parameters (mean values of steady-state volume of distribution 14."	( A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. Bataille, R; Bulabois, CE; Harousseau, JL; Kergueris, MF; Larousse, C; Le Tortorec, S; Mahé, B; Milpied, N; Moreau, P; Rapp, MJ, 1996)	0.59
" This method was used to determine the pharmacokinetic parameters of melphalan following high-dose (140 mg/m2) intravenous administration in patients with advanced malignancies undergoing peripheral blood hematopoietic progenitor-cell transplantation."	( High-performance liquid chromatographic assay for melphalan in human plasma. Application to pharmacokinetic studies. Astre, C; Bressolle, F; Grosse, PY; Joulia, JM; Martel, P; Pinguet, F, 1996)	0.78
" Plasma levels of melphalan declined in a biexponential fashion with a mean terminal half-life of 83 minutes (range 52-168 minutes)."	( Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. Astre, C; Bressolle, F; Canal, P; Culine, S; Fabbro, M; Martel, P; Petit, I; Pinguet, F, )	0.73
"The optimal dosing schedule for melphalan therapy of recurrent malignant melanoma in isolated limb perfusions has been examined using a physiological pharmacokinetic model with data from isolated rat hindlimb perfusions (IRHP)."	( Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb. Roberts, MS; Smithers, BM; Wu, ZY, 1997)	2.02
" The time course of melphalan concentrations in perfusate and tissues during a 60-min melphalan perfusion and 30-min drug-free washout in the single-pass perfused rat hindlimb was examined using a physiologically based pharmacokinetic model."	( Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. Roberts, MS; Smithers, BM; Wu, ZY, 1997)	0.89
" Three patients with severe renal impairment first received a low test dose of MEL (16 mg/m2) for pharmacokinetic studies."	( Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Alberts, DS; Barlogie, B; Bracy, D; Dorr, RT; Jagannath, S; Johnson, C; Meyers, R; Roe, DJ; Tricot, G; Vesole, DH, 1996)	0.56
" The temperature of the perfusate plasma and tissue, pH, administration method, and flow rate were modified and compared with regard to their influence on pharmacokinetic parameters."	( Pharmacokinetics of melphalan in isolated limb perfusion. Goehl, J; Hohenberger, W; Loos, U; Norda, A; Sastry, M, 1999)	0.63
"The objectives of the present study were to determine the following: (a) the maximum tolerated dose (MTD) of melphalan using a 24-h continuous infusion; (b) the clinical toxicity; and (c) the pharmacokinetic characteristics of melphalan at each dose level."	( A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies. Astre, C; Bressolle, F; Chevillard, C; Culine, S; Fabbro, M; Pinguet, F; Serre, MP, 2000)	0.79
"Pharmacokinetic and pharmacodynamic data were collected in 17 women entered in a phase II trial of sequential HDP, and high-dose melphalan and cyclophosphamide/thiotepa/carboplatin."	( The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. Balmaceda, CM; Egorin, MJ; Hesdorffer, CS; Huang, M; Kaufman, E; Papadopoulos, KP; Troxel, AB; Vahdat, LT, 2001)	0.52
" The degree of neurotoxicity subsequent to HDP was associated with the degree of baseline neuropathy but was not predictable from pharmacokinetic parameters."	( The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. Balmaceda, CM; Egorin, MJ; Hesdorffer, CS; Huang, M; Kaufman, E; Papadopoulos, KP; Troxel, AB; Vahdat, LT, 2001)	0.31
" We report pharmacokinetic data from 12 patients treated by ILI for tumours of the limb in Brisbane."	( Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Anissimov, YG; Roberts, MS; Siebert, GA; Smithers, BM; Thompson, JF; Wu, ZY, 2001)	0.58
"By studying the pharmacokinetic data of melphalan in the circuit and in the systemic circulation, we were able to validate the 99mTc procedure used during clinical perfusion."	( Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique. Buffa, E; Cattel, L; Ceruti, M; Cesana, P; De Simone, M; Dosio, F; Novello, S, )	1.84
"In order to control busulfan pharmacokinetic variability and toxicity, a specific monitoring protocol was instituted in our bone marrow transplant BMT paediatric patients including a test dose, daily Bayesian forecasting of busulfan plasma levels, and Bayesian individualization of busulfan dosage regimens."	( Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Aulagner, G; Bertrand, Y; Bleyzac, N; Dai, Q; Galambrun, C; Janoly, A; Jelliffe, RW; Magron, P; Maire, P; Martin, P; Souillet, G, 2001)	0.31
"166Ho-DOTMP has physical and pharmacokinetic characteristics compatible with high-dose myeloablative treatment of multiple myeloma."	( High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. Bensinger, W; Durack, LD; Eary, JF; Fritzberg, A; Rajendran, JG; Vernon, C, 2002)	0.31
" The population pharmacokinetic analysis was performed using NONMEM through the graphical interface Visual-NM."	( Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. Astre, C; Bressolle, F; Culine, S; Fabbro, M; Mougenot, P; Pinguet, F; Poujol, S, 2004)	0.61
"The population pharmacokinetic approach developed in this study should allow dosage to be individualized in order to decrease toxicity while maintaining good efficacy."	( Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. Astre, C; Bressolle, F; Culine, S; Fabbro, M; Mougenot, P; Pinguet, F; Poujol, S, 2004)	0.61
" The pharmacokinetic study showed that pelvic SFP was associated with a leakage rate higher than femoral SFP (38% vs 28%)."	( Hypoxic antiblastic stop-flow perfusion: clinical outcome and pharmacokinetic findings. Bertolo, S; Casara, D; Darisi, T; Foletto, M; Lise, M; Minante, M; Miotto, D; Mocellin, S; Nitti, D; Ori, C; Rossi, CR, 2004)	0.32
"3-18 years) and determine whether any clinical factors affect the pharmacokinetic parameters Additionally, to examine whether a test melphalan dose can predict the pharmacokinetics of a full dose, when there are 5 intervening days of carboplatin therapy."	( Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. Earl, JW; Montgomery, K; Nath, CE; Shaw, PJ, 2005)	1.98
" Pharmacodynamic correlations were noted between the docetaxel area under the curve and peripheral neuropathy or stomatitis."	( Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. Barón, AE; Bearman, SI; Cagnoni, PJ; Gustafson, D; Jones, RB; Long, M; Matthes, S; McSweeney, PA; Nieto, Y; Shpall, EJ, 2005)	0.57
" The use of heated intraoperative intraperitoneal melphalan may provide a pharmacokinetic and clinical advantage in this group of gastrointestinal cancer patients who cannot be made cancer-free with cytoreductive surgery."	( Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan. Stuart, OA; Sugarbaker, PH, 2007)	0.82
"In the present work, we report on the results of our pilot study of hyperthermic isolated hepatic perfusion (IHP) with melphalan alone for patients with unresectable metastatic liver tumors refractory to conventional treatments, with particular regard to the correlation between pharmacokinetic findings and hepatic toxicity."	( Correlation between melphalan pharmacokinetics and hepatic toxicity following hyperthermic isolated liver perfusion for unresectable metastatic disease. Casara, D; Corazzina, S; Da Pian, P; Forlin, M; Innocente, F; Lise, M; Mocellin, S; Nitti, D; Ori, C; Pilati, P; Rossi, CR; Ujka, F, 2007)	0.87
"To develop a population pharmacokinetic model for melphalan in children with malignant diseases and to evaluate limited sampling strategies for melphalan."	( Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Earl, JW; Montgomery, K; Nath, CE; Shaw, PJ, 2007)	0.88
" Population pharmacokinetic modelling was performed with the NONMEM software."	( Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Earl, JW; Montgomery, K; Nath, CE; Shaw, PJ, 2007)	0.63
"A population pharmacokinetic model for melphalan has been developed and validated and may now be used in conjunction with pharmacodynamic data to develop safe and effective dosing guidelines in children with malignant diseases."	( Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Earl, JW; Montgomery, K; Nath, CE; Shaw, PJ, 2007)	0.89
" As melphalan is a phenylalanine derivative, the pharmacokinetic variability may be determined by genetic polymorphisms in the L-type amino acid transporters LAT1 (SLC7A5) and LAT2 (SLC7A8)."	( Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan. Brockmöller, J; Heider, U; Hohloch, K; Kaiser, R; Kühne, A; Muhlke, S; Niere, W; Overbeck, T; Schirmer, M; Sezer, O; Trümper, L, 2007)	1.1
" A high interindividual pharmacokinetic variability was observed in 84 patients."	( Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. Brockmöller, J; Heider, U; Hohloch, K; Kaiser, R; Kühne, A; Meineke, I; Muhlke, S; Niere, W; Overbeck, T; Sezer, O; Trümper, L, 2008)	0.63
" We present the results of pharmacokinetic analysis of a phase I and extension trial."	( Pharmacokinetics of isolated lung perfusion with melphalan for resectable pulmonary metastases, a phase I and extension trial. De Bruijn, E; Grootenboers, MJ; Hendriks, JM; Knibbe, CA; Schramel, FM; Stockman, B; van Boven, WJ; van Putte, B; Van Schil, PE; Vermorken, JB, 2007)	0.59
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"Population pharmacokinetic modelling (using NONMEM) was performed with total and unbound concentration-time data from 100 patients (36-73 years) who had received a median 192 mg m(-2) melphalan dose."	( Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Duffull, SB; Earl, J; Gurney, H; Hegarty, G; Joshua, D; Kerridge, I; Kwan, YL; McLachlan, AJ; Nath, CE; Presgrave, P; Shaw, PJ; Tiley, C; Trotman, J; Zeng, L, 2010)	0.84
" Pharmacokinetic studies were fitted to a linear, 2-compartment model in which dose reduction led to incomplete saturation of CD52 binding sites and greater antibody clearance."	( Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Bloor, A; Chakraverty, R; Clark, A; Clark, R; Collin, M; Crawley, C; Fielding, A; Hale, G; Johnson, P; Kottaridis, P; Mackinnon, S; Milligan, D; Morris, E; Orti, G; Parker, A; Peggs, K; Pettengell, R; Pettitt, A; Roughton, M; Shen, J; Snowden, J; Thomson, K, 2010)	0.36
" Pharmacokinetic parameters, including half-life, volume of distribution, clearance and extent of renal elimination of melphalan were essentially unchanged between the two formulations."	( Preclinical comparison of intravenous melphalan pharmacokinetics administered in formulations containing either (SBE)7 m-β-cyclodextrin or a co-solvent system. Charman, SA; Katneni, K; Koltun, M; McIntosh, MP; Morizzi, J; Shackleford, DM, 2010)	0.84
" Standard pharmacokinetic parameters were calculated and nonparametric testing was applied to assess the differences between aprepitant and placebo treatment."	( The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Burhenne, J; Egerer, G; Eisenlohr, K; Gronkowski, M; Mikus, G; Riedel, KD, 2010)	0.58
" In addition, AUC and terminal elimination half-life were not changed by aprepitant."	( The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Burhenne, J; Egerer, G; Eisenlohr, K; Gronkowski, M; Mikus, G; Riedel, KD, 2010)	0.58
"To evaluate the ability of a physiology-based pharmacokinetic (PBPK) model to predict the systemic drug exposure of high- and low-dose etoposide in children from a model developed with adult data."	( Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. Boos, J; Hempel, G; Kersting, G; Lippert, J; Willmann, S; Würthwein, G, 2012)	0.38
" This approach could be useful for planning pharmacokinetic studies in children."	( Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. Boos, J; Hempel, G; Kersting, G; Lippert, J; Willmann, S; Würthwein, G, 2012)	0.38
" Pharmacokinetic and biodistribution studies of the optimized formulation in comparison to the pure drug suspension were done using γ-scintigraphy on female Balb/c mice."	( Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan. Bali, V; Pathak, K; Rajpoot, P, 2012)	0.59
" In patients, a large variability in pharmacokinetic parameters was observed and it was explained mainly by body weight (P<0."	( Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. Abramson, DH; Asprea, M; Bramuglia, GF; Buitrago, E; Ceciliano, A; Chantada, GL; Fandino, A; Requejo, F; Schaiquevich, P; Taich, P; Torbidoni, A, 2012)	0.67
"Single-center, prospective, clinical pharmacokinetic study."	( Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma. Buitrago, E; Ceciliano, A; Chantada, GL; Fandino, A; Lucena, E; Romero, L; Sampor, C; Schaiquevich, P; Taich, P; Villasante, F, 2014)	0.66
" Plasma samples were obtained for pharmacokinetic studies, and a population approach via nonlinear mixed effects modeling was used."	( Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma. Buitrago, E; Ceciliano, A; Chantada, GL; Fandino, A; Lucena, E; Romero, L; Sampor, C; Schaiquevich, P; Taich, P; Villasante, F, 2014)	0.66
"Melphalan and topotecan pharmacokinetic parameters and efficacy and safety parameters."	( Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma. Buitrago, E; Ceciliano, A; Chantada, GL; Fandino, A; Lucena, E; Romero, L; Sampor, C; Schaiquevich, P; Taich, P; Villasante, F, 2014)	2.11
" Concomitant topotecan administration did not influence melphalan pharmacokinetic parameters."	( Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma. Buitrago, E; Ceciliano, A; Chantada, GL; Fandino, A; Lucena, E; Romero, L; Sampor, C; Schaiquevich, P; Taich, P; Villasante, F, 2014)	0.91
"Relationships between pharmacokinetic (PK) parameters of etoposide and toxicity survivals were reported in cancer patients treated at standard doses."	( Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). Bachy, E; Casasnovas, O; Freyer, G; Guitton, J; Hénin, E; Ribrag, V; Salles, G; Sebban, C; Tilly, H; Tod, M; You, B, 2015)	0.42
" Melphalan was quantitated in the biological samples using a validated high-performance liquid-chromatography technique and pharmacokinetic parameters were calculated by means of compartmental models."	( Pharmacokinetics of Melphalan After Intravitreal Injection in a Rabbit Model. Asprea, M; Buitrago, E; Chantada, G; Schaiquevich, P; Williams, G; Winter, U, 2016)	1.67
" Also pharmacokinetic advantage of melphalan over systemic administration of the drug was shown."	( [Melphalan pharmacokinetics during isolated limb regional perfusion in patients with skin melanoma and soft tissue sarcoma]. Gafton, GI; Gafton, IG; Kireeva, GS; Petrov, VG; Semiletova, YV; Senchik, KY; Zinoviev, GV, 2015)	1.6
"We performed an experimental study of busulfan and melphalan pharmacodynamic and pharmacokinetics in iron overloaded mice."	( Iron Overload Exacerbates Busulfan-Melphalan Toxicity Through a Pharmacodynamic Interaction in Mice. Bouligand, J; Daudigeos-Dubus, E; Deroussent, A; Kessari, R; Mercier, L; Munier, F; Opolon, P; Orear, C; Paci, A; Richard, C; Simonnard, N; Tou, B; Valteau-Couanet, D; Vassal, G, 2016)	0.96
" This clearance alteration was exacerbated in iron overloaded mice demonstrating a pharmacokinetic interaction."	( Iron Overload Exacerbates Busulfan-Melphalan Toxicity Through a Pharmacodynamic Interaction in Mice. Bouligand, J; Daudigeos-Dubus, E; Deroussent, A; Kessari, R; Mercier, L; Munier, F; Opolon, P; Orear, C; Paci, A; Richard, C; Simonnard, N; Tou, B; Valteau-Couanet, D; Vassal, G, 2016)	0.71
"Iron overload increases melphalan and busulfan-melphalan toxicity through a pharmacodynamic interaction and reveals a pharmacokinetic drug interaction between busulfan and melphalan."	( Iron Overload Exacerbates Busulfan-Melphalan Toxicity Through a Pharmacodynamic Interaction in Mice. Bouligand, J; Daudigeos-Dubus, E; Deroussent, A; Kessari, R; Mercier, L; Munier, F; Opolon, P; Orear, C; Paci, A; Richard, C; Simonnard, N; Tou, B; Valteau-Couanet, D; Vassal, G, 2016)	1.02
" Pharmacokinetic dosing of busulfan (Bu) is frequently done for myeloablative conditioning, but evidence for its use is limited in RIC transplants."	( Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. Al-Kali, A; Alkhateeb, HB; Damlaj, M; Gangat, N; Gastineau, DA; Hashmi, S; Hefazi, M; Hogan, WJ; Litzow, MR; Partain, DK; Patnaik, MM; Wolf, RC, 2016)	0.66
" From a population pharmacokinetic model, we identified that fat-free mass, hematocrit, and creatinine clearance were significant covariates, as reported previously."	( Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial. Benson, DM; Cho, YK; Devine, SM; Efebera, YA; Gao, Y; Hade, EM; Hofmeister, CC; Lamprecht, M; Li, J; Phelps, MA; Poi, M; Rosko, AE; Sborov, DW; Tackett, K; Wang, J; Williams, N, 2017)	0.76
" In addition, Cmax was associated with a progression-free survival advantage."	( Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. Choi, K; Han, S; Hong, T; Lee, J; Lee, SE; Min, CK; Park, GJ; Yim, DS, 2017)	0.46
"A pharmacokinetic study was performed in 5 melanoma patients treated with surgical IPP and five with percutaneous IPP."	( Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability. Clementi, M; Fiorentini, G; Giordano, AV; Guadagni, S; Marsili, L; Masedu, F; Palumbo, G; Valenti, M, 2017)	0.67
"The purpose of this study was to develop a population pharmacokinetic model and optimal sampling strategy."	( Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation. Anaissie, EJ; Chandra, S; Dong, M; Fukuda, T; McConnell, S; Mehta, PA; Mizuno, K; Vinks, AA, 2018)	0.7
"The developed pharmacokinetic model-based sparse sampling strategy promises to achieve the target area under the curve as part of precision dosing."	( Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation. Anaissie, EJ; Chandra, S; Dong, M; Fukuda, T; McConnell, S; Mehta, PA; Mizuno, K; Vinks, AA, 2018)	0.7
" A population pharmacokinetic model was built for carboplatin to evaluate various dosing formulas."	( Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. Boddy, AV; Duong, JK; Errington, J; Ladenstein, R; Nath, CE; Shaw, PJ; Veal, GJ, 2019)	0.76
"Allometric weight was the only significant, independent covariate for the pharmacokinetic parameters of carboplatin, etoposide and melphalan."	( Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. Boddy, AV; Duong, JK; Errington, J; Ladenstein, R; Nath, CE; Shaw, PJ; Veal, GJ, 2019)	0.96
"GFR did not appear to influence the pharmacokinetics of carboplatin after adjusting pharmacokinetic parameters for weight."	( Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. Boddy, AV; Duong, JK; Errington, J; Ladenstein, R; Nath, CE; Shaw, PJ; Veal, GJ, 2019)	0.76
" Population pharmacokinetic analyses were conducted to determine the pharmacokinetics of intravenous daratumumab in combination therapy versus monotherapy, evaluate the effect of patient- and disease-related covariates on drug disposition, and examine the relationships between daratumumab exposure and efficacy/safety outcomes."	( Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma. Belch, A; Capra, M; Clemens, PL; Dimopoulos, MA; Gomez, D; Ho, PJ; Iida, S; Jansson, R; Leiba, M; Medvedova, E; Min, CK; Schecter, J; Sonneveld, P; Sun, YN; Xu, XS; Zhang, L, 2018)	0.48
" We hypothesized either one or a combination of factors: (1) frailty (assessed by IMWG frailty score), (2) generic melphalan pharmacokinetic area under the curve (AUC) assessed by high-performance liquid chromatography, and (3) pharmacogenetics of glutathione S-transferase (GSTP1) assessed by Sanger sequencing, to be associated with toxicity and survival outcomes post auto-HCT."	( Impact of frailty, melphalan pharmacokinetics, and pharmacogenetics on outcomes post autologous hematopoietic cell transplantation for multiple myeloma. Jain, A; Kasudhan, KS; Khadwal, A; Lad, DP; Malhotra, P; Malhotra, S; Nampoothiri, RV; Patil, AN; Prakash, G; Varma, N; Varma, S; Verma Attri, S, 2019)	1.05
" Our aim was to establish a method of pharmacokinetic (PK) testing for real-time melphalan dose adjustments."	( Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant. Calip, GS; Galvin, JP; Hofmeister, CC; Johnson, JJ; Mahmud, N; Patel, P; Rondelli, D; Sweiss, K; Vemu, B; Wenzler, E, 2020)	1.01
" We performed a single-center, prospective pharmacokinetic study of 37 pediatric patients undergoing HCT from March 2015 to 2019."	( Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation. Apsel Winger, B; Chan, D; Dvorak, CC; Gobburu, JVS; Li, S; Long-Boyle, J; Lu, Y, 2022)	1.01
"There exists considerably large interpatient variability in pharmacokinetic exposure of high dose melphalan in multiple myeloma patients with hematopoietic stem-cell transplantation."	( Evaluating the Impacts of CYP3A41B and CYP3A53 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant. Cho, YK; Hofmeister, CC; Li, J; Phelps, MA; Poi, MJ; Sborov, DW, )	0.35

Excerpt	Reference	Relevance
" Cis-dichlorodiammineplatinum (II) may be effectively combined with sarcolysin."	( [Antitumor action of cis-dichlorodiammineplatinum(II) and the effectiveness of a combination with sarcolysine]. Konovalova, AL; Presnov, MA; Romanova, LF; Sof'ina, ZP; Stetsenko, AI, 1978)	0.26
" The effect of the immunopotentiator when used in combination with alkylating agents was greater than that seen when it was used with the antimetabolite 5-fluorouracil."	( The effect of Corynebacterium parvum in combination with 5-fluorouracil, L-phenylalanine mustard, or methotrexate on the inhibition of tumor growth. Fisher, B; Rubin, H; Saffer, E; Wolmark, N, 1976)	0.26
" BSO demonstrated in vivo antitumor activity in B16 melanoma-bearing mice prolonging survival by 29% and in combination with 3,4-DHBA resulted in a slight (48% versus 38%) increase in life span as compared to 3,4-DHBA alone."	( Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan. FitzGerald, GB; Prezioso, JA; Wick, MM, 1992)	0.49
" The cytotoxic drug combination of methotrexate and melphalan, or nifedipine alone (0."	( The effect of nifedipine alone or combined with cytotoxic chemotherapy on the mouse NC carcinoma in-vitro and in-vivo. Bennett, A; Chambers, E; Gaffen, JD; Stamford, IF; Tavares, IA, 1991)	0.53
"This preliminary analysis of a phase II study suggests that high-dose rTNF alpha can be administered with acceptable toxicity by ILP with dopamine and hyperhydration."	( High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. Delmotte, JJ; Ewalenko, P; Lejeune, FJ; Lienard, D; Renard, N, 1992)	0.5
"We reported previously that treatment of mice bearing MOPC-315 plasmacytoma with the drugs L-PAM (phenylalanine mustard) or 5-FU (5-fluorouracil), in combination with low doses of THF-gamma 2, was more effective in increasing their survival time than treatment with the drug alone."	( Therapeutic effectiveness against MOPC-315 plasmacytoma of low or high doses of the synthetic thymic hormone THF-gamma 2 in combination with an "immunomodulating" or a "non-immunomodulating" drug. Ben-Efraim, S; Burstein, Y; Harshemesh, H; Ophir, R; Pecht, M; Trainin, N, 1991)	0.28
" In addition, the influence on the therapeutic efficacy of the combination with diazoxide, causing a mild, reversible diabetes, and with insulin was investigated."	( Antineoplastic efficacy of melphalan and N-(2-chloroethyl)-N-nitrosocarbamoyl-omega-lysine, in combination with diazoxide or insulin in autochthonous mammary carcinoma of the Sprague-Dawley rat. Berger, MR; Fink, M; Klenner, T; Schmähl, D; Zelezny, O, 1990)	0.58
" There was little evidence that either form of treatment was superior in prolonging survival, for in one study the patients treated with a drug combination lived significantly longer than those treated with MP, while in another the reverse was true, and there was no difference in the survival of the two groups in the remaining 11 studies."	( Melphalan/prednisone versus drug combinations for plasma cell myeloma. Bergsagel, DE, 1989)	1.72
" This reversal was inhibited when menogarol was combined with melphalan."	( Synergistic combination of menogarol and melphalan and other two drug combinations. Adams, EG; Bhuyan, BK; Crampton, SL; Johnson, M, 1985)	0.78
" New methods of administration are being studied giving interferon alfa-2b as a single agent or in combination with cisplatin by the intraperitoneal route to patients with relapsing ovarian carcinomas limited to the peritoneal cavity."	( Overview of preclinical and clinical studies of interferon alfa-2b in combination with cytotoxic drugs. Welander, CE, 1987)	0.27
" SHDAAs, including doxorubicin (DOX), cyclophosphamide (CTX), carmustine (BCNU) and melphalan (L-PAM) were then combined with L-BSO in mice bearing P388, MOPC-315 or colon 38 tumors."	( Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice. Dorr, RT; Soble, MJ, )	0.56
" Vitamin A induces cytotoxic effects: in combination with melphalan (MELPH), as can be deduced from the resulted synergism on induction of SCEs, the produced cell division delay and the suppressed mitotic index; in combination with caffeine (CAF), producing synergism on induction of SCEs and suppressing the mitotic index; and in combination with MELPH and CAF, producing cell-cycle delays and reducing the mitotic index."	( Induction of sister-chromatid exchanges and cell-cycle delays in human lymphocytes by vitamin A alone or in combination with melphalan and caffeine. Dozi-Vassiliades, J; Granitsas, A; Mourelatos, D; Myrtsiotis, A, 1985)	0.72
" When ibuprofen was given in combination with a cytotoxic drug, the primary cytoreductive effect was that of the cytotoxic agent."	( Response of human adenocarcinoma to chemotherapy: as sole agents and in combination with sodium ibuprofen. Braly, PS; DiSaia, PJ; Stratton, JA, 1984)	0.27
" In this study we determined the activity and toxicity of melphalan in combination with another GST-activity inhibitor, sulfasalazine, an agent used to treat ulcerative colitis."	( Activity of melphalan in combination with the glutathione transferase inhibitor sulfasalazine. Awasthi, S; Awasthi, YC; Fields, L; Gupta, V; Jacobs, S; Jani, JP; Levitt, M; Singh, SV; Sreevardhan, M; Xu, BH, 1995)	0.91
" We have used clonogenic cell survival assays and DNA flow cytometry to examine the effect of paclitaxel combined with melphalan, thiotepa, or cisplatin on the survival and cell-cycle parameters of human lung A549 and breast MCF-7 adenocarcinoma cells."	( Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Cook, JA; Fisher, J; Liebmann, JE; Teague, D, 1994)	0.5
"In vitro and clinical studies have shown antineoplastic effects of hyperthermia alone and in combination with other treatment modalities."	( Total body hyperthermia in combination with etoposide and melphalan in a child with acute myelomonocytic leukemia. Dehnen, H; Göbel, U; Jürgens, H; Wessalowski, R; Willnow, U, 1994)	0.53
"Three hundred thirty-five previously untreated patients with multiple myeloma in clinical stages II and III entered a randomized trial comparing intermittent oral melphalan and prednisone (MP) therapy (n = 171) with MP in combination with natural (leukocyte-derived) alpha-interferon (MP/IFN) (n = 164)."	( Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Björeman, M; Björkholm, M; Brenning, G; Carlson, K; Celsing, F; Gahrton, G; Grimfors, G; Gyllenhammar, H; Hast, R; Osterborg, A, 1993)	0.74
"The purpose of the study was to determine the maximum tolerated dose of continuous infusion of high-dose VP-16 in combination with high-dose melphalan (HDM) for conditioning before autologous bone marrow transplantation (ABMT)."	( Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. Benhamou, E; Bonnay, M; Couanet, D; Hartmann, O; Plantaz, D; Pondarré, C; Valteau-Couanet, D; Vassal, G, 1996)	0.71
"To determine the efficacy of isolated limb perfusion (ILP) with tumor necrosis factor-alpha (TNF) in combination with interferon-gamma (IFN) and melphalan as induction therapy to render tumors resectable and avoid amputation in patients with nonresectable extremity soft tissue sarcomas (STS)."	( Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. Eggermont, AM; Hoekstra, HJ; Kroon, BB; Lejeune, FJ; Liénard, D; Schraffordt Koops, H; van Geel, AN, 1996)	0.71
" We report the use of high-dose carboplatin, with the dose based on glomerular filtration rate (GFR), combined with melphalan followed by autologous stem cell rescue in children with advanced stage or chemoresistant solid tumours."	( Melphalan combined with a carboplatin dose based on glomerular filtration rate followed by autologous stem cell rescue for children with solid tumours. Pinkerton, CR; Shaw, PJ; Yaniv, I, 1996)	1.95
" We determined the cytotoxicity of BSO (dose range 0-1000 microM) alone and in combination with L-PAM (dose range 0-0 microM) in a panel of 18 human neuroblastoma cell lines."	( Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines. Anderson, CP; Chan, W; Forman, HJ; Lui, RM; Park, CK; Reynolds, CP; Tian, L; Tsai, J, 1997)	0.55
"The most promising developments in the field of isolated limb perfusion have centred around the use of the recombinant cytokine tumour necrosis factor-alpha (rTNF-alpha) in combination with melphalan."	( Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system. Altermatt, HJ; Althaus, U; Furrer, M; Lejeune, FJ; Liénard, D; Ris, HB; Rüegg, C, 1997)	0.7
"Treatment with (131)I-MIBG in combination with myeloablative chemotherapy and hematopoietic stem-cell rescue is feasible with acceptable toxicity."	( Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. Braun, T; Ferrara, JL; Hubers, D; Hutchinson, RJ; Levine, JE; Matthay, KK; Shapiro, B; Shulkin, BL; Sisson, JC; Spalding, S; Yanik, GA, 2002)	0.31
" The majority of patients received total body irradiation (TBI) combined with either melphalan (56."	( Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation. Cavenagh, J; Cook, G; Hunter, A; Hunter, HM; Littlewood, T; Mahendra, P; Marks David, I; Pagliuca, A; Peggs, K; Potter, M; Powles, R; Rahemtulla, A; Russell, NH; Towlson, K; Williams, CD, 2005)	0.75
"The purpose of this study was to define the maximal tolerated dose (MTD), extramedullary toxicities, and pharmacokinetics of docetaxel combined with high-dose melphalan and carboplatin with autologous hematopoietic progenitor cell support."	( Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. Barón, AE; Bearman, SI; Cagnoni, PJ; Gustafson, D; Jones, RB; Long, M; Matthes, S; McSweeney, PA; Nieto, Y; Shpall, EJ, 2005)	0.77
"To evaluate the potential benefit of histamine combined with melphalan in the isolated limb perfusion (ILP) as an alternative to TNF-alfa and melphalan combination, for the treatment of irresectable soft tissue sarcomas of the limbs in Brown Norway (BN) rats."	( Histamine combined with melphalan in isolated limb perfusion for the treatment of locally advanced soft tissue sarcomas: preclinical studies in rats. Brunstein, F; Eggermont, AM; Ferreira, LM; Santos, ID; Ten Hagen, TL; van Tiel, ST, )	0.68
"Histamine combined with melphalan had a promising effect in the ILP warranting future studies to better explore the mechanism of action as well as its potential use in organ perfusion."	( Histamine combined with melphalan in isolated limb perfusion for the treatment of locally advanced soft tissue sarcomas: preclinical studies in rats. Brunstein, F; Eggermont, AM; Ferreira, LM; Santos, ID; Ten Hagen, TL; van Tiel, ST, )	0.75
" After 9 months, the disease progressed and several chemotherapy agents, including three courses of rituximab combined with etoposide, sobuzoxane or methotrexate, only resulted in a stable disease response."	( Rituximab combined with a small dose of melphalan for a refractory follicular lymphoma patient. Chinzei, T; Kawano, S; Kondo, S; Kumagai, S; Okamura, A; Okumachi, Y; Saigo, K; Takenokuchi, M, 2006)	0.6
" This effect was less pronounced when FK866 was used in combination with another alkylating agent, melphalan."	( Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Azzam, K; Hasmann, M; Nüssler, V; Pelka-Fleischer, R; Pogrebniak, A; Schemainda, I, 2006)	0.55
"The purpose of this trial was to define the maximum tolerated duration (MTD), dose-limiting toxicity (DLT), regimen-related toxicities (RRT), and pharmacokinetics of gemcitabine infused at a fixed dose rate (FDR) of 10 mg/m2/min, combined with docetaxel/melphalan/carboplatin, using autologous stem cell transplantation (ASCT)."	( Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors. Aldaz, A; Aramendía, JM; Aristu, J; Centeno, C; Hernández, M; Moreno, M; Nieto, Y; Pérez-Calvo, J; Rifón, J; Sayar, O; Viteri, S; Viúdez, A; Zafra, A; Zufia, L, 2007)	0.73
"Treatment of tumor-bearing mice with mouse (m)TNF-alpha, targeted to tumor vasculature by the anti-ED-B fibronectin domain antibody L19(scFv) and combined with melphalan, induces a therapeutic immune response."	( Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan. Accolla, RS; Balza, E; Borsi, L; Carnemolla, B; Castellani, P; De Lerma Barbaro, A; Fossati, S; Mortara, L; Sassi, F; Tosi, G, 2007)	0.75
" Considered as a semi-malignant disease, CA is often a contraindication for HTx; however, depending on the type of CA, there are excellent treatment regimes that can be combined with HTx."	( Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Dengler, T; Goldschmidt, H; Karck, M; Koch, A; Kristen, A; Sack, FU; Schnabel, PA, 2008)	0.35
"Cardiac amyloidosis is a potentially curative disease after HTx when combined with either chemotherapy and SCT or LiverTx depending on the type of the amyloidosis."	( Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Dengler, T; Goldschmidt, H; Karck, M; Koch, A; Kristen, A; Sack, FU; Schnabel, PA, 2008)	0.35
"To determine the maximum-tolerated radiation-absorbed dose (RAD) to critical organs delivered by yttrium-90 ((90)Y) ibritumomab tiuxetan in combination with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy with autologous transplantation."	( Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. Erwin, W; Evens, AM; Gordon, LI; Inwards, DJ; Mehta, J; Micallef, I; Molina, A; Patton, D; Rademaker, AW; Singhal, S; Spies, S; Tallman, MS; Weitner, BB; White, CA; Williams, SF; Winter, JN; Wiseman, G; Zimmer, M, 2009)	0.54
"Dose-escalated (90)Y ibritumomab tiuxetan may be safely combined with high-dose BEAM with autologous transplantation and has the potential to be more effective than standard-dose radioimmunotherapy."	( Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. Erwin, W; Evens, AM; Gordon, LI; Inwards, DJ; Mehta, J; Micallef, I; Molina, A; Patton, D; Rademaker, AW; Singhal, S; Spies, S; Tallman, MS; Weitner, BB; White, CA; Williams, SF; Winter, JN; Wiseman, G; Zimmer, M, 2009)	0.35
" A phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with in-transit extremity melanoma was performed."	( A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Augustine, CK; Beasley, GM; McMahon, N; Norris, R; Peters, WP; Peterson, B; Ross, MI; Sanders, G; Selim, MA; Tyler, DS, 2009)	0.8
"Systemic ADH-1 at a dose of 4000 mg on Days 1 and 8 in combination with melphalan via isolated limb infusion is a well-tolerated, novel targeted therapy approach to regionally advanced melanoma."	( A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Augustine, CK; Beasley, GM; McMahon, N; Norris, R; Peters, WP; Peterson, B; Ross, MI; Sanders, G; Selim, MA; Tyler, DS, 2009)	0.83
" The results of five phase III trials assessing thalidomide in combination with melphalan and prednisone (MPT) have demonstrated significantly improved response rates compared with melphalan and prednisone (MP) alone."	( Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Bladé, J; Davies, F; Delforge, M; Facon, T; Garcia Sanz, R; Kropff, M; Leal da Costa, F; Moreau, P; Morgan, G; Palumbo, A; Schey, S, 2010)	0.79
" This phase 1/2 dose-escalation study aimed to determine the maximum tolerated dose (MTD) of lenalidomide in combination with melphalan and dexamethasone (M-dex), and assess the efficacy and tolerability of this therapy for patients with de novo AL amyloidosis."	( Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Alakl, M; Benboubker, L; Bridoux, F; Fermand, JP; Harousseau, JL; Hermine, O; Jaccard, A; Leblond, V; Leleu, X; Moreau, P; Planche, L; Roussel, M; Royer, B; Salles, G, 2010)	0.85
" In a preclinical animal model, systemic ADH-1 given with regional melphalan demonstrated synergistic antitumor activity, and in a phase I trial with M-ILI it had minimal toxicity."	( Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. Augustine, CK; Beasley, GM; Grobmyer, SR; Hochwald, SN; Peterson, B; Riboh, JC; Ross, MI; Royal, R; Tyler, DS; Zager, JS, 2011)	0.83
" In this study, by applying the US-MB strategy for melanoma chemotherapy, we evaluated the antitumor effect of melphalan combined with US-MB on a melanoma cell line (C32) in vitro and in vivo."	( Synergistic inhibition of malignant melanoma proliferation by melphalan combined with ultrasound and microbubbles. Endo, H; Feril, LB; Matsuo, M; Nakayama, J; Ogawa, K; Tachibana, K; Yamaguchi, K, 2011)	0.82
"This study was designed to evaluate the safety and efficacy of a conventional dose of yttrium-90 ((90)Y) ibritumomab tiuxetan combined with the etoposide rabinoside acytarabine melphalan (BEAM) regimen before autologous stem cell transplantation (ASCT) in chemosensitive relapsed or refractory low-grade B-cell lymphomas."	( (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. Bologna, S; Bosly, A; Bouabdallah, K; Brière, J; Coiffier, B; Decaudin, D; Delarue, R; Ghesquières, H; Gisselbrecht, C; Huynh, A; Le Gouill, S; Morschhauser, F; Mounier, N; Ribrag, V; Tilly, H, 2011)	0.56
"A bioanalytical assay for the new poly(ADP-ribose) polymerase-1 inhibitor olaparib in combination with melphalan was developed and validated."	( Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma. Beijnen, JH; den Hartigh, J; Martens, I; Schellens, JH; Sparidans, RW; Valkenburg-van Iersel, LB, 2011)	0.79
" In preclinical and clinical studies, panobinostat showed good anti-myeloma activity in combination with several agents."	( Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Alesiani, F; Ballanti, S; Boccadoro, M; Caraffa, P; Catarini, M; Cavallo, F; Corvatta, L; Gentili, S; Leoni, P; Liberati, AM; Offidani, M; Palumbo, A; Polloni, C; Pulini, S, 2012)	0.71
"Panobinostat is a histone deacetylase inhibitor that has shown synergistic preclinical anti-myeloma activity when combined with other agents, recently exhibiting synergy with the alkylating agent melphalan (Sanchez et al."	( A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Berenson, JR; Boccia, RV; Dressler, K; Ghazal, HH; Harb, WA; Hilger, JD; Jamshed, S; Kingsley, EC; Matous, J; Nassir, Y; Noga, SJ; Swift, RA; Vescio, R; Yellin, O, 2014)	0.84
"L19-tumor necrosis factor alpha (L19mTNF-α; L), a fusion protein consisting of mouse TNFα and the human antibody fragment L19 directed to the extra domain-B (ED-B) of fibronectin, is able to selectively target tumor vasculature and to exert a long-lasting therapeutic activity in combination with melphalan (M) in syngeneic mouse tumor models."	( Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine. Balza, E; Borsi, L; Carnemolla, B; Castellani, P; Mortara, L; Orecchia, P, 2013)	0.81
"To improve isolated hepatic perfusion (IHP), we performed a phase I dose-escalation study to determine the optimal oxaliplatin dose in combination with a fixed melphalan dose."	( Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study. de Leede, EM; den Hartigh, J; Gelderblom, H; Hartgrink, HH; Kuppen, PJ; Nortier, JW; Tijl, FG; Tollenaar, RA; Vahrmeijer, AL; van de Velde, CJ; van Iersel, LB, 2014)	0.84
"Between June 2007 and July 2008, 11 patients, comprising of 8 colorectal cancer and 3 uveal melanoma patients and all with isolated liver metastases, were treated with a one hour IHP with escalating doses of oxaliplatin combined with 100 mg melphalan."	( Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study. de Leede, EM; den Hartigh, J; Gelderblom, H; Hartgrink, HH; Kuppen, PJ; Nortier, JW; Tijl, FG; Tollenaar, RA; Vahrmeijer, AL; van de Velde, CJ; van Iersel, LB, 2014)	0.82
"The purpose of this study is to compare the efficacy and safety of Gefitinib versus VMP in combination with three-dimensional conformal radiotherapy (3D-CRT) for multiple brain metastases from non-small cell lung cancer (NSCLC)."	( Comparison of Gefitinib versus VMP in the combination with radiotherapy for multiple brain metastases from non-small cell lung cancer. Chen, S; Hao, Y; Li, B; Li, L; Liu, C; Ning, F; Wang, F; Yu, Z, 2015)	0.42
"To evaluate BSO-mediated glutathione (GSH) depletion in combination with L-PAM for children with recurrent or refractory high-risk neuroblastoma (NB) as a means to enhance alkylator sensitivity."	( Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Anderson, CP; Bailey, HH; Groshen, S; Hasenauer, B; Maris, JM; Matthay, KK; Neglia, JP; Perentesis, JP; Reynolds, CP; Seeger, RC; Villablanca, JG, 2015)	0.71
"3 (dose level 2) mg/m(2) in combination with melphalan 8 mg/m(2) on days 1-4 and dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, and 12."	( Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis. Abe, M; Ando, Y; Fuchida, S; Hata, H; Imai, H; Ishida, T; Miyamoto, T; Sawamura, M; Shimazaki, C; Suzuki, K; Takamatsu, H; Yamada, M, 2016)	0.95
"The aim of this study was to determine the efficacy of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for the treatment of endometrial cancer."	( Clinical assessment of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer. Chen, S; Lei, X; Tang, C; Xiong, YL; Xu, WJ; Zhao, KW; Zhou, Q, 2016)	0.43
"252Californium neutron intracavitary brachytherapy using a two-channel applicator combined with external beam radiotherapy was effective for treating endometrial cancer and the incidence of serious late complications related to this combination was within an acceptable range."	( Clinical assessment of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer. Chen, S; Lei, X; Tang, C; Xiong, YL; Xu, WJ; Zhao, KW; Zhou, Q, 2016)	0.43
"For treatment of metastatic lung lesions there was used the method of isolated chemoperfusion in combination with metastasectomy."	( [Immediate results of isolated chemoperfusion of the lung with melphalan and cisplatin in combination with metastasectomy in treatment for resectable metastatic lung lesions]. Barchuk, AS; Kalinin, PS; Levchenko, EV; Mamontov, OY; Mishchenko, AV; Senchik, KY, 2015)	0.66
"To evaluate the efficacy and adverse effects of low dose thalidomide (TD) combined with modified VCMP (vincristine+cyclophosphamide+melphalan+prednisone) (TD+mVCMP) and VAD (vincristine+doxorubicin+dexamethsone) (TD+VAD) regimens for treating aged patients with MM."	( [Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients]. Liu, HB; Wang, W, 2016)	0.64
"Low dose TD combined with modified VCMP regimen for treatment of newly diagnosed aged patients with MM is safe and effective, which may be used as the first line treatment regimen for population in aged MM patients."	( [Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients]. Liu, HB; Wang, W, 2016)	0.43
" Patients undergoing hematopoietic stem cell transplantation (HSCT) are exposed to various types of drugs, and understanding how these drugs interact is of the utmost importance."	( Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions. Andersson, BS; Hassan, M; Valdez, BC, 2017)	0.46
"0 μM and at 75 nM in combination with cisplatin or melphalan."	( Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Houghton, PJ; Kang, M; Kurmashev, D; Kurmasheva, RT; Reynolds, CP; Smith, MA; Wu, J, 2018)	0.94
"For treatment of metastatic lung lesions there was used the method isolated chemoperfusion of the lung in combination with metastasectomy."	( [Long-term results of isolated chemoperfusion of the lung with melphalan and cisplatin in combination with metastasectomy in treatment for resectable metastatic lung lesion]. Barchuk, AS; Gorokhov, LV; Kalinin, PS; Lemekhov, VG; Levchenko, EV; Mamontov, OY; Mikhnin, AE; Mishchenko, AV; Senchik, KY; Tin, V; Ven, C, )	0.37
" To investigate the effects of these compounds on bortezomib's anti-proliferative potency and its intracellular accumulation and potency to inhibit the chymotrypsin-like proteasomal subunit, seven myeloma cell lines were investigated after exposure to bortezomib alone or either combined with adriamycin plus dexamethasone (PAD regimen) or melphalan plus prednisolone (VMP regimen), respectively."	( Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro. Burhenne, J; Schäfer, J; Theile, D; Weiss, J, 2019)	0.96
" The VEO alone and in combination with D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) has significantly increased the MLN and SVN loading."	( Vitamin E Oil Incorporated Liposomal Melphalan and Simvastatin: Approach to Obtain Improved Physicochemical Characteristics of Hydrolysable Melphalan and Anticancer Activity in Combination with Simvastatin Against Multiple Myeloma. Eswara, BRM; Manjappa, AS; Nagadeepthi, N; Sambamoorthy, U; Sanapala, AK, 2021)	0.89
" Here, we retrospectively analyze CINV data of 100 patients who received either SEAM (semustine, etoposide, cytarabine, melphalan) or MEL140-200 (high-dose melphalan) before ASCT, evaluate the efficacy and safety of multiple-day administration of fosaprepitant combined with tropisetron and olanzapine (FTO), and compare the results to those of patients who received a standard regimen of aprepitant, tropisetron, and dexamethasone (ATD)."	( Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study. Cao, J; Chen, D; Du, X; Hu, Y; Jiang, L; Li, S; Liu, X; Lu, Y; Pei, R; Tang, S; Wang, T; Ye, P; Zhang, P, 2022)	0.93
" Studies on the interactions of HDACi with PARP inhibitors in hematologic cancers are limited, especially when combined with chemotherapeutic agents."	( HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs. Andersson, BS; Murray, D; Nieto, Y; Valdez, BC; Yuan, B, 2022)	0.72

Excerpt	Reference	Relevance
" Some instances of failure of tumor response to oral melphalan may be due to inadequate bioavailability rather than inherent tumor resistance."	( Oral melphalan kinetics. Alberts, DS; Chang, SY; Chen, HS; Evans, TL; Moon, TE, 1979)	1.02
" The bioavailability showed large interindividual variations, and was not significantly affected by the dose given."	( Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma. Ehrsson, H; Eksborg, S; Lindfors, A; Mellstedt, H; Osterborg, A, 1989)	0.79
" The oral bioavailability of BSO, based on plasma BSO levels, was extremely low."	( Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. Grieshaber, CK; Liao, JT; Page, JG; Smith, AC; Wientjes, MG, 1989)	0.51
"Previous studies have demonstrated that the bioavailability of melphalan and chlorambucil may be reduced under non-fasting conditions, and that the gastrointestinal and cellular absorption of melphalan is an active process, while that of chlorambucil is passive."	( The effect of dietary amino acids on the gastrointestinal absorption of melphalan and chlorambucil. Adair, CG; McElnay, JC, 1987)	0.74
" Flurbiprofen did not seem to alter the bioavailability of the chemotherapeutic agents."	( Increased survival of cancer-bearing mice treated with inhibitors of prostaglandin synthesis alone or with chemotherapy. Bennett, A; Berstock, DA; Carroll, MA, 1982)	0.26
"This study deals with the design of a new macrofilaricidal drug derived from melphalan and having a lymphotropism to avoid the hepatic first pass effect and enhance bioavailability after oral administration."	( Study of lymphotropic targeting and macrofilaricidal activity of a melphalan prodrug on the Molinema dessetae model. Deverre, JR; el Kihel, L; Gayral, P; Letourneux, Y; Loiseau, PM, 1994)	0.75
" Although intracellular events involved in the pharmacologic action of these compounds have been extensively studied, the role of plasma membrane transporters in nucleoside-derived drug bioavailability and action in leukemia cells has not been comprehensively addressed."	( Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Bellosillo, B; Casado, FJ; Colomer, D; Gil, J; Molina-Arcas, M; Montserrat, E; Pastor-Anglada, M, 2003)	0.32
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."	( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010)	0.36
"Defibrotide is a novel orally bioavailable polydisperse oligonucleotide with anti-thrombotic and anti-adhesive effects."	( Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Anderson, K; Benevolo, G; Boccadoro, M; Bringhen, S; Cavallo, F; Gaidano, G; Gay, F; Genuardi, M; Iacobelli, M; Kotwica, K; Larocca, A; Magarotto, V; Masini, L; Mitsiades, C; Palumbo, A; Richardson, P; Rossi, D; Rus, C, 2010)	1.8
" INCB16562 was developed as a novel, selective, and orally bioavailable small-molecule inhibitor of JAK1 and JAK2 markedly selective over JAK3."	( INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Arvanitis, A; Caulder, E; Combs, AP; Favata, M; Fridman, JS; Kelley, JA; Li, J; Newton, R; Rogers, JD; Scherle, PA; Solomon, KA; Sparks, RB; Thomas, B; Vaddi, K; Wen, X, 2010)	0.36
" CYT387 is a novel, orally bioavailable JAK1/2 inhibitor, which has recently been described."	( The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Burns, CJ; Khong, T; Monaghan, KA; Spencer, A, 2011)	0.37
"The objectives of the present study were to circumvent the moisture-associated instability, enhance bioavailability and achieve enhanced passive targeting of melphalan to the ovaries."	( Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan. Bali, V; Pathak, K; Rajpoot, P, 2012)	0.79
" Here, we analyzed the effects of the novel, orally bioavailable HSP90 inhibitor NVP-HSP990 on MM cell proliferation and survival."	( The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. Gao, Z; Heider, U; Jensen, MR; Kaiser, M; Lamottke, B; Mieth, M; Nikolova, Z; Sezer, O; Sterz, J; von Metzler, I, 2012)	0.58
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" The therapeutic effects of drug molecules are majorly dependent on the bioavailability and, in essence, on the solubility of the used drug molecules."	( Exploration on the drug solubility enhancement in aqueous medium with the help of endo-functionalized molecular tubes: a computational approach. Paul, R; Paul, S, 2021)	0.62

Excerpt	Relevance	Reference
" Because of rapid progression of the amyloidosis and further infections, cytotoxic drug therapy was stopped, corticosteroid dosage was decreased, and supplementary immunoglobulin therapy was instituted."	( Amyloidosis associated with dermatomyositis and features of multiple myeloma. The progression of amyloidosis associated with corticosteroid and cytotoxic drug therapy. Dawkins, RL; Zilko, PJ, 1975)	0.25
" This combination appears to be safe, provided the field of radiation is not so large that is may add significantly to the myelosuppressive effect of chemotherapy and the dosage of concomitantly administered radiopotentiating agent(s) is reduced."	( Feasibility of integration of modalities in melanomas and sarcomas. Berger, JL; Friedman, M; Holyoke, ED; Karakousis, CP; Lopez, R; Takita, H, 1979)	0.26
" Leukocyte and platelet counts must be performed every three weeks, and the dosage of melphalan adjusted accordingly."	( Treatment of scleromyxedema with melphalan. Harris, RB; Kyle, RA; Perry, HO; Winkelmann, RK, 1979)	0.76
" Most patients are put on a fixed oral dosage regimen."	( Oral melphalan kinetics. Alberts, DS; Chang, SY; Chen, HS; Evans, TL; Moon, TE, 1979)	0.77
"[14C]melphalan ([14C]L-PAM) was rapidly absorbed from the gut of dogs after oral dosing and reached a maximum concentration in the serum by 30 minutes."	( Pharmacokinetics of the absorption, distribution, and elimination of melphalan in the dog. Brown, RK; Duncan, G; Furner, RL, 1977)	1.01
" The body weight was the same in the two groups, indicating that the patient's weight is of minor importance for the dosage of melphalan."	( Factors responsible for bone marrow toxicity after treatment of myeloma patients with different alkylating agents. Lewensohn, R; Ringborg, U, 1978)	0.46
" Addition of ethacrynic acid (3 micrograms ml-1) to treatment of the cell lines with melphalan or with cisplatin did not alter the dose-response curves to these agents."	( A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines. Rhodes, T; Twentyman, PR, 1992)	0.76
" just prior to the injection of melphalan (10 mg/kg), cyclophosphamide (150 mg/kg) or BCNU (50 mg/kg), the greatest tumor growth delays were obtained with dosage levels between 4 g and 12 g of the perfluorochemical perfluorooctyl bromide/kg."	( A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents. Ara, G; Ha, CS; Herman, TS; Holden, SA; Northey, D; Teicher, BA, 1992)	0.57
") was administered just prior to an alkylating agent, the combination treatment produced significantly more tumor cell killing across the dosage range of each alkylating agent tested compared with the alkylating agent alone."	( Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. Bubley, G; Coleman, CN; Eder, JP; Frei, E; Herman, TS; Holden, SA; Tanaka, J; Teicher, BA, 1991)	0.28
" 15% of previously untreated myeloma patients achieve a clinical response to IFN alpha alone with a possible dose-response relationship."	( Treatment of multiple myeloma with interferon alpha: the Scandinavian experience. Björeman, M; Björkholm, M; Brenning, G; Gahrton, G; Grimfors, G; Gyllenhammar, H; Hast, R; Juliusson, G; Mellstedt, H; Osterborg, A, 1991)	0.28
" In vivo, coadministration of doxorubicin with verapamil increased animal survival when either continuous infusion or bolus dosing regimens were used."	( Drug resistance-reversal strategies: comparison of experimental data with model predictions. Michelson, S; Slate, D, 1991)	0.28
" When treatment response was related to the dosage of melphalan given by mg/kg of body weight, the numbers of responding and non-responding patients were similar in the group of patients without dose reduction as well as in that with dose reduction."	( Oral dosage of melphalan and response to treatment in multiple myeloma. Fernberg, JO; Johansson, B; Lewensohn, R; Mellstedt, H, 1990)	0.88
" Melphalan was given at a dosage greater than or equal to 140 mg/m2 followed 24 h later by autologous marrow rescue."	( High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France. Bergerat, JP; Dufour, P; Guastalla, JP; Herve, P; Legros, M; Maraninchi, D; Oberling, F; Philip, T; Plagne, R; Viens, P, 1990)	1.59
" On the other hand, results from isolated limb perfusion for satellitosis and in-transit metastasis suggest distinct dose-response correlations with tumoricidal properties of appropriate antineoplastic agents."	( [Systemically administered regional tumor therapy. Regional hemi-body chemotherapy of metastatic malignant melanoma--an experimental therapy concept]. Aigner, KR; Link, KH; Müller, H; Voigt, H; Walther, H, 1989)	0.28
"A melphalan-resistant human rhabdomyosarcoma xenograft, TE-671 MR, was established in athymic mice by serial melphalan treatment of the parent xenograft, TE-671, at the 10% lethal dosage (LD10); significant resistance was evident after ten passages of the tumor."	( Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion. Bigner, DD; Bigner, SH; Colvin, OM; Elion, GB; Friedman, HS; Griffith, OW; Horton, JK; Lilley, E; Rosenberg, MC, 1989)	1.33
" There was statistically significant greater myelosuppression, stomatitis, and diarrhea in the very high dosage DTIC and melphalan (Regimen A) compared with the other two regimens."	( High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. Carr, T; Chadwick, G; Craig, P; Jones, R; Lind, M; Morgenstern, G; Thatcher, D, 1989)	0.73
" A dose-response effect of melphalan against the drug-sensitive plasmacytomas was present in vivo."	( Glutathione and glutathione S-transferases in a human plasma cell line resistant to melphalan. Ahmad, H; Awasthi, YC; Gupta, V; Medh, RD; Singh, SV, 1989)	0.8
" This complication was no longer seen after adjustment of the dosage and dose distribution of doxorubicin, but the morbidity after perfusion with doxorubicin remained considerable."	( Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Albus-Lutter, CE; Benckhuijsen, C; Klaase, JM; Kroon, BB; van Geel, AN; Wieberdink, J, 1989)	0.28
"A previously untreated 31-yr old female with Ph-positive chronic myeloid leukaemia (CML) received busulphan and melphalan at high dosage followed by an autograft of peripheral blood stem cells collected 4 weeks earlier."	( Complete remission after autografting for chronic myeloid leukaemia. Apperley, JF; Brito-Babapulle, F; Dowding, C; Goldman, JM; Guo, AP; Rassool, F, 1987)	0.48
" Prior to each ABMT patients received massive chemotherapy with melphalan at a dosage of 140 mg/m2."	( Repeated courses of high dose melphalan and unpurged autologous bone marrow transplantation in children with acute non-lymphoblastic leukemia in first complete remission. Blaise, D; Demeocq, F; Gaspard, MH; Gastaut, JA; Lepeu, G; Maraninchi, D; Michel, G; Novakovitch, G; Perrimond, H; Stoppa, AM, 1988)	0.8
" Throughout the melphalan dosage range examined there is approximately 1 log greater tumor cell kill observed with the addition of Fluosol-DA and carbogen breathing compared to the drug treatment alone."	( Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. Holden, SA; Jacobs, JL; Teicher, BA, 1987)	0.84
" In dogs, melphalan should be dosed on a weight basis, and treatment groups should be stratified by weight in randomized clinical studies, particularly when the weight range of treated subjects is great."	( Unexpected toxicity associated with use of body surface area for dosing melphalan in the dog. Allen, SL; Dewhirst, MW; Gillette, EL; Heidner, GL; Macy, DW; McGee, ML; Page, RL; Sim, DA; Thrall, DE, 1988)	0.91
" Further studies should evaluate different dosing intervals to take advantage of the slower rate of GSH replenishment observed in normal tissues compared to solid tumor cells (Colon 38) in vivo."	( Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice. Dorr, RT; Soble, MJ, )	0.34
" The drug sensitivity of myeloma cells (MY-CFUc) compared with normal haemopoietic cells (GM-CFUc) can be measured using dose-response curves in individual patients."	( A simple method for culturing myeloma cells from human bone marrow aspirates and peripheral blood in vitro. Ayliffe, MJ; Bell, JB; Lakhani, A; McElwain, TJ; Millar, BC; Selby, PJ, 1988)	0.27
"119 dosage required to reduce the viable L1210 cell fraction by 50% (TCD50)."	( Multiple transport pathways for L1210 cells: uptake of PTT.119, a bifunctional alkylator with carrier amino acids. Bekesi, JG; Chin, SE; Holland, JF; Scanlon, KJ; Yagi, MJ, 1988)	0.27
" These results demonstrate the existence of a dose-response effect of high-dose melphalan regimens in relapsed acute leukemias, without marked increases in nonhematological toxicity with these doses."	( High-dose melphalan with or without marrow transplantation: a study of dose-effect in patients with refractory and/or relapsed acute leukemias. Beaujean, F; Gastaut, JA; Hartmann, O; Hayat, M; Kamioner, D; Maraninchi, D; Mascret, B; Novakovitch, G; Pico, JL; Sebahoun, G, 1986)	0.9
" In experimental models, a steep dose-response curve for colorectal cancer has been demonstrated using various agents."	( Phase II trial of high-dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma. Daly, MB; Johnson, DB; Knight, WA; Leff, RS; Messerschmidt, GL; Mosley, KR; Ruxer, RL; Thompson, JM, 1986)	0.57
" All two-drug combinations required attenuation to one-half the LD10 dosage for each."	( Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models. DeGraw, JI; Otter, GM; Schmid, FA; Sirotnak, FM, )	0.13
"Since the extent of host toxicity of cytostatics is considerably affected by dosing time, a chronopharmacologic approach was undertaken for optimizing the therapeutic index of the alkylating agent, peptichemio (PTC)."	( Circadian time dependence of murine tolerance for the alkylating agent peptichemio. Bailleul, F; Horvath, C; Lemaigre, G; Levi, F; Mathe, G; Mechkouri, M; Reinberg, A; Roulon, A, 1987)	0.27
" The resulting variation in total melphalan dosage gave rise to varying drug concentrations in the perfusate as the extracorporeal system was operated with a fixed volume of priming fluid."	( Pharmacokinetics of melphalan in isolated perfusion of the limbs. Benckhuijsen, C; Hart, AA; Noordhoek, J; Varossieau, FJ; Wieberdink, J, 1986)	0.87
" A dose-response relationship was apparent in 605 women receiving melphalan and suggested in 333 women receiving cyclophosphamide."	( Melphalan may be a more potent leukemogen than cyclophosphamide. Bennett, JM; Boice, JD; Dembo, AJ; Gershenson, DM; Greene, MH; Harris, EL; Malkasian, GD; Melton, LJ; Moloney, WC, 1986)	1.95
" Melphalan dosage was calculated per ml of blood and applied at 20 to 40 micrograms/ml."	( A simple and accurate new method for cytostatics dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination. Ghanem, GE; Lejeune, FJ, 1987)	1.18
" Different dosing regimens of BSO were found to potentiate L-PAM toxicity in a manner that depended upon the degree of GSH depletion."	( Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Ahmad, S; Greene, K; Kramer, RA; Vistica, DT, 1987)	0.27
" Despite an average increase of melphalan dosage of 18% above the maximum for iliac perfusions recommended in the literature, no increase in toxic tissue reactions was observed after hyperthermic iliac perfusions."	( Dosimetry of cytostatics in hyperthermic regional isolated perfusion. Oldhoff, J; Schraffordt Koops, H; van Os, J, 1985)	0.55
" Dose-response studies failed to demonstrate cross-resistance to the tripeptide by L-PAM resistant cells."	( PTT.119, p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met ethoxy HCl, a new chemotherapeutic agent active against drug-resistant tumor cell lines. Bekesi, JG; Chin, SE; Holland, JF; Scanlon, KJ; Yagi, MJ, 1985)	0.27
" The steep dose-response relationships in other lines support the rationale for high-dose therapy either by intraperitoneal or systemic administration of drugs."	( Pharmacologic reversal of drug resistance in ovarian cancer. Ozols, RF, 1985)	0.27
" In patients receiving melphalan RFS was not significantly affected by either the occurrence of amenorrhoea or the dosage of melphalan received."	( Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Bulbrook, RD; Bush, H; Chaudary, M; Crowther, D; Fentiman, IS; George, WD; Hayward, JL; Howat, JM; Howell, A; Knight, RK; Rubens, RD; Sellwood, RA, 1983)	0.83
" Bleomycin's and melphalan's reduced systemic availability after IP dosing suggests that their dose could be increased safely by a factor of two over their standard IV doses."	( The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. Alberts, DS; Chang, SY; Chen, HS; Peng, YM, 1980)	0.86
" A similar dose-response curve was obtained with melphalan for each of the four xenografts, despite previous treatment with an alkylating agent in two of the patients from whom the xenografts originated."	( Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8). Jones, AC; Steel, GG; Wilson, PA, 1984)	0.75
"One hundred and fifty-six patients with extremity melanomas of known level or thickness who were perfused prophylactically with l-phenylalanine mustard (1-PAM) between January 1974 and December 1978 were studied retrospectively to determine the effect of variation of drug dosage and temperature on regional toxicity and disease control."	( Effect of variation of drug dosage on disease control and regional toxicity in prophylactic perfusion for Stage I extremity melanoma. Ames, FC; Boddie, AW; McBride, CM; Mikhail, RA; Zimmerman, SO, 1984)	0.27
" However, a chronic low dosing schedule of MISO did not affect the plasma half-life of either cytotoxic drug, although a significant potentiation of each drug in combination with a chronic MISO dose has been obtained in some tumours."	( The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse. Hinchliffe, M; McNally, NJ; Stratford, MR, 1983)	0.51
" Cytostatics are dosed per liter of perfused extremity."	( [Technic of isolated perfusion of the extremities. Experience with 171 cases]. Aigner, K; Schwemmle, K, 1983)	0.27
"The pharmacokinetics of melphalan have been studied after intravenous and oral dosing (10 mg) in 6 patients with multiple myeloma."	( The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. Hamilton, P; Lennard, A; Rawlins, MD; Woodhouse, KW, 1983)	0.88
"The optimal single dosage of melphalan in isolation perfusion of the limbs for malignant melanoma was assessed."	( Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Benckhuysen, C; Braat, RP; Olthuis, GA; van Slooten, EA; Wieberdink, J, 1982)	0.56
"Twenty-three patients with Stage III, Stage IV, or recurrent epithelial ovarian cancer were treated with a combination of melphalan and levamisole to determine a tolerable dosage schedule, possible adverse effects, and a general estimate of response rate and duration."	( Chemotherapy of advanced ovarian epithelial carcinoma with melphalan and levamisole: a pilot study of the Gynecologic Oncology Group. Di Saia, PJ; Gusdon, JP; Heise, ER; Herbst, GA; Homesley, HD; Lovelace, JV; Muss, HB; Richards, F; Spurr, CL, 1981)	0.71
" There were no differences in response to therapy or in survival between the patients treated with melphalan followed by 5-fluorouracil and then by methotrexate in high dosage and the patients treated with the same agents in combination."	( Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer. Boyes, DA; Dodds, DJ; Gerulath, A; Kirk, ME; Klaassen, DJ; Levitt, M; Miller, AB; Pearson, JG; Wall, C, 1980)	0.75
" To obtain dose-response curves and quantitative comparisons of different treatments, an agar-colony assay was used to measure survival of cells from excised tumours."	( Response of two mouse tumours to hyperthermia with CCNU or melphalan. Joiner, MC; Steel, GG; Stephens, TC, 1982)	0.51
" Regrowth delay has been used as the assay, and by producing dose-response curves the effect has been classified as additive or interactive."	( Chemosensitization of mouse tumors by misonidazole. Denekamp, J; Randhawa, VS; Stewart, FA, )	0.13
" Dose-response studied indicated that melphalan concentrations of 2 X 10(-8) M had no effect, while concentrations of 8 X 10(-7) M were totally toxic, after 72-hr exposures to the drug."	( Decreased immunoglobulin production by a human lymphoid cell line following melphalan treatment. Atchley, CE; Griffin, GD; Novelli, GD; Owen, BA; Solomon, A, 1982)	0.76
" The differences in drug exposure and in cellular chemosensitivity between chambers and tumors suggest caution in the interpretation of drug testing using this system, but the log-linear nature of the dose-response curves is an important feature which may be useful in the eventual development of optimal chemosensitivity testing systems."	( Use of the agar diffusion chamber for the exposure of human tumor cells to drugs. Selby, PJ; Steel, GG, 1982)	0.26
" Combination chemotherapy of tumor bearing mice with thiamine and mechlorethamine increased the mechlorethamine dosage required for a 50 to 60 percent increase in survival time but did not improve survival over that obtained with mechlorethamine alone."	( Thiamine protection of murine L1210 leukemia cells against mechlorethamine cytotoxicity and its relation to the choline uptake system. Naujokaitis, SA, 1981)	0.26
" While earlier results suggested that adjuvant chemotherapy is especially effective in premenopausal women, newer studies and analyses indicate that appropriate dosage and consistent administration of chemotherapy are of decisive importance."	( [Results of, and indications for adjuvant chemotherapy in breast cancer]. Brunner, KW; Goldhirsch, A; Joss, R; Sonntag, RW; Tschopp, L, 1981)	0.26
" The extent of melphalan cross-linking was dependent on both drug dosage and exposure time."	( L-phenylalanine mustard (melphalan) uptake and cross-linking in the RPMI 6410 human lymphoblastoid cell line. Belch, A; Brox, LW; Gowans, B, 1980)	0.92
" Dose-response curves were obtained and the surviving fraction at drug levels estimated to be achieved in man was used as a measure of in vitro drug sensitivity."	( In vitro chemosensitivity tests on xenografted human melanomas. Bateman, AE; Selby, PJ; Steel, GG; Towse, GD, 1980)	0.26
" Time-dependent pharmacodynamic models are seen as a powerful means to design dosing regimens and to provide a mathematical platform for mechanistic based models."	( Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. Brennan, J; Gallo, JM; Halbherr, T; Hamilton, TC; Laub, PB; O'Dwyer, PJ; Ozols, RF, 1995)	0.48
"Melphalan has a steep dose-response curve, but the use of high doses results in unacceptable myelosuppression."	( A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Adamson, PC; Balis, FM; Belasco, JE; Berg, SL; Blaney, SM; Craig, C; Lange, B; Poplack, DG, 1995)	2
" The A2058 line showed the lowest level of synergism with hyperthermia, and displayed a marked plateau at 10% of controls in the dose-response for survival, yet no melphalan-resistant subpopulation could be isolated."	( Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Addison, RS; Clark, J; Grabs, AJ; Parsons, PG; Roberts, MS; Smithers, BM, 1994)	1.93
" The responses of the cell lines to TNF were in the rank order of 939 cells > 987 > 284 > C8161 > 852 > A2058 approximately 0, and all displayed shallow dose-response curves; no significant thermal enhancement of TNF cytotoxicity was apparent with this heat dose."	( Tetramodality treatment of human melanoma in vitro. Auzenne, E; Feig, B; Klostergaard, J; Ross, MI; Tomasovic, SP, 1995)	0.29
"Melphalan's lack of efficacy at the doses administered does not disprove the steep chemotherapy dose-response relationship postulated for many solid tumors."	( Phase II trial of intravenous melphalan in advanced colorectal carcinoma. Abbruzzese, JL; Moore, DF; Pazdur, R, 1994)	2.02
"In order to perform melphalan dosage adjustment, the linearity of melphalan kinetics was studied, in the case of previous carboplatin administration."	( [Effect of carboplatin on the pharmacokinetics of melphalan administered intravenously]. Ardiet, C; Biron, P; Bouffet, E; Brunat-Mentigny, M; Nasri, F; Philip, I; Tranchand, B, 1994)	0.87
" Melphalan dosage was 30 mg/m2 every three weeks."	( Phase II study of intravenous melphalan (NSC-8806) in the treatment of patients with advanced squamous carcinoma of the head and neck. Blough, R; Grinblatt, D; Kies, MS; Runge-Morris, M; Taylor, S; Watkins, A, 1994)	1.49
" The first series of 12 patients received a total dosage TNF-alpha of 2-4 mg, and the second series of 10 cases received an escalating dosage of TNF-alpha (1."	( Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan. Belli, F; Inglese, MG; Manzi, R; Persiani, L; Santinami, M; Santoro, N; Vaglini, M, 1994)	0.49
" Nevertheless, we found a dose-response effect in these patients with relapsed and resistant Hodgkin's disease."	( Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Chopra, R; Goldstone, AH; Hancock, B; Hudson, GV; Linch, DC; McMillan, A; Milligan, D; Moir, D; Winfield, D, 1993)	0.29
" Maximal GSH depletion (40% of baseline values, absolute values 200 to 250 ng/10(6) PBLs) was noted after the sixth BSO dose; extended BSO dosing schedules beyond six total BSO doses did not further deplete GSH."	( Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. Alberti, D; Arzoomanian, RZ; Bailey, HH; Mulcahy, RT; Pomplun, M; Spriggs, DR; Tombes, MB; Tutsch, KD; Wilding, G, 1994)	0.52
" We conclude that, in multidrug therapies, the continuation of corticosteroid at conventional dosage beyond the first course does not improve response rate or survival time in multiple myeloma."	( Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Finnish Leukaemia Group. Ala-Harja, K; Almqvist, A; Elonen, E; Hallman, H; Hänninen, A; Ilvonen, M; Isomaa, B; Järvenpää, E; Jouppila, J; Palva, IP, 1993)	0.29
"To complete research in this type of coagulation and cancer, a multicentric randomized clinical trial was performed, including 303 patients with small cell lung cancer (SCLC), treated by the addition of aspirin at 1 g/day (a dosage at which aspirin is considered to be a platelet aggregation inhibitor) to combined chemotherapy."	( No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules" Group. Chastang, C; Fabre, C; Lebeau, B; Massin, F; Muir, JF; Vincent, J, 1993)	0.29
" Melphalan given at the 90% lethal dosage produced severe gastrointestinal mucositis and mortality (13 of 23 treated mice)."	( Development of a model of melphalan-induced gastrointestinal toxicity in mice. Bigner, DD; Castellino, S; Cattley, RC; Dewhirst, M; Elion, GB; Friedman, HS; Griffith, OW; Kurtzberg, J; Scott, P, 1993)	1.5
" Under schedule B, HDM was followed by IL-3 alone at the same dosage from day 1 to day 3, IL-3 and G-CSF (idem) from day 4 to day 7 and G-CSF alone from day 8 until completion of apheresis."	( Mobilization of peripheral blood stem cells with chemotherapy and cytokines in multiple myeloma. Becker, M; Donatini, B; Eisenmann, JC; Hénon, PR; Sklenar, I; Sovalat, H, 1995)	0.29
" We measured plasma concentrations of R- and S-BSO by high-performance liquid chromatography (HPLC) in 22 patients throughout the dosing period."	( Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. Bookman, MA; Brennan, J; Comis, RL; Gallo, JM; Halbherr, T; Hamilton, TC; Hoffman, J; Kilpatrick, D; LaCreta, FP; O'Dwyer, PJ; Ozols, RF; Young, RC, 1996)	0.54
" Using this assay in the present study, dose-response relationships of cytotoxicity, PFC response and histology in the spleen were evaluated in rats receiving alkylating agents."	( Dose-response relationships of cytotoxicity, PFC response and histology in the spleen in rats treated with alkylating agents. Doi, T; Nagai, H; Suzuki, T; Tsukuda, R, 1996)	0.29
"The optimal dosing schedule for melphalan therapy of recurrent malignant melanoma in isolated limb perfusions has been examined using a physiological pharmacokinetic model with data from isolated rat hindlimb perfusions (IRHP)."	( Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb. Roberts, MS; Smithers, BM; Wu, ZY, 1997)	2.02
" IFN alpha, at 500 IU/ml, a noncytotoxic dosage significantly increased the cytotoxicity of Mel to K562/Mel."	( [Mechanisms of resistance to melphalan in leukemia cell line and reversal by interferon alpha]. Qian, Q; Yan, W; Yang, CZ, 1996)	0.59
" Combinations of haemopoietic growth factors and their dose-modifications should be investigated to improve PBPC collection, to allow a dosage reduction of the mobilization chemotherapy."	( Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Goldschmidt, H; Haas, R; Hegenbart, U; Hohaus, S; Wallmeier, M, 1997)	0.3
"The availability, mean transit time and normalised variance (CV2) obtained for labelled red blood cells, sucrose and water were similar before and after melphalan dosing and with the two methods of calculation but varied between the patients."	( Relative dispersion of intravascular transit times during isolated human limb perfusions for recurrent melanoma. Egerton, WS; Rivory, LP; Roberts, MS; Smithers, BM; Weiss, M; Wu, ZY, 1997)	0.5
" The EMT-6/PRK5 beta 1E tumor was markedly resistant to a dosage range of cyclophosphamide, cisplatin, melphalan and thiotepa compared with the EMT-6/Parent tumor."	( Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. Ara, G; Herbst, RS; Ikebe, M; Keyes, SR; Teicher, BA, )	0.35
" The possibility of increasing ILI response rates by using other drugs and drug combinations and by multiple fractionated dosing is being investigated."	( Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Harman, CR; Kam, PC; Thompson, JF; Waugh, RC, )	0.13
" Because alkylating agents generally have steep dose-response curves, mitomycin C (MMC) and melphalan (L-PAM) entered phase I/II studies on IHP."	( Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases? Kuppen, PJ; Vahrmeijer, AL; Van De Velde, CJ; Van Der Eb, MM; Van Dierendonck, JH, )	0.35
"The dose-response relationships for DNA fragmentation (assessed by pulsed-field gel electrophoresis, PFGE) and for viability (evaluated by measuring the reduction of MTT dye which can be accomplished by viable cells only) were investigated in order to discriminate between genotoxicity and cytotoxicity in the pathogenesis of DNA double-strand breaks (DSB)."	( Discrimination between genotoxicity and cytotoxicity in the induction of DNA double-strand breaks in cells treated with etoposide, melphalan, cisplatin, potassium cyanide, Triton X-100, and gamma-irradiation. Hoffmann, HD; Hormes, P; Lutz, WK; Vamvakas, S; Vock, EH, 1998)	0.5
"Among the drugs used in conditioning regimens for stem cell transplantation, high-dose melphalan (HDM) plays an important role for both its strong myeloablative effect and for its favourable dose-response ratio."	( Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Brunori, M; Centanni, M; Corvatta, L; Ferretti, GF; Leoni, P; Montanari, M; Offidani, M; Olivieri, A, 1998)	0.78
"High dosage melfalan chemotherapy with subsequent autologous blood stem cell transplantation in suitably selected patients with multiple myeloma greatly increases the probability that complete remission will be achieved and it prolongs the mean survival period as compared with classical chemotherapy."	( [Autologous transplantation of peripheral hematopoietic cells in a patient with multiple myeloma and renal insufficiency]. Adam, Z; Doubek, M; Hájek, R; Krejcí, M; Mayer, J; Vorlícek, J, 1997)	0.3
"In an attempt to improve tumor response and survival among patients with colorectal cancer metastases confined to the liver, we developed an experimental (rats and pigs) and clinical isolated hepatic perfusion (IHP) technique to exploit maximally the steep dose-response relation of may anticancer drugs."	( Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases. Marinelli, A; Vahrmeijer, AL; van de Velde, CJ, 1998)	0.53
" TNF dosage was 20 microgram for mice and 200 microgram for rats."	( Synergism of tumor necrosis factor-alpha and melphalan in systemic and regional administration: animal study. Gutman, M; Klausner, JM; Lev-Chelouche, D; Merimsky, O; Sofer, D, 1997)	0.56
"Melphalan (MEL) is probably the most effective chemotherapeutic agent in multiple myeloma (MM) with a clear dose-response effect."	( Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Alberts, DS; Barlogie, B; Bracy, D; Dorr, RT; Jagannath, S; Johnson, C; Meyers, R; Roe, DJ; Tricot, G; Vesole, DH, 1996)	2
" With all other chemicals, the dose-response curves for DNA fragmentation and viability were mirror images."	( Investigation of the induction of DNA double-strand breaks by methylenediphenyl-4-4'-diisocyanate in cultured human lung epithelial cells. Gahlmann, R; Lutz, WK; Vamvakas, S; Vock, EH, 1998)	0.3
"The time-dependent dose-response relationships for the induction of DNA double-strand breaks (DSB) assessed by pulsed-field gel electrophoresis (PFGE) and for viability (evaluated by the MTT cytotoxicity test) were investigated in order to discriminate between genotoxic and cytotoxic mechanisms of DNA fragmentation."	( Discrimination between genotoxicity and cytotoxicity for the induction of DNA double-strand breaks in cells treated with aldehydes and diepoxides. Ilinskaya, O; Lutz, WK; Vamvakas, S; Vock, EH, 1999)	0.3
" Epidoxorubicin (70 mg/m2) was added in patients who previously received a suboptimal dosage of antracycline."	( Stop-flow in mediastinum and thorax for resistant lymphoma. Abate, G; Aigner, KR; Amicucci, G; Benita, C; Capannolo, B; D'Alessandro, V; Filippo, R; Gianfranco, A; Giuseppe, A; Guadagni, S; Luca, M; Marsili, L; Pozone, T; Roland, AK; Russo, F; Stefano, G; Tullio, P; Valfredo, D, )	0.13
" There are several strategies for increasing dose intensity, one being a protracted daily dosing strategy without major dose reduction for toxicity."	( Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond. Albella, B; Bueren, JA; Keyes, KA; LoRusso, PM; Parchment, RE, 2000)	0.31
"A 14C study of chemobiokinetics of sarcolysin and its peptides of glutaminic acid, dosage and routes of administration was conducted in intact rats and those bearing Walker's carcinoma."	( [Chemobiokinetics of sarcolysin and its peptides with glutaminic acid]. Filov, VA; Kon'kov, SA; Korsakov, MV; Krasnov, VP; Mironiuk, TA; Reztsova, VV; Zhdanova, EA, 2000)	0.31
" Melphalan was administered at a dosage of 150-220 mg/m(2) (median 180)."	( High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation. Bagnulo, S; Caniggia, M; Cesaro, S; Lanino, E; Locatelli, F; Meloni, G; Messina, C; Pession, A; Pillon, M; Proglia, A, 2001)	1.62
"In order to control busulfan pharmacokinetic variability and toxicity, a specific monitoring protocol was instituted in our bone marrow transplant BMT paediatric patients including a test dose, daily Bayesian forecasting of busulfan plasma levels, and Bayesian individualization of busulfan dosage regimens."	( Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Aulagner, G; Bertrand, Y; Bleyzac, N; Dai, Q; Galambrun, C; Janoly, A; Jelliffe, RW; Magron, P; Maire, P; Martin, P; Souillet, G, 2001)	0.31
" Despite prompt initiation of antimycotic therapy the outcome was fatal; dosage of conventional and liposomal amphotericin B was limited due to treatment-related toxicities."	( A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation. Bethe, U; Cornely, OA; Pels, H; Ritzkowsky, A; Seibold, M; Soehngen, D; Toepelt, K, 2001)	0.31
" Further detailed pharmacokinetic studies of irinotecan in patients receiving concomitant therapy with enzyme-inducing anticonvulsants are required so that rational dosing recommendations can be provided for this patient population."	( Influence of phenytoin on the disposition of irinotecan: a case report. Berg, S; Bernstein, M; Blaney, SM; Cherrick, I; Kuttesch, N; Murry, DJ; Salama, V, 2002)	0.31
" We discuss such a risk-adapted approach to melphalan dosing in detail and conclude with a brief overview of current research using SCT to treat patients with AL."	( Autologous stem cell transplantation for primary systemic amyloidosis. Comenzo, RL; Gertz, MA, 2002)	0.58
" A dosage schedule based on body surface area should be used especially in young children to reduce the age-dependent difference in kinetics."	( A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. Aschan, J; Eber, S; Gungor, T; Hassan, M; Hassan, Z; Hentschke, P; Ljungman, P; Nilsson, C; Ringdén, O; Seger, R; Winiarski, J, 2002)	0.31
" The future research in HILP with TNFalpha is directed in increasing tumor sensitivity for TNF with lowering the dosage without decreasing tumor response."	( Hyperthermic isolated limb perfusion in the management of extremity sarcoma. Hoekstra, HJ; van Ginkel, RJ, 2003)	0.32
"Hyperthermic isolated limb perfusion (HILP) with melphalan as treatment for locally recurrent or in-transit malignant melanoma is frequently performed but the principle for calculating drug dosage remains poorly understood."	( Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Abdul-Wahab, O; Aloia, T; Cheng, TY; Colvin, M; Fedrau, R; Friedman, H; Grubbs, E; Hung, CF; Leu, SY; Petros, W; Pruitt, S; Tyler, D, 2003)	0.89
"The population pharmacokinetic approach developed in this study should allow dosage to be individualized in order to decrease toxicity while maintaining good efficacy."	( Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. Astre, C; Bressolle, F; Culine, S; Fabbro, M; Mougenot, P; Pinguet, F; Poujol, S, 2004)	0.61
"0% tended to have more proteinuria, more organs involved, lower serum albumin, more diuretic use, and dosage adjustment during mobilization."	( Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Cha, SS; Dispenzieri, A; Gertz, MA; Lacy, MQ; Leung, N; Leung, TR, 2005)	0.33
"The current study was performed to evaluate the efficacy and toxicity of a chemotherapy treatment using melphalan administered over a 24-h period with individual adapted dosing in advanced ovarian cancer."	( Phase II study of melphalan as a single-agent infused over a 24-hour period with individual adapted dosing in patients with recurrent epithelial ovarian cancer. Bressolle, F; Culine, S; Fabbro, M; Mougenot, P; Pinguet, F; Pouessel, D, 2006)	0.88
" There was no dose-response relationship for doses 30 Gy or higher, even for larger tumors."	( Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. Belkacémi, Y; Bolla, M; Castelain, B; Knobel, D; Landmann, C; Oner, FD; Ozsahin, M; Poortmans, P; Tsang, RW; Zouhair, A, 2006)	0.33
"03), with a positive trend also with regard to the dosage of the antiblastic drug employed (P<0."	( Hyperthermic antiblastic perfusion in the treatment of locoregional spreading limb melanoma. Anzà, M; Botti, C; Callopoli, A; Cavaliere, F; Di Filippo, F; Di Filippo, S; Frezza, F; Garinei, R; Giannarelli, D; Maialetti, R; Perri, P; Psaila, A; Sega, F; Viticci, C, 2003)	0.32
"6 mg, we conclude that 1 mg is the best dosage to be applied during HAP."	( Hyperthermic antiblastic perfusion with TNFalpha and melphalan in stage III limb melanoma patients: A phase I - II SITILO study. Anzà, M; Botti, C; Cavaliere, F; Di Angelo, P; Di Filippo, F; Di Filippo, S; Garinei, R; Laurenzi, L; Perri, P; Principi, F; Rossi, CR, 2003)	0.57
" However, lower TNF dosage produces a very strong effect that is to increase the drug penetration into the tumour, presumably by decreasing the intratumoural hypertension resulting in better tumour uptake."	( Recombinant human tumor necrosis factor: an efficient agent for cancer treatment. Lejeune, FJ; Rüegg, C, 2006)	0.33
" Data about BNP dosage for cardiovascular monitoring of patients with ALA on renal replacement therapy are lacking."	( Role of B-type natriuretic peptide in cardiovascular state monitoring in a hemodialysis patient with primary amyloidosis. Cantelli, S; Catizone, L; Fabbian, F; Molino, C; Russo, G; Russo, M; Sartori, S; Stabellini, N, 2006)	0.33
" The BSA dosing resulted in a wide range of melphalan doses given (2."	( Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Anaissie, EJ; Barlogie, B; Dong, L; Fassas, A; Grazziutti, ML; Kiwan, E; Klaus, H; Krishna, SG; Miceli, MH; Syed, N; van Rhee, F, 2006)	0.85
" Our findings suggest that drug dosage personalization based on the measurement of drug distribution volumes might minimize hepatic toxicity."	( Correlation between melphalan pharmacokinetics and hepatic toxicity following hyperthermic isolated liver perfusion for unresectable metastatic disease. Casara, D; Corazzina, S; Da Pian, P; Forlin, M; Innocente, F; Lise, M; Mocellin, S; Nitti, D; Ori, C; Pilati, P; Rossi, CR; Ujka, F, 2007)	0.66
" The TNFalpha was empirically employed at a dosage of 3-4 mg, that is ten times the systemic maximum tolerated dose (MTD)."	( Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis. Anzà, M; Botti, C; Cavaliere, F; Di Angelo, P; Di Filippo, F; Di Filippo, S; Garinei, R; Pasqualoni, R; Perri, P; Rossi, CR; Santinami, M, )	0.13
" Forty patients were treated with a TNFalpha dosage > 1 mg and 73 with 1 mg."	( Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis. Anzà, M; Botti, C; Cavaliere, F; Di Angelo, P; Di Filippo, F; Di Filippo, S; Garinei, R; Pasqualoni, R; Perri, P; Rossi, CR; Santinami, M, )	0.13
" We tried to correlate the typed tumor response (CR or not CR) and the TNFalpha dosage < or = 1 mg or > 1 mg, but no statistically significant difference was found between the two groups."	( Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis. Anzà, M; Botti, C; Cavaliere, F; Di Angelo, P; Di Filippo, F; Di Filippo, S; Garinei, R; Pasqualoni, R; Perri, P; Rossi, CR; Santinami, M, )	0.13
"A population pharmacokinetic model for melphalan has been developed and validated and may now be used in conjunction with pharmacodynamic data to develop safe and effective dosing guidelines in children with malignant diseases."	( Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Earl, JW; Montgomery, K; Nath, CE; Shaw, PJ, 2007)	0.89
" Cytotoxicity of deferoxamine for neuroblastoma cell lines measured by the DIMSCAN assay achieved dose-response curves similar to data obtained by manual trypan blue counts or colony formation in soft agar but with a wider dynamic range."	( A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Frgala, T; Kalous, O; Proffitt, RT; Reynolds, CP, 2007)	0.34
" BSA- or age-based dosing is used with therapeutic drug monitoring (TDM) to reduce this variability."	( Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Doz, F; Espérou, H; Galambrun, C; Gentet, JC; Mechinaud, F; Michel, G; Neven, B; Nguyen, L; Puozzo, C; Valteau-Couanet, D; Vassal, G; Zouabi, H, 2008)	0.35
"A new intravenous (IV) dosing of busulfan (Bu) based on body weight, designed to improve AUC targeting without TDM and dose-adjustment, was prospectively evaluated."	( Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Doz, F; Espérou, H; Galambrun, C; Gentet, JC; Mechinaud, F; Michel, G; Neven, B; Nguyen, L; Puozzo, C; Valteau-Couanet, D; Vassal, G; Zouabi, H, 2008)	0.35
" This new dosing enabled to achieve a mean exposure comparable to that in adults."	( Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Doz, F; Espérou, H; Galambrun, C; Gentet, JC; Mechinaud, F; Michel, G; Neven, B; Nguyen, L; Puozzo, C; Valteau-Couanet, D; Vassal, G; Zouabi, H, 2008)	0.35
" The dose-response relationships for melphalan and irinotecan in individual samples showed great variability."	( Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis. Glimelius, B; Graf, W; Grundmark, B; Larsson, R; Mahteme, H; Nygren, P; Påhlman, L; Tholander, B; von Heideman, A, 2008)	0.62
" These data may aid the design of studies to clarify optimal dosing and leukapheresis with pegfilgrastim."	( A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Baker, N; Barker, P; Boogaerts, M; Canizo, CD; Johnsen, HE; Mesters, R; Russell, N; Schmitz, N; Schubert, J; Skacel, T, 2008)	0.35
" Pharmacokinetic assays of mycophenolic acid (MPA) showed a therapeutic area under the curve (AUC) at the dosage of 3 g daily, although a large inter- and intraindividual variations of MPA plasma levels were found."	( Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. Caballero, D; Calvo, MV; de la Cámara, R; de Oteiza, JP; Heras, I; Martino, R; Pérez-Simón, JA; Rebollo, N; San Miguel, JF; Sierra, J; Valcarcel, D, 2008)	0.35
" The goal of dosing 200 mg per day was achieved in just 17 of 31 patients, and the median tolerated thalidomide dose was 100 mg per day."	( Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. Callander, NS; Chang, JE; Gangnon, RE; Juckett, MB; Kahl, BS; Longo, WL; Mitchell, TL, 2008)	0.61
" Weight-based dosing has been suggested to better predict toxicity of the conditioning regimen."	( Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Ansell, SM; Costa, LJ; Inwards, DJ; Johnston, PB; Litzow, MR; Micallef, IN; Porrata, LF, 2008)	0.35
" The optimal target area under the curve (AUC) and dosing schedule of intravenous busulfan in children undergoing hematopoietic stem cell transplantation (HSCT) remain unclear, however."	( Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Bartelink, IH; Belitser, SV; Bierings, M; Boelens, JJ; Bredius, RG; Egberts, AC; Egeler, M; Knibbe, CA; Lankester, AC; Suttorp, MM; Zwaveling, J, 2009)	0.35
" Further work is indicated to determine optimal dosing regimens, maximal tolerated dosage, and subsequent visual function in these patients."	( Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Abramson, DH; Brodie, SE; Dunkel, IJ; Kim, JW; Pierre Gobin, Y, 2009)	0.35
"This study aims to determine what effect correcting melphalan dosing for ideal body weight (IBW) has on toxicity and response in isolated limb infusion (ILI) in patients with advanced extremity melanoma."	( Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Augustine, CK; Beasley, GM; Cheng, TY; McMahon, N; Padussis, JC; Petros, W; Sanders, G; Spasojevic, I; Tyler, DS; Zipfel, P, 2009)	0.99
" Body surface area-based dosing in the FLU/MEL regimen led to a wide range of MEL doses administered per kilogram body weight (2."	( Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2. Karas, M; Koza, V; Steinerova, K; Vokurka, S, 2009)	0.35
"In isolated limb perfusion (ILP) with tumor necrosis factor-alpha (TNFalpha) and interferon (IFN)-gamma, pioneered by Lienard and Lejenne in 1988, TNFalpha was empirically employed at a dosage (3-4 mg) ten times higher than the systemic maximum tolerable dose (MTD)."	( Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion. Anzà, M; Armenti, A; Botti, C; Cavaliere, F; Corrias, F; Di Angelo, P; Di Filippo, F; Di Filippo, S; Ferraresi, V; Garinei, R; Giacomini, P; Ginebri, A; Pasqualoni, R; Perri, P; Rossi, CR; Santinami, M; Sofra, C; Sperduti, I, )	0.13
" Forty patients were treated with a TNFalpha dosage of >1 mg and 73 with 1 mg."	( Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion. Anzà, M; Armenti, A; Botti, C; Cavaliere, F; Corrias, F; Di Angelo, P; Di Filippo, F; Di Filippo, S; Ferraresi, V; Garinei, R; Giacomini, P; Ginebri, A; Pasqualoni, R; Perri, P; Rossi, CR; Santinami, M; Sofra, C; Sperduti, I, )	0.13
" The TNFalpha dosage of 1 mg was as effective as 3-4 mg, with lower toxicity and cost."	( Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion. Anzà, M; Armenti, A; Botti, C; Cavaliere, F; Corrias, F; Di Angelo, P; Di Filippo, F; Di Filippo, S; Ferraresi, V; Garinei, R; Giacomini, P; Ginebri, A; Pasqualoni, R; Perri, P; Rossi, CR; Santinami, M; Sofra, C; Sperduti, I, )	0.13
" We administered estradiol, in several dosing regimens, to male, female and ovariectomized nude rats in a survival study."	( Estrogen increases survival in an orthotopic model of glioblastoma. Barone, TA; Gorski, JW; Greenberg, SJ; Plunkett, RJ, 2009)	0.35
"Even after complete surgical resection of pulmonary metastases, many patients develop recurrent disease in the thorax despite the use of systemic chemotherapy, dosage of which is limited because of systemic toxicity."	( Locoregional therapy. Friedel, G; Furrer, M; Van Schil, PE, 2010)	0.36
"Because of the less graft-facilitating effect by bone marrow (BM), we need to assess a dosage of conditioning more accurately particularly in combination with reduced-intensity conditioning."	( A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies. Atsuta, Y; Imahashi, N; Ito, T; Kato, T; Miyamura, K; Morishita, Y; Murata, M; Naoe, T; Nishiwaki, S; Ohashi, H; Sawa, M; Suzuki, R; Terakura, S; Yasuda, T, 2011)	0.58
"Isolated limb infusion (ILI) with melphalan (M-ILI) dosing corrected for ideal body weight (IBW) is a well-tolerated treatment for patients with in-transit melanoma with a 29% complete response rate."	( Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. Augustine, CK; Beasley, GM; Grobmyer, SR; Hochwald, SN; Peterson, B; Riboh, JC; Ross, MI; Royal, R; Tyler, DS; Zager, JS, 2011)	0.88
" The empirical practice of body surface area-based (BSA) dosing (mg/m2) of melphalan has been critically analyzed in several observations."	( [The variance of melphalan doses related to kilogram of body weight and the consequences]. Vokurka, S, 2010)	0.93
"Obesity has implications for chemotherapy dosing and selection of patients for therapy."	( Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Ballen, K; Bashey, A; Freytes, C; Gibson, J; Hari, P; Heitjan, DF; Holmberg, L; Kamble, R; Kyle, RA; Lazarus, HM; Maharaj, D; Maiolino, A; McCarthy, PL; Pérez, WS; Roy, V; Stadtmauer, EA; Vesole, D; Vogl, DT; Wang, T; Weisdorf, D, 2011)	0.37
" Lenalidomide was dosed 10 mg on days 1 to 21 of a 28-day schedule for a total of 24 cycles."	( Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S, 2011)	0.37
"The PBPK model matched the pharmacokinetics in different dosing regimens in adults."	( Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. Boos, J; Hempel, G; Kersting, G; Lippert, J; Willmann, S; Würthwein, G, 2012)	0.38
" A risk-adapted approach to melphalan dosing with PBSCT is an effective treatment in patients with primary AL amyloidosis."	( [Three patients with primary AL amyloidosis treated by high-dose melphalan with autologous peripheral blood stem cell transplantation]. Kanashima, H; Mukai, S; Nakao, T; Ogawa, Y; Teshima, H; Yamane, T, 2012)	0.91
" The UE appears relatively resistant to toxic effects of melphalan-based ILI as currently performed, which suggests a potential for further optimization of drug dosing for UE ILI."	( A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion. Beasley, GM; Dewhirst, MW; Lidsky, M; Masoud, M; Miller, M; Mosca, PJ; Sharma, K; Turley, RS; Tyler, DS; Wong, J; Zager, JS, 2012)	0.83
" The primary objective was to determine the safest and best tolerated maintenance dosing (MD) of bortezomib (B)."	( Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma. Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Deol, A; Gul, Z; Lum, L; Mellon-Reppen, S; Ratanatharathorn, V; Uberti, J; Ventimiglia, M; Zonder, J, 2012)	0.61
" By the late 1960s, extended dosing with melphalan and prednisone tripled survival from diagnosis and became the standard of care for newly diagnosed MM."	( Evolving therapeutic paradigms for multiple myeloma: back to the future. Cherry, BM; Korde, N; Kwok, M; Landgren, O; Roschewski, M, 2013)	0.66
" Palifermin has permitted safe dose escalation of melphalan up to 280 mg/m(2), thus reaching the cumulative dosage of melphalan administered in tandem ASCT."	( A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function. Abidi, MH; Abrams, J; Agarwal, R; Al-Kadhimi, Z; Ayash, L; Cronin, S; Deol, A; Lum, L; Ratanatharathorn, V; Tageja, N; Uberti, J; Ventimiglia, M; Zonder, J, 2013)	0.9
" Meanwhile, the median dosage of MEL in our procedure was 103 mg/m(2) (range 68∼180), less than the recommended dose, and patients were maintained on miscellaneous therapies."	( [Clinical analysis of autologous stem cell transplantation for nine cases of cardiac amyloidosis]. Abe, Y; Iizuka, H; Kusaka, S; Nakagawa, Y; Nishiyama, S; Ogura, M; Sekine, R; Suzuki, K, 2012)	0.38
"The average concentration of melphalan required for inducing significant apoptosis was 61 μM, or about 3-fold less than the theoretical concentration of 192 μM, achieved in the hepatic artery during CS-PHP dosing with melphalan."	( Evaluation of melphalan, oxaliplatin, and paclitaxel in colon, liver, and gastric cancer cell lines in a short-term exposure model of chemosaturation therapy by percutaneous hepatic perfusion. Johnston, DS; Sheets, TP; Uzgare, RP, 2013)	1.04
" As a RIC regimen for CBT, 140 mg/m(2) melphalan with fludarabine and anti-lymphocyte globulin or anti-thymocyte globulin may be feasible, but further dosage optimization should be performed in controlled clinical trials."	( Feasibility of reduced-intensity conditioning followed by unrelated cord blood transplantation for primary hemophagocytic lymphohistiocytosis: a nationwide retrospective analysis in Japan. Atsuta, Y; Goto, H; Inagaki, J; Inoue, M; Ishii, E; Kato, K; Kawa, K; Koike, K; Ohga, S; Okada, K; Sawada, A; Suzuki, N; Suzuki, R; Yabe, H; Yasutomo, K, 2013)	0.66
" Further studies to examine intra-arterial chemotherapy's pharmacokinetics and dose-response relations are warranted in order to minimize the necessary exposure to chemotherapy."	( Intra-arterial chemotherapy for group C retinoblastoma with adjacent high-flow infantile hemangioma. Orbach, DB; Shah, AS; Trief, D; Vanderveen, DK; Yonekawa, Y, )	0.13
" Panobinostat + melphalan appears to have tolerability issues in a dosing regimen capable of producing a response."	( A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Berenson, JR; Boccia, RV; Dressler, K; Ghazal, HH; Harb, WA; Hilger, JD; Jamshed, S; Kingsley, EC; Matous, J; Nassir, Y; Noga, SJ; Swift, RA; Vescio, R; Yellin, O, 2014)	1
"Significant ocular complications following IViT for retinoblastoma are uncommon, and this risk may be reduced further by the use of careful injection technique and standard dosing regimens."	( Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review. Mohney, BG; Smith, BD; Smith, SJ, 2014)	0.4
"To evaluate whether blood-based genotoxicity endpoints can provide temporal and dose-response data within the low-dose carcinogenic range that could contribute to carcinogenic mode of action (MoA) assessments, we evaluated the sensitivity of flow cytometry-based micronucleus and Pig-a gene mutation assays at and below tumorigenic dose rate 50 (TD50) levels."	( Pig-a gene mutation and micronucleated reticulocyte induction in rats exposed to tumorigenic doses of the leukemogenic agents chlorambucil, thiotepa, melphalan, and 1,3-propane sultone. Avlasevich, SL; Bemis, JC; Cottom, J; Dertinger, SD; Macgregor, JT; Mereness, J; Phonethepswath, S; Torous, DK, 2014)	0.6
" This article reviews the current published literature on the dosing of pharmacologic agents used for HCT preparative regimens with specific focus on the obese patient population."	( Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Bubalo, J; Carpenter, PA; Leather, HL; Majhail, N; Marks, DI; Perales, MA; Pidala, J; Savani, BN; Shaughnessy, P; Wingard, J, 2014)	0.4
" Limited data exist on the comparison of the two dosing schedules."	( Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma. Alsina, M; Bookout, R; Kim, J; Nishihori, T; Parmar, SR; Perkins, J; Shapiro, JF; Tombleson, R; Tomblyn, M; Yue, B, 2014)	0.66
" The first step of the study was to assess the dose-response of Melphalan 21 days after engraftment."	( Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy. Bruchertseifer, F; Chérel, M; Davodeau, F; Faivre-Chauvet, A; Gaschet, J; Gouard, S; Kraeber-Bodéré, F; Matous, E; Maurel, C; Morgenstern, A; Pallardy, A, 2014)	0.86
"Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various twice-weekly and once-weekly bortezomib dosing schedules."	( Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Boccadoro, M; Bringhen, S; Desai, A; Di Raimondo, F; Esseltine, DL; García-Sanz, R; Lahuerta, JJ; Larocca, A; Londhe, A; Mateos, MV; Oriol, A; Palumbo, A; Richardson, PG; San Miguel, JF; van de Velde, H, 2014)	0.87
" We present a retrospective analysis of 73 consecutive patients aged over 65 years treated for aggressive or relapsed lymphoma by HDT with carmustine, etoposide, cytarabine and melphalan (BEAM) at full dosage followed by ASCT."	( High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A, 2015)	0.85
" In the phase 1 portion of the study, 24 patients received CMP at carfilzomib dosing levels of 20 mg/m(2), 27 mg/m(2), 36 mg/m(2), and 45 mg/m(2)."	( Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Chaleteix, C; Chiffoleau, A; Facon, T; Fortin, J; Hulin, C; Kolb, B; Leleu, X; Mary, JY; Moreau, P; Planche, L; Roussel, M; Tiab, M; Touzeau, C, 2015)	0.69
" Busulfan dosing targeted 4000 μM-minute/day (days -8 to -5)."	( Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hagemeister, F; Hosing, C; Jones, RB; Liu, Y; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC, 2015)	0.66
"Despite advances in cross-sectional imaging, chemotherapeutic dosing for isolated limb infusion (ILI) in melanoma is currently calculated through cumbersome and potentially imprecise manual measurements."	( Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma. Bashir, MR; Beasley, GM; Bhatti, L; Brys, AK; Jaffe, TA; Mosca, PJ; Nath, NS; Salama, AK; Tyler, DS, 2016)	0.43
"CT-based limb volume measurement is feasible for chemotherapy dosing in patients undergoing ILI for melanoma and has predictive value with respect to clinical response and toxicity."	( Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma. Bashir, MR; Beasley, GM; Bhatti, L; Brys, AK; Jaffe, TA; Mosca, PJ; Nath, NS; Salama, AK; Tyler, DS, 2016)	0.43
" Precision dosing trials are warranted."	( Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT. Davies, SM; Filipovich, AH; Jodele, S; Lane, A; Marsh, RA; Mehta, PA; Neumeier, L, 2016)	0.64
" This analysis of the pivotal phase 3 FIRST trial examined the impact of renally adapted dosing of lenalidomide and dexamethasone on outcomes of patients with different degrees of renal impairment."	( Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R, 2016)	0.43
" Melphalan and tumor necrosis factor-alpha are used at a dosage that depends on the volume of the limb."	( Calculating regional tissue volume for hyperthermic isolated limb perfusion: Four methods compared. Bodanza, V; Bui, F; Campana, LG; Cecchin, D; Frigo, AC; Gregianin, M; Negri, A; Rastrelli, M; Rossi, CR; Zucchetta, P, 2016)	1.34
" Pharmacokinetic dosing of busulfan (Bu) is frequently done for myeloablative conditioning, but evidence for its use is limited in RIC transplants."	( Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. Al-Kali, A; Alkhateeb, HB; Damlaj, M; Gangat, N; Gastineau, DA; Hashmi, S; Hefazi, M; Hogan, WJ; Litzow, MR; Partain, DK; Patnaik, MM; Wolf, RC, 2016)	0.66
" We retrospectively analyzed the outcome of 79 adult patients who underwent auto-HSCT for lymphoma using this regimen in two centers, with 1- and 2-day dosing of MEL, respectively."	( Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ashizawa, M; Fujiwara, S; Hatano, K; Ito, S; Kako, S; Kanda, Y; Kawasaki, Y; Mashima, K; Minakata, D; Muroi, K; Nakano, H; Oh, I; Ohmine, K; Okazuka, K; Sato, K; Sugimoto, M; Suzuki, T; Umino, K; Yamamoto, C; Yamasaki, R, 2016)	0.62
" This prompted us to explore the concept of less intense drug dosing with shorter intervals between courses with the aim of preventing inter-course relapse."	( Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Alapat, D; Avery, D; Bailey, C; Barlogie, B; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Jethava, Y; Khan, R; Mitchell, A; Morgan, G; Petty, N; Sawyer, J; Schinke, C; Smith, R; Stein, C; Steward, D; Thanendrarajan, S; Tian, E; van Rhee, F; Waheed, S; Yaccoby, S; Zangari, M, 2016)	0.43
"Stem cell transplantation (SCT), an effective therapy for amyloid light chain (AL) amyloidosis patients, is associated with low treatment-related mortality (TRM) with appropriate patient selection and risk-adapted dosing of melphalan (RA-SCT)."	( Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. Bello, C; Chou, JF; Comenzo, RL; Devlin, SM; Giralt, S; Hassoun, H; Landau, H; Landry, C; Smith, M, 2017)	0.88
" We previously suggested an optimal day 0 targeted range of alemtuzumab, but there are no pediatric data regarding the pharmacokinetics (PK) of subcutaneous alemtuzumab to guide precision dosing trials."	( Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab. Chandra, S; Emoto, C; Fukuda, T; Khandelwal, P; Marsh, RA; Mehta, PA; Neumeier, L; Teusink-Cross, A; Vinks, AA, 2017)	0.46
" These findings contribute to ongoing efforts to personalize melphalan dosing in transplant patients."	( Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial. Benson, DM; Cho, YK; Devine, SM; Efebera, YA; Gao, Y; Hade, EM; Hofmeister, CC; Lamprecht, M; Li, J; Phelps, MA; Poi, M; Rosko, AE; Sborov, DW; Tackett, K; Wang, J; Williams, N, 2017)	1
"High-dose chemotherapies to treat multiple myeloma (MM) can be life-threatening due to toxicities to normal cells and there is a need to target only tumor cells and/or lower standard drug dosage without losing efficacy."	( Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid. Allamargot, C; Coleman, KL; Frech, I; Nessler, R; Tricot, G; Xia, J; Xu, H; Zhan, F; Zhang, X, 2017)	0.46
" On day 1 of cycle 1, seven whole-blood samples were collected for 3 h after dosing completion to obtain the maximum plasma concentration and area under the time-concentration curve during 3 h postdose (AUC0-3) in each patient."	( Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. Choi, K; Han, S; Hong, T; Lee, J; Lee, SE; Min, CK; Park, GJ; Yim, DS, 2017)	0.46
" This study demonstrated that a fast analysis for the purpose of quantifying a chemically unstable drug, such as melphalan, is feasible and important for the development of commercial dosage forms."	( Rapid and simple flow injection analysis tandem mass spectrometric method for the quantification of melphalan in a lipid-based drug delivery system. Badea, I; El-Aneed, A; Michel, D; Mohammed-Saeid, W, 2017)	0.88
" The current dosing strategy based on body surface area results in a high incidence of oral mucositis and gastrointestinal and liver toxicity."	( Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation. Anaissie, EJ; Chandra, S; Dong, M; Fukuda, T; McConnell, S; Mehta, PA; Mizuno, K; Vinks, AA, 2018)	0.7
"Limited guidance exists for dosing melphalan for autologous stem cell transplantation (ASCT) in the obese patient population, because the current literature reports conflicting clinical outcomes between obese and nonobese patients."	( Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation. Arp, C; DeFrates, S; Shultes, KC; Stockerl-Goldstein, K; Trinkaus, K, 2018)	1.06
" This information can inform delivery location and dosing strategies on a patient-specific basis."	( Estimation of intra-arterial chemotherapy distribution to the retina in pediatric retinoblastoma patients using quantitative digital subtraction angiography. Alexander, M; Amans, MR; Cooke, DL; Damato, B; Darflinger, R; Dowd, CF; Halbach, VV; Hetts, SW; Higashida, RT; Kao, A; Kondapavulur, S; Matthay, KK, 2018)	0.48
" A daily melphalan dosing schedule reportedly is well tolerated and associated with favorable outcome."	( Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs. Chon, E; Fernández, R, 2018)	1.23
"Positive results support the use of either dosing regimen for the treatment of dogs with MM, and renal disease and NLR were negative prognostic factors."	( Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs. Chon, E; Fernández, R, 2018)	0.81
" We note that induction therapy may deprive some patients of the opportunity to proceed to SCT but is likely needed if the marrow plasmacytosis is > 10%, that risk-adapted melphalan dosing continues to be relevant, and that post-SCT consolidation improves the complete response rate as well as long-term overall survival."	( High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review. Comenzo, RL; Varga, C, 2019)	1.11
"Carboplatin dosage is calculated by using the estimated glomerular filtration rate (GFR) to achieve a target plasma area under the plasma concentration-time curve (AUC)."	( Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. Boddy, AV; Duong, JK; Errington, J; Ladenstein, R; Nath, CE; Shaw, PJ; Veal, GJ, 2019)	0.76
" A population pharmacokinetic model was built for carboplatin to evaluate various dosing formulas."	( Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. Boddy, AV; Duong, JK; Errington, J; Ladenstein, R; Nath, CE; Shaw, PJ; Veal, GJ, 2019)	0.76
" This model-based approach validates the use of weight-based dosing as an appropriate alternative for carboplatin in children with either mild renal impairment or normal renal function."	( Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. Boddy, AV; Duong, JK; Errington, J; Ladenstein, R; Nath, CE; Shaw, PJ; Veal, GJ, 2019)	0.76
" Using various dosing schedules, the majority of patients (684/694) received daratumumab at a dose of 16 mg/kg."	( Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma. Belch, A; Capra, M; Clemens, PL; Dimopoulos, MA; Gomez, D; Ho, PJ; Iida, S; Jansson, R; Leiba, M; Medvedova, E; Min, CK; Schecter, J; Sonneveld, P; Sun, YN; Xu, XS; Zhang, L, 2018)	0.48
"These data support the recommended 16 mg/kg dose of daratumumab and the respective dosing schedules in the POLLUX and CASTOR pivotal studies."	( Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma. Belch, A; Capra, M; Clemens, PL; Dimopoulos, MA; Gomez, D; Ho, PJ; Iida, S; Jansson, R; Leiba, M; Medvedova, E; Min, CK; Schecter, J; Sonneveld, P; Sun, YN; Xu, XS; Zhang, L, 2018)	0.48
" Mean dosage given showed significant difference between the groups."	( Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients. Meng, F; Qian, J; Ren, H; Xue, K; Zhang, R, 2019)	0.8
"5 mg, whereby a strict protocol with age-appropriate dosage was not used until 2015."	( Histopathology of retinoblastoma eyes enucleated after intra-arterial chemotherapy. Bechrakis, NE; Biewald, EM; Bornfeld, N; Göricke, S; Ketteler, P; Kiefer, T; Metz, KA; Radbruch, A; Schlüter, S; Sirin, S, 2020)	0.56
" The phase III VISTA trial established the bortezomib dosing schedule for VMP."	( Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. Cavo, M; Deraedt, W; Dimopoulos, MA; He, J; Jakubowiak, A; Kampfenkel, T; Lam, A; Mateos, MV; Qi, M; San-Miguel, J, 2020)	0.83
"Here we outline the methods to establish novel melphalan dosing using PK testing in MM patients undergoing ASCT to target a desired melphalan AUC."	( Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant. Calip, GS; Galvin, JP; Hofmeister, CC; Johnson, JJ; Mahmud, N; Patel, P; Rondelli, D; Sweiss, K; Vemu, B; Wenzler, E, 2020)	1.04
" One patient experienced renal dysfunction during the first HDCT, which was alleviated by sufficient hydration and diuretics and resulted in the reduction of melphalan dosage for the second HDCT."	( Tandem high-dose chemotherapy with autologous stem cell rescue for stage M high-risk neuroblastoma: Experience using melphalan/etoposide/carboplatin and busulfan/melphalan regimens. Arakawa, Y; Hiwatari, M; Hogetsu, K; Kato, S; Koh, K; Kubota, Y; Takita, J; Watanabe, K, 2020)	0.96
" To more thoroughly investigate the dose-response relationships, benchmark dose (BMD) analyses were performed with PROAST software."	( Pig-a gene mutation assay study design: critical assessment of 3- versus 28-day repeat-dose treatment schedules. Dertinger, SD; Elhajouji, A; Hove, TT; Martus, H; O'Connell, O, 2020)	0.56
"A validated PS-MS/MS assay for melphalan in patients undergoing HSCT is described that facilitates pharmacokinetic-guided individualized precision dosing with immediate bedside dose adjustments to improve outcomes by balancing toxicity and efficacy of melphalan."	( Paperspray Ionization Mass Spectrometry as a Tool for Predicting Real-Time Optimized Dosing of the Chemotherapeutic Drug Melphalan. Mehta, PA; Mizuno, K; Setchell, KDR; Sharat, C; Vinks, AA; Zhao, J, 2021)	1.12
" This model can be used to define the therapeutic window of melphalan, and subsequently to develop individualized dosing regimens aiming for that therapeutic window in all patients."	( Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens. Admiraal, R; Alperovich, A; Boelens, JJ; Carlow, D; Cruz Sitner, N; Dahi, P; Giralt, SA; Lin, A; Proli, A; Ruiz, J; Schofield, R; Scordo, M; Shah, GL; Tamari, R, 2022)	1.25
"To improve the therapeutic properties of the antitumor agent Sarcolysin, we have previously developed and characterized a dosage form representing its ester conjugate with decanol embedded in ultra-small phospholipid nanoparticles less than 30 nm in size ("Sarcolysin-NP")."	( [The effect of lipid derivative of anti-tumor drug sarcolysin embedded in phospholipid nanoparticles in the experiments in vivo]. Khudoklinova, YY; Kostryukova, LV; Sanzhakov, MA; Tereshkina, YA; Tikhonova, EG; Torkhovskaya, TI, 2021)	0.62
" Results suggest the empiric weight-based dosing (mg/kg) used in children <12 kg or 2 years of age may result in subtherapeutic exposure."	( Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation. Apsel Winger, B; Chan, D; Dvorak, CC; Gobburu, JVS; Li, S; Long-Boyle, J; Lu, Y, 2022)	1.01
" Measured GFR (mGFR) may better predict drug dosing to mitigate toxicity and increase the chances of successful engraftment."	( Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning. Alkhateeb, HB; Barreto, EF; Bartoo, GT; Hogan, WJ; Kutzke, JL; Leung, N; Litzow, MR; Mangaonkar, AA; Mara, KC; Merten, JA; Pawlenty, AG; Shah, MV, 2022)	0.95
" We found that the traditional fixed weight-based dosing of propylene glycol-free (captisol-enabled) melphalan in BEAM results in a wide variation in exposure as estimated by both models."	( Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation. Admiraal, R; Boelens, JJ; Carlow, D; Cho, C; Dahi, PB; DeRespiris, L; Devlin, SM; Flynn, JR; Giralt, SA; Lahoud, OB; Lin, A; Perales, MA; Ruiz, JD; Sauter, CS; Scordo, M; Shah, GL, 2022)	1.3
" Various dosing schedules and modifications, timing of administration, and novel drugs-based combination regimens are discussed."	( High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma. Al Hadidi, S; Ali, MO, 2022)	0.72
" So, time of exposure as well as the amount of exposure (total dosage administered) is critical in determining the magnitude of the damage in germ cell risk assessment."	( Juvenile exposure and adult risk assessment with single versus repeated exposure of melphalan in the germ cells of male SD rat: Deciphering the molecular mechanisms. Jena, G; Panghal, A; Sahu, C; Singla, S, 2022)	0.95
" Future studies will aim to modulate melphalan exposure by PK-targeted dosing and characterize patient taste preferences to personalize diets for improved nutritional intake."	( A prospective study of dysgeusia and related symptoms in patients with multiple myeloma after autologous hematopoietic cell transplantation. Adintori, PA; Barasch, A; Buchan, ML; Carino, CA; Carlow, DC; Chung, DJ; Devlin, SM; Giralt, SA; Klang, MG; Knezevic, A; Lahoud, OB; Landau, HJ; Lin, AP; Maloy, MA; Mastrogiacomo, B; Nguyen, LK; Peled, JU; Preston, EV; Rodriguez, NT; Schofield, RC; Scordo, M; Shah, GL; Sitner, NC; Slingerland, AE; Slingerland, JB; Stein-Thoeringer, CK; van den Brink, MRM, 2022)	0.99
" A protocol with repeated 10-day cyclical dosing of melphalan has been used at our institution but has not been described in the literature."	( Cyclical 10-day dosing of melphalan for canine multiple myeloma. Hume, KR; O'Connor, KS; Sylvester, SR; Teddy, L, 2023)	1.46

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
carcinogenic agent	A role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
alkylating agent	Highly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases.
immunosuppressive agent	An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response.
drug allergen	Any drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
organochlorine compound	An organochlorine compound is a compound containing at least one carbon-chlorine bond.
nitrogen mustard	Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
L-phenylalanine derivative	A proteinogenic amino acid derivative resulting from reaction of L-phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-phenylalanine by a heteroatom.
non-proteinogenic L-alpha-amino acid	Any L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	56.2341	0.0040	23.8416	100.0000	AID485290
glp-1 receptor, partial	Homo sapiens (human)	Potency	5.6234	0.0184	6.8060	14.1254	AID624417
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	79.4328	0.1000	20.8793	79.4328	AID588453
15-lipoxygenase, partial	Homo sapiens (human)	Potency	31.6228	0.0126	10.6917	88.5700	AID887
phosphopantetheinyl transferase	Bacillus subtilis	Potency	5.6234	0.1413	37.9142	100.0000	AID1490
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	11.2345	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
Fumarate hydratase	Homo sapiens (human)	Potency	16.7259	0.0030	8.7949	48.0869	AID1347053
USP1 protein, partial	Homo sapiens (human)	Potency	89.1251	0.0316	37.5844	354.8130	AID504865
GLS protein	Homo sapiens (human)	Potency	22.3872	0.3548	7.9355	39.8107	AID624170
TDP1 protein	Homo sapiens (human)	Potency	0.3880	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	26.5894	0.0007	14.5928	83.7951	AID1259392
AR protein	Homo sapiens (human)	Potency	26.2265	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID588516; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
thioredoxin glutathione reductase	Schistosoma mansoni	Potency	14.1254	0.1000	22.9075	100.0000	AID485364
Smad3	Homo sapiens (human)	Potency	10.0000	0.0052	7.8098	29.0929	AID588855
caspase 7, apoptosis-related cysteine protease	Homo sapiens (human)	Potency	31.4016	0.0133	26.9810	70.7614	AID1346978
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	2.8184	0.0112	12.4002	100.0000	AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	Homo sapiens (human)	Potency	50.1187	0.0013	7.7625	44.6684	AID2120
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	32.9540	0.0006	57.9133	22,387.1992	AID1259377
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	9.1286	0.0010	22.6508	76.6163	AID1224838; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	13.3332	0.0004	17.9460	75.1148	AID1346784
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	13.2459	0.0123	7.9835	43.2770	AID1346984; AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	3.5854	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	17.9465	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	19.4020	0.0008	17.5051	59.3239	AID1159527; AID1159531; AID588544
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	14.0730	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	27.8298	0.3758	27.4851	61.6524	AID588526; AID588527
pregnane X nuclear receptor	Homo sapiens (human)	Potency	31.9879	0.0054	28.0263	1,258.9301	AID1346982; AID1346985; AID720659
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	19.8940	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID588513; AID588514; AID743069; AID743075; AID743079; AID743080; AID743091
G	Vesicular stomatitis virus	Potency	38.9018	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	19.4971	0.0010	8.3798	61.1304	AID1645840
polyprotein	Zika virus	Potency	16.7259	0.0030	8.7949	48.0869	AID1347053
glucocerebrosidase	Homo sapiens (human)	Potency	39.8107	0.0126	8.1569	44.6684	AID2101
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	32.3254	0.0010	24.5048	61.6448	AID588534; AID588535
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	30.7981	0.0010	19.4141	70.9645	AID588536; AID588537; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	44.6684	0.0237	23.2282	63.5986	AID588543
caspase-3	Homo sapiens (human)	Potency	31.4016	0.0133	26.9810	70.7614	AID1346978
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	5.2276	0.0355	20.9770	89.1251	AID504332
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	33.2227	0.0007	23.0674	1,258.9301	AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	33.2227	0.0017	23.8393	78.1014	AID743083
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	34.5764	0.0391	47.5451	146.8240	AID1224845; AID1224896
Caspase-7	Cricetulus griseus (Chinese hamster)	Potency	33.4915	0.0067	23.4960	68.5896	AID1346980
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	15.8489	0.0178	9.6374	44.6684	AID588834
caspase-3	Cricetulus griseus (Chinese hamster)	Potency	33.4915	0.0067	23.4960	68.5896	AID1346980
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	6.9207	0.0003	23.4451	159.6830	AID743065; AID743067
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	125.8920	5.8048	36.1306	65.1308	AID540263
snurportin-1	Homo sapiens (human)	Potency	125.8920	5.8048	36.1306	65.1308	AID540263
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	54.4882	0.0006	27.2152	1,122.0200	AID651741; AID720636
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	2.5119	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	2.5119	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	2.5119	0.1585	5.2879	12.5893	AID540303
geminin	Homo sapiens (human)	Potency	9.8285	0.0046	11.3741	33.4983	AID624296; AID624297
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	9.5333	0.0056	12.3677	36.1254	AID624032; AID624044
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	14.1254	0.1259	12.2344	35.4813	AID1458
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	3.1623	0.0316	10.2792	39.8107	AID884; AID885
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	3.1623	1.0000	12.2248	31.6228	AID885
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	18.4146	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	38.9018	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	38.9018	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	25.0788	0.0023	19.5956	74.0614	AID651631; AID651743; AID720552
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	3.1623	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	3.1623	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	3.1623	1.0000	12.2248	31.6228	AID885
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	18.4146	0.0015	51.7393	15,848.9004	AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	3.1623	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	3.1623	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	3.1623	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	3.1623	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	3.1623	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	3.1623	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	3.1623	1.0000	12.2248	31.6228	AID885
Nuclear receptor ROR-gamma	Homo sapiens (human)	Potency	26.6032	0.0266	22.4482	66.8242	AID651802
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	31.6228	0.0096	10.5250	35.4813	AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	3.1623	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	3.1623	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	3.1623	1.0000	12.2248	31.6228	AID885
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	31.6228	1.7783	16.2081	35.4813	AID652104
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	3.1623	1.0000	12.2248	31.6228	AID885
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	38.9018	0.0123	8.9648	39.8107	AID1645842
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	30.4332	0.0119	17.9420	71.5630	AID651632; AID720516
Ataxin-2	Homo sapiens (human)	Potency	29.8493	0.0119	12.2221	68.7989	AID651632
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	3.1623	1.0000	12.2248	31.6228	AID885
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	38.9018	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	113.3750	0.1100	7.1903	10.0000	AID1449628; AID1473738
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Nuclear receptor ROR-gamma	Homo sapiens (human)
xenobiotic metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of glucose metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of steroid metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
intracellular receptor signaling pathway	Nuclear receptor ROR-gamma	Homo sapiens (human)
circadian regulation of gene expression	Nuclear receptor ROR-gamma	Homo sapiens (human)
cellular response to sterol	Nuclear receptor ROR-gamma	Homo sapiens (human)
positive regulation of circadian rhythm	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of fat cell differentiation	Nuclear receptor ROR-gamma	Homo sapiens (human)
positive regulation of DNA-templated transcription	Nuclear receptor ROR-gamma	Homo sapiens (human)
adipose tissue development	Nuclear receptor ROR-gamma	Homo sapiens (human)
T-helper 17 cell differentiation	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Nuclear receptor ROR-gamma	Homo sapiens (human)
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell population proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of B cell proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nuclear DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
signal transduction in response to DNA damage	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
isotype switching	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of isotype switching to IgG isotypes	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloading	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of cell cycle G2/M phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
protein binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
oxysterol binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
zinc ion binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
ligand-activated transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear receptor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleoplasm	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear body	Nuclear receptor ROR-gamma	Homo sapiens (human)
chromatin	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745850	Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745849	Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745846	Firefly Luciferase Counterscreen for Inhibitors of ATXN expression
AID1745848	Confirmatory qHTS for Inhibitors of ATXN expression
AID1745847	CMV-Luciferase Counterscreen for Inhibitors of ATXN expression
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID654073	Cytotoxicity against human HPLF cells after 48 hrs	2012	European journal of medicinal chemistry, May, Volume: 51	Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
AID1315402	Cytotoxicity against human A549 cells after 72 hrs by MTT assay	2016	European journal of medicinal chemistry, Aug-25, Volume: 119	Design and synthesis of novel pyrazolo[1,5-a]pyrimidine derivatives bearing nitrogen mustard moiety and evaluation of their antitumor activity in vitro and in vivo.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1191478	Cytostatic activity against human CEM cells	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Investigation of fatty acid conjugates of 3,5-bisarylmethylene-4-piperidone derivatives as antitumor agents and human topoisomerase-IIα inhibitors.
AID496821	Antimicrobial activity against Leishmania	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1185080	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	2014	ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7	Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates.
AID50735	Mean graph mid point was measured on colon cancer cells.	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds.
AID45823	Cytotoxicity against CEM T-lymphocytes.	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues.
AID1132956	Antitumor activity against mouse Walker 256 cells allografted in Sprague-Dawley rat assessed as increase in survival rate at 2.5 mg/kg/day, ip relative to control	1978	Journal of medicinal chemistry, Aug, Volume: 21, Issue:8	Antitumor agents 32. Synthesis and antitumor activity of cyclopentenone derivatives related to helenalin.
AID496820	Antimicrobial activity against Trypanosoma brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1594193	Selectivity ratio of IC50 for human SW620 cells under aerobic condition to IC50 for human SW620 cells under hypoxic condition	2019	Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10	Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
AID47647	Concentration required to inhibit 50% of cell growth on CEM lymphocytes.	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds.
AID396986	Cytotoxicity against human Caov3 cells after 72 hrs by MTT assay	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, cytotoxic and fluorescent properties of novel N-phosphorylalkyl substituted E,E-3,5-bis(arylidene)piperid-4-ones.
AID384309	Cytotoxicity against human HPC cells after 24 hrs by MTT assay	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells.
AID1916652	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Melphalan: Recent insights on synthetic, analytical and medicinal aspects.
AID99876	In vitro cytotoxicity against L1210 cells at a dose 10 ug/mL	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis of 5-[1-hydroxy(or methoxy)-2-bromo(or chloro)ethyl]-2'-deoxyuridines and related halohydrin analogues with antiviral and cytotoxic activity.
AID615291	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by crystal violet staining	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Bivalent bendamustine and melphalan derivatives as anticancer agents.
AID458819	Selectivity index, ratio of CC50 for human normal cells to CC50 for human HSC4 cells	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3	3,5-Bis(benzylidene)-1-[4-2-(morpholin-4-yl)ethoxyphenylcarbonyl]-4-piperidone hydrochloride: a lead tumor-specific cytotoxin which induces apoptosis and autophagy.
AID300175	Cytotoxicity against human Molt 4/C8 cells	2007	Bioorganic & medicinal chemistry, Sep-01, Volume: 15, Issue:17	E,E,E-1-(4-Arylamino-4-oxo-2-butenoyl)-3,5-bis(arylidene)-4-piperidones: a topographical study of some novel potent cytotoxins.
AID1191479	Cytostatic activity against human HeLa cells	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Investigation of fatty acid conjugates of 3,5-bisarylmethylene-4-piperidone derivatives as antitumor agents and human topoisomerase-IIα inhibitors.
AID496829	Antimicrobial activity against Leishmania infantum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID224730	Concentration required to inhibit 50% of cell growth on murine L1210 cells.	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds.
AID1916664	Plasma protein binding in human	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Melphalan: Recent insights on synthetic, analytical and medicinal aspects.
AID200785	The compound was tested for cytotoxicity against SF-188 (human) Glioma cell lines	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID653936	Cytotoxicity against human HGF cells after 48 hrs	2012	European journal of medicinal chemistry, May, Volume: 51	Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
AID1916661	Cytotoxicity against human K562 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Melphalan: Recent insights on synthetic, analytical and medicinal aspects.
AID539593	Growth inhibition of human NCI60 cells by SBR assay	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors.
AID393871	Cytotoxicity against HGF cells after 24 hrs by MTT assay	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	The cytotoxic properties and preferential toxicity to tumour cells displayed by some 2,4-bis(benzylidene)-8-methyl-8-azabicyclo[3.2.1] octan-3-ones and 3,5-bis(benzylidene)-1-methyl-4-piperidones.
AID496823	Antimicrobial activity against Trichomonas vaginalis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1439560	Cytotoxicity against mouse L1210 cells assessed as growth inhibition after 48 hrs by coulter counter method
AID384303	Cytotoxicity against mouse L1210 cells after 48 hrs	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells.
AID1594189	Cytotoxicity against human SW620 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay	2019	Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10	Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
AID92134	Evaluation for cytotoxicity to human tumor cell lines.	1998	Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7	Cytotoxic activities of Mannich bases of chalcones and related compounds.
AID393861	Cytotoxicity against human CEM cells after 72 hrs	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	The cytotoxic properties and preferential toxicity to tumour cells displayed by some 2,4-bis(benzylidene)-8-methyl-8-azabicyclo[3.2.1] octan-3-ones and 3,5-bis(benzylidene)-1-methyl-4-piperidones.
AID295417	Cytotoxicity against HSC2 cells	2007	Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10	3-(3,4,5-Trimethoxyphenyl)-1-oxo-2-propene: a novel pharmacophore displaying potent multidrug resistance reversal and selective cytotoxicity.
AID382490	Cytotoxicity against human gingival fibroblast by MTT method	2008	European journal of medicinal chemistry, Jan, Volume: 43, Issue:1	Cytotoxic 3,5-bis(benzylidene)piperidin-4-ones and N-acyl analogs displaying selective toxicity for malignant cells.
AID712166	Cytotoxicity against MMR-deficient human A2780/CP70 cells after 5 days by MTT assay in presence of 10 uM MGMT inactivator Patrin2	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR.
AID98496	Inhibitory effect on the biosyntheses of RNA in murine L1210 cells.	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues.
AID1439566	Cytotoxicity against human HPC after 48 hrs by MTT assay
AID225422	Concentration of compound required for 50% cross linking of plasmid pBR322 DNA was investigated using an assay involving linear double stranded DNA	2001	Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5	Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.
AID466506	Cytotoxicity against human CEM cells	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore.
AID1439567	Cytotoxicity against HPLF after 48 hrs by MTT assay
AID224731	Concentration required to inhibit 50% of cell growth on murine P388 D1 cells.	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds.
AID384992	Cytotoxicity against mouse L1210 cells after 72 hrs	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	1-Aryl-2-dimethylaminomethyl-2-propen-1-one hydrochlorides and related adducts: A quest for selective cytotoxicity for malignant cells.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID209939	Inhibitory effect on the biosyntheses of RNA using human Jurkat T cells.	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID88789	Concentration required to inhibit 50% growth of Human CEM T-lymphocytes cells	1998	Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7	Cytotoxic activities of Mannich bases of chalcones and related compounds.
AID1277012	Cytotoxicity against HGF assessed as cell death after 48 hrs by MTT assay	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID55444	The compound was tested for cytotoxicity against D283 MR (human) Glioma cell lines	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate.
AID629592	Cytotoxicity against human INA-6 cells assessed as viable fractions using annexin V-FITC/propidium iodide staining by flow cytometry	2011	European journal of medicinal chemistry, Dec, Volume: 46, Issue:12	Anti-tumoral activities of dioncoquinones B and C and related naphthoquinones gained from total synthesis or isolation from plants.
AID364034	Cytotoxicity against human KYSE520 cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID654083	Cytotoxicity against human RPMI8226 cells	2012	European journal of medicinal chemistry, May, Volume: 51	Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
AID1073152	Induction of apoptosis in human JJN-3 cells assessed as early apoptotic cells at 15 uM after 48 hrs by annexinV/propidium iodide staining (Rvb = 13.3%)	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells.
AID1916654	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability at 15 uM incubated for 24 hrs by MTT assay relative to control	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Melphalan: Recent insights on synthetic, analytical and medicinal aspects.
AID153691	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(12 for mortality range at an optimal dose of 5 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID393862	Cytotoxicity against mouse L1210 cells after 48 hrs	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	The cytotoxic properties and preferential toxicity to tumour cells displayed by some 2,4-bis(benzylidene)-8-methyl-8-azabicyclo[3.2.1] octan-3-ones and 3,5-bis(benzylidene)-1-methyl-4-piperidones.
AID283821	Cytotoxicity against human HCT116 cells	2007	European journal of medicinal chemistry, Jan, Volume: 42, Issue:1	Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds.
AID469472	Cytotoxicity against human Scov3 cells after 72 hrs by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, characterization and structure-activity relationship of novel N-phosphorylated E,E-3,5-bis(thienylidene)piperid-4-ones.
AID1777556	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay	2021	Bioorganic & medicinal chemistry, 09-01, Volume: 45	Design and synthesis of β-carboline derivatives with nitrogen mustard moieties against breast cancer.
AID615398	Cytostatic activity against mouse L1210 cells after 2 days by coulter counter assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design, synthesis and bioevaluation of novel candidate selective estrogen receptor modulators.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID103748	In vitro cytotoxicity activity against MCF-7	2002	Journal of medicinal chemistry, May-09, Volume: 45, Issue:10	Synthesis and in vitro evaluation of quaternary ammonium derivatives of chlorambucil and melphalan, anticancer drugs designed for the chemotherapy of chondrosarcoma.
AID477295	Octanol-water partition coefficient, log P of the compound	2010	European journal of medicinal chemistry, Apr, Volume: 45, Issue:4	QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
AID1136466	Immunosuppressive activity in mouse splenic lymphocytes isolated from 25 mg/kg, ip on days 2,3 and 5 treated CF1 mouse assessed as reduction in sheep red blood cell antigen-induced plaque-forming response (Rvb = 100%)	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Antitumor and antiinflammatory agents: N-benzoyl-protected cyanomethyl esters of amino acids.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID101740	In vitro cytotoxicity activity against M4 Beu, by colony forming assay	2002	Journal of medicinal chemistry, May-09, Volume: 45, Issue:10	Synthesis and in vitro evaluation of quaternary ammonium derivatives of chlorambucil and melphalan, anticancer drugs designed for the chemotherapy of chondrosarcoma.
AID408359	Induction of DNA interstrand cross linking in 20 Gy irradiated human H1299 cells at 200 uM after 1 hr by comet assay	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage.
AID24701	Degradation under physiological pH 9.0; Instantaneous	2000	Bioorganic & medicinal chemistry letters, Nov-06, Volume: 10, Issue:21	Stability of bioreductive drug delivery systems containing melphalan is influenced by conformational constraint and electronic properties of substituents.
AID496830	Antimicrobial activity against Leishmania major	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID364029	Cytotoxicity against human RT4 cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID594322	Antiproliferative activity against human Molt4/C8 cells assessed as inhibition of cell growth after 48 hrs by ZF-Coulter Counting	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Synthesis of novel antimitotic agents based on 2-amino-3-aroyl-5-(hetero)arylethynyl thiophene derivatives.
AID1292276	Cytotoxicity against human HSC2 cells after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Tumour-specific cytotoxicity and structure-activity relationships of novel 1-[3-(2-methoxyethylthio)propionyl]-3,5-bis(benzylidene)-4-piperidones.
AID462975	Binding affinity to DNA in human H1299 cells assessed as formation of DNA cross-links at 200 uM followed by irradiation by modified single cell gel electrophoresis comet assay	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Potent DNA-directed alkylating agents: Synthesis and biological activity of phenyl N-mustard-quinoline conjugates having a urea or hydrazinecarboxamide linker.
AID1594185	Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay	2019	Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10	Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
AID200783	The compound was tested for cytotoxicity against SF-126 (human) Glioma cell lines	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate.
AID444324	Cytotoxicity against human CEM cells	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Design, synthesis and bioevaluation of novel maleamic amino acid ester conjugates of 3,5-bisarylmethylene-4-piperidones as cytostatic agents.
AID385001	Cytotoxicity against human HSC4 cells	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	1-Aryl-2-dimethylaminomethyl-2-propen-1-one hydrochlorides and related adducts: A quest for selective cytotoxicity for malignant cells.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID398090	Growth inhibition of human Molt4/C8 cells after 3 days	2009	Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11	2-(3-Aryl-2-propenoyl)-3-methylquinoxaline-1,4-dioxides: a novel cluster of tumor-specific cytotoxins which reverse multidrug resistance.
AID98497	Inhibitory effect on the biosyntheses of protein in murine L1210 cells.	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues.
AID98495	Inhibitory effect on the biosyntheses of DNA in murine L1210 cells.	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues.
AID1277025	Selectivity index, ratio of CC50 for HPC to CC50 for human HL60 cells	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID354538	Cytotoxicity against rat C6 cells at 50 ug/mL to 2.5 mg/mL after 3 days treated 4 hrs before db-cAMP challenge by MTT assay	1996	Journal of natural products, Dec, Volume: 59, Issue:12	Cell-based screen for identification of inhibitors of tubulin polymerization.
AID153688	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(12 for median day of death at an optimal dose of 1 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID596215	Cytotoxicity against human HSC3 cells after 48 hrs	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.
AID101741	Comparative cellular uptake study performed on M4 Beu (melanoma cell line)	2002	Journal of medicinal chemistry, May-09, Volume: 45, Issue:10	Synthesis and in vitro evaluation of quaternary ammonium derivatives of chlorambucil and melphalan, anticancer drugs designed for the chemotherapy of chondrosarcoma.
AID1132955	Antitumor activity against mouse P388 cells allografted in DBA/2 mouse assessed as increase in survival rate at 25 mg/kg/day, ip administered for 2 weeks relative to control	1978	Journal of medicinal chemistry, Aug, Volume: 21, Issue:8	Antitumor agents 32. Synthesis and antitumor activity of cyclopentenone derivatives related to helenalin.
AID150684	Inhibition of proliferation of murine P388 cells	1998	Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7	Cytotoxic activities of Mannich bases of chalcones and related compounds.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1148042	Antitumor activity against mouse EAC allografted in CF1 mouse assessed as inhibition of tumor growth at 33 mg/kg/day measured on day 7	1977	Journal of medicinal chemistry, Dec, Volume: 20, Issue:12	Antineoplastic agents. 1. N-Protected vinyl, 1,2-dihaloethyl, and cyanomethyl esters of phenylalanine.
AID1148050	Antitumor activity against rat Walker 256 cells allografted in Sprague-Dawley rat assessed as animal survival days at 2.5 mg/kg/day, ip	1977	Journal of medicinal chemistry, Dec, Volume: 20, Issue:12	Antineoplastic agents. 2. Structure-activity studies on N-protected vinyl, 1,2-dibromoethyl, and cyanomethyl esters of several amino acids.
AID567542	Cytotoxicity against human renal cancer cells assessed as cell growth after 48 hrs by SRB assay	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Microwave supported synthesis of some novel 1,3-diarylpyrazino[1,2-a]benzimidazole derivatives and investigation of their anticancer activities.
AID744852	Cytotoxicity against human HeLa cells after 4 days by Coulter counter analysis	2013	European journal of medicinal chemistry, May, Volume: 63	Anticancer activity of novel hybrid molecules containing 5-benzylidene thiazolidine-2,4-dione.
AID712161	Cytotoxicity against human HCT116 cells after 5 days by MTT assay	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR.
AID1439593	Toxicity in ip dosed mouse
AID1275534	Cytotoxicity against human HSC2 cells after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	1-[3-(2-Hydroxyethylsulfanyl)propanoyl]-3,5-bis(benzylidene)-4-piperidones: A novel cluster of P-glycoprotein dependent multidrug resistance modulators.
AID524792	Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1178003	Antiproliferative activity against human CEM cells after 72 hrs by coulter counting analysis	2014	European journal of medicinal chemistry, Apr-22, Volume: 77	Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: structure-activity relationships and potent antileukemic and antilymphoma cytotoxicity.
AID221020	Effect on DNA biosyntheses in leukemia L1210 cells	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Correlations between cytotoxicity and topography of some 2-arylidenebenzocycloalkanones determined by X-ray crystallography.
AID300178	Cytotoxicity against human colon cancer cells	2007	Bioorganic & medicinal chemistry, Sep-01, Volume: 15, Issue:17	E,E,E-1-(4-Arylamino-4-oxo-2-butenoyl)-3,5-bis(arylidene)-4-piperidones: a topographical study of some novel potent cytotoxins.
AID666611	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and antitumor activity of formononetin nitrogen mustard derivatives.
AID99171	Tested in vivo for optimal non-toxic dose against L1210/LPAM cell line in CDF1 mice	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives.
AID99877	In vitro cytotoxicity against L1210 cells at a dose 50 ug/mL	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis of 5-[1-hydroxy(or methoxy)-2-bromo(or chloro)ethyl]-2'-deoxyuridines and related halohydrin analogues with antiviral and cytotoxic activity.
AID153372	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(14) for tumor free survivors at an optimal dose of 5 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID283823	Cytotoxicity against human KM12 cells	2007	European journal of medicinal chemistry, Jan, Volume: 42, Issue:1	Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds.
AID1292273	Cytotoxicity against human Molt4/C8 cells after 72 hrs by MTT assay	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Tumour-specific cytotoxicity and structure-activity relationships of novel 1-[3-(2-methoxyethylthio)propionyl]-3,5-bis(benzylidene)-4-piperidones.
AID382487	Cytotoxicity against human HSC2 by MTT method	2008	European journal of medicinal chemistry, Jan, Volume: 43, Issue:1	Cytotoxic 3,5-bis(benzylidene)piperidin-4-ones and N-acyl analogs displaying selective toxicity for malignant cells.
AID596211	Anticancer activity against human K562 cells	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.
AID654077	Cytotoxicity against human HCT15 cells	2012	European journal of medicinal chemistry, May, Volume: 51	Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID596201	Anticancer activity against human CCRF-CEM cells	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.
AID1178005	Antiproliferative activity against mouse L1210 cells after 72 hrs by coulter counting analysis	2014	European journal of medicinal chemistry, Apr-22, Volume: 77	Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: structure-activity relationships and potent antileukemic and antilymphoma cytotoxicity.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1916660	Lipophilicity, logP of the compound in n-octane/water by spectrophotometry	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Melphalan: Recent insights on synthetic, analytical and medicinal aspects.
AID1185725	Cytotoxicity against human HeLa cells after 72 hrs by Coulter counting method	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	2-(4-Chlorobenzyl)-6-arylimidazo[2,1-b][1,3,4]thiadiazoles: synthesis, cytotoxic activity and mechanism of action.
AID1584825	Growth inhibition of human MDA-MB-468 cells after 48 hrs by fluorescence polarisation assay	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Discovery and Optimization of Novel Hydrogen Peroxide Activated Aromatic Nitrogen Mustard Derivatives as Highly Potent Anticancer Agents.
AID444322	Cytotoxicity against mouse L1210 cells	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Design, synthesis and bioevaluation of novel maleamic amino acid ester conjugates of 3,5-bisarylmethylene-4-piperidones as cytostatic agents.
AID153695	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(12) for tumor free survivors at an optimal dose of 1 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID408376	Cytotoxicity against human Molt4/C8 cells after 72 hrs	2008	Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11	E,E-2-Benzylidene-6-(nitrobenzylidene)cyclohexanones: syntheses, cytotoxicity and an examination of some of their electronic, steric, and hydrophobic properties.
AID1185723	Cytotoxicity against mouse L1210 cells after 48 hrs by Coulter counting method	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	2-(4-Chlorobenzyl)-6-arylimidazo[2,1-b][1,3,4]thiadiazoles: synthesis, cytotoxic activity and mechanism of action.
AID481760	Antiproliferative activity against mouse FM3A cells after 48 hrs	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Symmetrical alpha-bromoacryloylamido diaryldienone derivatives as a novel series of antiproliferative agents. Design, synthesis and biological evaluation.
AID384306	Cytotoxicity against human HSC4 cells after 24 hrs by MTT assay	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells.
AID1277002	Antiproliferative activity against human Molt4/C8 cells assessed as cell survival after 72 hrs by coulter counter analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID654074	Cytotoxicity against human COLO205 cells	2012	European journal of medicinal chemistry, May, Volume: 51	Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
AID458803	Cytotoxicity against human HPLF cells	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3	3,5-Bis(benzylidene)-1-[4-2-(morpholin-4-yl)ethoxyphenylcarbonyl]-4-piperidone hydrochloride: a lead tumor-specific cytotoxin which induces apoptosis and autophagy.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID396987	Cytotoxicity against human Scov3 cells after 72 hrs by MTT assay	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, cytotoxic and fluorescent properties of novel N-phosphorylalkyl substituted E,E-3,5-bis(arylidene)piperid-4-ones.
AID1916657	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Melphalan: Recent insights on synthetic, analytical and medicinal aspects.
AID1277013	Cytotoxicity against HPC assessed as cell death after 48 hrs by MTT assay	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID654079	Cytotoxicity against human KM12 cells	2012	European journal of medicinal chemistry, May, Volume: 51	Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
AID1113479	Cytotoxicity against Mus musculus (mouse) L1210 cells assessed as growth inhibition after 48 hr by coulter counter analysis	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID153834	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(14) for % increase in life span at an optimal dose of 5 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID79237	In vitro cytotoxicity in chondrosarcoma cell line (H-EMC-SS) by Alamar blue assay	2002	Journal of medicinal chemistry, May-09, Volume: 45, Issue:10	Synthesis and in vitro evaluation of quaternary ammonium derivatives of chlorambucil and melphalan, anticancer drugs designed for the chemotherapy of chondrosarcoma.
AID1178013	Antileukemic activity against human K562 cells assessed as inhibition of tumor growth after 24 hrs	2014	European journal of medicinal chemistry, Apr-22, Volume: 77	Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: structure-activity relationships and potent antileukemic and antilymphoma cytotoxicity.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID295422	Cytotoxicity against HPLF cells	2007	Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10	3-(3,4,5-Trimethoxyphenyl)-1-oxo-2-propene: a novel pharmacophore displaying potent multidrug resistance reversal and selective cytotoxicity.
AID524796	Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1178010	Cytotoxicity against human KM12 cells assessed as inhibition of tumor growth after 24 hrs	2014	European journal of medicinal chemistry, Apr-22, Volume: 77	Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: structure-activity relationships and potent antileukemic and antilymphoma cytotoxicity.
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID153698	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(12) for total dose at an optimal dose of 5 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID209940	Inhibitory effect on the biosyntheses of protein using human Jurkat T cells.	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues.
AID1439570	Selectivity index, ratio of CC50 for HPLF to CC50 for human HL60 cells
AID596200	Anticancer activity against human SW620 cells	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.
AID1241933	Antiproliferative activity against mouse FM3A cells assessed as inhibition of cell proliferation incubated for 2 days by Coulter counter based assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Design, synthesis and antiproliferative activity of novel heterobivalent hybrids based on imidazo[2,1-b][1,3,4]thiadiazole and imidazo[2,1-b][1,3]thiazole scaffolds.
AID483885	Binding affinity to LAT1 in rat brain	2010	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12	Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood-brain barrier.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID496831	Antimicrobial activity against Cryptosporidium parvum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID98577	Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
AID653935	Selectivity index, ratio of CC50 for human normal cells to CC50 for human HL60 cells	2012	European journal of medicinal chemistry, May, Volume: 51	Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
AID1277022	Selectivity index, ratio of CC50 for HPC to CC50 for human HSC4 cells	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID1060756	Antitumor activity against mouse B16F10 cells xenografted in C57BL/6 mouse assessed as reduction of tumor size at 100 ug administered as intratumorally for 3 days	2014	European journal of medicinal chemistry, Jan, Volume: 71	Synthesis and analysis of activity of a potential anti-melanoma prodrug with a hydrazine linker.
AID594324	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 48 hrs by ZF-Coulter Counting	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Synthesis of novel antimitotic agents based on 2-amino-3-aroyl-5-(hetero)arylethynyl thiophene derivatives.
AID199113	Antitumor activity against S-180 cells after i.p. administration in mice up to 7 days at a dose of 16 umol/kg	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11	Esters of 2-(1-hydroxyalkyl)-1,4-dihydroxy-9,10-anthraquinones with melphalan as multifunctional anticancer agents.
AID393870	Cytotoxicity against human HL60 cells after 24 hrs by MTT assay in presence of 10% fetal bovine serum	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	The cytotoxic properties and preferential toxicity to tumour cells displayed by some 2,4-bis(benzylidene)-8-methyl-8-azabicyclo[3.2.1] octan-3-ones and 3,5-bis(benzylidene)-1-methyl-4-piperidones.
AID744854	Cytotoxicity against mouse FM3A cells after 2 days by Coulter counter analysis	2013	European journal of medicinal chemistry, May, Volume: 63	Anticancer activity of novel hybrid molecules containing 5-benzylidene thiazolidine-2,4-dione.
AID1916648	Cytotoxicity against human U2OS cells assessed as cell growth inhibition	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Melphalan: Recent insights on synthetic, analytical and medicinal aspects.
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1178008	Cytotoxicity against human HCC2998 cells assessed as inhibition of tumor growth after 24 hrs	2014	European journal of medicinal chemistry, Apr-22, Volume: 77	Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: structure-activity relationships and potent antileukemic and antilymphoma cytotoxicity.
AID1292279	Cytotoxicity against human HGF cells after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Tumour-specific cytotoxicity and structure-activity relationships of novel 1-[3-(2-methoxyethylthio)propionyl]-3,5-bis(benzylidene)-4-piperidones.
AID354543	Cytotoxicity against rat C6 cells assessed as cell release at 50 ug/mL to 2.5 mg/mL after 5 hrs by MTT assay in absence of db-cAMP	1996	Journal of natural products, Dec, Volume: 59, Issue:12	Cell-based screen for identification of inhibitors of tubulin polymerization.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID594321	Antiproliferative activity against mouse FM3A/0 cells assessed as inhibition of cell growth after 48 hrs by ZF-Coulter Counting	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Synthesis of novel antimitotic agents based on 2-amino-3-aroyl-5-(hetero)arylethynyl thiophene derivatives.
AID99422	Mean graph mid point was measured on leukemic cells.	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds.
AID385002	Cytotoxicity against human RPMI8226 cells	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	1-Aryl-2-dimethylaminomethyl-2-propen-1-one hydrochlorides and related adducts: A quest for selective cytotoxicity for malignant cells.
AID1439575	Selectivity index, ratio of CC50 for human HPC to CC50 for human HSC3 cells
AID1769487	Aqueous solubility of the compound
AID526437	Selectivity index, ratio of CC50 for normal cells to CC50 for human HL60 cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Sequential cytotoxicity: a theory examined using a series of 3,5-bis(benzylidene)-1-diethylphosphono-4-oxopiperidines and related phosphonic acids.
AID1073136	Induction of apoptosis in human JJN-3 cells assessed as late apoptotic cells at 15 uM after 48 hrs by annexinV/propidium iodide staining (Rvb = 9.59%)	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells.
AID55575	The compound was tested for cytotoxicity against D341 (human) Glioma cell lines	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate.
AID596310	Toxicity in mouse harboring P-388 cells	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.
AID526439	Selectivity index, ratio of CC50 for normal cells to CC50 for human HSC2 cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Sequential cytotoxicity: a theory examined using a series of 3,5-bis(benzylidene)-1-diethylphosphono-4-oxopiperidines and related phosphonic acids.
AID1178002	Antiproliferative activity against human Molt4/C8 cells after 72 hrs by coulter counting analysis	2014	European journal of medicinal chemistry, Apr-22, Volume: 77	Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: structure-activity relationships and potent antileukemic and antilymphoma cytotoxicity.
AID1777558	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay	2021	Bioorganic & medicinal chemistry, 09-01, Volume: 45	Design and synthesis of β-carboline derivatives with nitrogen mustard moieties against breast cancer.
AID1178012	Antileukemic activity against human HL-60(TB) cells assessed as inhibition of tumor growth after 24 hrs	2014	European journal of medicinal chemistry, Apr-22, Volume: 77	Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: structure-activity relationships and potent antileukemic and antilymphoma cytotoxicity.
AID55572	The compound was tested for cytotoxicity against D341 MR (human) Glioma cell lines	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate.
AID666612	Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis and antitumor activity of formononetin nitrogen mustard derivatives.
AID1185081	Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay	2014	ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7	Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates.
AID384995	Cytotoxicity against human SR cells	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	1-Aryl-2-dimethylaminomethyl-2-propen-1-one hydrochlorides and related adducts: A quest for selective cytotoxicity for malignant cells.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID462400	Toxicity in mouse	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Cytotoxic 2-benzylidene-6-(nitrobenzylidene)cyclohexanones which display substantially greater toxicity for neoplasms than non-malignant cells.
AID384301	Cytotoxicity against human Molt 4/C8 cells after 72 hrs	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1185724	Cytotoxicity against human CEM cells after 72 hrs by Coulter counting method	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	2-(4-Chlorobenzyl)-6-arylimidazo[2,1-b][1,3,4]thiadiazoles: synthesis, cytotoxic activity and mechanism of action.
AID221022	Effect on proliferation of leukemia L1210 cells	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Correlations between cytotoxicity and topography of some 2-arylidenebenzocycloalkanones determined by X-ray crystallography.
AID364038	Cytotoxicity against human LCLC-103H cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID712170	Induction of Escherichia coli pBR322 DNA alkylation assessed as formation of covalent DNA adducts after 2 hrs by Taq polymerase DNA stop assay	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR.
AID1292284	Selectivity index, ratio of CC50 for human HPLF cells to CC50 for human HSC2 cells	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Tumour-specific cytotoxicity and structure-activity relationships of novel 1-[3-(2-methoxyethylthio)propionyl]-3,5-bis(benzylidene)-4-piperidones.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID24699	Degradation under physiological pH 7.4 in the presence of glutathione	2000	Bioorganic & medicinal chemistry letters, Nov-06, Volume: 10, Issue:21	Stability of bioreductive drug delivery systems containing melphalan is influenced by conformational constraint and electronic properties of substituents.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID138602	Percentage inhibition as antitumor activity in carcinoma CF1 male mice.	1980	Journal of medicinal chemistry, Mar, Volume: 23, Issue:3	Antitumor agents: diazomethyl ketone and chloromethyl ketone analogues prepared from N-tosyl amino acids.
AID496817	Antimicrobial activity against Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1315404	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	2016	European journal of medicinal chemistry, Aug-25, Volume: 119	Design and synthesis of novel pyrazolo[1,5-a]pyrimidine derivatives bearing nitrogen mustard moiety and evaluation of their antitumor activity in vitro and in vivo.
AID1241932	Antiproliferative activity against mouse L1210 cells assessed as inhibition of cell proliferation incubated for 2 days by Coulter counter based assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Design, synthesis and antiproliferative activity of novel heterobivalent hybrids based on imidazo[2,1-b][1,3,4]thiadiazole and imidazo[2,1-b][1,3]thiazole scaffolds.
AID596197	Anticancer activity against human HCT15 cells	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.
AID1241935	Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 4 days by Coulter counter based assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Design, synthesis and antiproliferative activity of novel heterobivalent hybrids based on imidazo[2,1-b][1,3,4]thiadiazole and imidazo[2,1-b][1,3]thiazole scaffolds.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1439558	Cytotoxicity against human Molt4/C8 cells assessed as growth inhibition after 72 hrs by coulter counter method
AID1439561	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
AID1113478	Cytotoxicity against Homo sapiens (human) CEM cells assessed as growth inhibition after 72 hr by coulter counter analysis	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID91673	Mean graph mid point was measured on all cell lines.	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds.
AID382488	Cytotoxicity against human HSC4 cells by MTT method	2008	European journal of medicinal chemistry, Jan, Volume: 43, Issue:1	Cytotoxic 3,5-bis(benzylidene)piperidin-4-ones and N-acyl analogs displaying selective toxicity for malignant cells.
AID1277011	Cytotoxicity against human HL60 cells assessed as cell death after 48 hrs by MTT assay	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID567536	Cytotoxicity against human leukemia cells assessed as cell growth after 48 hrs by SRB assay	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Microwave supported synthesis of some novel 1,3-diarylpyrazino[1,2-a]benzimidazole derivatives and investigation of their anticancer activities.
AID364036	Cytotoxicity against human DAN-G cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID1292283	Selectivity index, ratio of CC50 for human HGF cells to CC50 for human HSC4 cells	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Tumour-specific cytotoxicity and structure-activity relationships of novel 1-[3-(2-methoxyethylthio)propionyl]-3,5-bis(benzylidene)-4-piperidones.
AID1148046	Antitumor activity against rat Walker 256 cells allografted in Sprague-Dawley rat assessed as host survival days at 2.5 mg/kg, ip qd	1977	Journal of medicinal chemistry, Dec, Volume: 20, Issue:12	Antineoplastic agents. 1. N-Protected vinyl, 1,2-dihaloethyl, and cyanomethyl esters of phenylalanine.
AID153966	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(14) for mortality range at an optimal dose of 5 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID150665	Inhibitory activity was tested against P388 cells	1999	Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8	Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones.
AID98045	In vitro cytotoxicity was determined against L1210 leukemia cells from mouse	1990	Journal of medicinal chemistry, Feb, Volume: 33, Issue:2	Synthesis and antiviral and cytotoxic activity of iodohydrin and iodomethoxy derivatives of 5-vinyl-2'-deoxyuridines, 2'-fluoro-2'-deoxyuridine, and uridine.
AID744855	Cytotoxicity against mouse L1210 cells after 2 days by Coulter counter analysis	2013	European journal of medicinal chemistry, May, Volume: 63	Anticancer activity of novel hybrid molecules containing 5-benzylidene thiazolidine-2,4-dione.
AID653928	Cytotoxicity against human HSC2 cells after 48 hrs	2012	European journal of medicinal chemistry, May, Volume: 51	Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
AID97133	Ratio between IC50 values on L1210 and L1210/L-PAM cells	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
AID1439563	Cytotoxicity against human HSC3 cells after 48 hrs by MTT assay
AID228488	Glutathione-s-transferase activity of the compound, expressed as percentage of control.	2002	Journal of medicinal chemistry, May-09, Volume: 45, Issue:10	Synthesis and in vitro evaluation of quaternary ammonium derivatives of chlorambucil and melphalan, anticancer drugs designed for the chemotherapy of chondrosarcoma.
AID1148056	Antitumor activity against rat Walker 256 cells allografted in Sprague-Dawley rat assessed as tumor growth inhibition at 2.5 mg/kg/day, ip	1977	Journal of medicinal chemistry, Dec, Volume: 20, Issue:12	Antineoplastic agents. 2. Structure-activity studies on N-protected vinyl, 1,2-dibromoethyl, and cyanomethyl esters of several amino acids.
AID23271	Partition coefficient (logD7.4)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID230140	Tested in vitro for the resistance index ratio (ID50) of L1210/LPAM to L1210 cell line	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives.
AID384997	Cytotoxicity against human HPC cells	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	1-Aryl-2-dimethylaminomethyl-2-propen-1-one hydrochlorides and related adducts: A quest for selective cytotoxicity for malignant cells.
AID46584	Inhibitory activity was tested against CEM cells	1999	Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8	Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones.
AID1292277	Cytotoxicity against human HSC3 cells after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Tumour-specific cytotoxicity and structure-activity relationships of novel 1-[3-(2-methoxyethylthio)propionyl]-3,5-bis(benzylidene)-4-piperidones.
AID364033	Cytotoxicity against human KYSE510 cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID1247222	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Synthesis, structure-activity relationship and biological evaluation of novel nitrogen mustard sophoridinic acid derivatives as potential anticancer agents.
AID153682	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(12 for change in body weight at an optimal dose of 1 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1277018	Selectivity index, ratio of CC50 for HGF to CC50 for human HSC3 cells	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID382492	Cytotoxicity against human periodontal ligament fibroblast by MTT method	2008	European journal of medicinal chemistry, Jan, Volume: 43, Issue:1	Cytotoxic 3,5-bis(benzylidene)piperidin-4-ones and N-acyl analogs displaying selective toxicity for malignant cells.
AID166691	The compound was tested for cytotoxicity against RG-2 (Rat) Glioma cell lines	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate.
AID384305	Cytotoxicity against human HSC3 cells after 24 hrs by MTT assay	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID152701	Cytotoxicity against murine P388 cells.	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues.
AID92264	Tested against human tumor cell lines, mean graph mid point values(MG MID) are determined.	1999	Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8	Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones.
AID596207	Anticancer activity against human Molt4/C8 cells after 72 hrs	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID596295	Cytotoxicity against human HPLF cells after 48 hrs	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.
AID458806	Cytotoxicity against human HSC4 cells	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3	3,5-Bis(benzylidene)-1-[4-2-(morpholin-4-yl)ethoxyphenylcarbonyl]-4-piperidone hydrochloride: a lead tumor-specific cytotoxin which induces apoptosis and autophagy.
AID153250	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(14) for mortality range at an optimal dose of 5 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID45824	Inhibitory concentration against CEM T-lymphocytes	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Correlations between cytotoxicity and topography of some 2-arylidenebenzocycloalkanones determined by X-ray crystallography.
AID654082	Cytotoxicity against human K562 cells	2012	European journal of medicinal chemistry, May, Volume: 51	Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1277009	Cytotoxicity against human HSC3 cells assessed as cell death after 48 hrs by MTT assay	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID1277016	Selectivity index, ratio of CC50 for HPC to CC50 for human HSC2 cells	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID653932	Cytotoxicity against human HSC4 cells after 48 hrs	2012	European journal of medicinal chemistry, May, Volume: 51	Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
AID227705	The apoptotic index [(number of human jurkat cells with apoptotic nuclei/number of cells counted) 100]	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues.
AID615399	Cytostatic activity against human Molt4/C8 cells after 3 days by coulter counter assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design, synthesis and bioevaluation of novel candidate selective estrogen receptor modulators.
AID1277024	Selectivity index, ratio of CC50 for HGF to CC50 for human HL60 cells	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID445446	Oral bioavailability in human	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID654078	Cytotoxicity against human HT-29 cells	2012	European journal of medicinal chemistry, May, Volume: 51	Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
AID496827	Antimicrobial activity against Leishmania amazonensis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID125499	Inhibitory activity was tested against Molt4/C8 cells	1999	Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8	Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones.
AID408377	Cytotoxicity against mouse L1210 cells after 48 hrs	2008	Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11	E,E-2-Benzylidene-6-(nitrobenzylidene)cyclohexanones: syntheses, cytotoxicity and an examination of some of their electronic, steric, and hydrophobic properties.
AID1292274	Cytotoxicity against human CEM cells after 72 hrs by MTT assay	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Tumour-specific cytotoxicity and structure-activity relationships of novel 1-[3-(2-methoxyethylthio)propionyl]-3,5-bis(benzylidene)-4-piperidones.
AID1916647	Cytotoxicity against mouse MC3T3-E1 cells assessed as cell growth inhibition	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Melphalan: Recent insights on synthetic, analytical and medicinal aspects.
AID594320	Antiproliferative activity against mouse L1210 cells assessed as inhibition of cell growth after 48 hrs by ZF-Coulter Counting	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Synthesis of novel antimitotic agents based on 2-amino-3-aroyl-5-(hetero)arylethynyl thiophene derivatives.
AID483884	Inhibition of LAT1-mediated L-[14C]leucine uptake in Sprague-Dawley rat brain by duel-labeled liquid scintillation counting	2010	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12	Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood-brain barrier.
AID567538	Cytotoxicity against human colon cancer cells assessed as cell growth after 48 hrs by SRB assay	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Microwave supported synthesis of some novel 1,3-diarylpyrazino[1,2-a]benzimidazole derivatives and investigation of their anticancer activities.
AID383748	Cytotoxicity against human EJ60 cells after 72 hrs by MTT assay	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis, computational study and cytotoxic activity of new 4-hydroxycoumarin derivatives.
AID1277010	Cytotoxicity against human HSC4 cells assessed as cell death after 48 hrs by MTT assay	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID153091	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for tumor free survivors at an optimal dose of 5 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID98125	Median survival time of treated to the control was determined in L1210 cell line	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives.
AID1439578	Selectivity index, ratio of CC50 for human HPC to CC50 for human HSC4 cells
AID458805	Cytotoxicity against human HSC2 cells	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3	3,5-Bis(benzylidene)-1-[4-2-(morpholin-4-yl)ethoxyphenylcarbonyl]-4-piperidone hydrochloride: a lead tumor-specific cytotoxin which induces apoptosis and autophagy.
AID364035	Cytotoxicity against human YAPC cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID445445	Permeability at pH 6.5 by PAMPA method	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID235488	Selectivity index is the ratio of MG MID value for all cell lines to that of colon cancer cells	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds.
AID384307	Cytotoxicity against human HL60 cells after 24 hrs by trypan blue exclusion assay	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells.
AID481762	Antiproliferative activity against human CEM cells after 48 hrs	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Symmetrical alpha-bromoacryloylamido diaryldienone derivatives as a novel series of antiproliferative agents. Design, synthesis and biological evaluation.
AID496825	Antimicrobial activity against Leishmania mexicana	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID567541	Cytotoxicity against human ovarian cancer cells assessed as cell growth after 48 hrs by SRB assay	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Microwave supported synthesis of some novel 1,3-diarylpyrazino[1,2-a]benzimidazole derivatives and investigation of their anticancer activities.
AID1483959	Induction of apoptosis in human PBMC after 3 days by V-FITC/ propidium iodide staining-based flow cytometric analysis	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Dioncophyllines C
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1178011	Cytotoxicity against human SW620 cells assessed as inhibition of tumor growth after 24 hrs	2014	European journal of medicinal chemistry, Apr-22, Volume: 77	Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: structure-activity relationships and potent antileukemic and antilymphoma cytotoxicity.
AID1178009	Cytotoxicity against human HCT15 cells assessed as inhibition of tumor growth after 24 hrs	2014	European journal of medicinal chemistry, Apr-22, Volume: 77	Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: structure-activity relationships and potent antileukemic and antilymphoma cytotoxicity.
AID458802	Cytotoxicity against human HPC cells	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3	3,5-Bis(benzylidene)-1-[4-2-(morpholin-4-yl)ethoxyphenylcarbonyl]-4-piperidone hydrochloride: a lead tumor-specific cytotoxin which induces apoptosis and autophagy.
AID384310	Cytotoxicity against human HPLF cells after 24 hrs by MTT assay	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells.
AID153082	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for median day of death at an optimal dose of 5 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1073142	Induction of apoptosis in human XG6 cells assessed as viable cells at 15 uM after 48 hrs by annexinV/propidium iodide staining (Rvb = 83.3%)	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells.
AID295421	Cytotoxicity against HGF cells	2007	Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10	3-(3,4,5-Trimethoxyphenyl)-1-oxo-2-propene: a novel pharmacophore displaying potent multidrug resistance reversal and selective cytotoxicity.
AID1277015	Selectivity index, ratio of CC50 for HGF to CC50 for human HSC2 cells	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID596297	Selectivity index, ratio of average CC50 for normal human cell line to CC50 for human HSC4 cells	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.
AID1439569	Selectivity index, ratio of CC50 for human HPC to CC50 for human HL60 cells
AID526436	Cytotoxicity against human HL60 cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Sequential cytotoxicity: a theory examined using a series of 3,5-bis(benzylidene)-1-diethylphosphono-4-oxopiperidines and related phosphonic acids.
AID596309	Toxicity in mouse harboring L1210 cells	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID596210	Anticancer activity against human HL60 cells	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.
AID153226	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for total dose at an optimal dose of 5 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID526446	Cytotoxicity against human HPLF cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Sequential cytotoxicity: a theory examined using a series of 3,5-bis(benzylidene)-1-diethylphosphono-4-oxopiperidines and related phosphonic acids.
AID221820	Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1315401	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	2016	European journal of medicinal chemistry, Aug-25, Volume: 119	Design and synthesis of novel pyrazolo[1,5-a]pyrimidine derivatives bearing nitrogen mustard moiety and evaluation of their antitumor activity in vitro and in vivo.
AID1292285	Selectivity index, ratio of CC50 for human HPLF cells to CC50 for human HSC3 cells	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Tumour-specific cytotoxicity and structure-activity relationships of novel 1-[3-(2-methoxyethylthio)propionyl]-3,5-bis(benzylidene)-4-piperidones.
AID153078	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for % increase in life span at an optimal dose of 5 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID384991	Cytotoxicity against human Molt4/C8 cells after 72 hrs	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	1-Aryl-2-dimethylaminomethyl-2-propen-1-one hydrochlorides and related adducts: A quest for selective cytotoxicity for malignant cells.
AID393873	Cytotoxicity against human HPLF cells after 24 hrs by MTT assay	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	The cytotoxic properties and preferential toxicity to tumour cells displayed by some 2,4-bis(benzylidene)-8-methyl-8-azabicyclo[3.2.1] octan-3-ones and 3,5-bis(benzylidene)-1-methyl-4-piperidones.
AID596196	Anticancer activity against human HCC2998 cells	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.
AID227164	Average potency of all four cell lines (P388 cell line, L1210 cell line, Molt 4/C8 cell line, CEM T-lymphocytes)	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues.
AID526441	Selectivity index, ratio of CC50 for normal cells to CC50 for human HSC3 cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Sequential cytotoxicity: a theory examined using a series of 3,5-bis(benzylidene)-1-diethylphosphono-4-oxopiperidines and related phosphonic acids.
AID496818	Antimicrobial activity against Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID444323	Cytotoxicity against human Molt4/C8 cells	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Design, synthesis and bioevaluation of novel maleamic amino acid ester conjugates of 3,5-bisarylmethylene-4-piperidones as cytostatic agents.
AID44482	The compound was tested for cytotoxicity against C6 (Rat) Glioma cell lines	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate.
AID1439572	Selectivity index, ratio of CC50 for human HPC to CC50 for human HSC2 cells
AID383747	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis, computational study and cytotoxic activity of new 4-hydroxycoumarin derivatives.
AID95088	IC80 concentrations of the compounds were used in determining the inhibition of protein synthesis using Jurkat T cells.	1999	Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8	Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones.
AID1136468	Immunosuppressive activity in mouse splenic lymphocytes isolated from 0.1 mg, ip on days 2,3 and 5 treated CF1 mouse assessed as reduction in sheep red blood cell antigen-induced plaque-forming response (Rvb = 100%)	1979	Journal of medicinal chemistry, Nov, Volume: 22, Issue:11	Antitumor and antiinflammatory agents: N-benzoyl-protected cyanomethyl esters of amino acids.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID458804	Cytotoxicity against human HL60 cells	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3	3,5-Bis(benzylidene)-1-[4-2-(morpholin-4-yl)ethoxyphenylcarbonyl]-4-piperidone hydrochloride: a lead tumor-specific cytotoxin which induces apoptosis and autophagy.
AID384308	Cytotoxicity against human HDF cells after 24 hrs by MTT assay	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells.
AID712163	Cytotoxicity against human HT-29 cells after 5 days by MTT assay	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR.
AID1916665	Plasma protein binding in human assessed as unbound fraction	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Melphalan: Recent insights on synthetic, analytical and medicinal aspects.
AID1185079	Antiproliferative activity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay	2014	ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7	Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates.
AID654080	Cytotoxicity against human SW620 cells	2012	European journal of medicinal chemistry, May, Volume: 51	Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
AID384994	Cytotoxicity against human K562 cells	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	1-Aryl-2-dimethylaminomethyl-2-propen-1-one hydrochlorides and related adducts: A quest for selective cytotoxicity for malignant cells.
AID539594	Cytotoxicity against human NCI60 cells by SBR assay	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors.
AID384998	Cytotoxicity against human HPLF cells	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	1-Aryl-2-dimethylaminomethyl-2-propen-1-one hydrochlorides and related adducts: A quest for selective cytotoxicity for malignant cells.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1113477	Cytotoxicity against Homo sapiens (human) HeLa cells assessed as growth inhibition after 96 hr by coulter counter analysis	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID384312	Neurotoxicity in ip dosed mouse by rotarod test	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells.
AID235489	Selectivity index is the ratio of MG MID value for all cell lines to that of leukemic cells	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds.
AID567543	Cytotoxicity against human prostate cancer cells assessed as cell growth after 48 hrs by SRB assay	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Microwave supported synthesis of some novel 1,3-diarylpyrazino[1,2-a]benzimidazole derivatives and investigation of their anticancer activities.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1178007	Cytotoxicity against human COLO205 cells assessed as inhibition of tumor growth after 24 hrs	2014	European journal of medicinal chemistry, Apr-22, Volume: 77	Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: structure-activity relationships and potent antileukemic and antilymphoma cytotoxicity.
AID224732	Inhibitory activity against Murine P388 cells	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Correlations between cytotoxicity and topography of some 2-arylidenebenzocycloalkanones determined by X-ray crystallography.
AID47330	Lethal dose was determined for antitumor activity against murine leukemia cells (CFU-C)	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Selective cytotoxicity of a system L specific amino acid nitrogen mustard.
AID28892	Partition coefficient (logD) (octanol/phosphate buffer)	2002	Journal of medicinal chemistry, May-09, Volume: 45, Issue:10	Synthesis and in vitro evaluation of quaternary ammonium derivatives of chlorambucil and melphalan, anticancer drugs designed for the chemotherapy of chondrosarcoma.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID596296	Selectivity index, ratio of average CC50 for normal human cell line to CC50 for human HL-60 cells	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.
AID1292281	Selectivity index, ratio of CC50 for human HGF cells to CC50 for human HSC2 cells	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Tumour-specific cytotoxicity and structure-activity relationships of novel 1-[3-(2-methoxyethylthio)propionyl]-3,5-bis(benzylidene)-4-piperidones.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID138285	Anticarcinoma activity of Diazomethyl Ketone against Ehrlich ascites Carcinoma pharmacological screens were reported; 6/6	1980	Journal of medicinal chemistry, Mar, Volume: 23, Issue:3	Antitumor agents: diazomethyl ketone and chloromethyl ketone analogues prepared from N-tosyl amino acids.
AID94731	Cytotoxicity against L-1210 cells	2001	Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11	Esters of 2-(1-hydroxyalkyl)-1,4-dihydroxy-9,10-anthraquinones with melphalan as multifunctional anticancer agents.
AID1148041	Antitumor activity against mouse EAC allografted in CF1 mouse assessed as tumor volume at 33 mg/kg/day measured on day 7	1977	Journal of medicinal chemistry, Dec, Volume: 20, Issue:12	Antineoplastic agents. 1. N-Protected vinyl, 1,2-dihaloethyl, and cyanomethyl esters of phenylalanine.
AID396988	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Design, cytotoxic and fluorescent properties of novel N-phosphorylalkyl substituted E,E-3,5-bis(arylidene)piperid-4-ones.
AID150512	Cytotoxicity evaluated against P388 cells.	1998	Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21	4-(beta-Arylvinyl)-3-(beta-arylvinylketo)-1-ethyl-4-piperidinols and related compounds: a novel class of cytotoxic and anticancer agents.
AID526443	Selectivity index, ratio of CC50 for normal cells to CC50 for human HSC4 cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Sequential cytotoxicity: a theory examined using a series of 3,5-bis(benzylidene)-1-diethylphosphono-4-oxopiperidines and related phosphonic acids.
AID384990	Cytotoxicity against human CEM cells after 72 hrs	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	1-Aryl-2-dimethylaminomethyl-2-propen-1-one hydrochlorides and related adducts: A quest for selective cytotoxicity for malignant cells.
AID629593	Cytotoxicity against human PBMC cells assessed as viable fractions using annexin V-FITC/propidium iodide staining by flow cytometry	2011	European journal of medicinal chemistry, Dec, Volume: 46, Issue:12	Anti-tumoral activities of dioncoquinones B and C and related naphthoquinones gained from total synthesis or isolation from plants.
AID393869	Cytotoxicity against human HSC4 cells after 24 hrs by MTT assay	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	The cytotoxic properties and preferential toxicity to tumour cells displayed by some 2,4-bis(benzylidene)-8-methyl-8-azabicyclo[3.2.1] octan-3-ones and 3,5-bis(benzylidene)-1-methyl-4-piperidones.
AID1439562	Cytotoxicity against human HSC2 cells after 48 hrs by MTT assay
AID654081	Cytotoxicity against human HL-60(TB) cells	2012	European journal of medicinal chemistry, May, Volume: 51	Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
AID1916649	Cytotoxicity against human SAOS-2 cells assessed as cell growth inhibition	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Melphalan: Recent insights on synthetic, analytical and medicinal aspects.
AID526445	Cytotoxicity against human HPC cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Sequential cytotoxicity: a theory examined using a series of 3,5-bis(benzylidene)-1-diethylphosphono-4-oxopiperidines and related phosphonic acids.
AID1439574	Selectivity index, ratio of CC50 for HGF to CC50 for human HSC3 cells
AID247839	Cytotoxicity against human leukemia cell line K562	2004	Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19	Design and synthesis of a nitrogen mustard derivative stabilized by apo-neocarzinostatin.
AID98567	Cytotoxicity evaluated against L1210 cells.	1998	Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21	4-(beta-Arylvinyl)-3-(beta-arylvinylketo)-1-ethyl-4-piperidinols and related compounds: a novel class of cytotoxic and anticancer agents.
AID91666	Cytotoxicity evaluated against human tumor.	1998	Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21	4-(beta-Arylvinyl)-3-(beta-arylvinylketo)-1-ethyl-4-piperidinols and related compounds: a novel class of cytotoxic and anticancer agents.
AID615284	Cytostatic effect against human MCF7 cells at 10 uM after 72 hrs by crystal violet staining relative to uncreate control	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Bivalent bendamustine and melphalan derivatives as anticancer agents.
AID712167	Cytotoxicity against human A2780 cells after 5 days by MTT assay in presence of 10 uM MGMT inactivator Patrin2	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR.
AID98173	Cytotoxicity against murine L1210 cells.	2001	Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4	A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues.
AID283820	Cytotoxicity against human COLO205 cells	2007	European journal of medicinal chemistry, Jan, Volume: 42, Issue:1	Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds.
AID1664699	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2020	Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15	Tetrazoles as anticancer agents: A review on synthetic strategies, mechanism of action and SAR studies.
AID524791	Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID221824	Inhibition of RNA synthesis was evaluated on human Jurkat T-cells after 8 hours.	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds.
AID94963	Inhibitory concentration against Human Jurkat T cells	1999	Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8	Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones.
AID1178004	Antiproliferative activity against human HeLa cells after 72 hrs by coulter counting analysis	2014	European journal of medicinal chemistry, Apr-22, Volume: 77	Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: structure-activity relationships and potent antileukemic and antilymphoma cytotoxicity.
AID1769491	Covalent binding affinity to salmon DNA measured after 30 mins by UV based spectroscopic method
AID95084	Inhibitory concentration against Human Jurkat T cells	1999	Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8	Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID139117	Volume of fluid collected 8 days after tumor transplantation in mice.	1980	Journal of medicinal chemistry, Mar, Volume: 23, Issue:3	Antitumor agents: diazomethyl ketone and chloromethyl ketone analogues prepared from N-tosyl amino acids.
AID153086	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for mortality range at an optimal dose of 5 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID24698	Degradation under physiological pH 7.4	2000	Bioorganic & medicinal chemistry letters, Nov-06, Volume: 10, Issue:21	Stability of bioreductive drug delivery systems containing melphalan is influenced by conformational constraint and electronic properties of substituents.
AID102210	Tested in vitro for inhibition after 144 hr against human colon carcinoma LoVo/DX cell line resistant to Doxorubicin (DX)	1994	Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25	Synthesis and antitumor activity of a new class of pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]diazepinone analogues of pyrrolo[1,4][2,1-c]benzodiazepines.
AID596195	Anticancer activity against human HCT116 cells	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.
AID295419	Cytotoxicity against HSC4 cells	2007	Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10	3-(3,4,5-Trimethoxyphenyl)-1-oxo-2-propene: a novel pharmacophore displaying potent multidrug resistance reversal and selective cytotoxicity.
AID99170	Tested in vitro for the cytotoxicity as number of viable cells against L1210/LPAM cell line after 72 hr treatment at conc. of 10E-6	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives.
AID98915	Inhibitory activity was tested against L1210 cells	1999	Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8	Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones.
AID526440	Cytotoxicity against human HSC3 cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Sequential cytotoxicity: a theory examined using a series of 3,5-bis(benzylidene)-1-diethylphosphono-4-oxopiperidines and related phosphonic acids.
AID99059	Tested in vitro for inhibition after 48 hr exposure against murine leukemia cell line L1210	1994	Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25	Synthesis and antitumor activity of a new class of pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]diazepinone analogues of pyrrolo[1,4][2,1-c]benzodiazepines.
AID248055	Antiproliferative activity in MCF-7 human breast cancer cells	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: studies on the mode of drug action.
AID1073143	Induction of apoptosis in human XG6 cells assessed as early apoptotic cells at 15 uM after 48 hrs by annexinV/propidium iodide staining (Rvb = 8.62%)	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells.
AID1277004	Antiproliferative activity against mouse L1210 cells assessed as cell survival after 48 hrs by coulter counter analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID408375	Cytotoxicity against human CEM cells after 72 hrs	2008	Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11	E,E-2-Benzylidene-6-(nitrobenzylidene)cyclohexanones: syntheses, cytotoxicity and an examination of some of their electronic, steric, and hydrophobic properties.
AID712156	Cytotoxicity against human U251 cells after 5 days by MTT assay	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR.
AID1185082	Antiproliferative activity against human MGC803 cells assessed as growth inhibition after 72 hrs by MTT assay	2014	ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7	Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates.
AID1277008	Cytotoxicity against human HSC2 cells assessed as cell death after 48 hrs by MTT assay	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1439573	Selectivity index, ratio of CC50 for HPLF to CC50 for human HSC2 cells
AID153239	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(14) for % increase in life span at an optimal dose of 5 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID221023	Effect on protein biosyntheses in leukemia L1210 cells	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Correlations between cytotoxicity and topography of some 2-arylidenebenzocycloalkanones determined by X-ray crystallography.
AID1439564	Cytotoxicity against human HSC4 cells after 48 hrs by MTT assay
AID596199	Anticancer activity against human KM12 cells	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.
AID86328	Tested in vitro for the dose inhibiting cell proliferation by 50% against HeLa cell line after 24 hr treatment at conc. of 10E-6	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives.
AID1594190	Cytotoxicity against human SW620 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay	2019	Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10	Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID153984	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(14) for total dose at an optimal dose of 5 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID458801	Cytotoxicity against human HGF cells	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3	3,5-Bis(benzylidene)-1-[4-2-(morpholin-4-yl)ethoxyphenylcarbonyl]-4-piperidone hydrochloride: a lead tumor-specific cytotoxin which induces apoptosis and autophagy.
AID230383	Resistance index as the ratio of IC50 against LoVo/Dx to that of LoVo	1994	Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25	Synthesis and antitumor activity of a new class of pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]diazepinone analogues of pyrrolo[1,4][2,1-c]benzodiazepines.
AID1439565	Cytotoxicity against HGF after 48 hrs by MTT assay
AID1132874	Antitumor activity against mouse P388 cells allografted in DBA/2 mouse assessed as survival rate at 25 mg/kg relative to control	1978	Journal of medicinal chemistry, Jul, Volume: 21, Issue:7	Antitumor agents. 31. Helenalin sym-dimethylethylenediamine reaction products and related derivatives.
AID384304	Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells.
AID98578	Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells,(cells resistant to melphalan (L-PAM)	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
AID653933	Selectivity index, ratio of CC50 for human normal cells to CC50 for human HSC4 cells	2012	European journal of medicinal chemistry, May, Volume: 51	Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
AID97895	Inhibitory activity against murine leukemia cells (L1210) was determined	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Selective cytotoxicity of a system L specific amino acid nitrogen mustard.
AID331134	Growth inhibition of human HepG2 cells	2008	Bioorganic & medicinal chemistry letters, May-15, Volume: 18, Issue:10	Possible chemical mechanisms underlying the antitumor activity of S-deoxyleinamycin.
AID283825	Cytotoxicity against human HCC2998 cells	2007	European journal of medicinal chemistry, Jan, Volume: 42, Issue:1	Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds.
AID466507	Cytotoxicity against mouse L1210 cells	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore.
AID393867	Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	The cytotoxic properties and preferential toxicity to tumour cells displayed by some 2,4-bis(benzylidene)-8-methyl-8-azabicyclo[3.2.1] octan-3-ones and 3,5-bis(benzylidene)-1-methyl-4-piperidones.
AID153686	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(12) for % increase in life span at an optimal dose of 1 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID496824	Antimicrobial activity against Toxoplasma gondii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID393868	Cytotoxicity against human HSC3 cells after 24 hrs by MTT assay	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	The cytotoxic properties and preferential toxicity to tumour cells displayed by some 2,4-bis(benzylidene)-8-methyl-8-azabicyclo[3.2.1] octan-3-ones and 3,5-bis(benzylidene)-1-methyl-4-piperidones.
AID283831	Cytotoxicity against human NCI49 cell lines	2007	European journal of medicinal chemistry, Jan, Volume: 42, Issue:1	Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds.
AID384993	Cytotoxicity against human CCRF-CEM cells	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	1-Aryl-2-dimethylaminomethyl-2-propen-1-one hydrochlorides and related adducts: A quest for selective cytotoxicity for malignant cells.
AID1777557	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay	2021	Bioorganic & medicinal chemistry, 09-01, Volume: 45	Design and synthesis of β-carboline derivatives with nitrogen mustard moieties against breast cancer.
AID466505	Cytotoxicity against human Molt4/C8 cells	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore.
AID354542	Inhibition of tubulin polymerization in rat C6 cells at 50 ug/mL to 2.5 mg/mL after 4 hrs	1996	Journal of natural products, Dec, Volume: 59, Issue:12	Cell-based screen for identification of inhibitors of tubulin polymerization.
AID364032	Cytotoxicity against human KYSE70 cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID1277003	Antiproliferative activity against human CEM cells assessed as cell survival after 72 hrs by coulter counter analysis	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID712164	Cytotoxicity against human DLD1 cells after 5 days by MTT assay	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR.
AID94808	In vitro cytotoxic activity against human leukemic cell line K562 after incubation for 1 hour	2003	Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12	Chemical synthesis and cytotoxicity of dihydroxylated cyclopentenone analogues of neocarzinostatin chromophore.
AID1584442	Antiproliferative activity against human NCI60 cells after 48 hrs by SRB assay	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches.
AID55448	The compound was tested for cytotoxicity against D283 (human) Glioma cell lines	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate.
AID96162	Inhibitory activity against K-562 (human chronic myeloid Leukemia) cells	1993	Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7	In vitro cytotoxicity of GC sequence directed alkylating agents related to distamycin.
AID1277019	Selectivity index, ratio of CC50 for HPC to CC50 for human HSC3 cells	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID1292286	Selectivity index, ratio of CC50 for human HPLF cells to CC50 for human HSC4 cells	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Tumour-specific cytotoxicity and structure-activity relationships of novel 1-[3-(2-methoxyethylthio)propionyl]-3,5-bis(benzylidene)-4-piperidones.
AID270650	Cytotoxicity against rat C6 glioma cell line	2006	Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19	Discovery of antiglioma activity of biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues.
AID97907	Lethal dose was determined for myelosuppressive activity against murine leukemia cells (L1210)	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Selective cytotoxicity of a system L specific amino acid nitrogen mustard.
AID283822	Cytotoxicity against human HCT15 cells	2007	European journal of medicinal chemistry, Jan, Volume: 42, Issue:1	Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds.
AID524790	Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID526438	Cytotoxicity against human HSC2 cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Sequential cytotoxicity: a theory examined using a series of 3,5-bis(benzylidene)-1-diethylphosphono-4-oxopiperidines and related phosphonic acids.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID153843	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(14) for median day of death at an optimal dose of 5 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID596212	Anticancer activity against human RPMI8226 cells	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins.
AID594323	Antiproliferative activity against human CEM/0 cells assessed as inhibition of cell growth after 48 hrs by ZF-Coulter Counting	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Synthesis of novel antimitotic agents based on 2-amino-3-aroyl-5-(hetero)arylethynyl thiophene derivatives.
AID712169	Binding affinity to Escherichia coli pBR322 DNA assessed as guanine-N7 alkylation on GC-rich region after 2 hrs by piperidine cleavage assay	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR.
AID1277020	Selectivity index, ratio of CC50 for HPLF to CC50 for human HSC3 cells	2016	Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins.
AID1315403	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	2016	European journal of medicinal chemistry, Aug-25, Volume: 119	Design and synthesis of novel pyrazolo[1,5-a]pyrimidine derivatives bearing nitrogen mustard moiety and evaluation of their antitumor activity in vitro and in vivo.
AID712159	Cytotoxicity against human A549 cells after 5 days by MTT assay	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR.
AID153233	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(14) for change in body weight at an optimal dose of 5 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID409956	Inhibition of mouse brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID283827	Cytotoxicity against human RPMI8226 cells	2007	European journal of medicinal chemistry, Jan, Volume: 42, Issue:1	Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds.
AID526442	Cytotoxicity against human HSC4 cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Sequential cytotoxicity: a theory examined using a series of 3,5-bis(benzylidene)-1-diethylphosphono-4-oxopiperidines and related phosphonic acids.
AID55598	The compound was tested for cytotoxicity against DAOY MR (human) Glioma cell lines	1997	Journal of medicinal chemistry, May-23, Volume: 40, Issue:11	Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID153245	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM(14) for median day of death at an optimal dose of 5 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1148054	Antineoplastic activity against mouse EAC allografted in CF1 mouse assessed as tumor growth inhibition on day 7 measured at 33 mg/kg	1977	Journal of medicinal chemistry, Dec, Volume: 20, Issue:12	Antineoplastic agents. 2. Structure-activity studies on N-protected vinyl, 1,2-dibromoethyl, and cyanomethyl esters of several amino acids.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2600 (33.96)	18.7374
1990's	1340 (17.50)	18.2507
2000's	1554 (20.30)	29.6817
2010's	1691 (22.08)	24.3611
2020's	472 (6.16)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,351 (16.61%)	5.53%
Reviews	642 (7.89%)	6.00%
Case Studies	1,123 (13.81%)	4.05%
Observational	23 (0.28%)	0.25%
Other	4,995 (61.41%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (706)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
S0833, Modified Total Therapy 3 (TT3) for Newly Diagnosed Patients With Multiple Myeloma (MM): A Phase II SWOG Trial for Patients Aged ≤ 65 Years [NCT01055301]	Phase 2	0 participants (Actual)	Interventional	2011-07-31	Withdrawn(stopped due to lack of accrual)
A Multicenter, Open-label, Phase Ii Study of Dasatinib in Combination With Melphalan and Prednisone (D-MP) in Advanced, Relapsed / Refractory Multiple Myeloma Patients [NCT01116128]	Phase 2	8 participants (Actual)	Interventional	2008-02-29	Terminated(stopped due to difficulty in enrolling patients)
Busulfan, Etoposide, Cytarabine and Melphalan (BuEAM) as a Conditioning for Autologous Stem Cell Transplantation in Patients With Diffuse Large B Cell Lymphoma (DLCBL) Previously Treated With Rituximab Based Regimen [NCT01063439]	Phase 2	42 participants (Anticipated)	Interventional	2010-01-31	Recruiting
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Poor Risk Recurrent Hodgkin's Disease [NCT00265889]	Phase 2	42 participants (Actual)	Interventional	2002-02-28	Completed
Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation for Patients Less Than 65 Years of Age With Newly Diagnosed Multiple Myeloma [NCT01341262]	Phase 2	378 participants (Actual)	Interventional	2002-03-31	Completed
A Phase II Study to Evaluate the Safety and Efficacy of IV Busulfan, Melphalan, and Thiotepa (BuMelTT) Followed By Autologous PBSC Infusion for Patients With Hodgkin's Disease and Non-Hodgkin's Lymphoma [NCT00238433]	Phase 2	37 participants (Actual)	Interventional	2005-03-31	Completed
A Phase I/II Pilot Study of Memory-like NK Cells to Consolidate TCRαβ T Cell Depleted Haploidentical Transplant in High-risk AML [NCT06158828]	Phase 1/Phase 2	48 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies [NCT04904588]	Phase 2	300 participants (Anticipated)	Interventional	2021-09-30	Recruiting
A Phase 3, Multicenter, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High [NCT03217812]	Phase 3	220 participants (Actual)	Interventional	2017-11-23	Active, not recruiting
Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II [NCT00233987]	Phase 2	98 participants (Actual)	Interventional	2005-10-31	Completed
(PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older [NCT01453088]	Phase 2	63 participants (Actual)	Interventional	2010-06-24	Terminated(stopped due to Lack of Accrual)
[NCT01250808]		0 participants	Expanded Access		Available
A Phase I Study of Intensity Modulated Total Marrow Irradiation (IMTMI) in Addition to Fludarabine/Melphalan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies [NCT02333162]	Phase 1	30 participants (Anticipated)	Interventional	2014-12-05	Recruiting
Pilot Study T Cell Depletion in the Setting of Autologous Stem Cell Transplantation for Patients With Multiple Myeloma [NCT01526096]	Phase 1	15 participants (Actual)	Interventional	2011-07-12	Active, not recruiting
A Randomized Open-label Multicenter Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-chain (AL) Amyloidosis [NCT01277016]	Phase 3	110 participants (Actual)	Interventional	2011-01-31	Completed
Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) as a Conditioning for Autologous Stem Cell Transplantation in Patients With T Cell or NK Cell Lymphoma [NCT01178658]	Phase 2	42 participants (Anticipated)	Interventional	2010-07-31	Recruiting
A Phase II Trial of Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors [NCT03615144]	Phase 2	1 participants (Actual)	Interventional	2018-07-23	Terminated(stopped due to Participant accrual low and the study was closed)
A Study of the Pharmacokinetics of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma and Impaired Renal Function [NCT03639610]	Phase 2	35 participants (Actual)	Interventional	2018-08-28	Terminated(stopped due to The sponsor decided to terminate the study following an FDA request of a partial clinical hold.)
A Phase I Trial of Ruxolitinib Combined With Tacrolimus and Sirolimus as Acute Graft-versus-Host Disease (aGVHD) Prophylaxis During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis [NCT02528877]	Phase 1	0 participants (Actual)	Interventional	2015-11-30	Withdrawn(stopped due to The study design was revised so a new protocol will be opened.)
A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma [NCT01758328]	Phase 1	29 participants (Anticipated)	Interventional	2012-12-31	Active, not recruiting
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (ADAPT) [NCT06028828]	Phase 2	60 participants (Anticipated)	Interventional	2023-09-11	Recruiting
Pilot Open-label Trial of Nivolumab Combined With Chemotherapy in Refractory Myelodysplastic Syndromes. [NCT03259516]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2017-05-25	Terminated(stopped due to Slow recruitment rate)
An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carci [NCT02406508]	Phase 2	0 participants (Actual)	Interventional	2014-10-31	Withdrawn(stopped due to No enrollment in the study)
An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangioca [NCT02415036]	Phase 2	17 participants (Actual)	Interventional	2014-06-30	Terminated(stopped due to Limited enrollment)
A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901) [NCT01339910]	Phase 3	272 participants (Actual)	Interventional	2011-06-30	Terminated(stopped due to Accrual terminated as recommended by the data and safety monitoring board.)
High Dose Chemotherapy With Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients (BMT CTN #0803) [NCT01141712]	Phase 2	43 participants (Actual)	Interventional	2010-04-30	Completed
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple [NCT01335685]	Phase 1/Phase 2	61 participants (Actual)	Interventional	2011-06-27	Completed
Ocular Conservative Treatment for Retinoblastoma: Efficacy of the New Management Strategies and Visual Outcome - RETINO 2018 [NCT04681417]	Phase 2/Phase 3	225 participants (Anticipated)	Interventional	2021-03-25	Recruiting
A Pilot Trial of Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With DLBCL [NCT03072771]	Phase 1	14 participants (Actual)	Interventional	2017-08-01	Completed
[NCT01342237]	Phase 2	33 participants (Anticipated)	Interventional	2011-03-31	Recruiting
CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease [NCT02061800]	Phase 1/Phase 2	15 participants (Anticipated)	Interventional	2013-06-03	Recruiting
Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (BMT CTN 1302) [NCT02440464]	Phase 2	57 participants (Actual)	Interventional	2015-08-31	Completed
Allogeneic Stem Cell Transplantation for Patients With Hematological Malignancies Using Multiple Unrelated Cord Blood Units [NCT00547196]		10 participants (Actual)	Interventional	2005-08-16	Active, not recruiting
A Phase I/II Clinical Trial of NK Cells Administration to Prevent Disease Relapse for Patient With High-Risk Myeloid Malignancies Undergoing Haploidentical Stem-Cell Transplantation [NCT01904136]	Phase 1/Phase 2	90 participants (Anticipated)	Interventional	2014-04-22	Completed
Phase II Study of RO4929097 to Eradicate Residual Disease in Patients With Multiple Myeloma Post Single Autologous Stem Cell Transplant [NCT01251172]	Phase 2	0 participants (Actual)	Interventional	2010-12-31	Withdrawn(stopped due to Lack of Drug Supply)
A Multi-institutional Feasibility Study of Intra-arterial Chemotherapy Given in the Ophthalmic Artery of Children With Retinoblastoma [NCT02097134]	Phase 1	14 participants (Actual)	Interventional	2014-10-31	Completed
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies [NCT00145626]	Phase 2	40 participants (Actual)	Interventional	2004-05-31	Completed
Phase II Study of High-Dose Topotecan, Cyclophosphamide and Melphalan for the Treatment of Multiple Myeloma [NCT01039025]	Phase 2	60 participants (Actual)	Interventional	2002-02-18	Completed
"First Line Treatment in HIV-related Large Cell Non Hodgkin Lymphoma at High Risk, Including Early Consolidation With High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation" [NCT01045889]	Phase 2	27 participants (Actual)	Interventional	2007-01-31	Completed
Randomized Trial of Unmanipulated Versus Expanded Cord Blood [NCT00067002]	Phase 2	110 participants (Actual)	Interventional	2003-04-30	Completed
A Randomized Controlled Clinical Trial Comparing Chidamide,Carmustine,Etoposide,Cytarabine and Melphalan With BEAM Regimen Combined With Autologus Hematopoietic Stem Cell Transplantation for the Treatment of Newly Diagnosed PTCL [NCT05931263]	Phase 3	104 participants (Anticipated)	Interventional	2023-06-01	Recruiting
A Randomized Phase II Trial Comparing Treosulfan and Melphalan With Melphalan Alone as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Myeloma Patients (TreoMel Trial) [NCT05636787]	Phase 2	120 participants (Anticipated)	Interventional	2023-06-06	Recruiting
Phase II Trial Of Non-Myeloablative Regimen Combining Melphalan, Fludarabine, And Anti-CD52 Monoclonal Antibody (CAMPATH-1H) Followed By An Unmodified Hematopoietic Cell Transplant From An HLA Compatible Related Or Unrelated Donor For Treatment Of Lymphoh [NCT00027560]	Phase 2	51 participants (Actual)	Interventional	2001-07-31	Completed
Sequential High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Peripheral Blood Progenitor Cell Rescue, Interferon/Thalidomide and Pamidronate for Patients With Multiple Myeloma [NCT00004088]	Phase 2	77 participants (Actual)	Interventional	1999-04-13	Completed
Phase IIa Study of Addition of Itacitinib With Tacrolimus/Sirolimus Regimen for GVHD Prophylaxis in Fludarabine and Melphalan Non-Myeloablative Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, MDS or MF [NCT04339101]	Phase 2	59 participants (Actual)	Interventional	2020-11-11	Active, not recruiting
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Hematologic Malignancies [NCT04282174]	Phase 2	0 participants (Actual)	Interventional	2022-09-30	Withdrawn(stopped due to Study was split into two new studies before the first participant was enrolled.)
A Phase I Study to Examine the Toxicity of Allogeneneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewings [NCT02472392]	Phase 1	10 participants (Anticipated)	Interventional	2013-04-30	Completed
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [NCT02206425]	Phase 1/Phase 2	45 participants (Actual)	Interventional	2014-09-30	Completed
Phase 1 Trial for Patients With Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells [NCT05088356]	Phase 1	40 participants (Anticipated)	Interventional	2021-09-07	Recruiting
Phase I/II Study Utilizing High Dose Busulfan and Melphalan With Escalating Carfilzomib as Conditioning in Autologous Peripheral Blood Stem Cell Transplantation for Patients With Multiple Myeloma [NCT03795597]	Phase 1/Phase 2	36 participants (Anticipated)	Interventional	2019-05-22	Recruiting
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies [NCT01652092]		30 participants (Anticipated)	Interventional	2012-09-04	Recruiting
Single-Arm, Open Label, Interventional Phase II Clinical Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy [NCT03674411]	Phase 2	22 participants (Actual)	Interventional	2019-01-02	Active, not recruiting
Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Myelodysplasia or Acute Leukemia in Remission [NCT01885689]	Phase 2	72 participants (Actual)	Interventional	2014-02-10	Active, not recruiting
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma [NCT01798004]	Phase 1	150 participants (Actual)	Interventional	2013-04-08	Active, not recruiting
A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG [NCT01256398]	Phase 2	66 participants (Actual)	Interventional	2010-12-14	Completed
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma [NCT01175356]	Phase 1	99 participants (Actual)	Interventional	2010-10-04	Active, not recruiting
Evaluation of the Safety and Efficacy of Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis [NCT03113162]	Phase 1	15 participants (Anticipated)	Interventional	2015-05-29	Recruiting
Phase III Trial of High-dose Melphalan and Stem Cell Transplantation Versus High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis [NCT02489500]	Phase 3	3 participants (Actual)	Interventional	2015-06-30	Terminated(stopped due to Enrollment held for toxicity evaluation; then closed due to competing trial)
A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis [NCT03426969]	Early Phase 1	3 participants (Actual)	Interventional	2018-01-31	Completed
Conservative Treatments of Retinoblastoma [NCT02866136]	Phase 2	133 participants (Anticipated)	Interventional	2012-02-29	Active, not recruiting
Population Pharmacokinetics (PK) of Melphalan in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) [NCT03609827]		25 participants (Actual)	Observational	2015-09-01	Completed
Phase 1b/2a Trial of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) From an HLA-partially Matched Related or Unrelated Donor After TCRαβ+ T-cell/CD19+ B-cell Depletion for Patients Who Will Receive a Kidney Transplant (KT) From the Same HSCT/KT [NCT05508009]	Phase 1/Phase 2	12 participants (Anticipated)	Interventional	2023-01-10	Recruiting
Hematopoietic Cell Transplantation in the Treatment of Infant Leukemia and Myelodysplastic Syndrome [NCT00357565]	Phase 2	20 participants (Anticipated)	Interventional	2005-11-30	Recruiting
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma [NCT02114502]	Phase 2	0 participants (Actual)	Interventional	2014-09-30	Withdrawn
A PHASE I-II MULTICENTER STUDY OF THE CLORETAZINE-DAUNORUBICIN-ARACYTINE COMBINATION FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH UNFAVORABLE CYTOGENETICS [NCT00840684]	Phase 1/Phase 2	135 participants (Anticipated)	Interventional	2009-01-31	Completed
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody [NCT02963493]	Phase 2	157 participants (Actual)	Interventional	2016-12-28	Completed
A Phase I/II Dose Escalation Trial of Clofarabine, in Addition to Melphalan and Thiotepa as Myeloablative Regimen Followed by an Allogeneic Unmodified Hematopoietic Stem Cell Transplant From HLA-Compatible Related or Unrelated Donors for the Treatment of [NCT00423514]	Phase 1/Phase 2	38 participants (Actual)	Interventional	2006-11-20	Completed
High-Dose Doxorubicin and Ifosfamide Followed by Melphalan and Cisplatin for Patients With High-Risk and Recurrent Sarcoma [NCT00002601]	Phase 2	13 participants (Actual)	Interventional	1994-09-30	Completed
A Phase I/II Study of Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan as a Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Patients With Advanced Multiple Myeloma [NCT01242267]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2010-05-11	Completed
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens [NCT03412565]	Phase 2	265 participants (Actual)	Interventional	2018-04-26	Active, not recruiting
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy [NCT02195479]	Phase 3	706 participants (Actual)	Interventional	2014-12-09	Active, not recruiting
An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma [NCT01998971]	Phase 1	242 participants (Actual)	Interventional	2014-02-18	Active, not recruiting
Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived CAR-NK Cells Combined With High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-Cell Lymphoma [NCT03579927]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2019-10-03	Withdrawn(stopped due to Lack of Funding)
A Randomized, Two-period, Cross-over, Phase 2 Study, Comparing Pharmacokinetics, and Assessing Safety and Tolerability of Peripheral and Central i.v. Administration of Melphalan Flufenamide (Melflufen) in RRMM Patients [NCT04412707]	Phase 2	27 participants (Actual)	Interventional	2020-08-04	Terminated(stopped due to The sponsor decided to terminate the study following an FDA request of a partial clinical hold.)
Phase I/II Study of Carboplatin, Melphalan and Etoposide Phosphate in Conjunction With Osmotic Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection, in Previously Treated Subjects With Anaplastic Oligodendroglioma [NCT00303849]	Phase 1/Phase 2	33 participants (Actual)	Interventional	2005-09-15	Completed
A Phase II Study of Enhancing Anti-Tetanus Vaccine Response After Autologous Stem Cell Transplantation [NCT02700841]	Phase 2	8 participants (Actual)	Interventional	2020-01-09	Terminated(stopped due to Study terminated prematurely due to poor recruitment.)
Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma (A Multicenter Prospective Single Arm Trial) [NCT04903678]		18 participants (Anticipated)	Interventional	2021-05-01	Recruiting
Reduce Intensity Conditioning (RIC) Allogenic Hematopoietic Stem Cell Transplantation (Allo HSCT) for Patients With Relapsed Multiple Myeloma: A Pilot Study [NCT04205240]	Phase 2	1 participants (Actual)	Interventional	2020-12-22	Terminated(stopped due to Poor accrual)
Phase I/II Study of VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non-Hodgkin's Lymphoma, Transformed or Mantle Cell Lymphoma [NCT00571493]	Phase 1/Phase 2	42 participants (Actual)	Interventional	2006-04-14	Completed
A Randomized Trial for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia [NCT01085617]	Phase 3	1,033 participants (Actual)	Interventional	2010-12-31	Active, not recruiting
Choice of Topotecan or Melphalan in Retinoblastoma Patients [NCT04799002]	Phase 3	50 participants (Anticipated)	Interventional	2021-03-11	Recruiting
Intra-Arterial (IA) Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma (ACPP) and Choroid Plexus Carcinoma (CPC) Prior to Second-Look Surgery [NCT04994977]	Phase 1	6 participants (Anticipated)	Interventional	2023-05-04	Recruiting
Phase 0 Microdose Study to Evaluate the Effect of Melphalan, Bortezomib and Dexamethasone on Cellular Gene-expression in Patients With Multiple Myeloma [NCT02109861]	Early Phase 1	6 participants (Actual)	Interventional	2014-01-31	Active, not recruiting
A Pilot Study Evaluating the Safety of Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Newly Diagnosed Advanced Intra-Ocular Retinoblastoma [NCT02116959]	Phase 1	6 participants (Actual)	Interventional	2014-07-23	Terminated(stopped due to Low accrual)
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a High Dose Melphalan Conditioning Regimen, With Administration of Interleukin-2, in Patients With Multiple Myeloma [NCT03506802]	Phase 1	0 participants (Actual)	Interventional	2018-07-10	Withdrawn(stopped due to No Participants Enrolled)
Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey [NCT03935074]		30 participants (Actual)	Observational	2016-08-30	Completed
S0115, A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m) And Autologous Peripheral Blood Stem Cell Supported Transplant (SCT) For High Risk Patients With Multiple Myeloma And/Or Light Chain Amyloidosis (AL Amyloidosis) (A BMT Study) [NCT00064337]	Phase 2	104 participants (Actual)	Interventional	2004-01-31	Completed
Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas [NCT00043979]	Phase 2	60 participants (Actual)	Interventional	2002-09-19	Completed
Pilot Study Of Allogeneic Peripheral Blood Progenitor Cell Transplantation In Patients With Chemotherapy-Refractory Or Poor-Prognosis Metastatic Breast Cancer [NCT00074269]	Phase 2	5 participants (Actual)	Interventional	2003-07-31	Terminated(stopped due to Terminated early due to poor enrollment)
High-Dose Chemo-Radiotherapy for Patients With Primary Refractory and Relapsed Hodgkin's Disease [NCT00003631]	Phase 2	118 participants (Actual)	Interventional	1998-08-31	Completed
A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Do [NCT00003199]	Phase 2	50 participants (Actual)	Interventional	1997-11-30	Completed
Multiple-center Randomized Study to Compare Fludarabine and Busulfan Versus Fludarabine, Busulfan and Melphalan in Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplasia Syndrome (MDS) [NCT05991908]	Phase 3	222 participants (Anticipated)	Interventional	2023-10-19	Recruiting
A Prospective Study of Tocilizumab for the Prevention of Graft Failure and Graft-versus-Host Disease in Haplo-Cord Transplantation [NCT04395222]	Phase 2	21 participants (Actual)	Interventional	2020-10-07	Active, not recruiting
Clinical Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma [NCT06140966]	Phase 2	54 participants (Anticipated)	Interventional	2023-10-20	Recruiting
Intravitreal Melphalan for Intraocular Retinoblastoma [NCT05504291]	Phase 2	28 participants (Anticipated)	Interventional	2022-11-04	Recruiting
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic [NCT05457556]	Phase 3	435 participants (Anticipated)	Interventional	2023-03-15	Recruiting
An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid(TM))(MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose T [NCT00602641]	Phase 3	306 participants (Actual)	Interventional	2008-02-29	Active, not recruiting
A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma [NCT00114101]	Phase 3	460 participants (Actual)	Interventional	2004-12-15	Active, not recruiting
A Pilot Study: Gene Expression and Bacterial Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant [NCT02589860]		0 participants (Actual)	Observational	2015-10-30	Withdrawn(stopped due to No accrual)
A National, Open-label, Multicenter, Randomized, Comparative Phase IIb Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) [NCT01237249]	Phase 2	250 participants (Actual)	Interventional	2011-02-28	Completed
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL) [NCT03126916]	Phase 3	724 participants (Anticipated)	Interventional	2018-05-14	Active, not recruiting
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Non-Hodgkin Lymphoma Using Zevalin, Fludarabine and Melphalan [NCT00577278]	Phase 2	41 participants (Actual)	Interventional	2007-10-03	Active, not recruiting
Randomized Phase II Multi-center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan as Conditioning Therapy for Autologous Stem-cell Transplantation(ASCT) in Patients With Non-Hodgkin's Lymphoma [NCT03794167]	Phase 2	75 participants (Actual)	Interventional	2012-06-01	Completed
Clinical Study of Mitoxantrone Hydrochloride Liposome, Carmostine, Etoposide and Cytarabine as Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Lymphoma [NCT05681403]		53 participants (Anticipated)	Interventional	2023-01-15	Not yet recruiting
Phase1b/2 Study Combining Hepatic Percutaneous Perfusion With Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma [NCT04283890]	Phase 1/Phase 2	83 participants (Anticipated)	Interventional	2019-12-04	Recruiting
JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study [NCT02251821]	Phase 2	99 participants (Actual)	Interventional	2014-10-20	Active, not recruiting
Melphalan vs Busulfan+ Cyclophosphamide+ Etoposide Conditioning Regimen for Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation [NCT03385096]	Phase 2/Phase 3	122 participants (Anticipated)	Interventional	2018-01-02	Recruiting
Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) as a Conditioning for Autologous Stem Cell Transplantation in Patients With B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma [NCT01178645]	Phase 2	42 participants (Anticipated)	Interventional	2010-07-31	Recruiting
Clinical Research of Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Children With Stage 4/M Neuroblastoma: A Prospective, Single-arm, Phase II, Multi-center Trial [NCT05303727]	Phase 2	64 participants (Anticipated)	Interventional	2022-08-31	Not yet recruiting
A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-Chain (AL) Amyloidosis Ineligible for Autologous Stem-Cell Transplantation [NCT01078454]	Phase 3	11 participants (Actual)	Interventional	2010-11-30	Completed
Efficacy and Safety of Venetoclax Combined With BEAM (Carmustine, Etoposide Cytarabine and Melphalan) Pretreatment in Autologous Stem Cell Transplantation for Diffuse Large B-cell Lymphoma: a Single-center, Randomized Clinical Study [NCT05863845]		52 participants (Anticipated)	Interventional	2023-06-01	Not yet recruiting
Randomized Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant [NCT03328936]	Phase 2	0 participants (Actual)	Interventional	2018-09-01	Withdrawn(stopped due to Sponsor decision)
Open-labelled, Multicenter Phase II Clinical Trial of Intravenous Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation in Patients With Poor-risk, Refractory or Relapsed Non-Hodgkin's Lymphoma [NCT03792815]	Phase 2	51 participants (Actual)	Interventional	2009-10-31	Completed
Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies [NCT05735717]	Phase 2	150 participants (Anticipated)	Interventional	2023-05-11	Recruiting
A Phase II Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma, With Randomization Depending on the Site of Relapse or on Previous Treatment [NCT04455139]	Phase 2	2 participants (Actual)	Interventional	2021-11-15	Terminated(stopped due to Difficulties in recruiting patients due to changing in treatment standards for the target population)
Pharmacokinetic (PK)-Directed Dosing of Captisol Enabled Melphalan for Patients With Multiple Myeloma or Light Chain (AL) Amyloidosis Undergoing High Dose Therapy and Autologous Hematopoietic Progenitor Cell Transplant [NCT02909036]	Phase 1	46 participants (Actual)	Interventional	2016-09-30	Active, not recruiting
Tandem Myeloablative Consolidation Therapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma [NCT02605421]	Phase 2	12 participants (Anticipated)	Interventional	2016-06-30	Recruiting
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma [NCT02678572]	Phase 3	102 participants (Actual)	Interventional	2016-02-01	Completed
Dose-Intense Chemotherapy and Stem Cell Rescue in the Treatment of Inflammatory Breast Carcinoma [NCT00003042]	Phase 2	41 participants (Actual)	Interventional	1997-05-30	Active, not recruiting
A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin®, as Graft-versus-Host- Disease Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation [NCT00691015]	Phase 2	48 participants (Actual)	Interventional	2008-05-31	Completed
Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals (BMT CTN #0903) [NCT01410344]	Phase 2	20 participants (Actual)	Interventional	2011-09-30	Completed
Clofarabine-melphalan-alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies [NCT00943592]	Phase 1/Phase 2	82 participants (Actual)	Interventional	2006-03-31	Completed
Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue. [NCT00747877]	Phase 3	460 participants (Anticipated)	Interventional	2008-04-30	Recruiting
An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy [NCT04115956]	Phase 1	6 participants (Actual)	Interventional	2020-08-06	Terminated(stopped due to The sponsor decided to terminate the study following an FDA request of a partial clinical hold.)
Targeted Intensification by a Preparative Regimen for Patients With High-grade B-Cell Lymphoma Utilizing Standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-dose BEAM Followed by Autologous Stem Cell Transpl [NCT00689169]	Phase 2	75 participants (Actual)	Interventional	2007-08-31	Completed
Randomized Phase II Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden in High Risk Patients With Multiple Myeloma or Amyloidosis [NCT00651937]	Phase 2	80 participants (Actual)	Interventional	2008-03-31	Completed
A Phase 1-2 Study of a Novel Conditioning Regimen of Bendamustine and Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma [NCT00916058]	Phase 1/Phase 2	57 participants (Actual)	Interventional	2009-04-23	Completed
Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes in the Autologous Transplant Setting in Multiple Myeloma [NCT00566098]	Phase 1/Phase 2	26 participants (Actual)	Interventional	2007-11-30	Completed
Reduced-dose Radiotherapy Following High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Central Nervous System Non-germinomatous Germ Cell Tumors [NCT02784054]	Phase 2	25 participants (Anticipated)	Interventional	2014-04-30	Recruiting
A Phase III Study for Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 (TT2, UARK 98-026): Bortezomib, Thalidomide and Dexamethasone Versus Bortezomib, Melphalan, and Dexamethasone [NCT00573391]	Phase 3	5 participants (Actual)	Interventional	2006-08-31	Terminated(stopped due to low accrual)
Post-Transplant Bendamustine (PT-BEN) for GVHD Prophylaxis [NCT04022239]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2020-03-13	Recruiting
Pilot Open-Label Study of Safety and Efficacy of Ruxolitinib Given Peri-Transplant During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients With Myelofibrosis [NCT02917096]	Phase 1	18 participants (Actual)	Interventional	2016-11-13	Completed
Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma [NCT01729091]	Phase 2	72 participants (Anticipated)	Interventional	2013-06-10	Active, not recruiting
A Randomized Phase II Dose Finding Study of Revlimid™ and Melphalan in Patients With Previously Untreated Multiple Myeloma [NCT00305812]	Phase 2	51 participants (Actual)	Interventional	2006-03-09	Completed
BMT-03: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Patients With Relapsed or Refractory Multiple Myeloma [NCT02043847]	Phase 1	12 participants (Actual)	Interventional	2014-01-14	Completed
A Trial of Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions for Patients With Relapsed or High-Risk Multiple Myeloma [NCT01131169]	Phase 2	66 participants (Actual)	Interventional	2010-05-31	Completed
Stem Cell Transplant as Standard Therapy for Symptomatic Multiple Myeloma [NCT00004165]	Phase 3	0 participants	Interventional	1999-10-31	Completed
Partially HLA-Mismatched Related Donor Hematopoietic Stem Cell Transplantation Using Killer Immunoglobulin Receptor and Human Leukocyte Antigen Based Donor Selection [NCT02880293]		44 participants (Actual)	Interventional	2016-08-23	Completed
High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders [NCT03602235]	Phase 1	9 participants (Anticipated)	Interventional	2019-03-05	Recruiting
A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) [NCT02570542]	Phase 2	59 participants (Actual)	Interventional	2015-10-31	Active, not recruiting
Autologous Stem Cell Transplantation With Nivolumab in Patients With Multiple Myeloma [NCT03292263]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2017-04-24	Recruiting
A Phase I Study of Melphalan, Bendamustine, and Carfilzomib for Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma [NCT02148913]	Phase 1	18 participants (Actual)	Interventional	2014-06-30	Completed
Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma: a Pilot Feasibility Study Using a Novel Protocol [NCT02447055]	Early Phase 1	0 participants (Actual)	Interventional	2015-12-31	Withdrawn
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma [NCT06172296]	Phase 3	478 participants (Anticipated)	Interventional	2024-02-14	Not yet recruiting
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) [NCT04682405]	Phase 2	51 participants (Actual)	Interventional	2021-05-05	Completed
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas [NCT02130869]	Phase 1	8 participants (Actual)	Interventional	2014-10-10	Completed
Combined Transplantation of Unmanipulated Haploidentical and a SingleCord Blood Unit for Patients With Hematologic Malignancies [NCT01359254]	Phase 2	1 participants (Actual)	Interventional	2010-04-30	Terminated(stopped due to did not accrue enough patients.)
A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administr [NCT03691376]	Phase 1	4 participants (Actual)	Interventional	2019-03-08	Active, not recruiting
NB2004 Trial Protocol for Risk Adapted Treatment of Children With Neuroblastoma [NCT00410631]	Phase 3	642 participants (Anticipated)	Interventional	2004-10-31	Recruiting
Phase II Randomized Study of Isolated Limb Perfusion Using Melphalan With or Without Tumor Necrosis Factor in Patients With Unresectable High Grade Soft Tissue Sarcomas of the Extremity [NCT00019968]	Phase 2	0 participants	Interventional	1999-08-31	Completed
Phase II Study of Isolated Hepatic Perfusion With Melphalan Followed By Postoperative Hepatic Arterial Chemotherapy in Patients With Unresectable Colorectal Cancer Metastatic to the Liver [NCT00019760]	Phase 2	0 participants	Interventional	1999-04-30	Completed
A Phase 1 Study to Assess Safety and Tolerability of Tremelimumab and Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant (HDT/ASCT) [NCT02716805]	Phase 1	6 participants (Actual)	Interventional	2016-12-13	Terminated(stopped due to FDA placed on partial hold due to additional data)
A Multicenter Phase II Trial of Bortezomib (Velcade), Melphalan, and Dexamethasone (V-MD) in Patients With Symptomatic AL-Amyloidosis or Light Chain Deposition Disease [NCT00520767]	Phase 2	35 participants (Actual)	Interventional	2007-09-30	Completed
A Phase II Study of Reduced Intensity Allogeneic Transplantation for Refractory Hodgkin Lymphoma [NCT00908180]	Phase 2	47 participants (Anticipated)	Interventional	2009-07-31	Not yet recruiting
A Reduced Intensity Conditioning Regimen With CD3-Depleted Hematopoietic Stem Cells to Improve Survival for Patients With Hematologic Malignancies Undergoing Haploidentical Stem Cell Transplantation [NCT00566696]	Phase 2	73 participants (Actual)	Interventional	2007-12-14	Completed
Phase III Trial Comparing Treatment With Melphalan+Prednisolon (MP) With Melphalan+Prednisolon+Thalidomide (MPT) for Previously Untreated Elderly Patients With Multiple Myeloma [NCT00934154]	Phase 3	122 participants (Actual)	Interventional	2006-03-31	Completed
Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts [NCT00968396]	Phase 2	0 participants (Actual)	Interventional	2013-02-28	Withdrawn
Phase II Open Lable Clinical Study Efficacy and Safety of the Holistic Treatment for Young Patients With High-Risk Multiple Myeloma [NCT04008888]		50 participants (Anticipated)	Interventional	2018-01-05	Recruiting
A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis [NCT00679367]	Phase 2	16 participants (Actual)	Interventional	2008-05-31	Completed
T-Cell or Natural Killer (NK) Cell Adback in Patients With Lymphoid Malignancies Receiving Allogeneic Stem Cell Transplantation With Campath-IH Containing Conditioning Regimens [NCT00536978]	Phase 2	22 participants (Actual)	Interventional	2007-09-30	Completed
Ensayo Fase II de Trasplante autólogo de Sangre periférica en Pacientes Con Mieloma múltiple Tras Acondicionamiento Con Busulfan Intravenoso y Melfalan [NCT00804947]	Phase 2	50 participants (Anticipated)	Interventional	2005-09-30	Recruiting
Phase I/II Study of the Combination of Bortezomib With Arsenic Trioxide, Ascorbic Acid and High-Dose Melphalan for Patients With Multiple Myeloma [NCT00469209]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2006-06-30	Completed
A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis [NCT00890552]		25 participants (Actual)	Interventional	2009-04-30	Completed
Phase II Trial of High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis [NCT00790647]	Phase 2	10 participants (Actual)	Interventional	2008-06-30	Completed
A Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation [NCT00641030]	Phase 1	20 participants (Actual)	Interventional	2007-07-31	Completed
Allogeneic Hematopoietic Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors [NCT03615105]	Phase 2	9 participants (Actual)	Interventional	2018-07-25	Active, not recruiting
A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma [NCT01208766]	Phase 3	1,503 participants (Actual)	Interventional	2011-01-31	Active, not recruiting
HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen [NCT02776202]	Phase 2	15 participants (Anticipated)	Interventional	2016-05-31	Recruiting
Clinical, Multicenter, Single-arm, Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma (MM) Newly Diagnosed Symptomatic ≥75 Years [NCT02773550]	Phase 4	24 participants (Actual)	Interventional	2014-01-31	Terminated(stopped due to Low recruiment.)
An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination With Either Bortezomib or Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma [NCT03481556]	Phase 1/Phase 2	56 participants (Actual)	Interventional	2018-04-12	Terminated(stopped due to The sponsor decided to terminate the study following an FDA request of a partial clinical hold.)
Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma [NCT00644306]	Phase 3	232 participants (Actual)	Interventional	2002-04-30	Terminated(stopped due to survival advantage demonstrated)
A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors [NCT02653196]	Early Phase 1	1 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to The Principal Investigator left the institution.)
Phase II Study of Carfilzomib-cyclophosphamide-dexamethasone and High-dose Melphalan (HDT) Followed by Randomization Between Observation or Maintenance With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma After HDT [NCT02572492]	Phase 2	200 participants (Actual)	Interventional	2015-01-31	Active, not recruiting
Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies [NCT00824135]	Phase 1	34 participants (Actual)	Interventional	2009-01-31	Completed
Intra-arterial (Ophthalmic Artery) Chemotherapy for Retinoblastoma [NCT00857519]		10 participants (Actual)	Interventional	2009-01-31	Completed
Phase II Study of VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Stage III/IV Extranodal NK-T-Cell Lymphoma [NCT02544425]	Phase 2	27 participants (Anticipated)	Interventional	2016-02-21	Recruiting
Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma [NCT00006747]	Phase 2	4 participants (Actual)	Interventional	2000-11-30	Completed
Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in [NCT00017680]	Phase 2	25 participants	Interventional	1999-07-31	Completed
Phase 1-2 Study of Injection of Melphalan Into the Ophthalmic Artery in Children With Retinoblastoma [NCT00906113]	Phase 1/Phase 2	10 participants (Anticipated)	Interventional	2011-06-30	Recruiting
A Randomised Phase II Clinical Trial Using Targeted Radiotherapy Delivered by an Yttrium-90 Radio-Labelled Anti-CD66 Monoclonal Antibody With High Dose Melphalan Compared to Melphalan Alone, Prior to Autologous Stem Cell Transplantation for Multiple Myelo [NCT00637767]	Phase 2	25 participants (Actual)	Interventional	2007-12-01	Terminated(stopped due to Low recruitment)
Randomized Phase 3b Study of Three Treatment Regimens in Subjects With Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE, Thalidomide, and Dexamethasone Ver [NCT00507416]	Phase 3	502 participants (Actual)	Interventional	2007-06-30	Completed
Infusion of Expanded Cord Blood T Cells Following Cord Blood Transplantation [NCT00972101]	Phase 1	0 participants (Actual)	Interventional	2009-09-30	Withdrawn(stopped due to Development of other studies led to termination without recruitment.)
Effects of Exercise in Combination With Epoetin Alfa During High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma [NCT00577096]		120 participants (Actual)	Interventional	2001-10-31	Completed
A Pilot Trial Of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan, And Low Dose Total Body Irradiation [NCT00856388]		62 participants (Actual)	Interventional	2009-01-14	Completed
A Phase II Clinical Trial for Untreated Patients With Multiple Myeloma Eligible for Stem Cell Transplant: Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell [NCT00807599]	Phase 2	67 participants (Actual)	Interventional	2008-12-10	Completed
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab Maintenance in Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphomas [NCT00591630]	Phase 2	30 participants (Actual)	Interventional	2007-11-14	Completed
Evaluation of Benefit and Side Effects of 131I-MIBG in Combination With Myeloablative Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma [NCT00798148]	Phase 1/Phase 2	10 participants (Anticipated)	Interventional	2008-09-30	Recruiting
A Phase I/II Study of Oral Melphalan Combined With LBH589 for Patients With Relapsed or Refractory Multiple Myeloma (MM) [NCT00743288]	Phase 1/Phase 2	40 participants (Actual)	Interventional	2008-07-31	Completed
Phase II Study of Low Intensity Allogeneic Transplantation in Mantle Cell Lymphoma [NCT00720447]	Phase 2	25 participants (Anticipated)	Interventional	2008-11-30	Not yet recruiting
Phase 1 of Exposure Targeted Melphalan Dosing [NCT04483206]	Phase 1	90 participants (Anticipated)	Interventional	2021-05-20	Recruiting
Three-arm Clinical Trial for Patients With Hematologic Malignancies and Mismatched Donors - Haploidentical, 1 Antigen Mismatch Related or Unrelated, and Matched Unrelated Donor (MUD)- Using a T-cell Replete Allograft and High-dose Post-transplant Cyclopho [NCT01010217]	Phase 2	176 participants (Actual)	Interventional	2009-11-05	Completed
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic Cell Support for Patients With Relapsed/Refractory Hodgkin's Disease [NCT01200329]	Phase 2	81 participants (Actual)	Interventional	2011-06-30	Completed
Anti-CD7 Universal CAR-T Cells for CD7+ T/NK Cell Hematologic Malignancies: a Multi-center, Uncontrolled Trial [NCT04264078]	Early Phase 1	30 participants (Anticipated)	Interventional	2021-03-01	Recruiting
A Phase I Study of Amifostine Followed by High-Dose Escalation of Melphalan With Stem Cell Reconstitution for Patients With Primary Systemic Amyloidosis [NCT00052884]	Phase 1	8 participants (Actual)	Interventional	2004-01-22	Terminated(stopped due to Slow accrual and changes in clinical practice)
Phase I/II Study of Oral Lenalidomide and High Dose Melphalan Supported by Autologous Peripheral Blood Stem Cell Infusion for Patients With Multiple Myeloma [NCT01142232]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2010-08-27	Completed
A Phase II Trial of Transplants From HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies and Other Lethal H [NCT01119066]	Phase 2	422 participants (Actual)	Interventional	2010-05-03	Completed
A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults With Severe Sickle Cell Disease (BMT CTN 1503) [NCT02766465]	Phase 2	138 participants (Actual)	Interventional	2016-11-30	Completed
A Phase I Study of Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematological Malignancies. [NCT00890500]	Phase 1	12 participants (Actual)	Interventional	2011-01-31	Completed
A Phase II Study of Reduced Intensity Sibling Allogeneic Transplantation for Relapsed, Chemosensitive, PET-positive Hodgkin Lymphoma [NCT00907036]	Phase 2	49 participants (Anticipated)	Interventional	2009-07-31	Not yet recruiting
A Randomized Phase I/II Study of BI-505 in Conjunction With High-dose Melphalan and Autologous Stem Cell Transplantation for Multiple Myeloma [NCT02756728]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2016-05-31	Terminated(stopped due to Full clinical hold from FDA)
A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation [NCT02750254]	Phase 1	5 participants (Actual)	Interventional	2016-06-27	Terminated(stopped due to Toxicity. Only enrolled patients in phase I portion of trial.)
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells [NCT00085449]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2006-05-31	Withdrawn(stopped due to Funding cut, no patients enrolled)
Allogeneic Stem Cell Transplantation For Multiple Myeloma: A Two Step Approach To Reduce Toxicity Involving High Dose Melphalan and Autologous Stem Cell Transplant Followed By PBSC Allografting After Low Dose TBI [NCT00003954]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	1999-03-31	Completed
A Phase II Trial of Reduced Intensity Conditioning and Partially HLA-mismatched (HLA-haploidentical) Related Donor Bone Marrow Transplantation for High-risk Solid Tumors [NCT01804634]	Phase 2	60 participants (Anticipated)	Interventional	2013-03-27	Recruiting
Phase I Trial of Tandem Chemotherapy Cycles as Consolidation Therapy for High-Risk Epithelial Ovarian and Primary Peritoneal Cancer Utilizing Intraperitoneal Paclitaxel/IV Cyclophosphamide Followed by IV Topotecan/Intraperitoneal Cisplatin/IV Melphalan Us [NCT00550784]	Phase 1	8 participants (Actual)	Interventional	2001-01-31	Completed
Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer (Clinical Studies), Tamoxifen Citrate Was Added to Adjunct Cytotoxic Chemotherapy- Treatment of Malignant Joint Tumor. [NCT06154590]		100 participants (Anticipated)	Observational [Patient Registry]	2024-07-31	Not yet recruiting
A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma [NCT03786783]	Phase 2	42 participants (Actual)	Interventional	2019-01-14	Active, not recruiting
An Open, Single-centre Non-randomized Phase II Clinical Trial on Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage [NCT01393769]	Phase 2	5 participants (Actual)	Interventional	2009-11-30	Terminated(stopped due to Only 5 subjects could be enrolled. Sample of 25 pat. not be achieved (rare disease).)
Addition of Inotuzumab Ozogamicin Pre- and Post-Allogeneic Transplantation [NCT03856216]	Phase 2	44 participants (Anticipated)	Interventional	2019-10-28	Recruiting
Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule(s) and Dose(s) of Melphalan for Injection (Evomela) as a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myel [NCT03417284]	Phase 1/Phase 2	62 participants (Actual)	Interventional	2019-10-09	Active, not recruiting
Study Characterizing the Impact of Different Therapeutic Strategies on Event Occurrence at 2 Years, 5 Years, 10 Years, and 15 Years, According to Prognostic Groups in Patients With Hodgkin Lymphoma [NCT00920153]	Phase 3	442 participants (Actual)	Interventional	2008-05-31	Terminated(stopped due to Other new drugs)
Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies [NCT02581007]	Phase 2	25 participants (Actual)	Interventional	2015-10-26	Completed
Phase I/II Study of Intra-Arterial Melphalan Given With Intra-Arterial Carboplatin, Osmotic Blood-Brain Barrier Disruption and Delayed Otoprotective Sodium Thiosulfate for Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors [NCT00983398]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2009-07-09	Active, not recruiting
Phase III Study of Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma [NCT00892346]	Phase 3	80 participants (Anticipated)	Interventional	2009-05-31	Suspended(stopped due to No avaliability of melphlan in mainland China)
A Phase I/II Dose Escalation Study Assessing the Toxicity and Efficacy of 153-Samarium-EDTMP in Place of TBI in the Conditioning Regimen for PBSCT for Patients With Multiple Myeloma [NCT00602706]	Phase 1/Phase 2	76 participants (Anticipated)	Interventional	2000-01-31	Completed
A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, an [NCT00689936]	Phase 3	1,623 participants (Actual)	Interventional	2008-08-21	Completed
Phase I/II Study Of The Combination Of Lenalidomide With High-Dose Melphalan For Autologous Transplant in Patients With Multiple Myeloma [NCT01079936]	Phase 1/Phase 2	61 participants (Actual)	Interventional	2010-03-31	Completed
A Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) in Multiple Myeloma Patients [NCT00899847]	Phase 2	9 participants (Actual)	Interventional	2009-05-31	Completed
"Revlimid®, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: A Phase 2 Study" [NCT00744536]	Phase 2	20 participants (Actual)	Interventional	2008-01-31	Completed
Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma [NCT00567567]	Phase 3	665 participants (Actual)	Interventional	2007-11-05	Completed
Pilot Study of Unrelated Cord Blood Transplantation in Patients With Poor Risk Haematological Malignancies [NCT00916045]	Phase 2	40 participants (Anticipated)	Interventional	2009-09-30	Terminated(stopped due to Recruitment issues)
Autologous Stem Cell Rescue With CD133+ Selected Hematopoietic Progenitor Cells in Patients With High-Risk Neuroblastoma [NCT00539500]	Phase 2/Phase 3	3 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to Slow Accrual.)
A Randomized, Multi-Center Phase III Trial Comparing Two Conditioning Regimens (CloFluBu and BuCyMel) in Children With Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. [NCT05477589]	Phase 3	170 participants (Anticipated)	Interventional	2022-06-07	Recruiting
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma [NCT05022901]	Phase 3	30 participants (Anticipated)	Interventional	2022-06-10	Active, not recruiting
A Phase I/II Study of Vaccination Against Minor Histocompatibility Antigens HA1 or HA2 After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies [NCT00943293]	Phase 1	1 participants (Actual)	Interventional	2003-05-31	Terminated(stopped due to Poor accrual; did not enter phase 2)
Natural Killer Cells in Allogeneic Cord Blood Transplantation [NCT01619761]	Phase 1	13 participants (Actual)	Interventional	2013-05-03	Active, not recruiting
A Phase II Study of GM-CSF (Sargramostim) and Rituximab Following Autologous Transplantation For Relapsed Follicular Lymphoma [NCT00521014]	Phase 2	14 participants (Actual)	Interventional	2007-10-31	Completed
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Myelodysplastic Syndrome [NCT05617625]	Phase 2	50 participants (Anticipated)	Interventional	2024-03-31	Suspended(stopped due to The study has been put on hold while pending CMS approval)
Phase II Single-Blind Randomized Trial Comparing Morbidity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis [NCT03073694]	Phase 2	100 participants (Anticipated)	Interventional	2017-07-14	Recruiting
UARK 2006-15: A Phase III Randomized Study of Tandem Transplants With or Without Bortezomib (Velcade) and Thalidomide (Thalomid) to Evaluate Its Effect on Response Rate and Durability of Response in Multiple Myeloma Patients [NCT00574080]	Phase 3	20 participants (Actual)	Interventional	2006-07-31	Terminated(stopped due to low accrual)
Phase 2 Study Of High Dose Chemotherapy Followed By Autologous Hematopoietic Stem Cell Support In Patients With Multiple Myeloma And Primary Light Chain Amyloidosis [NCT00007995]	Phase 2	75 participants (Anticipated)	Interventional	1999-07-31	Completed
Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation [NCT00008307]	Phase 2	52 participants (Anticipated)	Interventional	1998-04-30	Active, not recruiting
A National, Multi-Center, Open-Label Study of Velcade in Combination With Melphalan and Prednisone (V-MP) in Older Untreated Multiple Myeloma Patients. [NCT00388635]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2004-04-30	Completed
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver [NCT00001576]	Phase 1	28 participants	Interventional	1997-07-31	Completed
Lenalidomide, Melphalan, Prednisone, and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma [NCT00961467]	Phase 2	44 participants (Actual)	Interventional	2007-02-28	Completed
Dose Escalation Study of 131 I-Metaiodobenzylguanidine (MIBG) With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma - A Phase I Study [NCT00005978]	Phase 1	0 participants	Interventional	2000-05-31	Completed
A Pilot Study Of Tandem High Dose Chemotherapy With Stem Cell Rescue Following Induction Therapy In Children With High Risk Neuroblastoma [NCT00017368]	Phase 2	42 participants (Actual)	Interventional	2001-04-30	Completed
Phase I Study of Escalating Doses of Radiation Therapy Using Helical Tomotherapy in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With Advanced and [NCT00800150]	Phase 1	6 participants (Actual)	Interventional	2008-11-30	Terminated(stopped due to Protocol objective could not be met. A new study with amended eligibility criteria will be developed.)
Infusional Gemcitabine and High-dose Melphalan (HDM) Conditioning Prior to (ASCT) Autologous Stem Cell Transplantation for Patients With Relapsed/Refractory Lymphoma [NCT02295722]	Phase 1/Phase 2	100 participants (Actual)	Interventional	2015-04-30	Terminated(stopped due to It did not show a significant benefit to justify completing the full target accrual.)
Busulfan and Melphalan With Autologous Hematopoietic Stem Cell Support With Positively-Selected CD133+ Hematopoietic Cells for Children With High Risk Solid Tumors and Lymphomas [NCT00152126]		26 participants (Actual)	Interventional	2003-08-31	Completed
Phase II Study of Early Allogeneic Blood Stem Cell Transplantation During Induction-chemotherapy Induced Aplasia in High-risk Acute Myeloid Leukemia [NCT00188136]	Phase 2	32 participants (Actual)	Interventional	2002-08-31	Completed
A Phase II Trial of Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic [NCT00629798]	Phase 2	64 participants (Actual)	Interventional	2008-02-12	Completed
Pharmacogenomic Study to Predict Survival, Best Response and Toxicity in Newly Diagnosed Myeloma Patients Above the Age of 65 Treated With Either a Combination of Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone [NCT00907452]		143 participants (Actual)	Interventional	2009-07-29	Completed
High Dose Sequential Therapy for Poor Risk Recurrent or Refractory Hodgkin's Disease [NCT00544570]		30 participants (Anticipated)	Interventional	1998-04-30	Completed
Haploidentical Hematopoietic Stem Cell Transplantation for Pediatric Patients With Wiskott-Aldrich Syndrome: A Pilot Study [NCT00160355]	Phase 1	4 participants (Actual)	Interventional	2005-05-31	Completed
A Phase III, Multicentre, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study To Determine The Efficacy And Safety Of Lenalidomde (Revlimid®) In Combination With Melphalan And Prednisone Versus Placebo Plus Melphalan And Prednisone In [NCT00405756]	Phase 3	459 participants (Actual)	Interventional	2007-01-31	Completed
Bortezomib (Velcade®) and Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoid Malignancies [NCT00439556]	Phase 2	40 participants (Actual)	Interventional	2007-02-13	Completed
Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer [NCT00429572]	Phase 2	19 participants (Actual)	Interventional	1998-01-31	Completed
Adaptive Randomization of Fludarabine-Melphalan Versus Fludarabine-Cyclophosphamide Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor for Metastatic Renal Cell Carcinoma [NCT00429026]	Phase 2	40 participants (Actual)	Interventional	2004-01-31	Terminated(stopped due to Slow accrual, study terminated.)
A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma [NCT00001296]	Phase 3	122 participants	Interventional	1992-02-29	Completed
A Phase II Trial of a Chemotherapy Based Regimen of Intravenous Busulfan (Busulfex), Melphalan and Thiotepa as Myeloablative Regimen Followed by a T- Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant From and HLA-Compatible Donor in the Treatmen [NCT00357396]	Phase 2	10 participants (Actual)	Interventional	2005-06-30	Completed
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma [NCT00185614]	Phase 2	63 participants (Actual)	Interventional	2000-08-31	Completed
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma [NCT02506959]	Phase 2	83 participants (Actual)	Interventional	2015-09-14	Active, not recruiting
Study of Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma (CTCL) [NCT00506129]	Phase 2	33 participants (Actual)	Interventional	2003-09-30	Completed
An Evaluation of Bortezomib (VelcadeR ) Followed by High-Dose Melphalan and Bortezomib (VelcadeR) as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants in Patients With Primary Refractory Multiple Myeloma and Plasma Cell Leukemia [NCT00307086]	Phase 2	30 participants (Actual)	Interventional	2005-06-30	Completed
A Study of Intensive-Dose Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. [NCT00325416]	Phase 1/Phase 2	177 participants (Actual)	Interventional	2001-11-19	Completed
A Phase II Study of Concurrent Systemic Pembrolizumab and Isolated Limb Infusion (ILI) With Melphalan and Dactinomycin for Patients With Locally Advanced or Metastatic Extremity Sarcoma [NCT04332874]	Phase 2	30 participants (Anticipated)	Interventional	2020-04-01	Recruiting
Multiple Myeloma Treatment With Thalidomide. Three Randomized Studies on Thalidomide as Induction Treatment Before Autotransplant (MY-TAG) or With a Conventional Chemotherapy (MY-DECT) and as Consolidation/Maintenance at Plateau Phase (MY-PLAT). [NCT01070862]	Phase 3	0 participants	Interventional	2003-05-31	Completed
A Phase II Study of High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, Melphalan, Thymoglobulin and Autologous CD34+ Hematopoietic Stem Cell Transplant for the Treatment of Poor Prognosis Multiple Sclerosis [NCT00288626]	Phase 2	25 participants (Actual)	Interventional	2006-07-31	Completed
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies [NCT00683046]	Phase 2	204 participants (Actual)	Interventional	2001-11-30	Completed
A Randomized, National, Open-label, Multicenter, Phase III Trial Studying Induction Therapy With Bortezomib/Lenalidomide/Dexamethasone (VRD-GEM), Followed by High-dose Chemotherapy With Melphalan-200 (MEL-200) Versus Busulfan-melphalan (BUMEL), and Consol [NCT01916252]	Phase 3	460 participants (Anticipated)	Interventional	2013-09-30	Completed
Prospective Observational Study on Isolated Limb Perfusion of Melphalan in Treating Patients With Metastasis or Recidivism of Limb Melanoma or Sarcoma That Are Not Operable [NCT01920516]		40 participants (Anticipated)	Observational	2013-07-31	Recruiting
A Phase 2, Open-label, Prospective, Multicenter Study to Evaluate the Efficacy of Intravenous Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation [NCT01923935]	Phase 2	105 participants (Anticipated)	Interventional	2013-01-31	Recruiting
Phase I/II Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma [NCT01936090]	Phase 1	11 participants (Actual)	Interventional	2013-08-31	Completed
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies [NCT03849651]	Phase 2	140 participants (Anticipated)	Interventional	2019-01-31	Recruiting
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation [NCT01962415]	Phase 2	100 participants (Anticipated)	Interventional	2014-02-04	Recruiting
A Phase II Trial Of BEAM/Rituximab/Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Patients With CD20 Positive Non-Hodgkin's Lymphoma [NCT00080886]	Phase 2	68 participants (Actual)	Interventional	2002-05-08	Completed
International, Multi-center, Prospective, Double Randomized, Open Phase III Study Evaluating Thalidomide/Dexamethasone Versus Melphalan/Prednisone as Induction Therapy and Thalidomide/Interferon-alpha Versus Interferon-alpha as Maintenance Therapy in Newl [NCT00205751]	Phase 2/Phase 3	350 participants (Anticipated)	Interventional	2001-08-31	Completed
Efficacy of 6x R-CHOP Followed by Myeloablative Radiochemotherapy and Autologous Stem Cell Transplantation vs. 3 x (R-CHOP/R-DHAP) Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation [NCT00209222]	Phase 3	360 participants (Anticipated)	Interventional	2004-07-31	Recruiting
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma [NCT02961816]	Phase 2	0 participants (Actual)	Interventional	2017-06-30	Withdrawn(stopped due to Lack of funding)
A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma [NCT00004188]	Phase 3	495 participants (Actual)	Interventional	2001-02-28	Completed
A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma [NCT01840566]	Phase 1	17 participants (Actual)	Interventional	2013-04-30	Active, not recruiting
A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma [NCT01969942]	Phase 1	0 participants (Actual)	Interventional	2013-04-30	Withdrawn(stopped due to No subjects meeting study inclusion were enrolled.)
Personalized NK Cell Therapy in CBT [NCT02727803]	Phase 2	100 participants (Anticipated)	Interventional	2016-05-19	Recruiting
A Phase I/IIa, Open-label, Non-randomized, Study of ASC-101 in Patients With Hematologic Malignancies or Myelodysplastic Syndrome (MDS) Who Are Candidates for Dual-cord Umbilical Cord Blood Transplantation (UCBT) [NCT01983761]	Phase 1/Phase 2	25 participants (Anticipated)	Interventional	2013-11-30	Active, not recruiting
A Phase I-II Trial of Adoptive Immunotherapy Using Haploidentical, Related Donor-Lymphocyte Infusions and IL-2 After Autologous Stem Cell Transplantation for Advanced Lymphoid Malignancies [NCT00248430]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2003-08-31	Completed
Induction Therapy With Bortezomib and Dexamethasone Followed by Autologous Stem Cell Transplantation Versus Autologous Stem Cell Transplantation Alone in the Treatment of AL Amyloidosis [NCT01998503]	Phase 3	56 participants (Actual)	Interventional	2007-12-31	Completed
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma [NCT01908777]	Phase 2	47 participants (Actual)	Interventional	2013-07-16	Active, not recruiting
A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells [NCT02797470]	Phase 1/Phase 2	11 participants (Actual)	Interventional	2016-06-23	Active, not recruiting
A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma [NCT02008006]	Phase 2	21 participants (Actual)	Interventional	2014-07-09	Terminated(stopped due to Insufficient recruitment and unavailability of the treatment)
Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma [NCT01293539]	Phase 2	10 participants (Actual)	Interventional	2011-03-31	Terminated(stopped due to IAC is now recognized as part of standard of care treatment options in the US.)
"Phase I Study of Yttrium-90 Labeled Anti-CD25 (a-Tac) Monoclonal Antibody Plus BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients With Primary Refractory or Relapsed Hodgkin Lymphoma, the a-Tac BEAM Regimen" [NCT01476839]	Phase 1	25 participants (Actual)	Interventional	2012-11-09	Active, not recruiting
Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) T [NCT01163357]	Phase 1	18 participants (Actual)	Interventional	2011-01-28	Active, not recruiting
Double Dose Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Stage Neuroblastoma and Sarcomas [NCT00165139]	Phase 2	20 participants (Actual)	Interventional	1996-01-31	Completed
Anti-CD19 Universal CAR-T Cells for CD19+ B Cell Hematologic Malignancies: a Multi-center, Uncontrolled Trial [NCT04264039]	Early Phase 1	30 participants (Anticipated)	Interventional	2020-04-01	Not yet recruiting
AA Phase IIA Open-Label, Randomized, PK Comparative, Cross-Over Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in MM Patients Undergoing Autologous Transplantation [NCT00925782]	Phase 2	24 participants (Actual)	Interventional	2010-01-31	Completed
High Dose Chemotherapy And Autologous Peripheral Blood Stem Cell Rescue For High Risk Acute Leukemia [NCT00008190]	Phase 2	0 participants	Interventional	1999-03-31	Completed
A Phase III Multicenter, Randomized, Open-Label Trial Evaluating High Dose Melphalan Plus Holmium-166-DOTMP Versus High Dose Melphalan Alone When Given In Conjuction With Peripheral Blood Stem Cell Transplantation In Patients With Multiple Myeloma [NCT00008229]	Phase 3	0 participants	Interventional	2000-08-31	Completed
A Phase II Study Of Blood Stem Cell Mobilization With Intravenous Melphalan (60 MG/M2) + G-CSF In Patients With Multiple Myeloma [NCT00008268]	Phase 2	0 participants	Interventional	2000-08-31	Completed
A Phase II Trial of Rituxan and BEAM High-Dose Chemotherapy and Autologous Peripheral Blood Progenitor Transplant for Lymphoma [NCT00007852]	Phase 2	44 participants (Actual)	Interventional	2000-09-01	Completed
A Phase I Dose Escalation Trial to Evaluate Safety and Efficacy of Oral Sorafenib (Nexavar) With Regional Melphalan Via Normothermic Isolated Limb Infusion (ILI) in Patients With Intransit Extremity Melanoma [NCT00565968]	Phase 1	20 participants (Actual)	Interventional	2007-10-31	Completed
UARK 2007-01, A Phase II Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD) and Autologous Transplantation for Patients Relapsing or Progressing After Tandem Transplantation [NCT00577668]	Phase 2	0 participants (Actual)	Interventional	2007-04-30	Withdrawn(stopped due to Poor accrual)
MINIALO-VELCADE2005: A Phase II National, Open-label, Multicenter, no Controlled Study of Treated With Bortezomib (Velcade) Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning [NCT00564200]	Phase 2	30 participants (Anticipated)	Interventional	2007-11-30	Completed
Phase III Trial of Stem Cell Transplantation Compared to Parenteral Melphalan and Oral Dexamethasone in the Treatment of Primary Systemic Amyloidosis (AL) [NCT00477971]	Phase 3	89 participants (Actual)	Interventional	2005-10-31	Completed
Programma di Terapia Per Pazienti Affetti da Linfoma Diffuso a Grandi Cellule B CD20 Positive [NCT00556127]	Phase 2	94 participants (Actual)	Interventional	2002-06-30	Completed
Phase I/II Trial of Melphalan, Prednisone Plus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Stem Cell Transplant [NCT00477750]	Phase 1/Phase 2	33 participants (Actual)	Interventional	2005-06-30	Completed
An Expanded Access Program Protocol for Melphalan Flufenamide in Combination With Dexamethasone in Patients With Triple Class Refractory Multiple Myeloma [NCT04534322]		0 participants	Expanded Access		Approved for marketing
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype [NCT02443077]	Phase 3	302 participants (Anticipated)	Interventional	2016-10-12	Active, not recruiting
A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis [NCT01659658]	Phase 3	177 participants (Actual)	Interventional	2012-12-12	Terminated(stopped due to Sponsor's decision)
A Prospective Study of Optimal Cord Selection for Haplo-Cord Transplantation: Targeting the Inherited Paternal Antigen (IPA) and Matching for the Non-Inherited Maternal Antigen (NIMA) [NCT01810588]	Phase 2	273 participants (Actual)	Interventional	2012-10-16	Active, not recruiting
Reduced Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Randomised, Single-Center, Phase III Study [NCT05674539]	Phase 3	200 participants (Anticipated)	Interventional	2022-12-28	Recruiting
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related o [NCT00582933]	Phase 2	96 participants (Actual)	Interventional	2001-05-31	Completed
Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma [NCT00793845]	Phase 2	40 participants (Anticipated)	Interventional	2008-08-31	Completed
An International Single-Arm Study to Provide Further Safety and Efficacy Data on the Bortezomib(Velcade)/Melphalan/Prednisone Regimen in Previously Untreated Transplant Ineligible Multiple Myeloma Patients [NCT00799539]		0 participants	Expanded Access		No longer available
Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Ste [NCT05436418]	Phase 1/Phase 2	240 participants (Anticipated)	Interventional	2022-11-18	Recruiting
A Phase I Trial Evaluating Escalating Doses of 211At-Labeled Anti-CD38 Monoclonal Antibody (211At-OKT10-B10) Combined With Melphalan as Conditioning Prior to Autologous Hematopoietic Cell Transplantation for Patients With Multiple Myeloma [NCT04466475]	Phase 1	30 participants (Anticipated)	Interventional	2024-01-27	Recruiting
Lenalidomide and Low Dose Dexamethasone Induction Therapy Followed by Low Dose Melphalan, Prednisone, Lenalidomide and Bortezomib Sequential Maintenance Therapy for Newly Diagnosed High-risk Multiple Myeloma [NCT00691704]	Phase 2	18 participants (Actual)	Interventional	2008-08-31	Completed
S0629, Observational Study of Asymptomatic Waldenstrom's Macroglobulinemia and Phase II Study of Tandem Autologous Transplant and Maintenance Treatment for Patients With Symptomatic Disease [NCT00723658]	Phase 2	0 participants (Actual)	Interventional	2008-09-30	Withdrawn(stopped due to lack of accrual)
A Pilot Study of a Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by Allogeneic Stem-Cell Transplantation (SCT) Utilizing a Haplo-cord Graft for Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome [NCT03393611]	Phase 1	14 participants (Actual)	Interventional	2012-11-30	Completed
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma [NCT02701673]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2016-06-30	Withdrawn
Autologous and Allogeneic Transplantation for T-Cell Lymphoma: Impact of Campath -1H and Soluble CD52 [NCT00505921]	Phase 2	27 participants (Actual)	Interventional	2003-03-31	Terminated(stopped due to Slow Accrual.)
A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas [NCT00669812]	Phase 2	60 participants (Anticipated)	Interventional	2008-02-29	Recruiting
Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial [NCT02867800]	Phase 1	24 participants (Actual)	Interventional	2016-07-31	Active, not recruiting
Allogeneic Stem Cell Transplantation for Children and Adolescents With CML: Conditioning Regimen, Donor Selection, Supportive Care and Diagnostic Procedures [NCT02707393]	Phase 2/Phase 3	13 participants (Actual)	Interventional	2009-04-30	Completed
High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors [NCT00607984]		20 participants (Anticipated)	Interventional	2006-06-30	Recruiting
A Phase I Study of Hepatic Arterial Infusion of Escalating Dose Melphalan With Venous Filtration for Metastatic Unresectable Cancers of the Liver [NCT00030082]	Phase 1	0 participants	Interventional	2001-07-31	Completed
A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Combination With Melphalan and Dexamethasone in Subjects With Newly-diagnosed Light-chain (AL)-Amyloidosis [NCT00621400]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2008-01-31	Completed
A Phase II Study of Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) for Treatment of Hematologic Malignancies and Hematopoietic Failure States [NCT00997386]	Phase 2	16 participants (Actual)	Interventional	2009-09-30	Completed
Autologous Transplantation of Haematopoietic Stem Cells With Conditioning Including Zevalin + BEAM to Patients Suffering From Refractory Large B-cell Diffuse Lymphom [NCT00646750]	Phase 2	31 participants (Actual)	Interventional	2008-01-31	Completed
An Open-Label, Multicenter, Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-tumor Activity of Systemic Buthionine Sulfoximine (BSO) in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advan [NCT00661336]	Phase 1	0 participants (Actual)	Interventional	2008-04-30	Withdrawn(stopped due to The study was withdrawn due to lack of patients.)
Bortezomib* and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen [NCT00992446]	Phase 2	27 participants (Actual)	Interventional	2010-09-02	Completed
A Randomized, Open-Label, Phase 2 Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone Compared With VELCADE-Melphalan-Prednisone for the Treatment of Previously Untreated Multiple Myeloma [NCT00911859]	Phase 2	118 participants (Actual)	Interventional	2009-06-30	Completed
Evaluation of Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma After Cytoreductive Therapy [NCT00948922]	Phase 2	124 participants (Actual)	Interventional	2009-06-18	Completed
Safety, Tolerability and Efficacy of Ultra-low Doses of Alkylating Drug Melphalan Inhalations for the Treatment of Non-cystic Fibrosis Bronchiectasis [NCT04278040]	Phase 2	7 participants (Anticipated)	Interventional	2018-06-20	Recruiting
Reduced Intensity Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Sirolimus/Mycophenolate Mofetil/RGI-2001 Based GVHD Prevention: a Pilot Study [NCT04473911]	Phase 1	25 participants (Actual)	Interventional	2020-08-14	Active, not recruiting
A Phase I Study to Examine the Toxicity of Killer IG-Like Receptor (KIR) Mismatched Umbilical Cord Blood for Pediatric Patients With Malignant Solid Tumors [NCT00436761]	Phase 1	20 participants (Anticipated)	Interventional	2004-05-31	Active, not recruiting
Vorinostat (SAHA) Combined With High-Dose Gemcitabine, Busulfan, and Melphalan With Autologous Hematopoietic Cell Support for Patients With Relapsed or Refractory Lymphoid Malignancies [NCT01421173]	Phase 1	78 participants (Actual)	Interventional	2011-08-31	Completed
IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma [NCT02197221]	Phase 3	300 participants (Actual)	Interventional	2015-01-31	Completed
Phase II Study of Melphalan, Arsenic Trioxide, and Ascorbic Acid in Patients With Relapsed or Refractory Multiple Myeloma [NCT00085345]	Phase 2	0 participants (Actual)	Interventional		Withdrawn
Risk Adapted Intravenous Melphalan and Adjuvant Thalidomide and Dexamethasone for Untreated Patients With Primary Systemic Amyloidosis [NCT00089167]	Phase 2	0 participants	Interventional	2002-05-31	Completed
A Phase II Trial Of Isolated Hepatic Perfusion (IHP) With Melphalan For Subjects With Metastatic Unresectable Colorectal Cancers Of The Liver With Disease Refractory To First Line Systemic Chemotherapy [NCT00089401]	Phase 2	8 participants (Actual)	Interventional	2004-07-31	Completed
A Multicenter, Open-Label, Single Arm, Phase II Study of Daratumumab as Consolidation/Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma [NCT03346135]	Phase 2	31 participants (Actual)	Interventional	2019-07-17	Active, not recruiting
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation [NCT03159702]	Phase 2	43 participants (Anticipated)	Interventional	2017-12-08	Recruiting
Multicenter Phase I/II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts in Patients With Treatment Refractory Hematologic Malignancies [NCT00202917]	Phase 1/Phase 2	61 participants (Actual)	Interventional	2004-02-29	Completed
Phase 1b/2, Multicenter, Open-label Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma [NCT02072863]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2014-01-31	Completed
Loncastuximab Tesirine in Combination With BEAM (Carmustine, Etoposide, Ara-C, Melphalan) Conditioning Regimen Prior to Autologous Stem Cell Transplant (ASCT) and for Maintenance Therapy in Diffuse Large B-Cell Lymphoma (DLBCL) [NCT05228249]	Phase 1	0 participants (Actual)	Interventional	2023-04-30	Withdrawn(stopped due to PI left institution and funding sponsor closed study. Study did not open to accrual, and no participants were enrolled.)
Response-based Treatment for Children With Unresectable Localized Soft Tissue Sarcomas [NCT02784015]	Phase 2	41 participants (Anticipated)	Interventional	2016-05-31	Recruiting
MUK Nine b: OPTIMUM. A Phase II Study Evaluating Optimised Combination of Biological Therapy in Newly Diagnosed High Risk Multiple Myeloma and Plasma Cell Leukaemia. [NCT03188172]	Phase 2	95 participants (Anticipated)	Interventional	2017-09-28	Active, not recruiting
Gemcitabine Combined With Busulfan and Melphalan, With Hematopoietic Cell Transplantation, for Patients With Poor-prognosis Advanced Lymphoid Malignancies [NCT00410982]	Phase 1	145 participants (Actual)	Interventional	2006-12-31	Completed
A Phase II Study of Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors for Treatment of Hematologic Malignancies and Hematopoietic Failure States [NCT00618969]	Phase 2	2 participants (Actual)	Interventional	2008-02-29	Completed
Randomised, Non-blind, Parallel Group Study to Compare Tandem High Dose Melphalan (200mg/m²) Versus Triple Intermediate Dose Melphalan (100mg/m²) and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy in Ne [NCT00205764]	Phase 3	212 participants (Anticipated)	Interventional	1999-03-31	Completed
A Randomized Phase III Study of the Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia [NCT00186966]	Phase 3	394 participants (Actual)	Interventional	2002-03-31	Completed
Treatment Protocol for High-Risk PNET Brain Tumors in Children With Surgery, Sequential Chemotherapy, Conventional and High-Dose With Peripheral Blood Stem Cell Transplantation and Radiation Therapy [NCT00180791]	Phase 2	71 participants (Anticipated)	Interventional	2002-07-31	Recruiting
Phase II Trial of Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Primary Immune Deficiencies, Immune Dysregulatory Syndromes, and Inherited Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide [NCT04232085]	Phase 2	27 participants (Anticipated)	Interventional	2020-02-12	Recruiting
International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia [NCT00550992]		445 participants (Anticipated)	Interventional	2006-01-31	Recruiting
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies Using Melphalan for T-Cell Tolerization [NCT01350258]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2011-04-30	Terminated(stopped due to Poor accrual)
PILOT STUDY OF BUTHIONINE SULFOXIMINE (BSO) IN COMBINATION WITH MELPHALAN FOR HIGH RISK NEUROBLASTOMA PATIENTS [NCT00002730]	Phase 1	0 participants	Interventional	1996-06-30	Completed
PHASE III MULTICENTRE TRIAL OF TREATMENT OF NEUROBLASTOMA IN CHILDREN AND ADOLESCENTS [NCT00002802]	Phase 3	500 participants (Anticipated)	Interventional	1990-07-31	Completed
A Phase II Trial of ICE Chemotherapy Followed by High Dose BEAM Chemotherapy With Autologous Peripheral Blood Progenitor Cell Transplantation in Patients >= 60 Years Old With Refractory or Relapsed Intermediate Grade Non-Hodgkin's Lymphoma [NCT00002982]	Phase 2	0 participants	Interventional	1997-01-31	Completed
A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With Severe Aplastic Anemia, Inborn Errors in Metabolism, or Inherited Hematologic Stem Cell Disorders [NCT00003336]	Phase 2	6 participants (Actual)	Interventional	1998-01-31	Completed
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma [NCT01035463]	Phase 1/Phase 2	74 participants (Actual)	Interventional	2009-11-12	Completed
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies [NCT01471067]	Phase 1	33 participants (Actual)	Interventional	2012-07-13	Completed
A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP) [NCT01907009]	Phase 2/Phase 3	29 participants (Actual)	Interventional	2013-01-31	Terminated(stopped due to Early termination)
A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide / Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcad [NCT00443235]	Phase 3	260 participants (Anticipated)	Interventional	2005-03-31	Completed
An Open-Label, Multicenter, Phase 1/2 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-tumor Activity of Systemic ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malign [NCT00421811]	Phase 1/Phase 2	56 participants (Anticipated)	Interventional	2007-04-30	Completed
A Phase I Trial of Zevalin Radioimmunotherapy With High-Dose Melphalan and Stem Cell Transplant for Multiple Myeloma [NCT00477815]	Phase 1	30 participants (Actual)	Interventional	2005-05-31	Completed
Phase I Dose Escalation Trial of High Dose Melphalan Conditioning Regimen With Palifermin for Cytoprotection Followed by Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma [NCT00482846]	Phase 1	38 participants (Actual)	Interventional	2007-06-30	Completed
Phase I Clinical Trial of Dose Escalated Bortezomib + ATO (Arsenic Trioxide) + Melphalan as a Conditioning Regimen for Multiple Myeloma [NCT00504101]	Phase 1	0 participants (Actual)	Interventional	2007-06-30	Withdrawn(stopped due to Temporarily closed to accrual pending availablity of drug.)
A Randomised, International, Open-label, Phase II Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization and Engraftment With Pegfilgrastim or Filgrastim for Autologous Transplantation in Patients With Multiple Myeloma (MM) [NCT00526734]	Phase 2	100 participants (Anticipated)	Interventional	2006-02-28	Recruiting
A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma [NCT00516191]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2004-10-31	Withdrawn(stopped due to low accrual)
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients With Newly Diagnosed AL Amyloid [NCT06022939]	Phase 3	338 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Acalabrutinib Plus RICE for Patients With Relapsed/Refractory DLBCL Followed by Autologous Hematopoietic Cell Transplantation and Acalabrutinib Maintenance Therapy [NCT03736616]	Phase 2	47 participants (Anticipated)	Interventional	2019-08-16	Recruiting
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion [NCT03570983]	Phase 2	100 participants (Anticipated)	Interventional	2018-09-05	Recruiting
Phase 2 Study of Personalized r-ATG Dosing to Improve Survival Through Enhanced Immune Reconstitution in Pediatric and Adult Patients Undergoing Ex-vivo CD34-Selected Allogeneic-HCT (PRAISE-IR) [NCT04872595]	Phase 2	56 participants (Anticipated)	Interventional	2021-04-30	Recruiting
High-dose Gemcitabine, Busulfan and Melphalan With Autologous Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma [NCT01237951]	Phase 2	75 participants (Actual)	Interventional	2010-11-08	Completed
Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis [NCT00618540]	Phase 2	1 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to Slow accrual)
Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment [NCT03096782]	Phase 2	6 participants (Actual)	Interventional	2017-10-13	Completed
High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT) in Light-Chain Deposition Disease (LCDD) and Immunoglobulin Deposition Disease (IGDD) [NCT00681044]	Phase 2	5 participants (Actual)	Interventional	2006-10-31	Terminated(stopped due to Poor accrual)
An Open Label, Expanded Access Study of Melphalan Chemosaturation With the Delcath System in Patients With Ocular and Cutaneous Melanoma Metastatic to the Liver [NCT01728051]		0 participants	Expanded Access		No longer available
The Treatment of Multiple Myeloma Utilizing VBMCP Chemotherapy Alternating With High-Dose Cyclophosphamide and Alpha2b-Interferon Versus VBMCP: A Phase III Study for Previously Untreated Multiple Myeloma [NCT00002556]	Phase 3	312 participants (Actual)	Interventional	1994-07-31	Completed
Evaluation of Allogeneic Peripheral Blood Stem Cell Transplants From a Related Donor Without Graft-Versus-Host Prophylaxis in Patients With High Risk of Relapse [NCT00003396]	Phase 2	42 participants (Anticipated)	Interventional	1998-09-30	Completed
Autologous Transplantation With and High Dose BCNU and Melphalan Followed by Consolidation With DCEP Plus Taxol/Cisplatin in Patients With Poor Prognosis Low Grade Non-Hodgkin's Lymphoma and Chronic Lymphocyte Leukemia, Who Have Received < or = 12 Months [NCT00003402]	Phase 2	35 participants (Anticipated)	Interventional	1999-01-31	Completed
A Phase III Study of High-Dose Chemotherapy Using Busulfan, Melphalan and Thiotepa Versus Cyclophosphamide,Thiotepa, Carboplatin Followed by Autologous Stem Cell Transplantation in Patients With High-Risk Primary Stage II or III (Non-Inflammatory) Breast [NCT00003972]	Phase 3	280 participants (Anticipated)	Interventional	1998-07-31	Completed
Treatment of Newly Diagnosed Childhood AML Using a Timed-Sequential Remission Induction and Consolidation Followed by Single Dose Melphalan With Peripheral Stem Cell Rescue: A POG Pilot Study [NCT00004056]	Phase 1	35 participants (Actual)	Interventional	1999-10-31	Completed
A Phase I/II Study of Targeted Radiotherapy Using Holmium-166-DOTMP With Melphalan and Peripheral Blood Stem Cell Transplantation for Treatment of Multiple Myeloma [NCT00004158]	Phase 1/Phase 2	0 participants	Interventional	1999-06-30	Completed
A Phase II Trial of Tandem Transplantation in AL Amyloidosis [NCT00075621]	Phase 2	62 participants (Actual)	Interventional	2000-08-31	Completed
A Phase II/III Study of Immunomodulation After High Dose Myeloablative Therapy With Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin Disease [NCT00070187]	Phase 2/Phase 3	24 participants (Actual)	Interventional	2003-11-30	Completed
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation [NCT06001385]	Phase 2	170 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis [NCT03118492]	Phase 1	16 participants (Anticipated)	Interventional	2017-05-24	Recruiting
UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant) [NCT00871013]	Phase 2	160 participants (Anticipated)	Interventional	2009-03-31	Active, not recruiting
A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver [NCT00324727]	Phase 3	93 participants (Actual)	Interventional	2006-02-28	Completed
The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells [NCT00084695]	Phase 2	25 participants (Anticipated)	Interventional	2003-09-30	Recruiting
UARK 2003-18, A Phase II Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant in Relapsed Multiple Myeloma [NCT00089453]	Phase 1	10 participants (Actual)	Interventional	2003-09-30	Completed
Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation With a TLI Based Conditioning Regimen in Patients With Hematologic Malignancies [NCT01807611]	Phase 2	82 participants (Actual)	Interventional	2013-05-16	Completed
A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver [NCT00096083]	Phase 2	56 participants (Actual)	Interventional	2004-09-30	Completed
A Phase II Trial of Isolated Hepatic Perfusion (IHP) and Systemic FOLFOX4 for Subjects With Metastatic Unresectable Colorectal Cancers of the Liver With ≥ 40% Hepatic Tumor Burden [NCT00103298]	Phase 2	0 participants	Interventional	2004-12-31	Completed
Reduced Intensity Conditioning Regimen for Haplo-identical Family Donor Stem Cell Transplants for Hematologic Malignancies With Delayed Add-back of Non-alloreactive T Cells [NCT00104975]	Phase 1	20 participants (Anticipated)	Interventional	2005-02-28	Completed
Neuroblastoma Protocol 2005: Therapy for Children With Advanced Stage High-Risk Neuroblastoma [NCT00135135]	Phase 2	23 participants (Actual)	Interventional	2005-08-31	Completed
A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome [NCT00454480]	Phase 2/Phase 3	2,000 participants (Anticipated)	Interventional	2006-08-31	Completed
Cord Blood Expansion on Mesenchymal Stem Cells [NCT00498316]	Phase 1	98 participants (Actual)	Interventional	2007-07-03	Completed
Phase II Study of Sequential Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus as Graft Versus Host Disease Prophylaxis [NCT00133367]	Phase 2	32 participants (Anticipated)	Interventional	2005-08-31	Completed
High Dose Chemotherapy With Stem Cell Rescue Followed By Consolidation Treatment in Patients With Metastatic Hormone-Refractory Prostate Cancer [NCT00003400]	Phase 2	45 participants (Anticipated)	Interventional	1998-09-30	Completed
Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma With or Without Vaccination With Dendritic Cell/Myeloma Fusions (BMT CTN 1401) [NCT02728102]	Phase 2	203 participants (Actual)	Interventional	2016-07-31	Completed
A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer [NCT00001193]	Phase 2	200 participants	Interventional	1984-11-30	Completed
Treatment of High Risk, Inherited Lysosomal And Peroxisomal Disorders by Reduced Intensity Hematopoietic Stem Cell Transplantation [NCT00383448]	Phase 2	38 participants (Actual)	Interventional	2006-09-30	Completed
Allogeneic Stem Cell Transplantation Followed By Adoptive Immunotherapy for Patients With Relapsed and Refractory Hodgkin's Disease [NCT00385788]	Phase 2	52 participants (Actual)	Interventional	2005-07-31	Completed
Randomized Trial Using Standard Dose Versus High Dose Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Diffuse Large B Cell Lymphomas [NCT00472056]	Phase 2	93 participants (Actual)	Interventional	2005-03-31	Completed
A Phase II Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-Host-Exhausting and Timely Dose-Reduced Mel-80-CFZ-TD-Pace Transplant(s) With Interspersed Mel-20-CFZ-TD-Pace With CFZ-RD and CFZ-D Ma [NCT02128230]	Phase 2	20 participants (Actual)	Interventional	2014-06-10	Terminated(stopped due to Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program.)
Umbilical Cord Blood Transplantation From Unrelated Donors [NCT03016806]	Phase 1	30 participants (Anticipated)	Interventional	2015-06-30	Recruiting
Tandem Autologous HCT/Nonmyeloablative Allogeneic HCT From HLA-Matched Related and Unrelated Donors Followed by Bortezomib Maintenance Therapy for Patients With High-Risk Multiple Myeloma [NCT00793572]	Phase 2	32 participants (Actual)	Interventional	2008-10-31	Completed
Combination High Dose Melphalan and Autologous PBSC Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study [NCT00793650]	Phase 1/Phase 2	39 participants (Actual)	Interventional	2005-05-31	Terminated
Combined Haploidentical-Cord Blood Transplantation for Adults and Children [NCT00943800]		87 participants (Actual)	Interventional	2006-10-09	Completed
A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial) [NCT01005576]	Phase 2	21 participants (Actual)	Interventional	2010-01-31	Completed
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia [NCT01008462]	Phase 2	16 participants (Actual)	Interventional	2010-03-18	Completed
Autologous Stem Cell Transplant In Patients With Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL) [NCT03125642]	Phase 2	150 participants (Anticipated)	Interventional	2017-04-20	Recruiting
Trial Protocol for the Treatment of Children With High Risk Neuroblastoma (NB2004-HR) [NCT00526318]		360 participants (Anticipated)	Interventional	2007-01-31	Recruiting
Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance [NCT02896582]	Phase 2	86 participants (Actual)	Interventional	2016-10-31	Active, not recruiting
A Phase IIb, Multicenter, Open-Label, Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free)for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation [NCT01660633]	Phase 2	61 participants (Actual)	Interventional	2012-12-31	Completed
Isolated Pelvic and Limb Perfusion With 1mg TNFa in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle [NCT00181025]	Phase 2	33 participants (Anticipated)	Interventional	2004-05-31	Recruiting
Phase II Trial of Induction Therapy With Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation in Patients With AL Amyloidosis [NCT01083316]	Phase 2	35 participants (Actual)	Interventional	2009-09-30	Completed
A Feasibility Trial of Post-Transplant Infusion of Allogeneic Regulatory T Cells and Allogeneic Conventional T Cells in Patients With Hematologic Malignancies Undergoing Allogeneic Myeloablative Hematopoietic Cell Transplantation From Haploidentical-Relat [NCT01050764]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2009-06-30	Terminated(stopped due to Safety)
Dose Escalation of Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors [NCT00623077]	Phase 1	23 participants (Actual)	Interventional	2005-08-31	Terminated(stopped due to Replaced by another study)
A Phase I Study of Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for the Treatment of High-risk Hematologic Malignancies [NCT00477035]	Phase 1	22 participants (Actual)	Interventional	2006-05-31	Completed
A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients [NCT03352765]	Phase 1	28 participants (Anticipated)	Interventional	2017-11-20	Active, not recruiting
Risk-adapted Therapy for AL Amyloidosis [NCT01527032]	Phase 2	0 participants	Interventional	2002-09-30	Completed
Phase II Trial of Second Autologous Transplantation in AL Amyloidosis [NCT00075608]	Phase 2	12 participants (Actual)	Interventional	2001-08-31	Terminated(stopped due to poor accrual)
A Phase I/II Study of Isolated Limb Infusion and Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma [NCT01531244]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2014-12-31	Withdrawn
Iberoamerican Phase III International Study, Open, Multicenter, Randomized, Comparative of Thalidomide / Cyclophosphamide / Dexamethasone Versus Thalidomide / Dexamethasone Versus Thalidomide / Melphalan / Prednisone as Induction Therapy Followed by Maint [NCT01532856]	Phase 3	64 participants (Actual)	Interventional	2007-01-31	Active, not recruiting
Dose-Intensive Melphalan and Cyclophosphamide With Autologous Bone Marrow Rescue for Recurrent Medulloblastoma and Germ Cell Tumors [NCT00002594]	Phase 2	31 participants (Actual)	Interventional	1994-09-30	Completed
HIGH-DOSE MELPHALAN CHEMOTHERAPY AND TOTAL BODY RADIATION WITH PERIPHERAL BLOOD STEM-CELL RECONSTITUTION FOR PATIENTS WITH RELAPSING MULTIPLE MYELOMA [NCT00002630]	Phase 2	50 participants (Anticipated)	Interventional	1993-06-30	Completed
Randomised Comparisons, in Myeloma Patients of All Ages, of Thalidomide, Lenalidomide, Carfilzomib and Bortezomib Induction Combinations, and of Lenalidomide and Combination Lenalidomide Vorinostat as Maintenance (Myeloma XI) [NCT01554852]	Phase 3	4,420 participants (Actual)	Interventional	2010-05-31	Active, not recruiting
BEAM Plus Iodine-131 Anti-B1 Antibody and Autologous Hematopoietic Stem Cell Transplantation for Treatment of Recurrent Diffuse Large B-Cell Non-Hodgkin's Lymphoma [NCT00006695]	Phase 2	50 participants (Actual)	Interventional	2000-04-01	Completed
Myeloblative Therapy With Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma and B-Cell Malignancies [NCT00003163]	Phase 2	10 participants (Anticipated)	Interventional	1997-09-30	Active, not recruiting
Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma [NCT03086993]	Phase 2/Phase 3	295 participants (Anticipated)	Interventional	2018-04-10	Active, not recruiting
A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Pediatric Solid Tumors With Relapsed or Therapy Refractory Disease [NCT00112645]	Phase 1	10 participants (Anticipated)	Interventional	2005-04-30	Completed
A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan for Metastatic Unresectable Cancers of the Liver [NCT00019786]	Phase 2	67 participants (Anticipated)	Interventional	1999-08-31	Completed
European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99) [NCT00020566]	Phase 3	1,200 participants (Anticipated)	Interventional	2001-02-28	Recruiting
Autologous Transplantation for Multiple Myeloma [NCT00177047]	Phase 2/Phase 3	363 participants (Actual)	Interventional	2004-04-20	Completed
A Study Of The Treatment Of Metastatic Neuroblastoma In Children More Than One Year Of Age At Diagnosis [NCT00024193]	Phase 2	0 participants	Interventional	1999-04-30	Active, not recruiting
A Randomized Trial Of BEAM Plus PBSCT Versus Single Agent High-Dose Therapy Followed By BEAM Plus PBSCT In Patients With Relapsed Hodgkin's Disease [NCT00025636]	Phase 3	220 participants (Anticipated)	Interventional	2001-07-31	Active, not recruiting
A Phase II Study Of Mobilization Chemotherapy With GMCSF And GCSF Followed By High Dose Therapy Combined With IL2 Activated Autologous Peripheral Blood Stem Cells Followed By Sequential IL2 Therapy As Treatment For Solid Tumors And Lymphoma [NCT00027937]	Phase 2	0 participants	Interventional	2001-08-31	Completed
A Randomised Phase III Study On The Effect Of The Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) During Sequential Chemotherapy Followed By Autologous Stem Cell Transplantation In Patients With Relapse B-Cell Non-Hodgkin Lymphoma(HOVON 44 STUDY) [NCT00012051]	Phase 3	340 participants (Anticipated)	Interventional	2000-09-30	Completed
Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma [NCT00028600]	Phase 2	60 participants (Actual)	Interventional	2001-11-30	Completed
A Phase II Trial of IV Busulfan (Busulfex) and Melphalan as a Preparatory Regimen Prior to Allogeneic Bone Marrow Transplantation for the Treatment of Advanced and High Risk Hematologic Malignancies [NCT00014469]	Phase 2	0 participants	Interventional	2000-12-31	Completed
Treatment of Mantle Cell Lymphomas at Advanced Stages: Prospective Randomized Comparison of Myeloablative Radiochemotherapy Followed by Blood Stem Cell Transplantation Versus Maintenance With Interferon Alpha in First Remission After Initial Cytoreductive [NCT00016887]	Phase 3	0 participants	Interventional	2000-12-31	Active, not recruiting
A Multicenter Dosimetry Trial to Evaluate Radiation Absorbed Dose From Holmium-166-DOTMP in Patients With Multiple Myeloma [NCT00045136]	Phase 1/Phase 2	0 participants	Interventional	2002-01-31	Completed
High-Dose Therapy and Autologous Blood Stem Cell Transplantation (ASCT) Followed by Post-Transplant Immunotherapy With Costimulated Autologous T-Cells in Conjunction With Pneumococcal Conjugate Vaccine Immunization for Patients With Multiple Myeloma [NCT00046852]	Phase 1/Phase 2	0 participants	Interventional	2001-12-31	Completed
A Study of Allogeneic Blood Stem Cell Transplantation With Purine Analog-Based Conditioning For Patients With Advanced Hodgkin's Disease [NCT00423709]		46 participants (Actual)	Interventional	1998-01-31	Completed
Ibritumomab Tiuxetan and High-Dose Melphalan as Conditioning Regimen Before Autologous Stem Cell Transplantation for Elderly Patients With Lymphoma in Relapse or Resistant to Chemotherapy. A Multicenter Phase I Trial [NCT00392691]	Phase 1	20 participants (Actual)	Interventional	2006-10-31	Completed
Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab [NCT00137995]	Phase 3	481 participants (Actual)	Interventional	2003-06-30	Completed
A Randomized, Phase III, Placebo-Controlled Multicenter Study to Demonstrate the Effectiveness and Safety of the Combination Enzyme Tablet (Wobe-Mugos E) as Adjuvant Therapy to Standard of Care Treatment in Patients With Stages II or III Multiple Myeloma [NCT00014339]	Phase 3	0 participants	Interventional	2000-03-31	Active, not recruiting
A Pilot Study of Daunorubicin-cytarabine Liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) as Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia Followed by Consolidation With a CD34+-Selected Allograft [NCT04982354]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2022-07-05	Recruiting
Neuroblastoma Study Phase II Study of Various Therapies in Patients With Neuroblastoma [NCT00017225]	Phase 2	0 participants	Interventional	1997-05-31	Completed
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning: a Phase II Randomized Study From the Belgian Hematology Society (BHS) [NCT03852407]	Phase 2	114 participants (Anticipated)	Interventional	2019-02-04	Recruiting
A Phase I/II Clinical Trial of Pomalidomide With Melphalan and Dexamethasone in Patients With Newly Diagnosed Untreated Systemic AL Amyloidosis: Trial Stopped During Phase I [NCT01807286]	Phase 1	3 participants (Actual)	Interventional	2014-01-31	Terminated(stopped due to Sponsor requested termination)
Campath 1H (Alemtuzumab) Combined With High-Dose Therapy and Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia [NCT00276809]	Phase 2	30 participants (Anticipated)	Interventional	2001-06-30	Completed
Pivotal Study for High Dose Therapy and Autologous Stem Cell Transplantation in Early Stages of CLL [NCT00275015]	Phase 2	169 participants (Actual)	Interventional	1998-01-31	Completed
High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Rescue for Neuroblastoma: Standard of Care Considerations [NCT01526603]		20 participants (Anticipated)	Interventional	2012-03-28	Recruiting
Phase II Study of Autologous Myeloma-Derived Immunoglobulin Idiotype Conjugated to Keyhole Limpet Hemocyanin Plus Sargramostim (GM-CSF) in Patients With Multiple Myeloma Undergoing Second Autologous Peripheral Blood Stem Cell Transplantation [NCT00019097]	Phase 2	0 participants	Interventional	1995-07-31	Completed
A Phase III Prospective Random Assignment Trial of Regional and Systemic Chemotherapy With or Without Initial Isolated Hepatic Perfusion for Patients With Metastatic Unresectable Colorectal Cancers of the Liver [NCT00020501]	Phase 3	0 participants	Interventional	2001-03-31	Completed
Protocol For The Treatment Of Children And Adolescents With Hodgkin's Disease [NCT00025064]	Phase 2	260 participants (Anticipated)	Interventional	2000-01-31	Active, not recruiting
Protocol For The Treatment Of Relapsed And Refractory Wilms Tumour And Clear Cell Sarcoma Of The Kidney (CCSK) [NCT00025103]	Phase 2	75 participants (Anticipated)	Interventional	2001-05-31	Active, not recruiting
European Infant Neuroblastoma Study - Stage 2, 3, 4, and 4S; MYCN Amplified Tumors [NCT00025649]	Phase 2	0 participants	Interventional	1999-07-31	Completed
Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation [NCT00055653]	Phase 2	0 participants	Interventional	2003-01-31	Completed
A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma [NCT00028886]	Phase 3	450 participants (Anticipated)	Interventional	2001-03-31	Active, not recruiting
High Risk Neuroblastoma Study 1 Of Siop-Europe [NCT00030719]	Phase 3	175 participants (Anticipated)	Interventional	2001-12-31	Recruiting
Autologous Blood and Marrow Transplantation for Hematologic Malignancy and Selected Solid Tumors [NCT00060255]	Phase 2	451 participants (Actual)	Interventional	1991-12-31	Completed
A Pilot Induction Regimen Incorporating Topotecan for Treatment of Newly Diagnosed High Risk Neuroblastoma [NCT00070200]	Phase 1	31 participants (Actual)	Interventional	2004-03-31	Completed
Phase I/II Evaluation of Safety and Activity of Mylotarg Plus Melphalan and Fludarabine as Preparative Therapy for Older or Medically Infirm Patients Undergoing Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation [NCT00038831]	Phase 1/Phase 2	47 participants (Actual)	Interventional	2001-05-31	Completed
A Phase I/II, Multi-Center, Open Label Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Advanced and Refractory Multiple Myeloma Patients [NCT00406978]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2006-02-28	Completed
A Phase I Trial Combining IDEC-Y2B8 And High-Dose Beam Chemotherapy With Hematopoietic Progenitor Cell Transplant In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma [NCT00058292]	Phase 1	44 participants (Actual)	Interventional	2000-04-30	Completed
A Phase II Study of High-Dose Intravenous Busulfan Plus Melphalan With Allogeneic or Autologous Marrow or Peripheral Blood Progenitor Cell Transplantation for Lymphoid Malignancies or Multiple Myeloma [NCT00427765]	Phase 2	168 participants (Actual)	Interventional	2004-12-31	Completed
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors [NCT00936936]	Phase 2	64 participants (Actual)	Interventional	2009-06-02	Active, not recruiting
A Phase I/II Trial of Venetoclax and BEAM Conditioning Followed by Autologous Stem Cell Transplantation for Patients With Primary Refractory Non-Hodgkin Lymphoma [NCT03583424]	Phase 1/Phase 2	19 participants (Actual)	Interventional	2018-09-10	Active, not recruiting
A Randomized Phase II Trial of Fludarabine/Melphalan 140 VS. Fludarabine/Melphalan 100 Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation for Patients With Multiple Myeloma [NCT00505895]	Phase 2	52 participants (Actual)	Interventional	2002-01-31	Completed
Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis [NCT00572897]	Phase 2	66 participants (Actual)	Interventional	2007-08-31	Completed
Phase 1/2 Investigator Sponsored Study of Selinexor in Combination With High-Dose Melphalan Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma [NCT02780609]	Phase 1/Phase 2	22 participants (Actual)	Interventional	2017-07-20	Completed
Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) Combined With Fludarabine and Melphalan as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndro [NCT03494569]	Phase 1	36 participants (Anticipated)	Interventional	2018-07-06	Recruiting
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC) [NCT03821610]	Phase 2	242 participants (Anticipated)	Interventional	2018-11-22	Active, not recruiting
Transplantation of Two Partially Matched Umbilical Cord Blood Units Following Reduced Intensity Conditioning to Enhance Engraftment and Limit Transplant-Related Mortality in Adults With Hematologic Malignancies [NCT00827099]	Phase 2	5 participants (Actual)	Interventional	2006-06-30	Terminated(stopped due to Unacceptable morbidity & mortality)
"A Feasibility Study of Early Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory High-Grade Myeloid Neoplasms" [NCT02756572]	Phase 2	30 participants (Actual)	Interventional	2016-09-22	Completed
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis [NCT04384692]	Phase 2	45 participants (Anticipated)	Interventional	2020-12-18	Recruiting
Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas [NCT03259503]	Phase 1	50 participants (Actual)	Interventional	2019-09-13	Active, not recruiting
CNCT19 Following Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Aggressive B-cell Lymphoma [NCT04690192]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2021-01-01	Recruiting
Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation [NCT02960646]	Phase 1	11 participants (Actual)	Interventional	2017-01-18	Completed
A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime [NCT01821781]	Phase 2	20 participants (Anticipated)	Interventional	2013-03-31	Recruiting
Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). [NCT01688401]	Phase 1	3 participants (Actual)	Interventional	2013-03-08	Completed
Immune Consolidation With Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) After Peripheral Blood Stem Cell Transplant for High Risk CD20+ Non-Hodgkin's Lymphomas [NCT00244946]	Phase 1	15 participants (Actual)	Interventional	2004-03-31	Completed
Intra-Arterial Melphalan (L-Phenylalanine Mustard) Administered in Conjunction With Osmotic Blood-Brain Barrier Disruption in Patients With Brain Malignancies: A Phase I Study [NCT00253721]	Phase 1	21 participants (Actual)	Interventional	1998-05-31	Terminated(stopped due to Other competing clinical trials affecting enrollment)
Transplantation of Umbilical Cord Blood From Related and Unrelated Donors [NCT00290628]		43 participants (Actual)	Interventional	1999-10-31	Terminated(stopped due to Replaced with another study)
Feasibility of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation Followed by Donor Lymphocyte Infusions for Children at High Risk for Complications With Conventional Transplantation [NCT00301860]		8 participants (Actual)	Interventional	2003-01-31	Terminated(stopped due to lack of efficacy)
European Infant Neuroblastoma Study Final Protocol [NCT00417053]	Phase 3	0 participants	Interventional		Active, not recruiting
A Phase II Trial of Bortezomib + Ascorbic Acid + Melphalan (BAM) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma [NCT00317811]	Phase 2	35 participants (Anticipated)	Interventional	2005-11-30	Completed
Treatment in First Line of Mantle Cell Lymphoma for Patients Under 66 Years by the VAD-CHLORAMBUCIL -Rituximab Regimen Followed by Intensification and Autologous PBSC Transplantation After Marrow Purging With Rituximab [NCT00285389]	Phase 2	39 participants (Actual)	Interventional	2002-02-28	Completed
2015-12: A Phase II Study Exploring the Use of Early and Late Consolidation/Maintenance With Anti-CD38 (Protein) Monoclonal Antibody to Improve Progression Free Survival in Patients With Newly Diagnosed Multiple Myeloma [NCT03004287]	Phase 2	50 participants (Anticipated)	Interventional	2017-07-01	Active, not recruiting
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/ Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma [NCT00334932]	Phase 1/Phase 2	32 participants (Anticipated)	Interventional	2006-02-28	Recruiting
A Phase II Study of Intravenous Melphalan and Busulfan Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma [NCT00313625]	Phase 2	20 participants (Anticipated)	Interventional	2005-09-30	Completed
Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone in Patients With AL (Primary)Amyloidosis. A Prospective Randomized Trial . [NCT00344526]	Phase 3	100 participants	Interventional	2000-01-31	Completed
A Phase II Study Of Pooled Unrelated Donor Umbilical Cord Blood (UCB) Transplant For Patients With Hematologic Malignancies Needing Allogeneic Stem Cell Transplant But Do Not Have A Related HLA-Matched Donor [NCT01500161]	Phase 2	1 participants (Actual)	Interventional	2011-11-30	Terminated(stopped due to Insufficient accruals)
A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas [NCT01625351]	Phase 1	23 participants (Actual)	Interventional	2012-08-20	Completed
Selective Intra-arterial Chemotherapy in the Treatment Strategy of Metastatic Spinal Disease [NCT01637766]	Phase 1	12 participants (Actual)	Interventional	2012-04-30	Completed
Use of Umbilical Cord Blood Cell in the Preparative Regimen of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT00427557]	Phase 2	31 participants (Actual)	Interventional	2006-10-31	Completed
Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL) [NCT00003215]	Phase 3	400 participants (Anticipated)	Interventional	1997-04-30	Completed
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen [NCT02199041]	Phase 2	24 participants (Actual)	Interventional	2014-07-11	Terminated(stopped due to The study was halted early due to slow accrual.)
High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) [NCT01704716]	Phase 3	3,300 participants (Anticipated)	Interventional	2002-02-28	Recruiting
MRD-Guided Sequential Therapy For Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial [NCT05231629]	Phase 2	300 participants (Anticipated)	Interventional	2023-12-13	Recruiting
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies [NCT00968760]	Phase 1	34 participants (Actual)	Interventional	2011-06-20	Completed
A Multicenter Phase II Study of Subcutaneous Velcade Plus Oral Melphalan and Prdnisone or Plus Cycloposphamide and Prednisone or Plus Prednisone in Newly Diagnosed Elderly Multiple Myeloma Patients [NCT01190787]	Phase 2	150 participants (Anticipated)	Interventional	2010-07-31	Active, not recruiting
AUTOLOGOUS TRANSPLANTATION AND STEM CELL BASED-GENE THERAPY FOR THE TREATMENT OF HIV-ASSOCIATED LYMPHOMA [NCT01769911]		0 participants (Actual)	Interventional	2015-02-28	Withdrawn
UARK 2008-02, A Phase II Trial for High-risk Myeloma Evaluation Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-host-exhausting and Timely Dose-reduced MEL-80-VRD-PACE Tandem Transplants [NCT00869232]	Phase 2	90 participants (Actual)	Interventional	2008-10-31	Active, not recruiting
Phase III-study for Evaluation of Induction Therapy Before Stem Cell Mobilization and Tandem High-dose Melphalan in Multiple Myeloma Patients 60 to 70 Years of Age [NCT02288741]	Phase 3	549 participants (Actual)	Interventional	2001-08-31	Completed
Tandem Autotransplantation for Multiple Myeloma in Participants With Less Than 12 Months of Preceding Therapy, Incorporating Velcade (Bortezomib) With the Transplant Chemotherapy and During Maintenance [NCT01548573]	Phase 2	19 participants (Actual)	Interventional	2012-05-31	Terminated(stopped due to Met study stopping rules)
Intra-arterial Chemotherapy for Retinoblastoma (IAC) [NCT04342572]	Phase 1	5 participants (Actual)	Interventional	2020-08-11	Active, not recruiting
Autologous Blood and Marrow Transplantation for Hematologic Malignancies and Selected Solid Tumors [NCT00536601]		174 participants (Actual)	Interventional	2006-06-29	Completed
2015-10: A Phase II Pilot Study of Expanded Natural Killer Cells and Elotuzumab to Eradicate High-Risk Myeloma Post Autologous Stem Cell Transplant [NCT03003728]	Phase 2	0 participants (Actual)	Interventional	2019-11-01	Withdrawn(stopped due to Withdrawal of study support)
Treatment of High Risk, Inherited Lysosomal and Peroxisomal Disorders by Reduced-Intensity Hematopoietic Cell Transplantation and Low-Dose Total Body Irradiation With Marrow Boosting by Volumetric-Modulated Arc Therapy (VMAT) [NCT01626092]		3 participants (Actual)	Interventional	2012-07-11	Completed
Phase II Study Assessing the Efficacy and Toxicity of PK--directed Intravenous Busulfan in Combination With High--Dose Melphalan and Bortezomib as Conditioning Regimen for First--Line Autologous Hematopoietic Stem Cell Transplantation in Patients With Mul [NCT01605032]	Phase 2	19 participants (Actual)	Interventional	2012-02-29	Completed
Treatment Protocol: Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia Using Conditioning Regimen Without Radiation [NCT02007863]		2 participants (Actual)	Interventional	2008-08-31	Completed
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring ASCT for Relapsed DLBCL [NCT02366663]	Phase 3	3 participants (Actual)	Interventional	2015-01-31	Terminated(stopped due to Withdrawal of sponsor support)
A Phase I-II Study of Infusional Melphalan + Bortezomib for Myeloablative Therapy Prior to Autologous Transplant for Patients With Multiple Myeloma [NCT02353572]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2009-11-30	Terminated(stopped due to Principle investigator left the institution)
A Randomized Study of Combined Haplo-identical Umbilical Cord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies [NCT01745913]	Phase 2	2 participants (Actual)	Interventional	2012-10-26	Terminated(stopped due to Slow accrual)
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor [NCT01598025]		3 participants (Actual)	Interventional	2012-05-02	Terminated(stopped due to Closed due to poor accrual)
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor [NCT00523809]	Phase 2	5 participants (Actual)	Interventional	2007-08-31	Terminated(stopped due to Slow accrual.)
A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver [NCT00001587]	Phase 1	30 participants	Interventional	1997-09-30	Completed
A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation With Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation [NCT03192397]	Phase 1/Phase 2	35 participants (Actual)	Interventional	2017-08-09	Active, not recruiting
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112) [NCT00005835]	Phase 1	31 participants (Actual)	Interventional	2001-08-31	Completed
A Phase I/II Study of a Novel Reduced Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation in Patients With Multiple Myeloma [NCT00995059]	Phase 1/Phase 2	0 participants (Actual)	Interventional		Withdrawn
Phase I-II Single Cycle Melphalan/Total Marrow Irradiation (TMI) and Autologous Stem Cell Transplantation (ASCT) Followed by Maintenance in Patients With High-Risk Myeloma and/or Poor Response to Induction Therapy Within 12 Months of Diagnosis [NCT03100877]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2018-01-31	Withdrawn(stopped due to Feasibility Issues)
Reduced Intensity Matched Sibling Bone Marrow Transplantation for Sickle Cell Anemia in Patients 2-30 Years Old [NCT01877837]	Phase 3	30 participants (Actual)	Interventional	2011-06-30	Completed
High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases [NCT00716066]	Phase 2	80 participants (Anticipated)	Interventional	2008-06-30	Recruiting
A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders [NCT00544115]	Phase 2	260 participants (Actual)	Interventional	2001-10-16	Active, not recruiting
A Phase II Trial of Thymoglobulin and Melphalan in Patients With Relapsed Multiple Myeloma [NCT00635024]	Phase 2	1 participants (Actual)	Interventional	2008-05-31	Terminated(stopped due to Due to competing trials, this study is permanenlty closed to patient acrrual.)
Randomized Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic GM-CSF-based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma [NCT01045460]	Phase 2	36 participants (Actual)	Interventional	2010-01-15	Completed
Transplantation Of Umbilical Cord Blood From Unrelated Donors In Patients With Haematological Diseases Using A Myeloablative Conditioning Regimen [NCT02310997]	Phase 2	11 participants (Actual)	Interventional	2011-07-31	Terminated(stopped due to Trial closed early due to poor recruitment)
Phase II Study of Revlimid (Lenalidomide), Melphalan, and Dexamethasone (ReMeDex) for Newly Diagnosed Multiple Myeloma Patients Not Undergoing Autologous Transplantation [NCT00843310]	Phase 2	8 participants (Actual)	Interventional	2008-11-30	Terminated(stopped due to Due to slow accrual)
A Phase II Study of High-Dose Melphalan With Hematopoietic Stem Cell Reconstitution for Patients With Primary Systemic Amyloidosis [NCT00003353]	Phase 2	0 participants	Interventional	1998-11-16	Completed
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma [NCT00985907]	Phase 1/Phase 2	13 participants (Actual)	Interventional	2004-10-28	Terminated(stopped due to Low Accrual)
Standard Dose Versus Myeloablative Therapy for Previously Untreated Symptomatic Multiple Myeloma, A Phase III Intergroup Study [NCT00002548]	Phase 3	899 participants (Actual)	Interventional	1994-01-31	Completed
Phase II Trial of Sequential High-Dose Alkylating Agents in Metastatic Breast Cancer [NCT00002680]	Phase 2	40 participants (Actual)	Interventional	1994-02-28	Completed
Phase 2 Multi-center Study of Anti-Programmed-Death-1 [Anti-PD-1] During Lymphopenic State After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplant [HDT/ASCT] for Multiple Myeloma [NCT02331368]	Phase 2	32 participants (Actual)	Interventional	2015-06-30	Completed
Phase I Study of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Mature T-Cell Non-Hodgkin Lymphoma: the aTAC BEAM Regimen [NCT02342782]	Phase 1	20 participants (Actual)	Interventional	2020-06-08	Active, not recruiting
A Phase II Trial of The Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity [NCT01323517]	Phase 2	26 participants (Actual)	Interventional	2011-02-28	Completed
Allogeneic Stem Cell Transplant With a Novel Conditioning Therapy Using Helical Tomotherapy, Melphalan, and Fludarabine in Hematological Malignancies [NCT00544466]	Phase 1/Phase 2	75 participants (Actual)	Interventional	2006-07-31	Active, not recruiting
University of Arkansas (UARK 2001-12), A Phase III Study of DTPACE Followed by Tandem Transplant With MEL 200 Versus MEL/DTPACE Hybrid and DTPACE Consolidation in Patients With Active Multiple Myeloma [NCT00083915]	Phase 3	97 participants (Actual)	Interventional	2001-06-30	Completed
High-dose 131I-MIBG Treatment Incorporated Into Tandem High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With High-risk Neuroblastoma [NCT03061656]	Phase 2	40 participants (Anticipated)	Interventional	2009-01-01	Active, not recruiting
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes Preconditioned With Percutaneous Hepatic Perfusion With Melphalan in Patients With Melanoma and Liver Metastases [NCT05903937]	Phase 1	6 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
A Phase II Single-Center, Open-Label, Safety and Efficacy Study of Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation [NCT02994784]	Phase 2	27 participants (Actual)	Interventional	2018-01-08	Terminated(stopped due to Slow Accrual during COVID pandemic, alternative treatments available. Study halted early.)
Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell Transplantation [NCT02771197]	Phase 2	20 participants (Actual)	Interventional	2016-09-28	Completed
A Phase 1/2 Study of Vadastuximab Talirine Administered in Sequence With Allogeneic Hematopoietic Stem Cell Transplant in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) [NCT02614560]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2015-11-30	Terminated
A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression. [NCT01702831]	Phase 2	78 participants (Actual)	Interventional	2013-10-01	Completed
A Phase II Multicenter Study of Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy, Followed by High-dose Therapy With Melphalan and Autologous Peripheral Blood Stem Cell Transplantation, Consolidation With KRd, and Maintenance With Le [NCT02415413]	Phase 2	90 participants (Anticipated)	Interventional	2015-05-31	Active, not recruiting
A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction With High Dose Melphalan as a Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma [NCT00784823]	Phase 1/Phase 2	32 participants (Actual)	Interventional	2007-01-31	Completed
Busulfan, Cyclophosphamide, and Melphalan Followed by Allogeneic Hematopoietic Cell Transplantation in Patients With Hematological Malignancies [NCT00176839]	Phase 2/Phase 3	11 participants (Actual)	Interventional	2000-06-07	Terminated(stopped due to Replaced by a different study)
UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy [NCT00083551]	Phase 3	668 participants (Actual)	Interventional	1998-08-31	Completed
ChiCGB Versus BEAM With Autologous Stem-Cell Transplantation in High-risk Hodgkin and Non-Hodgkin Lymphoma - A Prospective, Multi-centered, Randomized Clinical Trial [NCT05466318]	Phase 3	306 participants (Anticipated)	Interventional	2022-07-01	Recruiting
A Phase II Trial Of Thalidomide/Dexamethasone Induction Followed By Tandem Melphalan Transplant And Prednisone/Thalidomide Maintenance (A BMT Study) [NCT00040937]	Phase 2	147 participants (Actual)	Interventional	2002-06-30	Completed
Reduced-Intensity Allogeneic HSC Transplantation From HLA-Matched Related and Unrelated Donors for Patients With Multiple Myeloma - A Multi-Center Trial [NCT00054353]	Phase 1/Phase 2	16 participants (Actual)	Interventional	2002-10-31	Completed
I-Metaiodobenzylguanidine (MIBG) With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma [NCT00253435]	Phase 2	50 participants (Actual)	Interventional	2005-09-30	Completed
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases [NCT00038857]	Phase 2	29 participants (Actual)	Interventional	2001-09-30	Completed
Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia [NCT00003816]	Phase 2/Phase 3	361 participants (Actual)	Interventional	1998-10-19	Completed
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation [NCT02790515]	Phase 2	52 participants (Anticipated)	Interventional	2016-07-14	Recruiting
A Pilot Study of Post-transplant High Dose Cyclophosphamide (PTCY) as Part of Graft-Versus-Host Disease (GVHD) Prophylaxis in T-Cell Replete HLA-Mismatched Unrelated Donor (MMUD) Ablative and Reduced Intensity Hematopoietic Cell Transplantation (HCT) for [NCT03128359]	Phase 2	38 participants (Actual)	Interventional	2017-05-30	Active, not recruiting
Intravitreal Injections of Melphalan for Retinoblastoma [NCT01558960]		10 participants (Anticipated)	Interventional	2012-03-31	Terminated(stopped due to Sufficient findings to draw conclusions)
A Multicenter, Single Arm, Open Label Study of Autologous Stem Cell Transplantation With High Dose Melphalan in Patients With Multiple Myeloma [NCT01572688]		60 participants (Anticipated)	Interventional	2011-11-30	Recruiting
A Phase II Study of CHOEP Induction Followed by Gemcitabine/Busulfan/Melphalan Autologous Stem Cell Transplantation for Patients With Newly Diagnosed T-Cell Lymphoma [NCT01746173]	Phase 2	5 participants (Actual)	Interventional	2013-07-31	Terminated(stopped due to Slow accrual and futility)
Autologous Peripheral Blood Stem Cell Transplantation and Maintenance Lenalidomide After High-dose Melphalan for Multiple Myeloma [NCT01617213]	Phase 2	1 participants (Actual)	Interventional	2012-04-30	Terminated(stopped due to Study is no longer needed as recent data have answered the primary hypotheses for this study.)
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma [NCT01413178]	Phase 3	205 participants (Actual)	Interventional	2011-09-30	Completed
Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma. [NCT02063022]	Phase 3	278 participants (Actual)	Interventional	2009-01-22	Completed
Pilot Study of High-Dose Chemotherapy With Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent Tumors [NCT00638898]	Phase 1	25 participants (Actual)	Interventional	2007-02-26	Active, not recruiting
A Phase II Study of Thiotepa Added to Fludarabine and Melphalan as the Preparative Regime for Alternative Donor Transplantation [NCT03342196]	Phase 2	40 participants (Actual)	Interventional	2018-03-21	Active, not recruiting
Treatment Protocol for Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence [NCT00317408]		96 participants (Anticipated)	Interventional	2004-04-30	Active, not recruiting
A Phase I/II Clinical Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT) [NCT00985959]	Phase 1	101 participants (Actual)	Interventional	2008-07-31	Completed
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype [NCT02589145]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2016-06-22	Terminated(stopped due to Closed due to very slow accrual)
Comparative Study of Dexamethasone vs Prednisone (Both in Combination With Melphalan) as Induction Therapy in Untreated Symptomatic Myeloma With an Additional Assessment of Dexamethasone vs no Additional Treatment as Maintenance Therapy in Non-Progressing [NCT00002678]	Phase 3	595 participants (Actual)	Interventional	1995-06-02	Completed
Phase I of Intrathecal Melphalan in Patients With Recurrent Neoplastic Meningitis [NCT00002750]	Phase 1	6 participants (Anticipated)	Interventional	1992-12-31	Completed
Double Umbilical Cord Blood Transplantation for Patients With Malignant and Non-Malignant Disorders [NCT00801931]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2007-09-06	Terminated(stopped due to Poor accrual)
Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for Injection in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma [NCT05438394]	Phase 1	24 participants (Anticipated)	Interventional	2022-10-13	Recruiting
A Phase I Trial of Sequential High Dose Chemotherapy Regimens Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With Persistent Stage III/IV Ovarian Cancer [NCT00003080]	Phase 1	0 participants	Interventional	1996-09-30	Completed
Phase I/II Study of Samarium 153 as Part of a Double (Sequential) Autologous Bone Marrow Transplant (ABMT) for Patients With Stage IV Breast Cancer [NCT00003086]	Phase 1/Phase 2	12 participants (Anticipated)	Interventional	1997-03-31	Terminated(stopped due to no participants enrolled in a three year period)
Autologous Peripheral Blood Stem Cell Transplantation With High Dose Melphalan For Treatment Of Primary Amyloidosis (AL) [NCT00002810]	Phase 2	0 participants	Interventional	1996-05-31	Completed
Multiple Cycles of High Dose Chemotherapy Supported With Filgrastim and Peripheral Blood Progenitor Cells in Patients With Metastatic Breast Cancer [NCT00003392]	Phase 2	61 participants (Actual)	Interventional	1997-09-30	Completed
MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL [NCT00002599]	Phase 3	750 participants (Anticipated)	Interventional	1994-09-30	Active, not recruiting
VIIITH MYELOMATOSIS TRIAL: A RANDOMISED TRIAL OF TREATMENT FOR INDUCING FIRST PLATEAU PHASE ABCM VS 3 COURSES OF ABCM FOLLOWED BY ORAL WEEKLY CYCLOPHOSPHAMIDE [NCT00002653]	Phase 3	1,000 participants (Anticipated)	Interventional	1993-09-30	Active, not recruiting
Rituxan in the Management of Multiple Myeloma [NCT00003554]	Phase 2	0 participants	Interventional	1998-11-30	Completed
A Randomized Trial to Evaluate Early High Dose Therapy and Autologous Bone Marrow Transplantation as Part of Planned Initial Therapy for Poor Risk Intermediate/High Grade NHL [NCT00003578]	Phase 3	500 participants (Anticipated)	Interventional	1993-01-31	Active, not recruiting
A Phase II Study of Intensive Methotrexate and Cytarabine Followed by High Dose Beam Chemotherapy With Autologous Peripheral Blood Progenitor Cell Transplantation in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma [NCT00003632]	Phase 2	30 participants (Anticipated)	Interventional	1998-09-30	Completed
A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Adults and Children With Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Diseases [NCT00003662]	Phase 2	90 participants (Anticipated)	Interventional	1998-08-31	Completed
A Phase I Study of the Chemoprotectant Amifostine With Autologous Stem Cell Transplantation for High Risk or Relapsed Pediatric Solid Tumors and Brain Tumors [NCT00003926]	Phase 1	13 participants (Actual)	Interventional	1998-11-30	Terminated(stopped due to Withdrawn due to slow accrual)
A Study of Intensive-Dose Melphalan, Topotecan, and VP-16 Phosphate (MTV) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma [NCT00005792]	Phase 1	131 participants (Actual)	Interventional	1998-06-02	Completed
A Phase I Trial of Melphalan and Thiotepa Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With a Complete Response Following Standard Therapy for Stage III/IV Epithelial Ovarian Cancer [NCT00002977]	Phase 1	45 participants (Anticipated)	Interventional	1997-01-31	Completed
Autologous Stem Cell Transplantation for Poor Prognosis, Relapsed, or Refractory Intermediate-High Grade B-Cell Lymphoma Using Gemcitabine Plus High Dose BCNU and Melphalan Followed by Anti-CD20 Moab (IDEC C2B8, Rituximab, Rituxan) and Consolidative Chemo [NCT00003397]	Phase 2	25 participants (Anticipated)	Interventional	1998-09-30	Completed
A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse [NCT00002989]	Phase 3	207 participants (Anticipated)	Interventional	1997-03-31	Active, not recruiting
Interferon Maintenance in Advanced Multiple Myeloma After Using High-Dose Melphalan as Myeloablative Chemotherapy: A Pilot Study [NCT00003007]	Phase 2	0 participants	Interventional	1996-07-31	Completed
A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Children and Adults With Hematologic Malignancies [NCT00003661]	Phase 2	3 participants (Actual)	Interventional	1998-06-30	Completed
Autotransplantation for Chronic Myelogenous Leukemia (CML) Followed by Immunotherapy With Ex-Vivo Expanded Autologous T Cells [NCT00003727]	Phase 2	22 participants (Anticipated)	Interventional	1999-03-31	Completed
A Phase II Study of High Dose Late Intensification Therapy in Patients With Chemotherapy Sensitive Multiple Myeloma [NCT00004903]	Phase 2	0 participants	Interventional	1999-10-31	Active, not recruiting
A Randomized Phase III Trial of Sequential High Dose Chemotherapy or Standard Chemotherapy for Optimally Debulked FIGO Stage III and IV Ovarian Cancer [NCT00004921]	Phase 3	0 participants	Interventional	1998-09-30	Completed
Transplantation of Unrelated Donor Hematopoietic Stem Cells for the Treatment of Hematological Malignancies [NCT00281879]	Phase 2	200 participants (Actual)	Interventional	2006-02-28	Terminated
Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity [NCT00001577]	Phase 1	30 participants	Interventional	1997-06-30	Completed
High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia [NCT00002945]	Phase 3	61 participants (Actual)	Interventional	1996-12-31	Completed
Phase II Evaluation of IV Melphalan (L-PAM) and Whole Body Hyperthermia (WBH) for Malignant Melanoma [NCT00002973]	Phase 2	34 participants (Anticipated)	Interventional	1995-12-31	Completed
A Phase I Trial of Busulfan, Thiotepa and Melphalan Followed by Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Followed by Total Marrow (Skeletal) Irradiation (TMI) in Patients With High-Risk Ewing's Sarcoma, PNET or Rhabdomyosarco [NCT00003081]	Phase 1	16 participants (Anticipated)	Interventional	1998-03-31	Completed
A Phase II, Open-Label, Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation [NCT02669615]	Phase 2	24 participants (Actual)	Interventional	2016-11-01	Completed
A Phase II Study of Melphalan HCl for Injection (Propylene Glycol-free), Combined With Carmustine, Etoposide, and Cytarabine (BEAM Regimen) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation [NCT01969435]	Phase 2	50 participants (Actual)	Interventional	2014-03-19	Completed
Autologous Transplantation With High Dose BCNU and Melphalan Followed by Consolidation With DCEP and Taxol/Cisplatin in Patients With Multiple Myeloma and < or = 12 Months of Standard Therapy [NCT00003399]	Phase 2	0 participants	Interventional	1998-09-30	Completed
Safety and Efficacy Study of KL-7SHRNA Injection Solution in the Treatment of AIDS Patients With Lymphoma [NCT05922384]		3 participants (Anticipated)	Interventional	2023-07-05	Recruiting
A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) WITH OR WITHOUT DARATUMUMAB (Dara-VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) WITH OR WITHOUT DARATUMUMAB (Dara-Rd) IN AUTOLOGOUS STEM CELL TR [NCT03829371]	Phase 4	450 participants (Anticipated)	Interventional	2019-01-03	Recruiting
A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Lenalidomide [NCT03151811]	Phase 3	495 participants (Actual)	Interventional	2017-06-12	Completed
A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients [NCT01160107]	Phase 2	46 participants (Actual)	Interventional	2008-07-31	Completed
A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE (V-MPT) Versus VELCADE, MELPHALAN, PREDNISONE (V-MP) IN ELDERLY UNTREATED MULTIPLE MYELOMA PATIENTS [NCT01063179]	Phase 3	511 participants (Actual)	Interventional	2006-05-31	Completed
A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS [NCT00551928]	Phase 3	402 participants (Actual)	Interventional	2007-06-30	Active, not recruiting
CD45A-Depleted Haploidentical Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation [NCT02259348]	Phase 2	12 participants (Actual)	Interventional	2014-10-31	Terminated(stopped due to Investigator's decision.)
A Phase I Study Using Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases [NCT04812470]	Phase 1	6 participants (Anticipated)	Interventional	2023-02-06	Recruiting
A Pilot Study Involving Administration of Combination Anti-Retroviral Therapy and Transplantation of HLA-Matched Sibling Peripheral Blood Stem Cells or Partially HLA-Matched Unrelated Umbilical Cord Blood In Adults With HIV Infection and Hematologic Malig [NCT00003435]	Phase 1	0 participants (Actual)	Interventional	1998-05-31	Withdrawn
A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma [NCT00002835]	Phase 3	116 participants (Actual)	Interventional	1995-10-30	Completed
A Phase II Trial of Multiple Cycles of Sequential High Dose Chemotherapy for Patients With Chemotherapy Sensitive Relapsed Non-Hodgkin's Lymphoma [NCT00003957]	Phase 2	3 participants (Actual)	Interventional	1998-12-31	Completed
A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma [NCT00003603]	Phase 3	660 participants (Anticipated)	Interventional	1998-03-31	Active, not recruiting
A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion and Melphalan With and Without Tumor Necrosis Factor in Patients With Localized Advanced Extremity Melanoma [NCT00003789]	Phase 3	216 participants (Actual)	Interventional	1999-03-31	Completed
Randomized Study of Rituximab (Mabthera) in Patients With Relapsed Follicular Lymphoma Prior to High-Dose Therapy as In Vivo Purging and to Maintain Remission Following High-Dose Therapy [NCT00005589]	Phase 3	460 participants (Anticipated)	Interventional	1999-10-31	Completed
Evaluation of Pretargeted Anti-CD20 Radioimmunotherapy Combined With BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk B-Cell Malignancies [NCT02483000]	Phase 1	3 participants (Actual)	Interventional	2017-02-01	Terminated(stopped due to Closed early due to lack of funding)
Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma [NCT03019640]	Phase 2	22 participants (Actual)	Interventional	2017-10-10	Completed
Comparison of High Dose Rapid Schedule With Conventional Schedule Chemotherapy for Stage 4 Neuroblastoma Over the Age of One Year [NCT00365755]	Phase 3	0 participants	Interventional		Completed
Multicenter Phase II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts After a Reduced Intensity Conditioning Regimen for Adult Patients With Acute Leukemia [NCT00961142]	Phase 2	23 participants (Actual)	Interventional	2009-06-30	Terminated(stopped due to slow recruitment)
SHARON: Study of Metastatic Cancers in Patients With a Defect in a Homologous Recombination Gene Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives [NCT04150042]	Phase 1	10 participants (Anticipated)	Interventional	2021-01-13	Recruiting
BMT-02: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Multiple Myeloma Following Initial Induction Therapy [NCT02043860]	Phase 1	3 participants (Actual)	Interventional	2014-01-10	Terminated(stopped due to low accrual)
Melphalan Pharmacokinetics in Children Undergoing Hematopoietic Stem Cell Transplantation: A Pilot Study [NCT02390544]	Phase 1	34 participants (Actual)	Interventional	2015-05-08	Completed
Alkylator-Intense Conditioning Followed by Autologous Transplantation for Patients With High Risk or Relapsed Solid or CNS Tumors [NCT01505569]		20 participants (Anticipated)	Interventional	2011-10-20	Recruiting
A Phase II Trial of Thiotepa, Busulfan, and Melphalan Followed by Autologous or Syngeneic Marrow or Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma [NCT00003146]	Phase 2	0 participants	Interventional	1997-11-30	Completed
S9805, Phase II Study of Tandem High Dose Melphalan Supported by Peripheral Blood Stem Cell Support in Waldenstrom's Macroglobulinemia (WM) [NCT00003416]	Phase 2	9 participants (Actual)	Interventional	1998-09-30	Completed
A Randomized Phase II Trial Comparing Bendamustine and Melphalan With Melphalan Alone as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Myeloma Patients [NCT03187223]	Phase 2	121 participants (Actual)	Interventional	2017-07-20	Completed
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021) [NCT05518383]	Phase 4	300 participants (Anticipated)	Interventional	2022-05-25	Recruiting
A Phase II Trial of Isolated Limb Infusion With Melphalan and Dactinomycin for Regional Melanoma and Soft Tissue Sarcoma of the Extremity [NCT00004250]	Phase 2	35 participants (Anticipated)	Interventional	1999-08-31	Completed
Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Hematologic Malignancies [NCT05084027]	Phase 2	50 participants (Anticipated)	Interventional	2021-10-07	Recruiting
A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma [NCT00014508]	Phase 2	0 participants	Interventional	2001-11-19	Completed
A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation [NCT00589563]	Phase 2	32 participants (Actual)	Interventional	2007-05-31	Completed
Phase I/II Study of the Combination of Arsenic Trioxide With Ascorbic Acid and High-Dose Melphalan for Patients With Multiple Myeloma [NCT00661544]	Phase 1/Phase 2	48 participants (Actual)	Interventional	2004-03-31	Completed
A Phase II Study of Yttrium-90-Labeled Anti-CD20 Monoclonal Antibody in Combination With High-Dose Beam Followed by Autologous Stem Cell Transplantation for Poor Risk/Relapsed B-Cell Lymphoma [NCT00695409]	Phase 2	122 participants (Actual)	Interventional	2008-03-18	Completed
High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma [NCT00349778]	Phase 2	102 participants (Actual)	Interventional	2006-08-31	Completed
Epigenetic Priming With 5-Azacytidine Prior to in Vivo T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With High Risk Myeloid Malignancies in Morphologic Remission [NCT02497404]	Phase 2	40 participants (Actual)	Interventional	2015-02-13	Completed
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH HIGH RISK HEMOGLOBINOPATHIES LIKE SICKLE CELL DISEASE AND β-THALESSEMIA-MAJOR USING REDUCED INTENSITY CONDITIONING REGIMEN [NCT02435901]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2008-12-31	Completed
A Phase 1/2 Trial Evaluating Treatment of Emergent Graft Versus Host Disease (GvHD) With AP1903 After Planned Donor Infusions (DLIs) of T-cells Genetically Modified With the iCasp9 Suicide Gene in Patients With Hematologic Malignancies [NCT01875237]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2013-12-27	Terminated
A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma [NCT01818752]	Phase 3	955 participants (Actual)	Interventional	2013-07-08	Completed
Phase 1/2A Study Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma [NCT01690143]	Phase 1/Phase 2	45 participants (Actual)	Interventional	2012-05-31	Completed
A Phase 1/2 Trial of Carfilzomib and Melphalan and Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL) [NCT01842308]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2013-06-04	Completed
Phase I Study of Escalating Doses of 90Y-DOTA-Anti-CD25 Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan, and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Trans [NCT05139004]	Phase 1	12 participants (Anticipated)	Interventional	2022-07-19	Recruiting
A Phase 3, Intergroup Multicentre, Randomized, Controlled 3 Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide in Combination With Dexamethasone (RD) Versus Melphalan, Prednisone and Lenalidomide (MPR) Versus Cyclophosphamide, P [NCT01093196]	Phase 3	660 participants (Anticipated)	Interventional	2009-10-31	Active, not recruiting
A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects [NCT01091831]	Phase 3	389 participants (Actual)	Interventional	2009-07-31	Active, not recruiting
Phase 2 Study of Planned Donor Lymphocyte Infusion After Reduced Intensity Allogeneic Stem Cell Transplantation [NCT01518153]	Phase 2	16 participants (Actual)	Interventional	2012-02-29	Terminated(stopped due to Objectives not met.)
A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies [NCT01921387]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2013-10-09	Completed
Immunotherapy for Autologous/Syngeneic Peripheral Blood Stem Cell (PBSC) Transplant Patients as Treatment for Advanced Multiple Myeloma [NCT00006244]	Phase 2	36 participants (Actual)	Interventional	2000-02-29	Completed
A Multi-Center Phase III Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine With Melphalan 200 mg/m2 + Amifostine [NCT00217438]	Phase 3	130 participants (Actual)	Interventional	2005-07-31	Completed
Multicenter Randomized Controlled Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Carmustine, Etoposide and Cytarabine (Modified BEAM Protocol) for T Cell Lymphoma Underwent Autologous Stem Cell Transplantation [NCT05814718]		122 participants (Anticipated)	Interventional	2023-04-15	Not yet recruiting
A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric and Adolescent-Young Adults Patients With High Risk Solid Tumors [NCT04530487]	Phase 2	40 participants (Anticipated)	Interventional	2020-08-19	Recruiting
Nonmyeloablative Allogeneic Stem Cell Transplantation For Relapsed Hodgkin's or Non-Hodgkin's Lymphoma After Autologous Transplantation ( A BMT Study) [NCT00121186]	Phase 2	1 participants (Actual)	Interventional	2005-07-31	Terminated(stopped due to poor accrual)
A Phase II Study of Reduced Intensity Double Umbilical Cord Blood Transplantation Using Fludarabine, Melphalan, and Low Dose Total Body Radiation [NCT01408563]	Phase 2	33 participants (Actual)	Interventional	2011-12-31	Completed
BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus CEM (Carboplatin, Etoposide, Melphalan) in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation [NCT05813132]		60 participants (Actual)	Interventional	2022-12-01	Completed
An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma [NCT00574496]	Phase 2	25 participants (Actual)	Interventional	2007-11-13	Completed
Single Autologous Transplant Followed by Consolidation and Maintenance for Participants ≥ 65 Years of Age Diagnosed With Multiple Myeloma or a Related Plasma Cell Malignancy [NCT01849783]	Phase 2	41 participants (Actual)	Interventional	2013-04-04	Completed
A Phase II Study of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) as Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation for Multiple Myeloma [NCT01653418]	Phase 2	10 participants (Actual)	Interventional	2012-09-30	Terminated(stopped due to Due to the high rate of morbidity and mortality)
A Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes [NCT00789256]		26 participants (Actual)	Interventional	2004-09-30	Completed
A Phase II Study of Maintenance Treatment With Sequential Bortezomib, Thalidomide and Dexamethasone Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Multiple Myeloma [NCT00792142]	Phase 2	45 participants (Actual)	Interventional	2008-01-16	Completed
Neuroblastoma Protocol 2012: Therapy for Children With Advanced Stage High-Risk Neuroblastoma [NCT01857934]	Phase 2	153 participants (Actual)	Interventional	2013-07-05	Active, not recruiting
Single-center, Prospective, Open-label, Comparator Study, Blind for Central Accessor to Access the Efficacy, Safety, and Tolerability of Inhalations of Low-doses of Melphalan in Patients With Pneumonia With Confirmed or Suspected COVID-19 [NCT04380376]	Phase 2	60 participants (Anticipated)	Interventional	2020-04-30	Recruiting
Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation [NCT04937634]	Phase 1	20 participants (Anticipated)	Interventional	2020-09-11	Recruiting
A Clinical Study of Low-dose Total Body Irradiation and Fludarabine/Busulfan/Melphalan as a Conditioning Regimen for Secondary Umbilical Cord Blood Transplantation in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT [NCT06125483]		38 participants (Anticipated)	Interventional	2023-11-01	Recruiting
Haploidentical Donor Hematopoietic Stem Cell Transplantation [NCT02660281]	Phase 1	74 participants (Actual)	Interventional	2015-10-31	Completed
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Leukemia or Lymphoma [NCT05565105]	Phase 2	100 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
Autologous Transplantation With Gemcitabine and High Dose BCNU Plus Melphalan Followed by Consolidation With DCEP Plus Gemcitabine and Taxol/Cisplatin in Patients With Multiple Myeloma and >12 Months of Standard Therapy [NCT00003401]	Phase 2	0 participants	Interventional	1999-01-31	Completed
High Dose Chemotherapy With Stem Cell Rescue in Recently Diagnosed Patients With Advanced (Stage III and IV) Ovarian Cancer With > 1 cm Residual Disease After Debulking Surgery [NCT00003413]	Phase 2	32 participants (Anticipated)	Interventional	1998-09-30	Completed
Phase I/II Study of Escalating Dose Melphalan With Autologous Pluripotent Hematopoietic Stem Cell Support and Amifostine Cytoprotection in Cancer Patients [NCT00003425]	Phase 1/Phase 2	25 participants (Anticipated)	Interventional	1997-12-31	Completed
A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With High Risk Hematologic Malignancies [NCT00003335]	Phase 2	44 participants (Actual)	Interventional	1998-01-31	Completed
Melphalan Intra-arterial Chemotherapy for Choroidal Melanoma Chemoreduction - a Phase I Clinical Trial [NCT05893654]	Phase 1/Phase 2	10 participants (Anticipated)	Interventional	2021-05-01	Enrolling by invitation
A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in Combination With Daratumumab Compared With Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma [NCT04649060]	Phase 3	54 participants (Actual)	Interventional	2020-12-21	Terminated(stopped due to The sponsor decided to terminate the study due to financial issues following an FDA request for a partial clinical hold.)
Pilot Study of JAK Inhibitor Therapy Followed by Reduced Intensity Haploidentical Transplantation for Patients With Myelofibrosis [NCT04370301]	Phase 2	10 participants (Anticipated)	Interventional	2021-02-09	Recruiting
A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups [NCT00003815]	Phase 3	0 participants	Interventional	1994-06-30	Active, not recruiting
High-Dose Consolidation With Escalating Doses of Melphalan and Thiotepa for Stage IV Breast Cancer [NCT00003899]	Phase 1	0 participants	Interventional	1999-01-31	Completed
Phase 1-2 Study of the Combination of Escalated Total Bone Marrow Irradiation (TBMI) by Helicoidal Tomotherapy and a Fixed High-dose Melphalan (140 mg/m²) Followed by Peripheral Stem Cell Rescue (PSC) in First Relapsed Multiple Myeloma. [NCT01794572]	Phase 1/Phase 2	13 participants (Actual)	Interventional	2013-04-24	Terminated(stopped due to Low patient recruitement rate and modification of the therapeutic standard)
A Pilot Study of Whole-body MRI-guided Intensity Modulated Radiation Therapy Combined With Systemic Chemotherapy Followed by High-Dose Chemotherapy With Busulfan, Melphalan and Topotecan and Stem Cell Rescue in Patients With Poor Risk Ewing's Sarcoma [NCT01795430]		0 participants (Actual)	Interventional	2013-07-31	Withdrawn(stopped due to No participants enrolled.)
Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma [NCT01658904]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2012-07-31	Terminated(stopped due to study closed prematurely because investigator left National Institutes of Health)
A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation [NCT01529827]	Phase 2	94 participants (Actual)	Interventional	2012-02-28	Completed
Bevacizumab Combined With High-Dose Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Patients With Advanced Epithelial Ovarian Cancer [NCT00583622]	Phase 2	13 participants (Actual)	Interventional	2007-12-31	Terminated(stopped due to Slow Accrual)
Phase I/II Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma. [NCT01279694]	Phase 1/Phase 2	72 participants (Actual)	Interventional	2010-10-31	Completed
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation [NCT00744692]	Phase 1	22 participants (Actual)	Interventional	2008-10-31	Completed
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies [NCT01499147]		100 participants (Actual)	Interventional	2000-02-29	Completed
Isolated Limb Perfusion for Advanced Melanoma or Sarcoma Limited to Extremity With or Without Distant Metastases [NCT02507076]		0 participants (Actual)	Interventional	2012-04-30	Withdrawn(stopped due to no enrollment)
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Using a Conditioning Regimen of Fludarabine, Melphalan, and Bortezomib [NCT01453101]	Phase 2	54 participants (Actual)	Interventional	2010-06-09	Completed
Study With High Doses of Chemotherapy, Radiotherapy and Consolidation Therapy With Ciclofosfamide and Anticyclooxygenase 2, for the Metastatic Ewing Sarcoma [NCT02727387]	Phase 2	155 participants (Actual)	Interventional	2009-06-01	Completed
Y Zevalin, BEAM and Rituximab In Autologous Stem Cell Transplantation (ASCT) For Lymphoma [NCT01538472]	Phase 1/Phase 2	40 participants (Actual)	Interventional	2003-09-30	Completed
A Multicenter Open Label Phase 2 Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma [NCT02302495]	Phase 2	80 participants (Anticipated)	Interventional	2014-01-31	Active, not recruiting
Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study [NCT01054196]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2010-08-31	Active, not recruiting
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Ages 65 and Under: A Trial Enrolling Subjects to Standard Total Therapy 3 (S-TT3) [NCT00734877]	Phase 3	382 participants (Actual)	Interventional	2008-07-31	Active, not recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) [NCT04221035]	Phase 3	800 participants (Anticipated)	Interventional	2019-11-05	Recruiting
Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Pediatric and Adult Patients With Severe Crohn's Disease [NCT00692939]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2012-06-26	Recruiting
"A Phase I/II Clinical Trial of Off-the-shelf NK Cell Administration in Combination With Allogeneic SCT to Decrease Disease Relapse in Patients With High-risk Myeloid Malignancies Undergoing Matched Related, Matched Unrelated, One Antigen Mismatched Unrel [NCT05115630]	Phase 1/Phase 2	24 participants (Anticipated)	Interventional	2022-04-08	Recruiting
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies [NCT04191187]	Phase 2	37 participants (Anticipated)	Interventional	2019-12-06	Active, not recruiting
Early HLA Matched Sibling Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: A Sickle Transplant Advocacy and Research Alliance (STAR) Trial [NCT04018937]	Phase 2	58 participants (Anticipated)	Interventional	2019-03-22	Recruiting
A Prospective Study of Bortezomib in Combination With Melphalan and Prednisone for Patients With Previously Untreated Multiple Myeloma [NCT00734149]	Phase 2	45 participants (Actual)	Interventional	2004-07-31	Completed
Induction Therapy With Bortezomib-melphalan and Prednisone (VMP) Followed by Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab, 18 Cycles, Followed by Consolidation and Maintenance Therapy [NCT03742297]	Phase 3	462 participants (Actual)	Interventional	2018-10-22	Active, not recruiting
[NCT01274403]	Phase 2	130 participants (Actual)	Interventional		Completed
A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Nonmyeloablative Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Lymphoma - A Multi-center Trial [NCT00005803]	Phase 1/Phase 2	76 participants (Actual)	Interventional	1999-09-30	Completed
A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children With Juvenile Myelomonocytic Leukemia (JMML) [NCT01824693]	Phase 2	30 participants (Actual)	Interventional	2013-06-24	Completed
A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning [NCT05031897]	Phase 2	67 participants (Anticipated)	Interventional	2021-10-25	Recruiting
A Feasibility Study of Myeloablative BEAM Allogeneic Transplantation Followed by Oral Ixazomib Maintenance Therapy in Patients With Relapsed High-Risk Multiple Myeloma [NCT02504359]	Phase 1	11 participants (Actual)	Interventional	2015-07-20	Completed
A Prospective, Open-label, Multicenter, Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone(VMP) for Initial Treatment in Patients With Multiple Myeloma Who do Not Undergo Autologous Stem Cell Transplantation [NCT02474563]		171 participants (Actual)	Observational	2011-05-31	Completed
A Pilot Study to Assess Impact of Low Dose Melphalan on Disease Burden Measured by Next Generation Sequencing Before Autologous Hematopoietic Cell Transplant (AHCT) for Multiple Myeloma Patients [NCT05013437]	Early Phase 1	20 participants (Anticipated)	Interventional	2023-03-31	Recruiting
A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma [NCT01731886]	Phase 4	60 participants (Actual)	Interventional	2012-09-30	Completed
A Pilot Study of Allogeneic Hematopoietic Cell Transplantation for Patients With High Grade Central Nervous System Malignancies [NCT04521946]	Phase 1	0 participants (Actual)	Interventional	2021-01-14	Withdrawn(stopped due to No participants enrolled.)
A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Conditioning Prior to Ex-vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation [NCT04098393]	Phase 1	45 participants (Anticipated)	Interventional	2019-09-18	Recruiting
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism [NCT00176865]	Phase 2	19 participants (Actual)	Interventional	2002-08-31	Completed
Phase II Study of Tandem Cycle Dose-Intense Chemotherapy of Melphalan and Carboplatin, Thiotepa and Cyclophosphamide (STMP V) ± Trastuzumab Followed by Helical Tomotherapy or Local Regional Radiation Therapy for Stage IV Metastatic and Stage IIIB/C Breast [NCT00182793]	Phase 2	32 participants (Actual)	Interventional	2005-07-31	Completed
BEAM + 131Iodine-Anti-B1 Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Recurrent Non-Hodgkin's Lymphoma [NCT00574509]	Phase 1	34 participants (Actual)	Interventional	1996-03-04	Completed
Tandem High-Dose Therapy With Melphalan and Total Marrow Irradiation (TMI) With Peripheral Blood Progenitor Cell Support and Lenalidomide Maintenance in Multiple Myeloma: A Phase I/II Trial [NCT00112827]	Phase 1/Phase 2	54 participants (Actual)	Interventional	2004-11-30	Completed
A Current Practice Study of Rituxan in Patient Receiving BEAM Chemotherapy and Autologous Blood Stem Cell Transplantation for High Risk Lymphoma or Hodgkin's Disease [NCT01702961]		75 participants (Actual)	Interventional	2002-06-30	Completed
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation [NCT02112045]	Phase 2	90 participants (Actual)	Interventional	2015-01-20	Terminated(stopped due to Terminated due to results of interim analysis)
A Pilot Study of a Sequential Regimen of Intensive Chemotherapy Followed by Autologous or Allogeneic Transplantation for Refractory Lymphoma (Non-Hodgkin's and Hodgkin's) and Phase 2 Expansion Cohort [NCT02059239]	Phase 1/Phase 2	34 participants (Actual)	Interventional	2014-06-04	Completed
Azacitidine/Vorinostat/GemBuMel With Autologous Stem-Cell Transplant (SCT) in Patients With Refractory Lymphomas [NCT01983969]	Phase 1/Phase 2	61 participants (Actual)	Interventional	2013-11-07	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00002601 (4) [back to overview]	Toxicities Counts
NCT00002601 (4) [back to overview]	5-year Progression-free Survival
NCT00002601 (4) [back to overview]	Number of Participants With Grade 3 Bilirubin
NCT00002601 (4) [back to overview]	5-year Overall Survival
NCT00003042 (2) [back to overview]	Three-year Relapse-free Survival
NCT00003042 (2) [back to overview]	Five-year Overall Survival
NCT00003199 (3) [back to overview]	Event-free Survival
NCT00003199 (3) [back to overview]	Number of Participants With Toxicity of a Combination of Low-dose IL-2 and GM-CSF
NCT00003199 (3) [back to overview]	Overall Survival
NCT00003631 (1) [back to overview]	Objective Response
NCT00003816 (4) [back to overview]	4 Year PFS
NCT00003816 (4) [back to overview]	4 yr OS
NCT00003816 (4) [back to overview]	CR Rate
NCT00003816 (4) [back to overview]	Toxicity/TRM at Day 100
NCT00004088 (2) [back to overview]	Three-year Overall Survival
NCT00004088 (2) [back to overview]	Progression-free Survival
NCT00005803 (4) [back to overview]	Progression Free-survival (PFS)
NCT00005803 (4) [back to overview]	Overall Survival (OS)
NCT00005803 (4) [back to overview]	Non-Relapse Mortality
NCT00005803 (4) [back to overview]	Engraftment of HLA Identical PBSC Allografts
NCT00006244 (6) [back to overview]	Proportion of Patients Alive and in Remission
NCT00006244 (6) [back to overview]	Time to Disease Progression
NCT00006244 (6) [back to overview]	Initial Response to Therapy
NCT00006244 (6) [back to overview]	Overall Survival
NCT00006244 (6) [back to overview]	Number of Patients ≥56 Years Old Experiencing Grade 3-4 Regimen Related Toxicity
NCT00006244 (6) [back to overview]	Number of Patients <56 Years Old Experiencing Grade 3-4 Regimen Related Toxicity
NCT00027560 (6) [back to overview]	Extensive Chronic Graft-versus-Host Disease Matched Related Patients
NCT00027560 (6) [back to overview]	Overall Survival
NCT00027560 (6) [back to overview]	Overall Survival
NCT00027560 (6) [back to overview]	Extensive Chronic Graft-versus-Host Disease Unrelated and Mismatched Related Patients
NCT00027560 (6) [back to overview]	Acute Graft-versus-Host Disease Unrelated and Mismatched Related Patients
NCT00027560 (6) [back to overview]	Acute Graft-versus-Host Disease Matched Related Patients
NCT00038857 (1) [back to overview]	Number of Participants With Absolute Neutrophil Count Engraftment
NCT00040937 (2) [back to overview]	Overall Survival
NCT00040937 (2) [back to overview]	Assess Toxicity of Thalidomide/Dexamethasone as a Pre-transplant Induction Regimen.
NCT00043979 (14) [back to overview]	Toxicity
NCT00043979 (14) [back to overview]	Number of Participants With Engraftment
NCT00043979 (14) [back to overview]	Number of Participants Who Experienced Graft Versus Tumor Effect (GVT)
NCT00043979 (14) [back to overview]	Median Progression Free Survival
NCT00043979 (14) [back to overview]	Early Post Transplantation Relapse
NCT00043979 (14) [back to overview]	Cluster of Differentiation 4 (CD4) Reconstitution
NCT00043979 (14) [back to overview]	Median Time to Reach Absolute Neutrophil Count of 500/mm(3)
NCT00043979 (14) [back to overview]	Median Survival From Date of Progression
NCT00043979 (14) [back to overview]	Number of Participants to Complete Conversion to >95% Donor Chimerism
NCT00043979 (14) [back to overview]	Number of Participants With Acute and Chronic GVHD
NCT00043979 (14) [back to overview]	Median Time to Reach a Platelet Count of 50,000/mm(3)
NCT00043979 (14) [back to overview]	Post-Hematopoietic Stem Cell Transplant (HSCT) Radiotherapy
NCT00043979 (14) [back to overview]	Two Year Survival Rate for Patients Undergoing Allo-Hematopoietic Stem Cell Transplant
NCT00043979 (14) [back to overview]	Best Response Post-Hematopoietic Stem Cell Transplant EOCH (Etoposide, Vincristine, Cyclophosphamide, and Doxorubicin)
NCT00054353 (8) [back to overview]	OS
NCT00054353 (8) [back to overview]	Relapse Rate
NCT00054353 (8) [back to overview]	Engraftment
NCT00054353 (8) [back to overview]	PFS
NCT00054353 (8) [back to overview]	Response Rate
NCT00054353 (8) [back to overview]	Incidence of Acute GVHD (Grades III-IV)
NCT00054353 (8) [back to overview]	Incidence of Chronic (Extensive) GVHD
NCT00054353 (8) [back to overview]	Non-relapse Mortality
NCT00064337 (2) [back to overview]	Hematologic Response
NCT00064337 (2) [back to overview]	Overall Survival
NCT00067002 (5) [back to overview]	Time To Neutrophil Engraftment
NCT00067002 (5) [back to overview]	Number of Participants Severity of Acute GVHD by Treatment Arm
NCT00067002 (5) [back to overview]	Rate of Chronic GVHD
NCT00067002 (5) [back to overview]	Number of Participants With Engraftment
NCT00067002 (5) [back to overview]	Rate of Acute Graft Versus Host Disease (GVHD)
NCT00074269 (7) [back to overview]	Frequency of the Induction of Full Donor Chimerism of Lymphocytes as Measured at 1 Month Post Allografting
NCT00074269 (7) [back to overview]	Number of Participants With Acute and Chronic Graft-versus-host Disease (GVHD)
NCT00074269 (7) [back to overview]	Number of Participants With Adverse Events
NCT00074269 (7) [back to overview]	Number of Participants With Long-term Engraftment of Allogeneic Stem Cells and Lymphocytes
NCT00074269 (7) [back to overview]	Progression-free Survival
NCT00074269 (7) [back to overview]	Response as Measured at 12 Months Post Allografting
NCT00074269 (7) [back to overview]	Overall Survival
NCT00083551 (1) [back to overview]	Overall Survival
NCT00112827 (3) [back to overview]	Maximum Tolerated Dose (MTD)
NCT00112827 (3) [back to overview]	Number of Subjects With Response
NCT00112827 (3) [back to overview]	Overall Survival
NCT00114101 (4) [back to overview]	Time to Progression
NCT00114101 (4) [back to overview]	Response to Autologous Hematopoietic Stem-cell Transplant (HSCT) at Day 100
NCT00114101 (4) [back to overview]	Number of Participants With Progression, Death or Diagnosis of Second Primary Malignancy
NCT00114101 (4) [back to overview]	Overall Survival
NCT00121186 (2) [back to overview]	Progression-free Survival
NCT00121186 (2) [back to overview]	Overall Survival
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Minimal Residual Disease (MRD)
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Median Dose of CD34
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Median Dose of NK Cells
NCT00145626 (13) [back to overview]	Number of Transplant-Related Adverse Outcomes: Engraftment Failure
NCT00145626 (13) [back to overview]	Number of Transplant-Related Adverse Outcomes: Fatal Acute Graft-Versus Host Disease (GVHD)
NCT00145626 (13) [back to overview]	Number of Transplant-Related Adverse Outcomes: Regimen-Related Mortality
NCT00145626 (13) [back to overview]	One-year Survival
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Disease Status at HSCT
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Donor Type
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Match N/6 HLA Loci
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Median Age of Donor at HSCT
NCT00145626 (13) [back to overview]	Kinetics of Lymphohematopoietic Reconstitution
NCT00145626 (13) [back to overview]	Frequency of and Clinical Relevance of Minimal Residual Disease (MRD) Before and After Transplantation
NCT00176839 (6) [back to overview]	Incidence Chronic Graft-versus-host Disease (GVHD)
NCT00176839 (6) [back to overview]	Incidence of Relapse
NCT00176839 (6) [back to overview]	Probability of Long-term Disease-free Survival (DFS)
NCT00176839 (6) [back to overview]	Incidence of Acute Graft-versus-host Disease (GVHD)
NCT00176839 (6) [back to overview]	Incidence of Regimen-related Toxicity 100 Days Post Transplant
NCT00176839 (6) [back to overview]	Probability of Engraftment
NCT00176865 (9) [back to overview]	Number of Subjects Alive at One Year
NCT00176865 (9) [back to overview]	Percentage of Donor Chimerism at 365 Days
NCT00176865 (9) [back to overview]	Incidence of Grade 2-4 Acute Graft Versus Host Disease (aGVHD)
NCT00176865 (9) [back to overview]	Number of Subjects Alive at 100 Days
NCT00176865 (9) [back to overview]	Incidence of Chronic Graft Versus Host Disease (cGVHD)
NCT00176865 (9) [back to overview]	Percentage of Donor Chimerism at 180 Days
NCT00176865 (9) [back to overview]	Incidence of Grade 3-4 Acute Graft Versus Host Disease (aGVHD)
NCT00176865 (9) [back to overview]	Percentage of Donor Chimerism at 100 Days
NCT00176865 (9) [back to overview]	Number of Subjects With Mixed Chimerism
NCT00177047 (17) [back to overview]	Number of Participants Experiencing Incidence of Relapse
NCT00177047 (17) [back to overview]	Time to Attainment of CR
NCT00177047 (17) [back to overview]	Time to Relapse
NCT00177047 (17) [back to overview]	Time to Progression
NCT00177047 (17) [back to overview]	Number of Participants With Overall Survival
NCT00177047 (17) [back to overview]	Count of Participants Experiencing Transplant Related Mortality
NCT00177047 (17) [back to overview]	Number of Participants Achieving a Complete Response
NCT00177047 (17) [back to overview]	Number of Participants Achieving a Complete Response
NCT00177047 (17) [back to overview]	Number of Participants Achieving a Complete Response
NCT00177047 (17) [back to overview]	Number of Participants With Absolute Neutrophil Recovery
NCT00177047 (17) [back to overview]	Number of Participants With Disease Progression
NCT00177047 (17) [back to overview]	Number of Participants With Overall Survival
NCT00177047 (17) [back to overview]	Number of Participants With Infections
NCT00177047 (17) [back to overview]	Time to Attainment of CR+PR
NCT00177047 (17) [back to overview]	Number of Participants With Overall Survival
NCT00177047 (17) [back to overview]	Number of Patients With Extended Disease-free Survival
NCT00177047 (17) [back to overview]	Number of Participants With Toxicities
NCT00182793 (2) [back to overview]	5-Year Overall Survival Rate
NCT00182793 (2) [back to overview]	5-Year Relapse-free Survival Rate
NCT00185614 (4) [back to overview]	Acute Graft-vs-Host-Disease (aGvHD)
NCT00185614 (4) [back to overview]	Event-free Survival (EFS)
NCT00185614 (4) [back to overview]	Relapse Rate
NCT00185614 (4) [back to overview]	Overall Survival (OS)
NCT00217438 (2) [back to overview]	CR and Near CR Rates
NCT00217438 (2) [back to overview]	Relative Toxicities Between Melphalan 280 mg/m^2 or Melphalan 200 mg/m^2
NCT00233987 (4) [back to overview]	2-year Progression-free Survival
NCT00233987 (4) [back to overview]	Overall Survival
NCT00233987 (4) [back to overview]	Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT00233987 (4) [back to overview]	Response Rate
NCT00238433 (2) [back to overview]	Therapy-Related Toxicities
NCT00238433 (2) [back to overview]	Disease-Free Survival
NCT00253435 (4) [back to overview]	Dose Limiting Veno-occlusive Disease (VOD) / Sinusoidal Obstruction Syndrome SOS
NCT00253435 (4) [back to overview]	Engraftment DLT
NCT00253435 (4) [back to overview]	Event-free Survival (EFS) at 3 Years
NCT00253435 (4) [back to overview]	Response (Complete Response, Very Good Partial Response, and Partial Response) at 60-days Post Stem Cell Infusion
NCT00265889 (3) [back to overview]	Progression-free Survival
NCT00265889 (3) [back to overview]	Response Rate
NCT00265889 (3) [back to overview]	Number of Patients That Experience Pulmonary Toxicity
NCT00288626 (20) [back to overview]	Overall Survival
NCT00288626 (20) [back to overview]	Percent Change From Screening in Brain Volume
NCT00288626 (20) [back to overview]	Survival From Treatment-Related Mortality
NCT00288626 (20) [back to overview]	MS Relapse-Free Survival Probability After Transplant
NCT00288626 (20) [back to overview]	Number of New T2-Weighted Lesions From Baseline
NCT00288626 (20) [back to overview]	MS Progression-Free Survival Probability After Transplant
NCT00288626 (20) [back to overview]	MRI Activity-Free Survival Probability After Transplant
NCT00288626 (20) [back to overview]	Event-Free Survival Probability After Transplant
NCT00288626 (20) [back to overview]	Disease-Modifying Therapy Survival Probability After Transplant
NCT00288626 (20) [back to overview]	Change From Baseline in T2-Weighted Lesion Volume
NCT00288626 (20) [back to overview]	Survival From MS-Related Mortality
NCT00288626 (20) [back to overview]	Change From Baseline in T1-Weighted Lesion Volume
NCT00288626 (20) [back to overview]	Change From Baseline in Number of Gadolinium-Enhanced Lesions
NCT00288626 (20) [back to overview]	Change From Baseline in Extended Disability Status Scale (EDSS)
NCT00288626 (20) [back to overview]	Time to Platelet Engraftment
NCT00288626 (20) [back to overview]	Time to Neutrophil Engraftment
NCT00288626 (20) [back to overview]	Percent of Participants Who Experienced All-Cause Morbidity Within 12 Months of Post-HCT
NCT00288626 (20) [back to overview]	Percent of Participants Who Experienced All-Cause Morbidity
NCT00288626 (20) [back to overview]	Event-Free Survival Probability During the 3 Years After Transplant
NCT00288626 (20) [back to overview]	Event-Free Survival Probability During the 5 Years After Transplant
NCT00307086 (1) [back to overview]	Overall Survival (OS)
NCT00325416 (4) [back to overview]	Phase II Overall Survival (OS)
NCT00325416 (4) [back to overview]	Phase II Event Free Survival (EFS)
NCT00325416 (4) [back to overview]	Phase I - Maximum Tolerated Dose (MTD) Level
NCT00325416 (4) [back to overview]	Phase II Participants - Overall Response Rate
NCT00349778 (3) [back to overview]	Number of Participants With Pulmonary Toxicity
NCT00349778 (3) [back to overview]	Number of Participants That Relapse After Autologous Transplantation
NCT00349778 (3) [back to overview]	Overall Participant Survival (OS)
NCT00357396 (1) [back to overview]	Overall Objective Response
NCT00383448 (4) [back to overview]	Number of Patients With Chronic Graft Versus Host Disease (GVHD)
NCT00383448 (4) [back to overview]	Number of Patients With Donor Cell Engraftment
NCT00383448 (4) [back to overview]	Number of Patients With Acute Graft Versus Host Disease (GVHD)
NCT00383448 (4) [back to overview]	Number of Patients Whose Death Was Related to the Transplant
NCT00385788 (1) [back to overview]	Transplant Related Mortality Rate
NCT00405756 (28) [back to overview]	Kaplan Meier Estimates of Overall Survival (OS)
NCT00405756 (28) [back to overview]	Kaplan Meier Estimates for Time to Next Antimyeloma Therapy
NCT00405756 (28) [back to overview]	Kaplan Meier Estimates for Duration of Response as Determined by the Central Adjudication Committee (CAC)
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Financial Difficulties Scale
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Insomnia Scale
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Nausea and Vomiting Scale
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Pain Scale
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Physical Functioning Scale
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Role Functioning Scale
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Social Functioning Scale
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Body Image Scale
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Side Effects of Treatment Scale
NCT00405756 (28) [back to overview]	Number of Participants in Disease Response Categories Representing Their Best Response During the Double-blind Treatment Period
NCT00405756 (28) [back to overview]	Summary of Participants With Treatment-Emergent Adverse Events (TEAE) During the Double-Blind Treatment Period
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Future Perspective Scale
NCT00405756 (28) [back to overview]	Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC)
NCT00405756 (28) [back to overview]	Kaplan Meier Estimates of Progression-free Survival (PFS) From Start of Maintenance Therapy Period Based on the Response Assessment by the Central Adjudication Committee (CAC)
NCT00405756 (28) [back to overview]	Kaplan Meier Estimates of Time to Progression (TTP) Based on the Response Assessment by the Central Adjudication Committee (CAC)
NCT00405756 (28) [back to overview]	Time to First Response
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Quality of Life Scale
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Appetite Loss Scale
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Congitive Functioning Scale
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Constipation Scale
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Diarrhoea Scale
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Dyspnoea Scale
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Emotional Functioning Scale
NCT00405756 (28) [back to overview]	Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Scale
NCT00423514 (1) [back to overview]	Participants Evaluated for Early Post-transplant Regimen-related Severe Morbidity (Grade III to IV Nonhematologic Toxicity) and Mortality as Measured by the NCI Cancer Therapy Evaluation Program CTCAE v 3.0
NCT00427557 (1) [back to overview]	Number of Participants With Engraftment
NCT00427765 (1) [back to overview]	Average Overall Survival Time
NCT00429572 (5) [back to overview]	Time to Progressive Disease
NCT00429572 (5) [back to overview]	Grade II-IV Toxicity
NCT00429572 (5) [back to overview]	Overall Survival
NCT00429572 (5) [back to overview]	Number of Participants With Tumor Response
NCT00429572 (5) [back to overview]	Number of Participants With Acute or Chronic GVHD And Response to Therapy
NCT00439556 (2) [back to overview]	Disease-free Survival
NCT00439556 (2) [back to overview]	Number of Participants With Dose Limiting Toxicity (DLT)
NCT00469209 (1) [back to overview]	Number of Patients Reaching Complete Response (CR)
NCT00472056 (1) [back to overview]	Disease-free Survival (DFS)
NCT00477750 (5) [back to overview]	Percentage of Participants With Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3)
NCT00477750 (5) [back to overview]	Progression-free Survival
NCT00477750 (5) [back to overview]	Overall Survival (OS) at 3 Years
NCT00477750 (5) [back to overview]	Patients With Overall Confirmed Response
NCT00477750 (5) [back to overview]	Duration of Response (DOR)
NCT00477971 (4) [back to overview]	3-Year Progression Free Survival
NCT00477971 (4) [back to overview]	Organ Response to Treatment
NCT00477971 (4) [back to overview]	Hematologic Response Rate
NCT00477971 (4) [back to overview]	3 Year Overall Survival
NCT00505895 (2) [back to overview]	Number of Participants With Successful Engraftment at Day 100
NCT00505895 (2) [back to overview]	Acute Grade II-IV Graft Versus Host Disease (GVHD)
NCT00505921 (1) [back to overview]	Participant Progression Free Survival at 2 Years
NCT00506129 (2) [back to overview]	Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA)
NCT00506129 (2) [back to overview]	Average Overall Survival (OS) Length
NCT00507416 (8) [back to overview]	Change From Baseline in EORTC QLQ-C30 - Global Health Status
NCT00507416 (8) [back to overview]	Time to Alternative Therapy
NCT00507416 (8) [back to overview]	Progression Free Survival (PFS)
NCT00507416 (8) [back to overview]	Percentage of Participants With an Overall Response
NCT00507416 (8) [back to overview]	Percentage of Participants With a Complete Response or a Very Good Partial Response
NCT00507416 (8) [back to overview]	Percentage of Participants With a Complete Response
NCT00507416 (8) [back to overview]	Overall Survival
NCT00507416 (8) [back to overview]	Duration of Response
NCT00520767 (3) [back to overview]	Complete Hematologic Response
NCT00520767 (3) [back to overview]	Overall Survival
NCT00520767 (3) [back to overview]	Time to Treatment Failure (TTF)
NCT00521014 (1) [back to overview]	Progression-free Survival Rate
NCT00536601 (8) [back to overview]	Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors)
NCT00536601 (8) [back to overview]	Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors)
NCT00536601 (8) [back to overview]	Regimen-related Toxicity Grade 2-4 in Any Organ (Measured by Bearman Score, Values Range From 0 (None) to 4 (Fatal))
NCT00536601 (8) [back to overview]	Response Rate (Complete Remission)
NCT00536601 (8) [back to overview]	Overall Survival, Presented as the Estimate at 10-yrs (Median Follow-up Time in Survivors)
NCT00536601 (8) [back to overview]	Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors)
NCT00536601 (8) [back to overview]	Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors)
NCT00536601 (8) [back to overview]	Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors)
NCT00539500 (3) [back to overview]	Number of Treated Participants With Engraftment Failure at Day 42
NCT00539500 (3) [back to overview]	Engraftment Failure Rate
NCT00539500 (3) [back to overview]	Number of Participants With Device-related Toxicity Associated With Transplantation of CD133+ Cells
NCT00544115 (2) [back to overview]	Two-year Overall Survival
NCT00544115 (2) [back to overview]	Neutrophil Engraftment - The Days Till ANC Recovery
NCT00544466 (2) [back to overview]	Number of Grade 3 and Above Toxicities of Helical Tomotherapy (HT) in Combination With Fludarabine and Melphalan Followed by Allogeneic Stem Cell Transplantation.
NCT00544466 (2) [back to overview]	Overall Survival on Day 180 Days Post-transplant
NCT00547196 (2) [back to overview]	Survival Rate at Day 100 After Allogeneic Transplant From Umbilical Cord Blood (UCB)
NCT00547196 (2) [back to overview]	Survival Rate at Day 180 After Allogeneic Transplant From Umbilical Cord Blood (UCB)
NCT00566098 (7) [back to overview]	Disease Response
NCT00566098 (7) [back to overview]	Hematopoietic Engraftment
NCT00566098 (7) [back to overview]	Anti-tumor Immune Responses
NCT00566098 (7) [back to overview]	Feasibility of MILs Generation as Assessed by Percentage of Participants With Successful MIL Generation
NCT00566098 (7) [back to overview]	Survival
NCT00566098 (7) [back to overview]	T-cell Reconstitution as Determined by Absolute Lymphocyte Count (ALC)
NCT00566098 (7) [back to overview]	Pneumococcal-specific Vaccine Responses
NCT00566696 (7) [back to overview]	Incidence of Regimen-related Mortality
NCT00566696 (7) [back to overview]	Overall Survival (OS)
NCT00566696 (7) [back to overview]	To Estimate the Rate of Overall Grade III-IV Acute GVHD, and the Rate and Severity of Chronic GVHD in Research Participants.
NCT00566696 (7) [back to overview]	Event-free Survival (EFS)
NCT00566696 (7) [back to overview]	To Estimate the Cumulative Incidence of Relapse for Research Participants Who Receive This Study Treatment.
NCT00566696 (7) [back to overview]	Incidence of Non-hematologic Regimen-related Toxicities
NCT00566696 (7) [back to overview]	Disease-Free Survival (DFS)
NCT00567567 (14) [back to overview]	Topotecan Systemic Clearance
NCT00567567 (14) [back to overview]	Event-free Survival Rate
NCT00567567 (14) [back to overview]	Incidence Rate of Local Recurrence
NCT00567567 (14) [back to overview]	Peak Serum Concentration of Isotretinoin in Patients Enrolled on Either A3973, ANBL0032, ANBL0931, ANBL0532 and Future High Risk Studies
NCT00567567 (14) [back to overview]	Proportion of Patients With a Polymorphism
NCT00567567 (14) [back to overview]	Intraspinal Extension
NCT00567567 (14) [back to overview]	Response After Induction Therapy
NCT00567567 (14) [back to overview]	Surgical Response
NCT00567567 (14) [back to overview]	EFS Pts Non-randomly Assigned to Single CEM (12-18 Mths, Stg. 4, MYCN Nonamplified Tumor/Unfavorable or Indeterminant Histopathology/Diploid DNA Content & Pts>547 Days, Stg.3, MYCN Nonamplified Tumor AND Unfavorable or Indeterminant Histopathology).
NCT00567567 (14) [back to overview]	Type of Surgical or Radiotherapy Complication
NCT00567567 (14) [back to overview]	OS in Patients 12-18 Months, Stage 4, MYCN Nonamplified Tumor/Unfavorable Histopathology/Diploid DNA Content/Indeterminant Histology/Ploidy and Patients > 547 Days, Stage 3, MYCN Nonamplified Tumor AND Unfavorable Histopathology/Indeterminant Histology
NCT00567567 (14) [back to overview]	Enumeration of Peripheral Blood Cluster of Differentiation (CD)3, CD4, and CD8 Cells
NCT00567567 (14) [back to overview]	Duration of Greater Than or Equal to Grade 3 Neutropenia
NCT00567567 (14) [back to overview]	Duration of Greater Than or Equal to Grade 3 Thrombocytopenia
NCT00571493 (3) [back to overview]	Maximum Tolerated Dose (MTD) of Bortezomib
NCT00571493 (3) [back to overview]	Preliminary Estimate of Overall Response Rate (ORR)
NCT00571493 (3) [back to overview]	Progression-free Survival (PFS), and Overall Survival (OS)
NCT00572897 (6) [back to overview]	Transplant-related Mortality
NCT00572897 (6) [back to overview]	Response Outcomes
NCT00572897 (6) [back to overview]	PLT
NCT00572897 (6) [back to overview]	The Primary Endpoint is Progression-free Survival.
NCT00572897 (6) [back to overview]	Absolute Neutrophil Count (ANC)
NCT00572897 (6) [back to overview]	Overall Survival
NCT00574496 (3) [back to overview]	Disease Relapse or Progression as Measured by CT Scan or PET
NCT00574496 (3) [back to overview]	Overall Survival
NCT00574496 (3) [back to overview]	Progression-free Survival at 1 Year
NCT00577096 (10) [back to overview]	Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets. (Long Term)
NCT00577096 (10) [back to overview]	Number of Stem Cell Collection Attempts (Long Term)
NCT00577096 (10) [back to overview]	Total Number of Days of Stem Cell Collection (Long Term)
NCT00577096 (10) [back to overview]	Number of Stem Cell Collection Attempts (Short Term)
NCT00577096 (10) [back to overview]	Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Short Term)
NCT00577096 (10) [back to overview]	Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Long Term)
NCT00577096 (10) [back to overview]	Total Number of Days of Stem Cell Collection (Short Term)
NCT00577096 (10) [back to overview]	Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets.(Short Term)
NCT00577096 (10) [back to overview]	Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Long Term)
NCT00577096 (10) [back to overview]	Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Short Term)
NCT00577278 (3) [back to overview]	Progression-free Survival at Two Years
NCT00577278 (3) [back to overview]	Relapse/Progression Rate at Two Years
NCT00577278 (3) [back to overview]	Overall Survival at Two Years
NCT00582933 (1) [back to overview]	Death From GVHD
NCT00583622 (1) [back to overview]	Participant Response
NCT00589563 (14) [back to overview]	Cumulative Incidence of Chronic GVHD
NCT00589563 (14) [back to overview]	Cumulative Incidence of Grade II-IV Acute Graft-Versus-Host Disease (GVHD) at Day 100
NCT00589563 (14) [back to overview]	Incidence of Disease Relapse/Progression at 2 Years Post HSCT
NCT00589563 (14) [back to overview]	Event Free Survival at Two Years Post HSCT
NCT00589563 (14) [back to overview]	Non-relapse Mortality at 100 Days Post HSCT
NCT00589563 (14) [back to overview]	Non-relapse Mortality at Two Years Post HSCT
NCT00589563 (14) [back to overview]	Occurence of Sinusoidal Obstructive Syndrome (SOS)
NCT00589563 (14) [back to overview]	Occurrence of Thrombotic Microangiopathy
NCT00589563 (14) [back to overview]	Overall Survival at Two Years Post HSCT
NCT00589563 (14) [back to overview]	Time to Absolute Neutrophil Count Recovery (Engraftment)
NCT00589563 (14) [back to overview]	Time to Platelet Count Recovery (Engraftment)
NCT00589563 (14) [back to overview]	Occurence of Infections Including Cytomegalovirus and Epstein-Barr Virus Reactivation
NCT00589563 (14) [back to overview]	Severity of Acute GVHD
NCT00589563 (14) [back to overview]	Severity of Chronic GVHD
NCT00591630 (1) [back to overview]	Number of Participants With a 2-Year Progression-Free Survival (PFS)
NCT00602641 (4) [back to overview]	Very Good Partial Response (VGPR) Rate
NCT00602641 (4) [back to overview]	Progression-Free Survival (PFS)
NCT00602641 (4) [back to overview]	Change in Functional Assessment of Cancer Therapy-Neurotoxicity Trial Outcome Index (FACT-Ntx TOI) Score From Baseline to Cycle 12
NCT00602641 (4) [back to overview]	Overall Survival
NCT00618540 (8) [back to overview]	Incidence of Chronic GVHD
NCT00618540 (8) [back to overview]	Incidence of Grade II-IV Acute Graft-versus-host-disease (GVHD)
NCT00618540 (8) [back to overview]	Incidence of Grade III-IV Acute Graft-versus-host-disease (GVHD)
NCT00618540 (8) [back to overview]	Neutrophil Engraftment
NCT00618540 (8) [back to overview]	Overall Survival
NCT00618540 (8) [back to overview]	Platelet Engraftment
NCT00618540 (8) [back to overview]	Transplantation-related Death
NCT00618540 (8) [back to overview]	Disease-free Survival at 12 Months Post Transplantation
NCT00635024 (4) [back to overview]	Overall Survival (OS)
NCT00635024 (4) [back to overview]	Hematological Response Rate Defined as the Number of Participants Who Achieve a Confirmed Response
NCT00635024 (4) [back to overview]	Number of Participants With Severe Non-hematological Adverse Events
NCT00635024 (4) [back to overview]	Progression-free Survival (PFS)
NCT00651937 (2) [back to overview]	Mean Symptom Severity Burden as Measured by MDASI Scores
NCT00651937 (2) [back to overview]	Mean Symptom Severity Burden as Measured by MDASI Scores
NCT00661544 (1) [back to overview]	Response Rate
NCT00679367 (3) [back to overview]	Number of Organs Improved or Stable Based on Description Below:
NCT00679367 (3) [back to overview]	Number of Participants With Hematologic Response
NCT00679367 (3) [back to overview]	Number of Participants Removed From Study Due to Toxicities
NCT00683046 (2) [back to overview]	Median Overall Survival
NCT00683046 (2) [back to overview]	Median Disease-free Survival
NCT00689936 (43) [back to overview]	Number of Participants With Adverse Events (AEs) During the Active Treatment Phase
NCT00689936 (43) [back to overview]	Shift From Baseline to Most Extreme Postbaseline Value in Absolute Neutrophil Count During the Active Treatment Phase
NCT00689936 (43) [back to overview]	Shift From Baseline to Most Extreme Postbaseline Value in Creatinine Clearance (CrCl) During the Active Treatment Phase
NCT00689936 (43) [back to overview]	Kaplan Meier Estimates of Time to Treatment Failure (TTF) at the Time of Final Analysis
NCT00689936 (43) [back to overview]	Change From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Health Utility Index Score
NCT00689936 (43) [back to overview]	Kaplan Meier Estimates for Time to Second-line Anti-myeloma Treatment (AMT)
NCT00689936 (43) [back to overview]	Kaplan Meier Estimates of Duration of Myeloma Response as Determined by an Investigator Assessment at Time of Final Analysis
NCT00689936 (43) [back to overview]	Kaplan Meier Estimates of Duration of Myeloma Response as Determined by the IRAC
NCT00689936 (43) [back to overview]	Kaplan Meier Estimates of Overall Survival at the Time of Final Analysis (OS)
NCT00689936 (43) [back to overview]	Kaplan Meier Estimates of Time to Second Line Therapy AMT at the Time of Final Analysis
NCT00689936 (43) [back to overview]	Kaplan Meier Estimates of Time to Treatment Failure (TTF)
NCT00689936 (43) [back to overview]	Shift From Baseline to Most Extreme Postbaseline Value in Platelet Count During the Active Treatment Phase.
NCT00689936 (43) [back to overview]	Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis
NCT00689936 (43) [back to overview]	Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)
NCT00689936 (43) [back to overview]	Percentage of Participants With a Myeloma Response by Adverse Risk Cytogenetic Risk Category Based on IRAC Review.
NCT00689936 (43) [back to overview]	Percentage of Participants With a Myeloma Response by Favorable Hyperdiploidy Risk Cytogenetic Risk Category Based on IRAC Review
NCT00689936 (43) [back to overview]	Percentage of Participants With a Myeloma Response by Normal Risk Cytogenetic Risk Category Based on IRAC Review
NCT00689936 (43) [back to overview]	Percentage of Participants With a Myeloma Response by Uncertain Risk Cytogenetic Risk Category Based on IRAC Review
NCT00689936 (43) [back to overview]	Shift From Baseline to Most Extreme Postbaseline Value in Hemoglobin During the Active Treatment Phase
NCT00689936 (43) [back to overview]	Percentage of Participants With an Objective Response After Second-line Anti-myeloma Treatment at the Time of Final Analysis
NCT00689936 (43) [back to overview]	Percentage of Participants With an Objective Response Based on Investigator Assessment at Time of Final Analysis
NCT00689936 (43) [back to overview]	Percentage of Participants With an Objective Response Based on IRAC Review
NCT00689936 (43) [back to overview]	Time to First Response Based on the Investigator Assessment at the Time of Final Analysis
NCT00689936 (43) [back to overview]	Time to First Response Based on the Review by the IRAC
NCT00689936 (43) [back to overview]	Change From Baseline in the EORTC QLQ-C30 Appetite Loss Domain
NCT00689936 (43) [back to overview]	Change From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain
NCT00689936 (43) [back to overview]	Change From Baseline in the EORTC QLQ-C30 Constipation Domain
NCT00689936 (43) [back to overview]	Change From Baseline in the EORTC QLQ-C30 Diarrhea Domain
NCT00689936 (43) [back to overview]	Change From Baseline in the EORTC QLQ-C30 Dyspnea Domain
NCT00689936 (43) [back to overview]	Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain
NCT00689936 (43) [back to overview]	Change From Baseline in the EORTC QLQ-C30 Fatigue Domain
NCT00689936 (43) [back to overview]	Change From Baseline in the EORTC QLQ-C30 Financial Difficulties Domain
NCT00689936 (43) [back to overview]	Change From Baseline in the EORTC QLQ-C30 Insomnia Domain
NCT00689936 (43) [back to overview]	Change From Baseline in the EORTC QLQ-C30 Nausea/Vomiting Domain
NCT00689936 (43) [back to overview]	Change From Baseline in the EORTC QLQ-C30 Pain Domain
NCT00689936 (43) [back to overview]	Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain
NCT00689936 (43) [back to overview]	Change From Baseline in the EORTC QLQ-C30 Role Functioning Domain
NCT00689936 (43) [back to overview]	Change From Baseline in the EORTC QLQ-C30 Social Functioning Domain
NCT00689936 (43) [back to overview]	Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain
NCT00689936 (43) [back to overview]	Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Body Image Scale
NCT00689936 (43) [back to overview]	Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale
NCT00689936 (43) [back to overview]	Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale
NCT00689936 (43) [back to overview]	Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Side Effects Treatment Scale
NCT00691015 (8) [back to overview]	Severity of Acute Graft-versus-host Disease (GVHD)
NCT00691015 (8) [back to overview]	Safety, as Defined by Serious Adverse Events and Adverse Events Related to Study Treatment.
NCT00691015 (8) [back to overview]	Overall Survival.
NCT00691015 (8) [back to overview]	Karnofsky Performance Status Performance Status
NCT00691015 (8) [back to overview]	Incidence of Infections, Including Bacterial, Fungal, and Viral Infections (i.e., CMV and EBV Reactivation, Including Post-transplant Lymphoproliferative Disorders)
NCT00691015 (8) [back to overview]	Incidence of Chronic GVHD.
NCT00691015 (8) [back to overview]	Incidence of Acute Graft-versus-host Disease (GVHD)
NCT00691015 (8) [back to overview]	Time to Engraftment (i.e., Absolute Neutrophil Recovery [ANC > 500/mm³] )
NCT00691704 (5) [back to overview]	Time to Response
NCT00691704 (5) [back to overview]	Overall Survival
NCT00691704 (5) [back to overview]	Time to Progression
NCT00691704 (5) [back to overview]	Progression Free Survival
NCT00691704 (5) [back to overview]	Duration of Response
NCT00695409 (8) [back to overview]	Number of Patients With RIT/ZBEAM Developing Therapy Induced MDS and AML
NCT00695409 (8) [back to overview]	Time to Platelet Recovery
NCT00695409 (8) [back to overview]	Time to Neutrophil Recovery
NCT00695409 (8) [back to overview]	Number of Patients With Active Disease at ASCT Achieving CR/PR by Day 100 After ASCT
NCT00695409 (8) [back to overview]	2-Year Progression-Free Survival
NCT00695409 (8) [back to overview]	2-Year Cumulative Incidence of Progression
NCT00695409 (8) [back to overview]	100-Day Treatment-Related Mortality
NCT00695409 (8) [back to overview]	2-Year Overall Survival
NCT00734149 (3) [back to overview]	Median Duration of Response
NCT00734149 (3) [back to overview]	Response
NCT00734149 (3) [back to overview]	Number of Patients With Any Grade or Severe Adverse Event
NCT00743288 (5) [back to overview]	Time to Progression
NCT00743288 (5) [back to overview]	Overall Response Rate (ORR) and Clinical Benefit Rate (CBR) [ORR= Complete Response (CR) + Very Good Partial Response (VGPR) + Partial Response (PR)]; CBR=ORR + Minimal Response (MR)] Following Treatment With Panobinostat and Melphalan
NCT00743288 (5) [back to overview]	Duration of Response
NCT00743288 (5) [back to overview]	Maximum Tolerated Dose (MTD)
NCT00743288 (5) [back to overview]	MTD
NCT00744692 (9) [back to overview]	To Describe the Incidence of Grade 3-4 Organ Toxicity
NCT00744692 (9) [back to overview]	To Describe the Pace of Neutrophil Recovery
NCT00744692 (9) [back to overview]	To Describe the Pace of Platelet Recovery
NCT00744692 (9) [back to overview]	To Determine the Overall Survival at day180 Post-transplant
NCT00744692 (9) [back to overview]	To Evaluate Long-term Complications, Such as Sterility, Endocrinopathy, and Growth Failure
NCT00744692 (9) [back to overview]	To Describe Incidence of Acute Graft Versus Host Disease (GVHD) (II - IV)
NCT00744692 (9) [back to overview]	To Evaluate the Incidence of Late Graft Failures at 2 Years Post-transplant
NCT00744692 (9) [back to overview]	To Evaluate the Pace of Immune Reconstitution.
NCT00744692 (9) [back to overview]	Determine the Feasibility of Attaining Acceptable Rates of Donor Cell Engraftment (>25% Donor Cells at 180 Days) Following RIC Regimens in Children < 21 Years Receiving UCBT for Non-malignant Disorders.
NCT00784823 (1) [back to overview]	The Maximum Tolerated Dose of Bortezomib (MTD)
NCT00789256 (1) [back to overview]	Response Rate of the Combination of Bortezomib and Melphalan in Patients With AML and High-risk MDS.
NCT00790647 (4) [back to overview]	Number of Participants Surviving at 2 Years
NCT00790647 (4) [back to overview]	Number of Participants With Hematologic Response
NCT00790647 (4) [back to overview]	Number of Participants Surviving at 1 Year
NCT00790647 (4) [back to overview]	Number of Participants Surviving at 100 Days From Transplant
NCT00792142 (3) [back to overview]	One Year Overall Survival
NCT00792142 (3) [back to overview]	One Year Progression-free Survival (PFS)
NCT00792142 (3) [back to overview]	Number of Participants With Adverse Events
NCT00793572 (6) [back to overview]	Number of Patients Surviving Progression-free
NCT00793572 (6) [back to overview]	Number of Patients Surviving Overall
NCT00793572 (6) [back to overview]	Number of Patients With Chronic GVHD
NCT00793572 (6) [back to overview]	Number of Patients With Grade II-IV Acute GVHD
NCT00793572 (6) [back to overview]	Number of Patients With Non-relapse Mortality
NCT00793572 (6) [back to overview]	Number of Patients With Toxicities Related to Bortezomib Maintenance Therapy
NCT00793650 (2) [back to overview]	Safety and Engraftment
NCT00793650 (2) [back to overview]	Response Rate Using EBMT(European Group for Blood and Bone Marrow Transplan) Criteria at Day +100 After Transplant.
NCT00807599 (2) [back to overview]	Progression Free Survival (PFS) Rate at 2 Years After Enrollment in Untreated Patients With Multiple Myeloma.
NCT00807599 (2) [back to overview]	Overall Survival
NCT00827099 (2) [back to overview]	Number of Patients That Engrafted Blood Counts by 30 Days After Transplant
NCT00827099 (2) [back to overview]	Number of Participants With 100 Day Transplant-related Mortality (TRM)
NCT00856388 (8) [back to overview]	Rate of Complete Donor Chimerism - Blood
NCT00856388 (8) [back to overview]	Median Time to Platelet Engraftment
NCT00856388 (8) [back to overview]	Day 100 TRM
NCT00856388 (8) [back to overview]	Acute GVHD Grade III-IV
NCT00856388 (8) [back to overview]	3 yr Overall Survival
NCT00856388 (8) [back to overview]	1 yr Extenstive Chronic GVHD
NCT00856388 (8) [back to overview]	Median Time to ANC Engraftment
NCT00856388 (8) [back to overview]	Rate of Complete Donor Chimerism - Blood
NCT00890552 (4) [back to overview]	Duration of Response
NCT00890552 (4) [back to overview]	Event-free Survival (EFS)
NCT00890552 (4) [back to overview]	Overall Survival (OS)
NCT00890552 (4) [back to overview]	Hematologic Response Rate
NCT00899847 (8) [back to overview]	Overall Response Rate (ORR)
NCT00899847 (8) [back to overview]	Overall Survival (OS)
NCT00899847 (8) [back to overview]	Partial Response Rate (PRR)
NCT00899847 (8) [back to overview]	Median Time to Engraftment After Allo-PBSC Transplant
NCT00899847 (8) [back to overview]	Median Time to Engraftment After Auto-PBSC Transplant
NCT00899847 (8) [back to overview]	Event-free Survival (EFS)
NCT00899847 (8) [back to overview]	Complete Response Rate (CRR)
NCT00899847 (8) [back to overview]	Incidence of Graft Versus Host Disease (GvHD)
NCT00911859 (9) [back to overview]	Overall Survival
NCT00911859 (9) [back to overview]	Duration of Response (DOR)
NCT00911859 (9) [back to overview]	Change From Baseline to Cycle 9 in Global Health Status/Quality of Life Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30)
NCT00911859 (9) [back to overview]	1-year Survival Rate
NCT00911859 (9) [back to overview]	1-year Progression-Free Survival (PFS) Rate
NCT00911859 (9) [back to overview]	Percentage of Participants Who Achieved Overall Response ie, Complete Response (CR) or Partial Response (PR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria
NCT00911859 (9) [back to overview]	Progression-Free Survival (PFS)
NCT00911859 (9) [back to overview]	Percentage of Participants Who Achieved Stringent Complete Response (sCR) - International Myeloma Working Group (IMWG) Criteria
NCT00911859 (9) [back to overview]	Percentage of Participants Who Achieved Complete Response (CR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria
NCT00916058 (6) [back to overview]	Progression-Free Survival (Phase 1)
NCT00916058 (6) [back to overview]	Overall Survival at 3 Years (Phase 2)
NCT00916058 (6) [back to overview]	Overall Response Rate (Phase 2) - Number of Participants Achieving at Least a Partial Response or Better in Disease Status at Day 100 Post-transplant
NCT00916058 (6) [back to overview]	Progression-Free Survival (Phase 2)
NCT00916058 (6) [back to overview]	Maximum Tolerated Dose (Phase 1)
NCT00916058 (6) [back to overview]	Overall Survival at 2 Years (Phase 1)
NCT00925782 (4) [back to overview]	Area Under the Curve (0-t)
NCT00925782 (4) [back to overview]	Concentration-Max (Cmax)
NCT00925782 (4) [back to overview]	Determination of Engraftment Following Melphalan-alkeran Sequence and Alkeran-melphalan Sequence Followed by ASCT
NCT00925782 (4) [back to overview]	Determination of Myeloablation Following Melphalan-alkeran Sequence and Alkeran-melphalan Sequence Followed by ASCT
NCT00943592 (8) [back to overview]	Number of Participants With Skin Adverse Events During the Conditioning Regimen Prior to Stem Cell Transplantation
NCT00943592 (8) [back to overview]	Treatment-related Mortality (TRM)
NCT00943592 (8) [back to overview]	Number of Participants With Renal Adverse Events During the Conditioning Regimen Prior to Stem Cell Transplantation
NCT00943592 (8) [back to overview]	Number of Participants With Other Adverse Events During the Conditioning Regimen Prior to Stem Cell Transplantation
NCT00943592 (8) [back to overview]	Number of Participants With Hepatic Adverse Events During the Conditioning Regimen Prior to Stem Cell Transplantation
NCT00943592 (8) [back to overview]	Relapse Rate
NCT00943592 (8) [back to overview]	Progression-free Survival (PFS)
NCT00943592 (8) [back to overview]	Overall Survival (OS)
NCT00943800 (3) [back to overview]	Percentage of Participants With Incidence of Acute (Grade II-IV) and Chronic Graft-vs-host Disease(GVHD)
NCT00943800 (3) [back to overview]	Overall Survival- Percentage of Participants Who Survived at 2 Years and 5 Years
NCT00943800 (3) [back to overview]	Percentage of Participants With Neutrophil Engraftment
NCT00948922 (3) [back to overview]	Progression Free Survival (PFS)
NCT00948922 (3) [back to overview]	Percentage of Participants With Acute or Chronic Graft-versus-host Disease (GVHD) Following Transplant
NCT00948922 (3) [back to overview]	Overall Survival (OS) Rate
NCT00985907 (1) [back to overview]	Number of Participants With Dose Limiting Toxicities (DLT) (Phase 1)
NCT00985959 (7) [back to overview]	Number of Participants With Dose Limiting Toxicity During the Phase I (Cycle 1)
NCT00985959 (7) [back to overview]	Number of Participants With Overall Response (Complete Response [CR] + Partial Response [PR]) - Phase I and II
NCT00985959 (7) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Melphalan - Phase I
NCT00985959 (7) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Prednisolone - Phase I
NCT00985959 (7) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Bortezomib (JNJ-26866138 Alone) - Phase I
NCT00985959 (7) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Bortezomib (JNJ-26866138 in Combination With Melphalan and Prednisolone) - Phase I
NCT00985959 (7) [back to overview]	Median Time to First Response - Phase II
NCT00992446 (4) [back to overview]	Event-free Survival
NCT00992446 (4) [back to overview]	Overall Survival
NCT00992446 (4) [back to overview]	Median Time to Disease Progression
NCT00992446 (4) [back to overview]	Toxicity of Vorinostat Bortezomib Maintenance Therapy After Autologous Transplant
NCT01005576 (4) [back to overview]	Median Time to Platelet Engraftment
NCT01005576 (4) [back to overview]	Primary Objective: Event-free Survival at 1 Year.
NCT01005576 (4) [back to overview]	Incidence of Disease Recurrence
NCT01005576 (4) [back to overview]	Median Time to ANC Engraftment
NCT01008462 (7) [back to overview]	Event-Free Survival (EFS)
NCT01008462 (7) [back to overview]	Number of Patients Who Engrafted
NCT01008462 (7) [back to overview]	Number of Patients With Grade II-IV Acute Graft-versus-Host-Disease and/or Chronic Extensive Graft-versus-Host-Disease
NCT01008462 (7) [back to overview]	Non-relapse Mortality (NRM)
NCT01008462 (7) [back to overview]	Overall Survival
NCT01008462 (7) [back to overview]	Number of Patients With Relapsed/Progressive Disease
NCT01008462 (7) [back to overview]	Number of Patients Who Had Infections
NCT01010217 (6) [back to overview]	Number of Participants With Non-relapse Mortality (NRM)
NCT01010217 (6) [back to overview]	Number of Participants With Non Related Mortality (NRM)
NCT01010217 (6) [back to overview]	Disease Free Survival
NCT01010217 (6) [back to overview]	cGVHD
NCT01010217 (6) [back to overview]	Engraftments
NCT01010217 (6) [back to overview]	Grade III-IV aGVHD
NCT01035463 (3) [back to overview]	Event-free Survival
NCT01035463 (3) [back to overview]	Overall Survival
NCT01035463 (3) [back to overview]	Maximum Tolerated Dose of Lenalidomide (Phase I)
NCT01045460 (5) [back to overview]	Response Rates by Blade Criteria
NCT01045460 (5) [back to overview]	Safety as Measured by Grade 3-5 Adverse Events
NCT01045460 (5) [back to overview]	Overall Survival
NCT01045460 (5) [back to overview]	Progression-free Survival
NCT01045460 (5) [back to overview]	Feasibility as Measured by Participant Withdrawal or Removal
NCT01050764 (6) [back to overview]	Serious Infections
NCT01050764 (6) [back to overview]	Overall Survival (OS), 1 Year
NCT01050764 (6) [back to overview]	Median Overall Survival (OS)
NCT01050764 (6) [back to overview]	Maximum-tolerated Dose (MTD) of Regulatory and Conventional T-cells
NCT01050764 (6) [back to overview]	Acute Graft-versus-Host-Disease (aGvHD)
NCT01050764 (6) [back to overview]	To Measure the Incidence and Severity of Acute and Chronic GvHD
NCT01078454 (1) [back to overview]	Proportion of Patients With Hematologic Overall Response (Partial Response [PR]+ Very Good PR [VGPR]+ Amyloid Complete Response [ACR]+ Stringent Complete Response [sCR]) After 3 Months (3 Cycles) of Therapy
NCT01079936 (4) [back to overview]	Number of Participants With Response (CR at Day 90)
NCT01079936 (4) [back to overview]	Participants With Grade 3 =/> Adverse Events
NCT01079936 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Lenalidomide
NCT01079936 (4) [back to overview]	Number of Participants With Day 30 DLT (Overall Study, Phase I/Phase II)
NCT01083316 (4) [back to overview]	Number of Participants Surviving at 5 Years
NCT01083316 (4) [back to overview]	Number of Participants With Disease Response
NCT01083316 (4) [back to overview]	Number of Participants Proceeding to Transplant Following Induction
NCT01083316 (4) [back to overview]	Number of Participants Surviving at 100 Days Post Transplant
NCT01119066 (6) [back to overview]	Survival and Disease-free Survival (DFS)
NCT01119066 (6) [back to overview]	Number of Participants With Acute and Chronic GVHD Following T-cell Depleted, CD34+ Progenitor Cell Enriched Transplants Fractionated by the CliniMACS System.
NCT01119066 (6) [back to overview]	Survival and Disease-free Survival (DFS)
NCT01119066 (6) [back to overview]	Survival and Disease-free Survival (DFS)
NCT01119066 (6) [back to overview]	The Incidence of Durable Hematopoietic Engraftment for T-cell Depleted Transplants Fractionated by the CliniMACS System Administered After Each of the Four Disease Targeted Cytoreduction Regimens.
NCT01119066 (6) [back to overview]	Incidence of Non-relapse Mortality (Transplant-related Mortality) Following Each Cytoreduction Regimen and a Transplant Fractionated by the CliniMACS System.
NCT01131169 (2) [back to overview]	Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS)
NCT01131169 (2) [back to overview]	Proportion of Participants With Relapsed Multiple Myeloma Alive at 2 Years
NCT01141712 (12) [back to overview]	Immunologic Reconstitution
NCT01141712 (12) [back to overview]	HIV Single-Copy Polymerase Chain Reaction (PCR)
NCT01141712 (12) [back to overview]	Hematologic Function
NCT01141712 (12) [back to overview]	Complete Remission (CR) and/or Partial Response (PR)
NCT01141712 (12) [back to overview]	Relapse/Progression
NCT01141712 (12) [back to overview]	Treatment-Related Mortality (TRM)
NCT01141712 (12) [back to overview]	Progression-Free Survival (PFS)
NCT01141712 (12) [back to overview]	Number of Participants Experiencing Toxicity
NCT01141712 (12) [back to overview]	Number of Participants Experiencing Infections
NCT01141712 (12) [back to overview]	Cumulative Incidence of Platelet Recovery
NCT01141712 (12) [back to overview]	Cumulative Incidence of Neutrophil Recovery
NCT01141712 (12) [back to overview]	Overall Survival (OS)
NCT01142232 (3) [back to overview]	Phase I: Number of Patients With Dose Limiting Toxicity
NCT01142232 (3) [back to overview]	Phase II: Treatment-Related Adverse Events Grade 3 or Higher
NCT01142232 (3) [back to overview]	Phase II: Overall Response Rate
NCT01175356 (3) [back to overview]	Percentage of MIBG Avid Patients Treated With Meta-iodobenxylguanide (MIBG) Labeled With Iodine-131
NCT01175356 (3) [back to overview]	Percentage of MIBG Avid Patients Treated With MIBG Labeled With Iodine-131 and Bu/Mel Chemotherapy
NCT01175356 (3) [back to overview]	Incidence of Unacceptable Toxicity and Sinusoidal Obstruction Syndrome (SOS), Assessed by Common Terminology Criteria (CTV)v.4.0 for Toxicity Assessment and Grading for I-MIBG
NCT01200329 (2) [back to overview]	Overall Survival (OS) of These Patients.
NCT01200329 (2) [back to overview]	Event-free Survival (EFS) of Patients
NCT01237951 (4) [back to overview]	Overall Survival
NCT01237951 (4) [back to overview]	Participants Who Had Measurable Disease at Time of Transplant and Achieved a Stringent Complete Remission
NCT01237951 (4) [back to overview]	Progression-free Survival (PFS)
NCT01237951 (4) [back to overview]	Percent of Participants Dying From Treatment-Related Complications
NCT01242267 (4) [back to overview]	Treatment Free Interval/PFS
NCT01242267 (4) [back to overview]	Toxicity Assessment
NCT01242267 (4) [back to overview]	Maximum Tolerated Dose of Thalidomide
NCT01242267 (4) [back to overview]	Complete Response (CR) and Very Good Partial Response (VgPR) Rate
NCT01256398 (6) [back to overview]	Feasibility of Maintenance Therapy in This Patient Population (Restricted to Those Patients Achieving a CR). Feasibility Will be Defined as the Number of Deaths Ocuring.
NCT01256398 (6) [back to overview]	Disease Free Survival Defined From the Date of First Induction Complete Response (CR) to Relapse or Death Due to Any Cause
NCT01256398 (6) [back to overview]	Disease Free Survival (DFS)
NCT01256398 (6) [back to overview]	Probability of Being BCR-ABL Negative in the Bone Marrow and Peripheral Blood at the Completion of the CNS Prophylaxis Course (Restricted to Those Patients Achieving a CR)
NCT01256398 (6) [back to overview]	Overall Survival (OS)
NCT01256398 (6) [back to overview]	Response
NCT01293539 (1) [back to overview]	Number of Patients Who Complete Therapy Without the Need for Additional Treatment Including Systemic Chemotherapy, External Beam Radiation, or Enucleation.
NCT01323517 (3) [back to overview]	Progression Free Survival at One Year.
NCT01323517 (3) [back to overview]	To Define the Immunologic Events and Signatures at the Tumor Site and in the Periphery That Corresponds to Response to Ipilimumab.
NCT01323517 (3) [back to overview]	Toxicity of Additional Ipilimumab Will be Evaluated for All Treated Patients Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0
NCT01335685 (27) [back to overview]	AUCtau: Area Under the Plasma Concentration-time Curve Over the Dosing Interval for Ixazomib (Phase 1)
NCT01335685 (27) [back to overview]	AUCtau: Area Under the Plasma Concentration-time Curve Over the Dosing Interval for Ixazomib (Phase 1)
NCT01335685 (27) [back to overview]	Terminal Elimination Rate Constant (λz) for Ixazomib (Phase 1)
NCT01335685 (27) [back to overview]	AUCtau: Area Under the Plasma Concentration-time Curve Over the Dosing Interval for Ixazomib (Phase 1)
NCT01335685 (27) [back to overview]	Time to Progression (TTP) (Phase 2)
NCT01335685 (27) [back to overview]	Time to First Response (Phase 2)
NCT01335685 (27) [back to overview]	Progression Free Survival (Phase 2)
NCT01335685 (27) [back to overview]	Overall Survival (Phase 2)
NCT01335685 (27) [back to overview]	Overall Response Rate (ORR)
NCT01335685 (27) [back to overview]	Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Ixazomib (Phase 1)
NCT01335685 (27) [back to overview]	Duration of Response (DOR) (Phase 2)
NCT01335685 (27) [back to overview]	Very Good Partial Response (VGPR) or Better Response Rate (Phase 2)
NCT01335685 (27) [back to overview]	Terminal Phase Elimination Half-life (T1/2) for Ixazomib (Phase 1)
NCT01335685 (27) [back to overview]	Terminal Phase Elimination Half-life (T1/2) for Ixazomib (Phase 1)
NCT01335685 (27) [back to overview]	Terminal Phase Elimination Half-life (T1/2) for Ixazomib (Phase 1)
NCT01335685 (27) [back to overview]	Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib (Phase 1)
NCT01335685 (27) [back to overview]	Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib (Phase 1)
NCT01335685 (27) [back to overview]	Terminal Elimination Rate Constant (λz) for Ixazomib (Phase 1)
NCT01335685 (27) [back to overview]	Terminal Elimination Rate Constant (λz) for Ixazomib (Phase 1)
NCT01335685 (27) [back to overview]	Observed Accumulation Ratio for AUCtau (Rac) (Phase 1)
NCT01335685 (27) [back to overview]	Observed Accumulation Ratio for AUCtau (Rac) (Phase 1)
NCT01335685 (27) [back to overview]	Observed Accumulation Ratio for AUCtau (Rac) (Phase 1)
NCT01335685 (27) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
NCT01335685 (27) [back to overview]	Cmax: Maximum Observed Plasma Concentration for Ixazomib (Phase 1)
NCT01335685 (27) [back to overview]	Cmax: Maximum Observed Plasma Concentration for Ixazomib (Phase 1)
NCT01335685 (27) [back to overview]	Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib (Phase 1)
NCT01335685 (27) [back to overview]	Cmax: Maximum Observed Plasma Concentration for Ixazomib (Phase 1)
NCT01339910 (10) [back to overview]	Number of Participants With Donor Cell Engraftment
NCT01339910 (10) [back to overview]	Percentage of Participants With Neutrophil and Platelet Engraftment
NCT01339910 (10) [back to overview]	Percentage of Participants With Acute Graft Versus Host Disease (GVHD)
NCT01339910 (10) [back to overview]	Percentage of Participants With Treatment-related Mortality
NCT01339910 (10) [back to overview]	Percentage of Participants With Relapse-Free Survival (RFS)
NCT01339910 (10) [back to overview]	Percentage of Participants With Overall Survival (OS)
NCT01339910 (10) [back to overview]	Percentage of Participants With Chronic GVHD
NCT01339910 (10) [back to overview]	Number of Participants With Secondary Graft Failure
NCT01339910 (10) [back to overview]	Number of Participants With Primary Graft Failure
NCT01339910 (10) [back to overview]	Percentage of Participants With Disease Relapse
NCT01408563 (12) [back to overview]	1 Year Relapse Rate
NCT01408563 (12) [back to overview]	100-day Treatment Related Mortality
NCT01408563 (12) [back to overview]	Immune Reconstitution - Median CD4 Count at 12 Months
NCT01408563 (12) [back to overview]	Median Thrombopoietin Levels After Transplant
NCT01408563 (12) [back to overview]	Median Time to Neutrophil Engraftment
NCT01408563 (12) [back to overview]	Median Time to Platelet Engraftment
NCT01408563 (12) [back to overview]	Number of Participants With Primary Graft Failure
NCT01408563 (12) [back to overview]	Rate of Post-transplant Lymphoma
NCT01408563 (12) [back to overview]	Rates of Grade II-IV and Grade III-IV Acute Graft Versus Host Disease (GVHD) at 100 Days
NCT01408563 (12) [back to overview]	Relapse-free Survival
NCT01408563 (12) [back to overview]	Overall Survival
NCT01408563 (12) [back to overview]	The Rate of Chronic GVHD
NCT01410344 (7) [back to overview]	Chimerism
NCT01410344 (7) [back to overview]	Percentage of Participants With Overall Survival
NCT01410344 (7) [back to overview]	Percentage of Participants With Non-Relapse Mortality
NCT01410344 (7) [back to overview]	Percentage of Participants Recovering Hematologic Function
NCT01410344 (7) [back to overview]	Percentage of Participants With Relapse/Progression
NCT01410344 (7) [back to overview]	Percentage of Participants With Chronic Graft-Versus-Host Disease (GVHD)
NCT01410344 (7) [back to overview]	Percentage of Participants With Acute Graft-Versus-Host Disease (GVHD)
NCT01413178 (5) [back to overview]	Number of Participants That Had Grade 3-4 Toxicities.
NCT01413178 (5) [back to overview]	Number of Participants With Complete Response (CR)
NCT01413178 (5) [back to overview]	Progression-Free Survival (PFS)
NCT01413178 (5) [back to overview]	Treatment-Related Mortality (TRM) Between 2 Arms.
NCT01413178 (5) [back to overview]	Overall Survival (OS)
NCT01453088 (2) [back to overview]	Progression Free Survival Rate
NCT01453088 (2) [back to overview]	Overall Survival Rate
NCT01453101 (3) [back to overview]	Progression Free Survival
NCT01453101 (3) [back to overview]	Overall Survival (OS)
NCT01453101 (3) [back to overview]	Overall Response Rate
NCT01499147 (4) [back to overview]	Number of Participants With Moderate to Severe (Grade 2-4) Acute Graft Versus Host Disease (GVHD).
NCT01499147 (4) [back to overview]	Number of Participants With Engraftment.
NCT01499147 (4) [back to overview]	Time to ANC and Platelet Engraftment
NCT01499147 (4) [back to overview]	Participants With 100 Day Transplant-related Mortality.
NCT01518153 (2) [back to overview]	Overall Survival (OS)
NCT01518153 (2) [back to overview]	Success Rate
NCT01529827 (4) [back to overview]	Clinical Response
NCT01529827 (4) [back to overview]	Median Time to Neutrophil Engraftment
NCT01529827 (4) [back to overview]	Transplant Related Mortality (TRM)
NCT01529827 (4) [back to overview]	Progression Free Survival (PFS) at One Year
NCT01538472 (2) [back to overview]	Overall Survival Median
NCT01538472 (2) [back to overview]	3-Year Overall Survival
NCT01548573 (4) [back to overview]	Event-Free Survival (EFS)
NCT01548573 (4) [back to overview]	Overall Survival
NCT01548573 (4) [back to overview]	Identification of Drug Resistant Genes
NCT01548573 (4) [back to overview]	Number of Grade 3 Non-hematologic and Grade 4 Hematologic Serious Adverse Events Associated With the Addition of Bortezomib, Thalidomide, and Dexamethasone Into Autologous Transplant Regimens.
NCT01605032 (5) [back to overview]	Overall Response Rate
NCT01605032 (5) [back to overview]	Mortality
NCT01605032 (5) [back to overview]	Rate of Complete Response as Determined by the IMWG Criteria
NCT01605032 (5) [back to overview]	Progression-free Survival
NCT01605032 (5) [back to overview]	Overall Survival
NCT01626092 (2) [back to overview]	Transplant-Related Mortality
NCT01626092 (2) [back to overview]	Donor (Allogeneic) Hematopoietic Engraftment
NCT01653418 (9) [back to overview]	Number of Participants With Overall Survival (OS)
NCT01653418 (9) [back to overview]	Number of Participants With Progression-free Survival (PFS)
NCT01653418 (9) [back to overview]	Time to Platelet Engraftment After V-BEAM.
NCT01653418 (9) [back to overview]	Overall Response Rate (ORR)
NCT01653418 (9) [back to overview]	Toxicity of V-BEAM
NCT01653418 (9) [back to overview]	Very Good Partial Response Rate (VGPR+nCR+sCR+CR)
NCT01653418 (9) [back to overview]	Complete Response Rate (Complete Response + Stringent Complete Response)
NCT01653418 (9) [back to overview]	Time to Neutrophil Engraftment After V-BEAM.
NCT01653418 (9) [back to overview]	Treatment Related Mortality (TRM) of V-BEAM
NCT01658904 (2) [back to overview]	Engraftment Failure Transplant Related Mortality
NCT01658904 (2) [back to overview]	Number of Participants With Adverse Events
NCT01659658 (21) [back to overview]	Change From Baseline in Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) Score at Week 28 of the PFS Follow-up
NCT01659658 (21) [back to overview]	Change From Baseline in SF-36 Physical Component Summary Score at Week 28 of the PFS Follow-up
NCT01659658 (21) [back to overview]	Duration of Hematologic Response
NCT01659658 (21) [back to overview]	EuroQol 5-Dimension 3-Level (EQ-5D-3L) Visual Analogue Scale Score
NCT01659658 (21) [back to overview]	Number of Hospitalizations
NCT01659658 (21) [back to overview]	Number of Participants With Serious Adverse Events (SAEs)
NCT01659658 (21) [back to overview]	Overall Survival
NCT01659658 (21) [back to overview]	Percentage of Participants With Best Vital Organ (Cardiac and/or Kidney) Response
NCT01659658 (21) [back to overview]	Percentage of Participants With Complete Hematologic Response
NCT01659658 (21) [back to overview]	Percentage of Participants With Overall Hematologic Response
NCT01659658 (21) [back to overview]	Hematologic Disease Progression Free Survival
NCT01659658 (21) [back to overview]	Progression Free Survival (PFS)
NCT01659658 (21) [back to overview]	2-Year Vital Organ (Heart or Kidney) Deterioration and Mortality Rate
NCT01659658 (21) [back to overview]	Change From Baseline in 36-item Short Form General Health Survey (SF-36) Mental Component Summary Score at Week 28 of the PFS Follow-up
NCT01659658 (21) [back to overview]	Change From Baseline in Amyloidosis Symptom Scale Total Score at Week 28 of the PFS Follow-up
NCT01659658 (21) [back to overview]	Plasma Concentration of Ixazomib
NCT01659658 (21) [back to overview]	Number of Participants in Each Category of the EuroQol 5-Dimensional (EQ-5D) Questionnaire Score
NCT01659658 (21) [back to overview]	Vital Organ Progression Free Survival
NCT01659658 (21) [back to overview]	Time to Vital Organ (Heart or Kidney) Deterioration and Mortality Rate
NCT01659658 (21) [back to overview]	Time To Treatment Failure (TTF)
NCT01659658 (21) [back to overview]	Time To Subsequent Anticancer Treatment
NCT01690143 (5) [back to overview]	Maximum Tolerated Dose (MTD) of Carfilzomib Plus Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Relapsed Multiple Myeloma(MM) [Phase I Portion of Study]
NCT01690143 (5) [back to overview]	Frequency of Grades 3 and 4 Non-hematologic Adverse Events During the Transplant Component ( 135 Days)
NCT01690143 (5) [back to overview]	Complete Response (CR) Rate.
NCT01690143 (5) [back to overview]	Median Time for Neutrophil and Platelet Engraftment.
NCT01690143 (5) [back to overview]	Very Good Partial Response (VGPR) Rate.
NCT01702961 (3) [back to overview]	Median Days to Neutrophil Engraftment
NCT01702961 (3) [back to overview]	Disease-free Survival
NCT01702961 (3) [back to overview]	Number of Participants With Overall Best Response Achieved After Transplantation
NCT01731886 (5) [back to overview]	Complete Response Rate
NCT01731886 (5) [back to overview]	Overall Survival Rate (OS)
NCT01731886 (5) [back to overview]	Progression Free Survival (PFS)
NCT01731886 (5) [back to overview]	Progression Free Survival (PFS)
NCT01731886 (5) [back to overview]	Overall Survival Rate (OS)
NCT01746173 (2) [back to overview]	Induction Response
NCT01746173 (2) [back to overview]	24-month Progression-Free Survival Rate
NCT01798004 (1) [back to overview]	The Tolerability of BuMel Regimen
NCT01807611 (6) [back to overview]	Overall Survival
NCT01807611 (6) [back to overview]	Number of Transplant Recipients With Successful Engraftment
NCT01807611 (6) [back to overview]	Number of Transplant Recipients With Malignant Relapse
NCT01807611 (6) [back to overview]	Number of Transplant Recipients With Acute and/or Chronic Graft Versus Host Disease (GVHD)
NCT01807611 (6) [back to overview]	Event-free Survival
NCT01807611 (6) [back to overview]	Number of Transplant Recipients With Transplant-related Mortality (TRM)
NCT01818752 (7) [back to overview]	Number of Participants With Adverse Events
NCT01818752 (7) [back to overview]	European Organisation for Research and Treatment of Cancer Quality of Life Core Module (EORTC QLQ-C30) Global Health Status/Quality of Life (QOL) Scores
NCT01818752 (7) [back to overview]	Progression-Free Survival (PFS)
NCT01818752 (7) [back to overview]	Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy
NCT01818752 (7) [back to overview]	Overall Survival (OS)
NCT01818752 (7) [back to overview]	Overall Response Rate
NCT01818752 (7) [back to overview]	Complete Response Rate
NCT01824693 (4) [back to overview]	Percent Probability of Event-free Survival (EFS)
NCT01824693 (4) [back to overview]	Number of Participants Who Experience Treatment-Related Mortality (TRM) by Day 100
NCT01824693 (4) [back to overview]	Percent Probability of 18 Months-relapse Event Between Arms
NCT01824693 (4) [back to overview]	Percentage of Participants Who Experience Primary Graft Failure Event Between Arms
NCT01842308 (5) [back to overview]	Complete Response Rate at Day 100
NCT01842308 (5) [back to overview]	Adverse Event Rate, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
NCT01842308 (5) [back to overview]	Progression Free Percentage at 1 and 2 Years Post Registration
NCT01842308 (5) [back to overview]	Percentage of Patients With Complete Responses, Defined as a Complete Response Noted as the Objective Status on Two Consecutive Evaluations (Phase II)
NCT01842308 (5) [back to overview]	Determine Maximum Tolerated Dose by the Number of Patients With a DLT Per Dose Level
NCT01849783 (4) [back to overview]	Percentage of Participants Able to Complete Full Course Therapy
NCT01849783 (4) [back to overview]	Median Progression Free Survival (mPFS)
NCT01849783 (4) [back to overview]	Mean Change in Quality-Of-Life Indicators Post-Transplant
NCT01849783 (4) [back to overview]	Percentage of Participants With Serious Treatment-Related Complications
NCT01857934 (6) [back to overview]	Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)]
NCT01857934 (6) [back to overview]	Local Failure Rate and Pattern of Failure
NCT01857934 (6) [back to overview]	Feasibility of Delivering hu14.18K322A to 6 Cycles of Induction Therapy
NCT01857934 (6) [back to overview]	Event-free Survival (EFS)
NCT01857934 (6) [back to overview]	Dose Limiting Toxicity (DLT) or Severe (Grade 3 or 4) VOD With hu14.18K322A With Allogeneic NK Cells in Consolidation
NCT01857934 (6) [back to overview]	Dose Limiting Toxicity (DLT)
NCT01875237 (8) [back to overview]	Number of Participants Assessed Post Donor Lymphocyte Infusion (DLI): Disease-free Survival & Non-relapse Mortality, Chimerism and GVHD.
NCT01875237 (8) [back to overview]	To Assess the Incidence of Acute GvHD Flare After CR/PR Requiring Additional Agent for Systemic Therapy Before Day 56 Post-administration of AP1903.
NCT01875237 (8) [back to overview]	To Evaluate the Safety of Donor Lymphocyte Infusion Followed by Dimerizer Drug, AP1903 by Number of Participants With Adverse Events.
NCT01875237 (8) [back to overview]	To Assess Post Donor Lymphocyte Infusion (DLI) Chimerism
NCT01875237 (8) [back to overview]	To Assess the Proportions of GvHD Response Post-administration of AP1903.
NCT01875237 (8) [back to overview]	To Assess the Incidence of GvHD Treatment Failure Post-administration of AP1903.
NCT01875237 (8) [back to overview]	To Assess the Proportion of Patients Developing Grade I-IV Acute GvHD
NCT01875237 (8) [back to overview]	To Assess the Incidence of Epstein-Barr Virus -PTLD or EBV Reactivation Requiring Therapy Post DLI.
NCT01877837 (2) [back to overview]	Number of Participants With Graft Failure
NCT01877837 (2) [back to overview]	Overall Survival
NCT01885689 (2) [back to overview]	Overall Survival at 2 Years
NCT01885689 (2) [back to overview]	Progression-free Survival at 2 Years
NCT01921387 (4) [back to overview]	Progression-free Survival Following Autologous Stem Cell Transplant (ASCT)
NCT01921387 (4) [back to overview]	The Lowest Antibody (Yttrium 90-BC8-DOTA) Dose (mg/kg) That is Consistent With a Favorable Biodistribution Rate >= 80% in Lymphoma Patients
NCT01921387 (4) [back to overview]	Maximum-tolerated Dose (MTD) of Yttrium-90-BC8-DOTA
NCT01921387 (4) [back to overview]	Estimated Dose to Tumor Sites Based on the Tumor to Normal Organ Ratios Derived From Dosimetry Estimates Coupled With the Absorbed Dose to Normal Organs Based on the Administered Activity of Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
NCT01969435 (11) [back to overview]	Disease-free Survival
NCT01969435 (11) [back to overview]	Disease-free Survival
NCT01969435 (11) [back to overview]	Safety and Toxicity as Measured by Treatment Related Non-hematologic Adverse Events
NCT01969435 (11) [back to overview]	Efficacy as Measured by Response Rates
NCT01969435 (11) [back to overview]	Overall Survival (OS) Rate
NCT01969435 (11) [back to overview]	Treatment-related Mortality (TRM)
NCT01969435 (11) [back to overview]	Time to Engraftment (Platelet)
NCT01969435 (11) [back to overview]	Time to Engraftment (Neutrophil)
NCT01969435 (11) [back to overview]	Relapse Free Survival
NCT01969435 (11) [back to overview]	Progression-free Survival Rate (PFS)
NCT01969435 (11) [back to overview]	Progression-free Survival (PFS) Rate
NCT01983969 (2) [back to overview]	Frequency of DLT
NCT01983969 (2) [back to overview]	Participants With Event-free Survival (EFS)
NCT02007863 (1) [back to overview]	Number of Successful Unrelated Cord Blood (UCB) Transplants
NCT02059239 (8) [back to overview]	Disease Response 30 Days Post-Transplant
NCT02059239 (8) [back to overview]	Disease Response at 1 Year Post-Transplant
NCT02059239 (8) [back to overview]	Overall Survival at Day 365 Post-Transplant
NCT02059239 (8) [back to overview]	Number of Patients Achieving Platelet Engraftment
NCT02059239 (8) [back to overview]	Number of Patients Achieving Neutrophil Engraftment
NCT02059239 (8) [back to overview]	Disease Response Following Salvage Chemotherapy
NCT02059239 (8) [back to overview]	Progression-Free Survival After Stem Cell Transplant
NCT02059239 (8) [back to overview]	Transplant-Related Mortality
NCT02097134 (4) [back to overview]	Rate of Metastases of Retinoblastoma
NCT02097134 (4) [back to overview]	Incidence of Grade 3 or Higher CTCAE Adverse Events Associated With Multiple Doses of IA Chemotherapy
NCT02097134 (4) [back to overview]	Probability of Ocular Salvage
NCT02097134 (4) [back to overview]	Number of Patients Experiencing Feasibility Failure
NCT02112045 (7) [back to overview]	Number of Participants With Overall Response
NCT02112045 (7) [back to overview]	Number of Participants With Platelet Engraftment
NCT02112045 (7) [back to overview]	Overall Survival as Measured by Number of Participants Alive at Last Follow-up
NCT02112045 (7) [back to overview]	Progression-free Survival as Measured by Number of Participants Without Disease Progression at Last Follow-up
NCT02112045 (7) [back to overview]	Number of Participants With Adverse Events
NCT02112045 (7) [back to overview]	Number of Participants With Neutrophil Engraftment
NCT02112045 (7) [back to overview]	Number of Participants With Complete Response or Stringent Complete Response
NCT02128230 (1) [back to overview]	The Remission Rate for Participants With High-risk Myeloma
NCT02195479 (16) [back to overview]	Time to Response
NCT02195479 (16) [back to overview]	Time to Next Treatment (TNT)
NCT02195479 (16) [back to overview]	Time to Disease Progression (TTP)
NCT02195479 (16) [back to overview]	Progression Free Survival on Next Line of Therapy (PFS2)
NCT02195479 (16) [back to overview]	Progression Free Survival (PFS)
NCT02195479 (16) [back to overview]	Percentage of Participants With Very Good Partial Response (VGPR) or Better
NCT02195479 (16) [back to overview]	Percentage of Participants With Stringent Complete Response (sCR)
NCT02195479 (16) [back to overview]	Percentage of Participants With Negative Minimal Residual Disease (MRD)
NCT02195479 (16) [back to overview]	Percentage of Participants With Complete Response (CR) or Better
NCT02195479 (16) [back to overview]	Overall Survival (OS)
NCT02195479 (16) [back to overview]	Overall Response Rate (ORR)
NCT02195479 (16) [back to overview]	Change From Baseline in EuroQol 5 Dimensions-5 Level (EQ-5D-5L) Utility Score
NCT02195479 (16) [back to overview]	Duration of Response (DOR)
NCT02195479 (16) [back to overview]	Percentage of Participants With Best M-protein Response
NCT02195479 (16) [back to overview]	Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L): Visual Analogue Scale (VAS)
NCT02195479 (16) [back to overview]	Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30: Emotional Functioning Score
NCT02199041 (9) [back to overview]	Number of Participants by Severity With Acute Graft Versus Host Disease (GVHD) in the First 100 Days After HCT
NCT02199041 (9) [back to overview]	Number of Participants With Transplant-related Mortality (TRM)
NCT02199041 (9) [back to overview]	Number of Participants With Transplant-related Morbidity
NCT02199041 (9) [back to overview]	Number of Participants With Secondary Graft Failure
NCT02199041 (9) [back to overview]	Number of Participants by Severity With Chronic Graft Versus Host Disease (GVHD) in the First 100 Days After HCT
NCT02199041 (9) [back to overview]	Number of Participants With Event-free Survival (EFS)
NCT02199041 (9) [back to overview]	Number of Participants With Malignant Relapse
NCT02199041 (9) [back to overview]	Number of Participants With Neutrophil Engraftment
NCT02199041 (9) [back to overview]	Number of Participants With Overall Survival (OS)
NCT02259348 (9) [back to overview]	Incidence and Severity of Acute GvHD
NCT02259348 (9) [back to overview]	Rate of Transplant-related Mortality (TRM)
NCT02259348 (9) [back to overview]	Incidence of Malignant Relapse
NCT02259348 (9) [back to overview]	Percentage of Participants Engrafted by Day 42 Post-transplant
NCT02259348 (9) [back to overview]	Overall Survival (OS)
NCT02259348 (9) [back to overview]	Median Days to Absolute Neutrophil Count (ANC) Engraftment
NCT02259348 (9) [back to overview]	Mean of Days to Absolute Neutrophil Count (ANC) Engraftment
NCT02259348 (9) [back to overview]	Event-free Survival (EFS)
NCT02259348 (9) [back to overview]	Incidence and Severity of Chronic GvHD
NCT02331368 (3) [back to overview]	The Estimated Percentage of Patients Alive at 2 Years
NCT02331368 (3) [back to overview]	The Estimated Percentage of Patients Alive Without Relapse or Progression at 2 Years
NCT02331368 (3) [back to overview]	The Number of Patients That Achieve Complete Response
NCT02366663 (4) [back to overview]	Number of Patients With Grade 3-5 Toxicities Graded by the NCI CTCAE Version 4.0
NCT02366663 (4) [back to overview]	Number of Patients With Complete or Partial Response at Day 30
NCT02366663 (4) [back to overview]	Time to Neutrophil Engraftment
NCT02366663 (4) [back to overview]	Time to Platelet Engraftment
NCT02435901 (3) [back to overview]	Number of Participants With Sustained Cell Engraftment of Donor Cells
NCT02435901 (3) [back to overview]	Event Free Survival; Number of Participants Who Survived at 2 Years
NCT02435901 (3) [back to overview]	Assessment of Treatment Related Mortality and Morbidity
NCT02440464 (14) [back to overview]	Percentage of Participants With Infections Post-randomization by Time Point
NCT02440464 (14) [back to overview]	Percentage of Participants With Infections Post-randomization by Infection Type
NCT02440464 (14) [back to overview]	Percentage of Participants With Disease Progression
NCT02440464 (14) [back to overview]	Percentage of Participants With Chronic GVHD
NCT02440464 (14) [back to overview]	Functional Assessment of Cancer Therapy (FACT) - Bone Marrow Transplant (BMT) Total Score
NCT02440464 (14) [back to overview]	Percentage of Participants With Acute GVHD (Grades III-IV)
NCT02440464 (14) [back to overview]	Medical Outcomes Study (MOS) - Short Form 36 (SF-36) Score
NCT02440464 (14) [back to overview]	Percentage of Participants With Response to Treatment
NCT02440464 (14) [back to overview]	Percentage of Participants With Best Response to Treatment After Randomization
NCT02440464 (14) [back to overview]	Percentage of Participants With Treatment-Related Mortality (TRM)
NCT02440464 (14) [back to overview]	Percentage of Participants With Toxicities Post-randomization by Toxicity Type
NCT02440464 (14) [back to overview]	Percentage of Participants With Toxicities Post-randomization by Time Point
NCT02440464 (14) [back to overview]	Percentage of Participants With Progression-Free Survival
NCT02440464 (14) [back to overview]	Percentage of Participants With Overall Survival (OS)
NCT02483000 (3) [back to overview]	Incidence of Toxicity, Defined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
NCT02483000 (3) [back to overview]	Dosimetry of Yttrium Y 90 DOTA-biotin
NCT02483000 (3) [back to overview]	Overall Survival
NCT02489500 (3) [back to overview]	Overall Survival
NCT02489500 (3) [back to overview]	Number of Participants With Hematologic Response
NCT02489500 (3) [back to overview]	Toxicities
NCT02497404 (9) [back to overview]	Overall Survival at 6 Months Post-transplant
NCT02497404 (9) [back to overview]	Overall Survival at 2 Years Post-Transplant
NCT02497404 (9) [back to overview]	Overall Survival at 1 Year Post-Transplant
NCT02497404 (9) [back to overview]	High-Risk Extensive Chronic Graft-versus-Host-Disease
NCT02497404 (9) [back to overview]	Graft Failure
NCT02497404 (9) [back to overview]	Disease Free Survival at 6 Months Post-transplant
NCT02497404 (9) [back to overview]	Disease Free Survival at 2 Years Post-transplant
NCT02497404 (9) [back to overview]	Disease Free Survival at 1 Year Post-transplant
NCT02497404 (9) [back to overview]	Acute Graft-versus-Host Disease (GVHD)
NCT02581007 (4) [back to overview]	GVHD Incidence
NCT02581007 (4) [back to overview]	Relapse Incidence
NCT02581007 (4) [back to overview]	Overall Survival
NCT02581007 (4) [back to overview]	Graft Rejection
NCT02614560 (7) [back to overview]	Best Response of CR or CRi
NCT02614560 (7) [back to overview]	1-year Survival Rate
NCT02614560 (7) [back to overview]	Duration of Response
NCT02614560 (7) [back to overview]	Overall Survival
NCT02614560 (7) [back to overview]	Incidence of Adverse Events
NCT02614560 (7) [back to overview]	Incidence of Laboratory Abnormalities
NCT02614560 (7) [back to overview]	Rate of MRD Negativity
NCT02669615 (3) [back to overview]	Cmax (Pharmacokinetics)
NCT02669615 (3) [back to overview]	AUC0-t (Pharmacokinetics)
NCT02669615 (3) [back to overview]	Transplant-Related Mortality (TRM) Following Autologous Stem-Cell Transplantation (ASCT)
NCT02716805 (2) [back to overview]	Number of Subjects With Treatment-emergent Adverse Events
NCT02716805 (2) [back to overview]	Number of Subjects With Best Response According to International Myeloma Working Group (IMWG) Consensus Criteria
NCT02728102 (15) [back to overview]	Number of Participants With Minimal Residual Disease (MRD)
NCT02728102 (15) [back to overview]	Participants Response to Treatment
NCT02728102 (15) [back to overview]	Percentage of Participants With Myeloma Progression of Vaccine and Non-vaccine Arms
NCT02728102 (15) [back to overview]	Percentage of Participants With Myeloma Progression in Pairwise Analysis
NCT02728102 (15) [back to overview]	Percentage of Participants With Grade 2 and 3 Infections in Pairwise Analysis
NCT02728102 (15) [back to overview]	Percentage of Participants With Grade 2 and 3 Infections
NCT02728102 (15) [back to overview]	Percentage of Participants With 1-year Response Rate of CR/sCR
NCT02728102 (15) [back to overview]	Participants With Grade ≥ 3 Toxicities
NCT02728102 (15) [back to overview]	Percentage of Participants With Treatment-related Mortality (TRM)
NCT02728102 (15) [back to overview]	Percentage of Participants With Overall Survival in Pairwise Analysis
NCT02728102 (15) [back to overview]	Percentage of Participants With Progression-Free Survival
NCT02728102 (15) [back to overview]	Number of Grade ≥ 3 Toxicities
NCT02728102 (15) [back to overview]	Number of Grade 2 and 3 Infections
NCT02728102 (15) [back to overview]	Percentage of Participants With Overall Survival
NCT02728102 (15) [back to overview]	Percentage of Participants With Progression-Free Survival in Pairwise Analysis
NCT02756572 (19) [back to overview]	Factors That Distinguish Patients Who Received Early Transplant From Those Who Did Not - TREATMENT RELATED MORTALITY
NCT02756572 (19) [back to overview]	Overall Survival (OS) Among Patients Who Did Not Receive Early Transplant
NCT02756572 (19) [back to overview]	Event-free Survival (EFS) Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Factors That Distinguish Patients Who Received Early Transplant From Those Who Did Not - GENDER
NCT02756572 (19) [back to overview]	Response Assessments After Early Allogeneic Hematopoietic Cell Transplant, Day 28
NCT02756572 (19) [back to overview]	Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Relapsed-free Survival 6 Months After Transplant
NCT02756572 (19) [back to overview]	Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Enrollment and Incidence of Early Transplant
NCT02756572 (19) [back to overview]	Demonstrate the Feasibility of Collecting Patient-reported Outcomes for Trial Participants
NCT02756572 (19) [back to overview]	Treatment Related Mortality Among Patients Who Received Early Transplant vs Patients Who Did Not Receive Early Transplant
NCT02756572 (19) [back to overview]	Relapse-free Survival (RFS) Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Relapse-free Survival (RFS) Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Overall Survival (OS) Among Patients Who Received Early Transplant.
NCT02756572 (19) [back to overview]	Overall Survival (OS) Among Patients Who Received Early Transplant.
NCT02756572 (19) [back to overview]	Overall Survival (OS) Among Patients Who Did Not Receive Early Transplant
NCT02756572 (19) [back to overview]	Event-free Survival (EFS) Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Response Assessments After Early Allogeneic Hematopoietic Cell Transplant, Day 84
NCT02756572 (19) [back to overview]	Acute Graft Versus Host Disease Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Demonstrate the Feasibility of Collecting Resource Utilization Data for Trial Participants
NCT02756572 (19) [back to overview]	Factors That Distinguish Patients Who Received Early Transplant From Those Who Did Not - AGE
NCT02771197 (2) [back to overview]	Number of Patients With 2-year Relapse Risk
NCT02771197 (2) [back to overview]	Assess Safety of Pembrolizumab by Recording the Number of Participants With Treatment-related Adverse Events
NCT02780609 (5) [back to overview]	Overall Survival (OS)
NCT02780609 (5) [back to overview]	Phase 1 and Phase 2 Percentage of Participants Treated at Dose Level 3/RP2D With Progression Free Survival (PFS)
NCT02780609 (5) [back to overview]	Phase I: Recommended Phase II Dose (RPh2D)
NCT02780609 (5) [back to overview]	Rate of Minimal Residual Disease (MRD)
NCT02780609 (5) [back to overview]	Complete Response (CR)
NCT02797470 (1) [back to overview]	Percentage of Participants Who Achieve a Timely Engraftment
NCT02963493 (9) [back to overview]	Overall Response Rate (ORR)
NCT02963493 (9) [back to overview]	Functional Status and Well-being: EQ-5D-3L
NCT02963493 (9) [back to overview]	Functional Status and Well-being: EORTC QLQ-C30
NCT02963493 (9) [back to overview]	Time to Response
NCT02963493 (9) [back to overview]	Duration of Response
NCT02963493 (9) [back to overview]	Clinical Benefit Rate
NCT02963493 (9) [back to overview]	Overall Survival
NCT02963493 (9) [back to overview]	Progression Free Survival (PFS)
NCT02963493 (9) [back to overview]	Time to Progression
NCT02994784 (8) [back to overview]	Number of Participants With Cardiac Dysfunction (New Arrhythmia)
NCT02994784 (8) [back to overview]	Neutrophil Engraftment
NCT02994784 (8) [back to overview]	Hematologic Overall Response Rate
NCT02994784 (8) [back to overview]	Platelet Engraftment
NCT02994784 (8) [back to overview]	Treatment Related Mortality
NCT02994784 (8) [back to overview]	Participants With Peri-transplant Hospitalizations
NCT02994784 (8) [back to overview]	Organ Response
NCT02994784 (8) [back to overview]	Number of Participants With Renal Dysfunction
NCT03019640 (2) [back to overview]	Number of Participants Who Survived
NCT03019640 (2) [back to overview]	Treatment-related Mortality Within 30 Days (TRM30)
NCT03096782 (3) [back to overview]	Overall Survival
NCT03096782 (3) [back to overview]	Disease-free Survival
NCT03096782 (3) [back to overview]	Time to Engraftment
NCT03128359 (3) [back to overview]	Graft-Versus-Host Disease-Free, Relapse-Free Survival (GRFS) at 1 Year
NCT03128359 (3) [back to overview]	Acute Graft Versus Host Disease (aGVHD) of Grades 2-4 According to the Consensus Grading
NCT03128359 (3) [back to overview]	Overall Survival (OS) at 1 Year
NCT03151811 (4) [back to overview]	Overall Response Rate (ORR)
NCT03151811 (4) [back to overview]	Progression Free Survival (PFS)
NCT03151811 (4) [back to overview]	Safety and Tolerability: Number of Patients With Treatment-emergent Adverse Events, Including Clinical Laboratory and Vital Signs Abnormalities, as Assessed by CTCAE v4.0
NCT03151811 (4) [back to overview]	Duration of Response (DOR)
NCT03412565 (14) [back to overview]	Percentage of Participants With Anti-Daratumumab Antibodies
NCT03412565 (14) [back to overview]	Maximum Observed Serum Concentration (Cmax) of Daratumumab
NCT03412565 (14) [back to overview]	D-VMP, D-Rd, and D-Kd Cohorts: Overall Response Rate (ORR)
NCT03412565 (14) [back to overview]	Maximum Observed Serum Concentration (Cmax) of Daratumumab
NCT03412565 (14) [back to overview]	Maximum Observed Serum Concentration (Cmax) of Daratumumab
NCT03412565 (14) [back to overview]	D-VRd Cohort: Overall Response Rate (ORR)
NCT03412565 (14) [back to overview]	D-VRd Cohort: Percentage of Participants With Very Good Partial Response (VGPR) or Better Response
NCT03412565 (14) [back to overview]	D-VMP, D-Rd and D-Kd Cohorts: Duration of Response (DOR)
NCT03412565 (14) [back to overview]	D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With VGPR or Better Response
NCT03412565 (14) [back to overview]	D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With Minimal Residual Disease (MRD) Negative Rate
NCT03412565 (14) [back to overview]	Maximum Observed Serum Concentration (Cmax) of Daratumumab
NCT03412565 (14) [back to overview]	Percentage of Participants With Infusion-Related Reactions (IRRs)
NCT03412565 (14) [back to overview]	Percentage of Participants With CR or Better Response
NCT03412565 (14) [back to overview]	Percentage of Participants With Anti-rHuPH20 Antibodies
NCT03481556 (12) [back to overview]	Progression-Free Survival (PFS)
NCT03481556 (12) [back to overview]	Clinical Benefit Rate (≥ Minimal Response)
NCT03481556 (12) [back to overview]	Time to Next Treatment (TTNT)
NCT03481556 (12) [back to overview]	Time to Progression (TTP)
NCT03481556 (12) [back to overview]	Time to Response (TTR)
NCT03481556 (12) [back to overview]	Best Response (BR)
NCT03481556 (12) [back to overview]	Duration of Clinical Benefit (DOCB)
NCT03481556 (12) [back to overview]	Duration of Response (DOR)
NCT03481556 (12) [back to overview]	Overall Survival (OS)
NCT03481556 (12) [back to overview]	Phase 1: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)
NCT03481556 (12) [back to overview]	Phase 2: Overall Response Rate (ORR)
NCT03481556 (12) [back to overview]	Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
NCT03639610 (14) [back to overview]	Tmax of Melphalan
NCT03639610 (14) [back to overview]	Best Confirmed Response
NCT03639610 (14) [back to overview]	Area Under the Curve (Inf) of Melphalan
NCT03639610 (14) [back to overview]	Area Under the Curve (0-t) of Melphalan
NCT03639610 (14) [back to overview]	Time to Response
NCT03639610 (14) [back to overview]	Time to Clinical Benefit
NCT03639610 (14) [back to overview]	Cmax of Melphalan
NCT03639610 (14) [back to overview]	Clinical Benefit Rate
NCT03639610 (14) [back to overview]	Duration of Clinical Benefit
NCT03639610 (14) [back to overview]	Progression-free Survival
NCT03639610 (14) [back to overview]	Duration of Response
NCT03639610 (14) [back to overview]	Overall Response Rate
NCT03639610 (14) [back to overview]	Overall Survival
NCT03639610 (14) [back to overview]	T1/2 of Melphalan
NCT03786783 (5) [back to overview]	Response Rate
NCT03786783 (5) [back to overview]	Percentage of Participants With Unacceptable Toxicity
NCT03786783 (5) [back to overview]	Overall Survival
NCT03786783 (5) [back to overview]	Event-free Survival
NCT03786783 (5) [back to overview]	"Percentage of Participants Who Are Feasibility Failure"
NCT04205240 (2) [back to overview]	Number of Patients With a Partial Response
NCT04205240 (2) [back to overview]	Number of Patients With Grade II-IV Acute Graft-versus Host Disease (GvHD (aGVHD)
NCT04339101 (3) [back to overview]	Cumulative Incidence of Grade II-IV Acute GVHD
NCT04339101 (3) [back to overview]	Graft-versus-host Disease Free Relapse Free (GRFS) at 1 Year
NCT04339101 (3) [back to overview]	Progression Free Survival (PFS)
NCT04395222 (2) [back to overview]	Proportion of Failure of the Haplo-Graft
NCT04395222 (2) [back to overview]	Percentage of Subjects With Successful Haplo-derived Neutrophil Engraftment
NCT04412707 (20) [back to overview]	Best Response (Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), Partial Response (PR), Minimal Response (MR), Stable Disease (SD) or Progressive Disease (PD)
NCT04412707 (20) [back to overview]	ORR
NCT04412707 (20) [back to overview]	PFS
NCT04412707 (20) [back to overview]	TTNT
NCT04412707 (20) [back to overview]	TTP
NCT04412707 (20) [back to overview]	TTR
NCT04412707 (20) [back to overview]	Area Under the Plasma Concentration Versus Time Curve AUC(0-inf) of Melflufen and Desethyl-melflufen
NCT04412707 (20) [back to overview]	Area Under the Plasma Concentration Versus Time Curve AUC(0-inf) of Melphalan
NCT04412707 (20) [back to overview]	Area Under the Plasma Concentration Versus Time Curve AUC(0-t) of Melflufen and Desethyl-melflufen
NCT04412707 (20) [back to overview]	Area Under the Plasma Concentration Versus Time Curve AUC(0-t) of Melphalan
NCT04412707 (20) [back to overview]	Elimination Half-life (t1/2) of Melflufen, Melphalan and Desethyl-melflufen
NCT04412707 (20) [back to overview]	Frequency of Treatment-Emergent Adverse Events (TEAEs) by MedDRA SOC and PT
NCT04412707 (20) [back to overview]	Grade 3/4 Treatment-Emergent Adverse Events (TEAEs)
NCT04412707 (20) [back to overview]	Grade 5 Treatment-Emergent Adverse Events (TEAEs)
NCT04412707 (20) [back to overview]	Peak Plasma Concentration for Melflufen and Desethyl-melflufen
NCT04412707 (20) [back to overview]	Peak Plasma Concentration for Melphalan
NCT04412707 (20) [back to overview]	Number of Participants With Local Reactions Including Phlebitis at Infusion Site After Peripheral Intravenous Administration
NCT04412707 (20) [back to overview]	CBR
NCT04412707 (20) [back to overview]	DOCB
NCT04412707 (20) [back to overview]	DOR
NCT04649060 (9) [back to overview]	Progression Free Survival (PFS)
NCT04649060 (9) [back to overview]	Overall Survival (OS)
NCT04649060 (9) [back to overview]	Overall Response Rate (ORR)
NCT04649060 (9) [back to overview]	Duration of Response (DOR)
NCT04649060 (9) [back to overview]	Duration of Clinical Benefit (DOCB)
NCT04649060 (9) [back to overview]	Clinical Benefit Rate (CBR)
NCT04649060 (9) [back to overview]	Time to Response (TTR)
NCT04649060 (9) [back to overview]	Time to Progression (TTP)
NCT04649060 (9) [back to overview]	Time to Next Treatment (TTNT)
NCT04682405 (24) [back to overview]	Change in Abdominal Pain as Assessed Per CTCAE v5.0
NCT04682405 (24) [back to overview]	Change in Bristol Stool Scale
NCT04682405 (24) [back to overview]	Change in Diarrhea as Assessed Per CTCAE v5.0
NCT04682405 (24) [back to overview]	Change in Enterocolitis as Assessed Per CTCAE v5.0
NCT04682405 (24) [back to overview]	Change in Esophageal Pain as Assessed Per CTCAE v5.0
NCT04682405 (24) [back to overview]	Change in Esophagitis as Assessed Per CTCAE v5.0
NCT04682405 (24) [back to overview]	Change in Gastritis as Assessed Per CTCAE v5.0
NCT04682405 (24) [back to overview]	Change in Oral Mucositis as Assessed Per CTCAE v5.0
NCT04682405 (24) [back to overview]	Change in Proctitis as Assessed Per CTCAE v5.0
NCT04682405 (24) [back to overview]	Change in Vomiting as Assessed Per CTCAE v5.0
NCT04682405 (24) [back to overview]	Median Change in Scores of Patient Reported Outcomes as Measured by the CTCAE Pro Form v1.0
NCT04682405 (24) [back to overview]	Median Change in Scores of Patient Reported Outcomes as Measured by the CTCAE Pro Form v1.0
NCT04682405 (24) [back to overview]	Median Change in Scores of Quality of Life as Measured by the CTCAE Pro Form v 1.0
NCT04682405 (24) [back to overview]	Change in Nutritional Status as Assessed by Change in Standing Weight
NCT04682405 (24) [back to overview]	Median Daily Dose of Anti-diarrheal Medications
NCT04682405 (24) [back to overview]	Duration of Hospital Length of Stay
NCT04682405 (24) [back to overview]	Change in Nutritional Status as Assessed by Total Parenteral Nutrition (TPN) Days
NCT04682405 (24) [back to overview]	Median Daily Dose of Pain Medications
NCT04682405 (24) [back to overview]	Change in Hemorrhoids as Assessed Per CTCAE v5.0
NCT04682405 (24) [back to overview]	Change in Nausea as Assessed Per CTCAE v5.0
NCT04682405 (24) [back to overview]	Time to First Antibiotics
NCT04682405 (24) [back to overview]	Incidence of Infection Assessed by Rates of Bacteremia (With Organism Reported When Available)
NCT04682405 (24) [back to overview]	Time to Neutrophil Engraftment
NCT04682405 (24) [back to overview]	Incidence of Clostridium Difficile Infections

Toxicities Counts

Number of patients with grade 3 and 4 toxicities observed during cycles 1 & 2 using the Common Toxicity Criteria Version for Chemotherapy. (NCT00002601)
Timeframe: 2 months after completion of second cycle of treatment.

Intervention	Participants (Count of Participants)
	Anemia	Leukopenia	Neutropenia	Febrile neutropenia	Thrombocytopenia	Mucositis	Bacteremia/sepsis	Hyperglycemia	Pulmonary function impairment (FEV1)	Pulmonary infiltrates	Diarrhea	Arrhythmia	Hematuria	Mood	Elevated PTT
Cycle 1	8	13	13	13	13	13	2	5	1	0	1	1	1	1	1
Cycle 2	3	11	11	9	11	1	4	1	0	2	0	1	0	1	0

Intervention	percentage of participants (Number)
Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue	61.5
High-dose Chemo With Rescue	77.8

Intervention	percentage of participants (Number)
Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue	69.2
High-dose Chemo With Rescue	70.4

Intervention	Participants (Count of Participants)
	Stage IIIB Disease	Stage IV Disease
TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer	11	9

Intervention	participants (Number)
	Failure	Minor Response (MR)	Partial Response (PR)	Progression Free (P-Free)	Complete Response (CR)	Progression of Disease (POD)
Group A - Favorable Prognostic Group	3	2	1	41	0	0
Group B - Intermediate Prognostic Group	6	1	2	31	2	1
Group C - Unfavorable Prognostic Group	3	0	4	7	1	0

Intervention	Participants (Count of Participants)
	6 Months	1 Year	1.5 Years	2 Years	3 Years
Chemoresistant Group	12	8	8	8	8
Chemosensitive Group	36	27	25	25	22
Unknown Chemosensitivity Group	1	0	0	0	0

Intervention	Participants (Count of Participants)
	Patients in Complete Remission	Patients in Partial Remission	Patients with Stable resposne	Patients with Disease Progression
Immunotherapy Treatment	15	8	10	3

Intervention	Months (Median)
	Participants who did not receive a transplant(n=7)	Participants who received a transplant (n=23)
Arm 2-Recipients	3.3	19.1

Intervention	participants (Number)
	acute GVHD	chronic GVHD
Recipients -Cyclosporine GVHD Prophylaxis	12	12
Recipients -Tacrolimus/Sirolimus GVHD Prophylaxis	5	5

Intervention	Participants (Count of Participants)
	Chest wall; G2 skin	Abdomen; G4 GI	Pancreas; G4 LFTs, G4 pancreatitis	Pleura, mediastinum; G4 LFTs, G2 mucositis	Chest wall; G4 skin, G3 mucositis	Spine, skull; G2 nausea+vomiting, G2 fatigue	Pelvis; G4 enteritis	Pulmonary (cyberknife)	Brain; B3 mucositis	Whole lung; G3 mucositis, G3 skin, G5 lung	L arm, R shoulder, B/L femur
Arm 2-Recipients	1	1	1	1	1	1	1	1	1	1	1

Intervention	percentage of participants (Number)
	From date of enrollment	From date of transplantation
Arm 2-Recipients	39.1	34.8

Intervention	percentage of participants (Number)
BuCy	49.1
CyTBI	52.2
FluMel	33.2
VpCyTBI	26.1
Other	40

Intervention	percentage of participants (Number)
BuCy	56.4
CyTBI	56.5
FluMel	38.2
VpCyTBI	39.1
Other	53.3

Intervention	Participants (Count of Participants)
BuCy	42
CyTBI	55
FluMel	134
VpCyTBI	18
Other	7

Intervention	Participants (Count of Participants)
	Complete Response (CR)	Progressive Disease (PD)	Partial Response (PR)	Very Good Partial Response (VGPR)
Arm 2-Recipients	2	4	4	2

Intervention	Participants (Count of Participants)
	Grade ≤ 2	Grade ≥ 3	No GVHD
Expanded CB Arm	15	2	27
Un-Manipulated CB Arm	20	6	19

Intervention	Participants (Count of Participants)
	Overall Chronic GVHD	Limited	Extensive
Expanded CB Arm	20	14	13
Un-Manipulated CB Arm	16	10	9

Intervention	Participants (Count of Participants)
Phase 1 Cohort 1 (Total TMI Dose: 1000 cGy)	3
Phase 1 Cohort 2 (Total TMI Dose: 1200 cGy)	3
Phase 1 Cohort 3 (Total TMI Dose: 1400 cGy)	2
Phase 1 Cohort 4 & Phase 2 MTD (Total TMI Dose:1600 cGy)	20
Phase 1 Cohort 5 (Total TMI Dose: 1800 cGy)	4

Intervention	participants (Number)
	Complete response	Partial response	Marginal response	Stable disease	Progressive disease	Unknown
Lenalidomide Maintenance	67	115	11	38	0	0
Placebo Maintenance	79	109	5	32	3	1

Intervention	participants (Number)
	Negative for MRD	Positive for MRD
Alive	2	1
Expired	1	0
Study Participants	3	1

Intervention	participants (Number)
	Active Disease	Complete Remission-1	Complete Remission-2	Progressive Disease	Relapse
Alive	0	6	0	1	0
Expired	1	2	1	0	3
Study Participants	1	8	1	1	3

Intervention	participants (Number)
	3/6 HLA Loci	4/6 HLA Loci
Alive	6	1
Expired	3	4
Study Participants	9	5

Intervention	cells *10^3/µl (Median)
	CD3 Lymphocyte	CD3 Gamma Delta	CD4 Lymphocyte	CD8 Lymphocyte	CD19 Lymphocyte	CD56 Lymphocyte	CD4/CD8 Ratio	Absolute Lymphocyte Value
0-3 Months After HSCT	0.22	0.00	0.13	0.01	0.26	0.36	2.60	0.88
1-2 Years After HSCT	1.65	0.70	0.96	0.61	0.45	0.22	1.88	2.59
2-3 Years After HSCT	2.88	0.24	1.56	1.05	0.56	0.32	1.38	3.76
3-4 Years After HSCT	2.65	0.21	1.33	1.10	0.56	0.34	1.30	3.65
3-6 Months After HSCT	0.57	0.04	0.42	0.09	0.48	0.33	5.53	1.29
4-5 Years After HSCT	1.87	0.38	1.94	0.70	0.43	0.19	1.30	2.40
6-9 Months After HSCT	1.15	0.08	0.92	0.29	0.61	0.20	3.36	1.95
9-12 Months After HSCT	2.24	0.09	1.37	0.36	0.52	0.19	1.90	2.90

Intervention	Participants (Count of Participants)
	Patient 172467502			Patient 172467503	Patient 172467501	Patient 272467501	Patient 272467502	Patient 272467503	Patient 372467501	Patient 372467502	Patient 372467503	Patient 472467501	Patient 472467502	Patient 472467503
	Data Not Collected	Positive MRD	Negative MRD
Study Participants: 1 Year Post HSCT	1
Study Participants: 5 Years Post HSCT	1
Study Participants: 1 Year Post HSCT	0
Study Participants: Before HSCT	0
Study Participants: Before HSCT	1
Study Participants: 5 Years Post HSCT	0

melphalan

Description

Cross-References

Synonyms (187)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (5)

Drug Classes (4)

Protein Targets (87)

Potency Measurements

Inhibition Measurements

Biological Processes (250)

Molecular Functions (84)

Ceullar Components (55)

Bioassays (687)

Research

Studies (7,657)

Market Indicators

Research Demand Index: 74.77

Study Types

Clinical Trials (706)

Trial Overview

Trial Outcomes

Toxicities Counts

5-year Progression-free Survival

Number of Participants With Grade 3 Bilirubin

5-year Overall Survival

Three-year Relapse-free Survival

Five-year Overall Survival

Event-free Survival

Number of Participants With Toxicity of a Combination of Low-dose IL-2 and GM-CSF

Overall Survival

Objective Response

4 Year PFS

4 yr OS

CR Rate

Toxicity/TRM at Day 100

Three-year Overall Survival

Progression-free Survival

Progression Free-survival (PFS)

Overall Survival (OS)

Non-Relapse Mortality

Engraftment of HLA Identical PBSC Allografts

Proportion of Patients Alive and in Remission

Time to Disease Progression

Initial Response to Therapy

Overall Survival

Number of Patients ≥56 Years Old Experiencing Grade 3-4 Regimen Related Toxicity

Number of Patients <56 Years Old Experiencing Grade 3-4 Regimen Related Toxicity

Extensive Chronic Graft-versus-Host Disease Matched Related Patients

Overall Survival

Overall Survival

Extensive Chronic Graft-versus-Host Disease Unrelated and Mismatched Related Patients

Acute Graft-versus-Host Disease Unrelated and Mismatched Related Patients

Acute Graft-versus-Host Disease Matched Related Patients

Number of Participants With Absolute Neutrophil Count Engraftment

Overall Survival

Assess Toxicity of Thalidomide/Dexamethasone as a Pre-transplant Induction Regimen.

Toxicity

Number of Participants With Engraftment

Number of Participants Who Experienced Graft Versus Tumor Effect (GVT)

Median Progression Free Survival

Early Post Transplantation Relapse

Cluster of Differentiation 4 (CD4) Reconstitution

Median Time to Reach Absolute Neutrophil Count of 500/mm(3)

Median Survival From Date of Progression

Number of Participants to Complete Conversion to >95% Donor Chimerism

Number of Participants With Acute and Chronic GVHD

Median Time to Reach a Platelet Count of 50,000/mm(3)

Post-Hematopoietic Stem Cell Transplant (HSCT) Radiotherapy

Two Year Survival Rate for Patients Undergoing Allo-Hematopoietic Stem Cell Transplant

Best Response Post-Hematopoietic Stem Cell Transplant EOCH (Etoposide, Vincristine, Cyclophosphamide, and Doxorubicin)

Intervention	participants (Number)
Arm 1 - Matched Sibling Donor	3
Arm 2 - Matched Unrelated Donor	7
Arm 3 - Mismatched Double Cord Donors	3

Intervention	percentage of donor cells (Mean)
Arm 1 - Matched Sibling Donor	81.9
Arm 2 - Matched Unrelated Donor	78.6
Arm 3 - Mismatched Double Cord Donors	91.7

Intervention	percentage of donor cells (Mean)
Arm 1 - Matched Sibling Donor	88.9
Arm 2 - Matched Unrelated Donor	73.3
Arm 3 - Mismatched Double Cord Donors	90.5

Intervention	percentage of donor cells (Mean)
Arm 1 - Matched Sibling Donor	96.5
Arm 2 - Matched Unrelated Donor	75.5
Arm 3 - Mismatched Double Cord Donors	100

Intervention	Participants (Count of Participants)
	Auto-HCT only	Auto-HCT then Allo-HCT	All Participants
Auto- Then Allo-HCT	0	24	24

Intervention	percentage of participants (Number)
Arm I (High Dose Melphalan, Amifostine Trihydrate, Transplant)	39
Arm II (Low Dose Melphalan, Amifostine Trihydrate, Transplant)	22

Intervention	Participants (Number)
	ALT, SGPT (serum glutamic pyruvic transaminase)	AST, SGOT	Allergic reaction/hypersensitivity	Anorexia	Bilirubin (hyperbilirubinemia)	Calcium, serum-low (hypocalcemia)	Colitis, infectious (e.g., Clostridium difficile)	Confusion	Constitutional Symptoms-Other (Specify)	Cough	Dehydration	Dermatology/Skin-Other (Specify)	Diarrhea	Distention/bloating, abdominal	Dry mouth/salivary gland (xerostomia)	Dysphagia (difficulty swallowing)	Dyspnea (shortness of breath)	Edema: limb	Esophagitis	Fatigue (asthenia, lethargy, malaise)	Febrile neutropenia	Fever in absence of neutropenia, ANC lt1.0x10e9/L	Glucose, serum-high (hyperglycemia)	Hemoglobin	Hemorrhage, pulmonary/upper respiratory - Nose	Hemorrhage/Bleeding-Other (Specify)	Hypotension	Hypoxia	Inf (clin/microbio) w/Gr 3-4 neuts - Abdomen NOS	Inf (clin/microbio) w/Gr 3-4 neuts - Blood	Inf (clin/microbio) w/Gr 3-4 neuts - Catheter-rel	Inf (clin/microbio) w/Gr 3-4 neuts - Foreign body	Inf (clin/microbio) w/Gr 3-4 neuts - Lung	Inf (clin/microbio) w/Gr 3-4 neuts - Rectum	Inf (clin/microbio) w/Gr 3-4 neuts - Sinus	Inf (clin/microbio) w/Gr 3-4 neuts - Skin	Inf (clin/microbio) w/Gr 3-4 neuts - Stomach	Inf (clin/microbio) w/Gr 3-4 neuts - Upper airway	Inf w/normal ANC or Gr 1-2 neutrophils - Blood	Inf w/normal ANC or Gr 1-2 neutrophils - Catheter	Infection with unknown ANC - Blood	Infection with unknown ANC - Skin (cellulitis)	Infection-Other (Specify)	Leukocytes (total WBC)	Lymphatics-Other (Specify)	Lymphopenia	Magnesium, serum-high (hypermagnesemia)	Mood alteration - depression	Mucositis/stomatitis (clinical exam) - Oral cavity	Mucositis/stomatitis (clinical exam) - Pharynx	Mucositis/stomatitis (functional/symp) - Oral cav	Mucositis/stomatitis (functional/symp) - Pharynx	Nausea	Neutrophils/granulocytes (ANC/AGC)	Opportunistic inf associated w/gt=Gr 2 lymphopenia	Pain - Head/headache	Pain - Joint	Pain - Oral cavity	Pain - Throat/pharynx/larynx	Pain-Other (Specify)	Phosphate, serum-low (hypophosphatemia)	Platelets	Pneumonitis/pulmonary infiltrates	Potassium, serum-low (hypokalemia)	Pruritus/itching	Psychosis (hallucinations/delusions)	Pulmonary hypertension	Rash/desquamation	SVT and nodal arrhythmia - SVT tachycardia	Sodium, serum-low (hyponatremia)	Syndromes-Other (Specify)	Thrombosis/thrombus/embolism	Uric acid, serum-high (hyperuricemia)	Vomiting
High-dose Therapy Plus Tandem Transplant	6	4	3	20	1	1	1	1	1	1	6	1	8	1	1	6	5	1	5	4	47	3	6	22	2	1	10	4	1	2	1	1	3	1	1	1	1	1	2	1	1	1	5	65	1	50	1	2	9	8	6	10	32	67	1	2	2	2	3	2	25	70	3	13	1	1	1	4	1	11	2	2	1	12

Intervention	participants (Number)
	Complete Response	Partial Response	Unconfirmed Complete Response	Unconfirmed Partial Response	No Response	Assessment Inadequate
High-dose Therapy Plus Tandem Transplant	15	8	3	2	33	26

Intervention	Participants (Count of Participants)
	Dermatological Toxicities	Gastrointestinal Toxicities	Immune System Toxicites	Infections	Metabolic Toxicities	Respiratory Toxicities	Vascular Toxicities
Busulfan/Melphalan/Thiotepa	3	26	1	33	3	2	1

Intervention	Participants (Count of Participants)
	3 months	6 months	9 months	12 months	18 months	24 months
Busulfan/Melphalan/Thiotepa	34	30	28	25	24	22